Abstract:
This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of interleukin and/or interleukin receptor genes such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, and IL-27 genes and IL-IR, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, IL-15R, IL-16R, IL-17R, IL-18R, IL-19R, IL-20R, IL-21R, IL-22R, IL-23R, IL-24R, IL-25R, IL-26R, and IL-27R genes.

Description:
[0001]     This application is a continuation-in-part of International Patent Application No. PCT/US03/04566 filed Feb. 14, 2003. This application is also a continuation-in-part of International Patent Application No. PCT/US04/16390, filed May 24, 2004, which is a continuation-in-part of U.S. patent application Ser. No. 10/826,966, filed Apr. 16, 2004, which is continuation-in-part of U.S. patent application Ser. No. 10/757,803, filed Jan. 14, 2004, which is a continuation-in-part of U.S. patent application Ser. No. 10/720,448, filed Nov. 24, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10/693,059, filed Oct. 23, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10/444,853, filed May 23, 2003, which is a continuation-in-part of International Patent Application No. PCT/US03/05346, filed Feb. 20, 2003, and a continuation-in-part of International Patent Application No. PCT/US03/05028, filed Feb. 20, 2003, both of which claim the benefit of U.S. Provisional Application No. 60/358,580 filed Feb. 20, 2002, U.S. Provisional Application No. 60/363,124 filed Mar. 11, 2002, U.S. Provisional Application No. 60/386,782 filed Jun. 6, 2002, U.S. Provisional Application No. 60/406,784 filed Aug. 29, 2002, U.S. Provisional Application No. 60/408,378 filed Sep. 5, 2002, U.S. Provisional Application No. 60/409,293 filed Sep. 9, 2002, and U.S. Provisional Application No. 60/440,129 filed Jan. 15, 2003. This application is also a continuation-in-part of International Patent Application No. PCT/US04/13456, filed Apr. 30, 2004, which is a continuation of patent application Ser. No. 10/780,447, filed Feb. 13, 2004, which is a continuation-in-part of U.S. patent application Ser. No. 10/427,160, filed Apr. 30, 2003, which is a continuation-in-part of International Patent Application No. PCT/US02/15876 filed May 17, 2002, which claims the benefit of U.S. Provisional Application No. 60/362,016, filed Mar. 6, 2002, and U.S. Provisional Application No. 60/292,217, filed May 18, 2001. This application is also a continuation-in-part of U.S. patent application Ser. No. 10/727,780 filed Dec. 3, 2003. This application also claims the benefit of U.S. Provisional Application No. 60/543,480 filed Feb. 10, 2004. The instant application claims the benefit of all the listed applications, which are hereby incorporated by reference herein in their entireties, including the drawings.  
     
    
     FIELD OF THE INVENTION  
       [0002]     The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of interleukin gene expression and/or activity, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, and IL-27 genes and genes encoding interleukin receptors of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, and IL-27 genes. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in interleukin gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against interleukin gene expression. Such small nucleic acid molecules are useful, for example, in providing compositions for treatment or prevention of traits, diseases and conditions that can respond to modulation of interleukin gene expression in a subject, such as inflammatory, respiratory, pulmonary, autoimmune, cardiovascular, neurodegenerative, and/or proliferative and cancerous diseases, traits, or conditions.  
       BACKGROUND OF THE INVENTION  
       [0003]     The following is a discussion of relevant art pertaining to RNAi. The discussion is provided only for understanding of the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention.  
         [0004]     RNA interference refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Zamore et al., 2000, Cell, 101, 25-33; Fire et al., 1998 , Nature,  391, 806; Hamilton et al., 1999 , Science,  286, 950-951; Lin et al., 1999 , Nature,  402, 128-129; Sharp, 1999, Genes &amp; Dev., 13:139-141; and Strauss, 1999, Science, 286, 886). The corresponding process in plants (Heifetz et al., International PCT Publication No. WO 99/61631) is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes and is commonly shared by diverse flora and phyla (Fire et al., 1999 , Trends Genet.,  15, 358). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or from the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response through a mechanism that has yet to be fully characterized. This mechanism appears to be different from other known mechanisms involving double stranded RNA-specific ribonucleases, such as the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2′,5′-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L (see for example U.S. Pat. Nos. 6,107,094; 5,898,031; Clemens et al., 1997 , J Interferon  &amp;  Cytokine Res.,  17, 503-524; Adah et al., 2001 , Curr. Med. Chem.,  8, 1189).  
         [0005]     The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer (Bass, 2000, Cell, 101, 235; Zamore et al., 2000, Cell, 101, 25-33; Hammond et al., 2000, Nature, 404, 293). Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Zamore et al., 2000, Cell, 101, 25-33; Bass, 2000, Cell, 101, 235; Berstein et al., 2001 , Nature,  409, 363). Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes (Zamore et al., 2000, Cell, 101, 25-33; Elbashir et al., 2001 , Genes Dev.,  15, 188). Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001 , Science,  293, 834). The RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir et al., 2001 , Genes Dev.,  15, 188).  
         [0006]     RNAi has been studied in a variety of systems. Fire et al., 1998 , Nature,  391, 806, were the first to observe RNAi in  C. elegans . Bahramian and Zarbl, 1999 , Molecular and Cellular Biology,  19, 274-283 and Wianny and Goetz, 1999 , Nature Cell Biol.,  2, 70, describe RNAi mediated by dsRNA in mammalian systems. Hammond et al., 2000 , Nature,  404, 293, describe RNAi in  Drosophila  cells transfected with dsRNA. Elbashir et al., 2001 , Nature,  411, 494 and Tuschl et al., International PCT Publication No. WO 01/75164, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in  Drosophila  embryonic lysates (Elbashir et al., 2001 , EMBO J,  20, 6877 and Tuschl et al., International PCT Publication No. WO 01/75164) has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21-nucleotide siRNA duplexes are most active when containing 3′-terminal dinucleotide overhangs. Furthermore, complete substitution of one or both siRNA strands with 2′-deoxy (2′-H) or 2′-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3′-terminal siRNA overhang nucleotides with 2′-deoxy nucleotides (2′-H) was shown to be tolerated. Single mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5′-end of the siRNA4 guide sequence rather than the 3′-end of the guide sequence (Elbashir et al., 2001 , EMBO J,  20, 6877). Other studies have indicated that a 5′-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5′-phosphate moiety on the siRNA (Nykanen et al., 2001 , Cell,  107, 309).  
         [0007]     Studies have shown that replacing the 3′-terminal nucleotide overhanging segments of a 21-mer siRNA duplex having two-nucleotide 3′-overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to four nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well tolerated, whereas complete substitution with deoxyribonucleotides results in no RNAi activity (Elbashir et al., 2001 , EMBO J,  20, 6877 and Tuschl et al., International PCT Publication No. WO 01/75164). In addition, Elbashir et al., supra, also report that substitution of siRNA with 2′-O-methyl nucleotides completely abolishes RNAi activity. Li et al., International PCT Publication No. WO 00/44914, and Beach et al., International PCT Publication No. WO 01/68836 preliminarily suggest that siRNA may include modifications to either the phosphate-sugar backbone or the nucleoside to include at least one of a nitrogen or sulfur heteroatom, however, neither application postulates to what extent such modifications would be tolerated in siRNA molecules, nor provides any further guidance or examples of such modified siRNA. Kreutzer et al., Canadian Patent Application No. 2,359,180, also describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double-stranded RNA-dependent protein kinase PKR, specifically 2′-amino or 2′-O-methyl nucleotides, and nucleotides containing a 2′-O or 4′-C methylene bridge. However, Kreutzer et al. similarly fails to provide examples or guidance as to what extent these modifications would be tolerated in dsRNA molecules.  
         [0008]     Parrish et al., 2000 , Molecular Cell,  6, 1077-1087, tested certain chemical modifications targeting the unc-22 gene in  C. elegans  using long (&gt;25 nt) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that RNAs with two phosphorothioate modified bases also had substantial decreases in effectiveness as RNAi. Further, Parrish et al. reported that phosphorothioate modification of more than two residues greatly destabilized the RNAs in vitro such that interference activities could not be assayed. Id. at 1081. The authors also tested certain modifications at the 2′-position of the nucleotide sugar in the long siRNA transcripts and found that substituting deoxynucleotides for ribonucleotides produced a substantial decrease in interference activity, especially in the case of Uridine to Thymidine and/or Cytidine to deoxy-Cytidine substitutions. Id. In addition, the authors tested certain base modifications, including substituting, in sense and antisense strands of the siRNA, 4-thiouracil, 5-bromouracil, 5-iodouracil, and 3-(aminoallyl)uracil for uracil, and inosine for guanosine. Whereas 4-thiouracil and 5-bromouracil substitution appeared to be tolerated, Parrish reported that inosine produced a substantial decrease in interference activity when incorporated in either strand. Parrish also reported that incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in a substantial decrease in RNAi activity as well.  
         [0009]     The use of longer dsRNA has been described. For example, Beach et al., International PCT Publication No. WO 01/68836, describes specific methods for attenuating gene expression using endogenously-derived dsRNA. Tuschl et al., International PCT Publication No. WO 01/75164, describe a  Drosophila  in vitro RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001 , Chem. Biochem.,  2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due to the danger of activating interferon response. Li et al., International PCT Publication No. WO 00/44914, describe the use of specific long (141 bp-488 bp) enzymatically synthesized or vector expressed dsRNAs for attenuating the expression of certain target genes. Zernicka-Goetz et al., International PCT Publication No. WO 01/36646, describe certain methods for inhibiting the expression of particular genes in mammalian cells using certain long (550 bp-714 bp), enzymatically synthesized or vector expressed dsRNA molecules. Fire et al., International PCT Publication No. WO 99/32619, describe particular methods for introducing certain long dsRNA molecules into cells for use in inhibiting gene expression in nematodes. Plaetinck et al., International PCT Publication No. WO 00/01846, describe certain methods for identifying specific genes responsible for conferring a particular phenotype in a cell using specific long dsRNA molecules. Mello et al., International PCT Publication No. WO 01/29058, describe the identification of specific genes involved in dsRNA-mediated RNAi. Pachuck et al., International PCT Publication No. WO 00/63364, describe certain long (at least 200 nucleotide) dsRNA constructs. Deschamps Depaillette et al., International PCT Publication No. WO 99/07409, describe specific compositions consisting of particular dsRNA molecules combined with certain anti-viral agents. Waterhouse et al., International PCT Publication No. 99/53050 and 1998, PNAS, 95, 13959-13964, describe certain methods for decreasing the phenotypic expression of a nucleic acid in plant cells using certain dsRNAs. Driscoll et al., International PCT Publication No. WO 01/49844, describe specific DNA expression constructs for use in facilitating gene silencing in targeted organisms.  
         [0010]     Others have reported on various RNAi and gene-silencing systems. For example, Parrish et al., 2000 , Molecular Cell,  6, 1077-1087, describe specific chemically-modified dsRNA constructs targeting the unc-22 gene of  C. elegans . Grossniklaus, International PCT Publication No. WO 01/38551, describes certain methods for regulating polycomb gene expression in plants using certain dsRNAs. Churikov et al., International PCT Publication No. WO 01/42443, describe certain methods for modifying genetic characteristics of an organism using certain dsRNAs. Cogoni et al., International PCT Publication No. WO 01/53475, describe certain methods for isolating a  Neurospora  silencing gene and uses thereof. Reed et al., International PCT Publication No. WO 01/68836, describe certain methods for gene silencing in plants. Honer et al., International PCT Publication No. WO 01/70944, describe certain methods of drug screening using transgenic nematodes as Parkinson&#39;s Disease models using certain dsRNAs. Deak et al., International PCT Publication No. WO 01/72774, describe certain  Drosophila -derived gene products that may be related to RNAi in  Drosophila . Arndt et al., International PCT Publication No. WO 01/92513 describe certain methods for mediating gene suppression by using factors that enhance RNAi. Tuschl et al., International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs. Pachuk et al., International PCT Publication No. WO 00/63364, and Satishchandran et al., International PCT Publication No. WO 01/04313, describe certain methods and compositions for inhibiting the function of certain polynucleotide sequences using certain long (over 250 bp), vector expressed dsRNAs. Echeverri et al., International PCT Publication No. WO 02/38805, describe certain  C. elegans  genes identified via RNAi. Kreutzer et al., International PCT Publications Nos. WO 02/055692, WO 02/055693, and EP 1144623 B1 describes certain methods for inhibiting gene expression using dsRNA. Graham et al., International PCT Publications Nos. WO 99/49029 and WO 01/70949, and AU 4037501 describe certain vector expressed siRNA molecules. Fire et al., U.S. Pat. No. 6,506,559, describe certain methods for inhibiting gene expression in vitro using certain long dsRNA (299 bp-1033 bp) constructs that mediate RNAi. Martinez et al., 2002 , Cell,  110, 563-574, describe certain single stranded siRNA constructs, including certain 5′-phosphorylated single stranded siRNAs that mediate RNA interference in Hela cells. Harborth et al., 2003, Antisense &amp; Nucleic Acid Drug Development, 13, 83-105, describe certain chemically and structurally modified siRNA molecules. Chiu and Rana, 2003, RNA, 9, 1034-1048, describe certain chemically and structurally modified siRNA molecules. Woolf et al., International PCT Publication Nos. WO 03/064626 and WO 03/064625 describe certain chemically modified dsRNA constructs.  
       SUMMARY OF THE INVENTION  
       [0011]     This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of interleukin and/or interleukin receptor genes.  
         [0012]     A siNA of the invention can be unmodified or chemically-modified. A siNA of the instant invention can be chemically synthesized, expressed from a vector or enzymatically synthesized. The instant invention also features various chemically-modified synthetic short interfering nucleic acid (siNA) molecules capable of modulating interleukin and/or interleukin receptor gene expression or activity in cells by RNA interference (RNAi). The use of chemically-modified siNA improves various properties of native siNA molecules through increased resistance to nuclease degradation in vivo and/or through improved cellular uptake. Further, contrary to earlier published studies, siNA having multiple chemical modifications retains its RNAi activity. The siNA molecules of the instant invention provide useful reagents and methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.  
         [0013]     In one embodiment, the invention features one or more siNA molecules and methods that independently or in combination modulate the expression of interleukin and/or interleukin receptor genes encoding proteins, such as proteins comprising interleukins (e.g., IL-1-IL-27) and interleukin receptors (e.g., IL-1R-IL-27R), such as genes encoding sequences comprising those sequences referred to by GenBank Accession Nos. shown in Table I, referred to herein generally as interleukin and/or interleukin receptor. The description below of the various aspects and embodiments of the invention is provided with reference to exemplary interleukin and interleukin receptor genes referred to herein as interleukin and/or interleukin receptor. However, the various aspects and embodiments are also directed to other interleukin and/or interleukin receptor genes, such as interleukin and/or interleukin receptor homolog genes, transcript variants, and polymorphisms (e.g., single nucleotide polymorphism, (SNPs)) associated with certain interleukin and/or interleukin receptor genes, for example genes associated with diseases, traits, or conditions described herein or otherwise known in the art. As such, the various aspects and embodiments are also directed to other genes that are involved in interleukin and/or interleukin receptor mediated pathways of signal transduction or gene expression. These additional genes can be analyzed for target sites using the methods described for interleukin and/or interleukin receptor genes herein. Thus, the modulation of other genes and the effects of such modulation of the other genes can be performed, determined, and measured as described herein.  
         [0014]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene, wherein said siNA molecule comprises about 19 to about 21 base pairs.  
         [0015]     In one embodiment, the invention features a siNA molecule that down-regulates expression of a interleukin and/or interleukin receptor gene, for example, wherein the interleukin and/or interleukin receptor gene comprises interleukin and/or interleukin receptor encoding sequence. In one embodiment, the invention features a siNA molecule that down-regulates expression of a interleukin and/or interleukin receptor gene, for example, wherein the interleukin and/or interleukin receptor gene comprises interleukin and/or interleukin receptor non-coding sequence or regulatory elements involved in interleukin and/or interleukin receptor gene expression.  
         [0016]     In one embodiment, a siNA of the invention is used to inhibit the expression of interleukin and/or interleukin receptor genes or a interleukin and/or interleukin receptor gene family, wherein the genes or gene family sequences share sequence homology. Such homologous sequences can be identified as is known in the art, for example using sequence alignments. siNA molecules can be designed to target such homologous sequences, for example using perfectly complementary sequences or by incorporating non-canonical base pairs, for example mismatches and/or wobble base pairs, that can provide additional target sequences. In instances where mismatches are identified, non-canonical base pairs, for example mismatches and/or wobble bases, can be used to generate siNA molecules that target both more than one gene sequences. In a non-limiting example, non-canonical base pairs such as UU and CC base pairs are used to generate siNA molecules that are capable of targeting sequences for differing interleukin and/or interleukin receptor targets that share sequence homology (e.g., differing interleukin genes or differing allelic variants thereof). As such, one advantage of using siNAs of the invention is that a single siNA can be designed to include nucleic acid sequence that is complementary to the nucleotide sequence that is conserved between the homologous genes. In this approach, a single siNA can be used to inhibit expression of more than one interleukin and/or interleukin receptor gene instead of using more than one siNA molecule to target the different genes.  
         [0017]     In one embodiment, the invention features a siNA molecule having RNAi activity against interleukin and/or interleukin receptor RNA, wherein the siNA molecule comprises a sequence complementary to any RNA having interleukin and/or interleukin receptor encoding sequence, such as those sequences having GenBank Accession Nos. shown in Table I. In another embodiment, the invention features a siNA molecule having RNAi activity against interleukin and/or interleukin receptor RNA, wherein the siNA molecule comprises a sequence complementary to an RNA having variant interleukin and/or interleukin receptor encoding sequence, for example other mutant interleukin and/or interleukin receptor genes not shown in Table I but known in the art to be associated with diseases, traits, or conditions described herein or otherwise known in the art. Chemical modifications as shown in Tables III and IV or otherwise described herein can be applied to any siNA construct of the invention. In another embodiment, a siNA molecule of the invention includes a nucleotide sequence that can interact with nucleotide sequence of a interleukin and/or interleukin receptor gene and thereby mediate silencing of interleukin and/or interleukin receptor gene expression, for example, wherein the siNA mediates regulation of interleukin and/or interleukin receptor gene expression by cellular processes that modulate the chromatin structure or methylation patterns of the interleukin and/or interleukin receptor gene and prevent transcription of the interleukin and/or interleukin receptor gene.  
         [0018]     In one embodiment, siNA molecules of the invention are used to down regulate or inhibit the expression of interleukin and/or interleukin receptor proteins arising from interleukin and/or interleukin receptor haplotype polymorphisms that are associated with a disease or condition, (e.g., proliferative, inflammatory, autoimmune, respiratory, pulmonary, cardiovascular, neurodegenerative diseases). Analysis of interleukin and/or interleukin receptor genes, or interleukin and/or interleukin receptor protein or RNA levels can be used to identify subjects with such polymorphisms or those subjects who are at risk of developing traits, conditions, or diseases described herein. These subjects are amenable to treatment, for example, treatment with siNA molecules of the invention and any other composition useful in treating diseases related to interleukin and/or interleukin receptor gene expression. As such, analysis of interleukin and/or interleukin receptor protein or RNA levels can be used to determine treatment type and the course of therapy in treating a subject. Monitoring of interleukin and/or interleukin receptor protein or RNA levels can be used to predict treatment outcome and to determine the efficacy of compounds and compositions that modulate the level and/or activity of certain interleukin and/or interleukin receptor proteins associated with a trait, condition, or disease.  
         [0019]     In one embodiment of the invention a siNA molecule comprises an antisense strand comprising a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof encoding a interleukin and/or interleukin receptor protein. The siNA further comprises a sense strand, wherein said sense strand comprises a nucleotide sequence of a interleukin and/or interleukin receptor gene or a portion thereof.  
         [0020]     In another embodiment, the invention features a siNA molecule comprising a nucleotide sequence in the antisense region of the siNA molecule that is complementary to a nucleotide sequence or portion of sequence of a interleukin and/or interleukin receptor gene. In another embodiment, the invention features a siNA molecule comprising a region, for example, the antisense region of the siNA construct, complementary to a sequence comprising a interleukin and/or interleukin receptor gene sequence or a portion thereof.  
         [0021]     In one embodiment, the antisense region of interleukin and/or interleukin receptor siNA constructs comprises a sequence complementary to sequence having any of SEQ ID NOs. 1-81, 163-213, 265-464, 665-735, 807-1029, or 1253-1260. In one embodiment, the antisense region of interleukin and/or interleukin receptor constructs comprises sequence having any of SEQ ID NOs. 82-162, 214-264, 465-664, 736-806, 1030-1252, 1319-1326, 1335-1342, 1351-1358, 1367-1374, 1383-1406, 1415-1422, 1431-1438, 1447-1454, 1463-1470, 1479-1502, 1511-1518, 1527-1534, 1543-1550, 1559-1566, 1575-1598, 1607-1614, 1623-1630, 1649-1656, 1665-1682, 1691-1714, 1723-1730, 1739-1746, 1755-1762, 1771-1778, 1787-1810, 1812, 1814, 1816, 1819, 1821, 1823, 1825, or 1828. In another embodiment, the sense region of interleukin and/or interleukin receptor constructs comprises sequence having any of SEQ ID NOs. 1-81, 163-213, 265-464, 665-735, 807-1029, 1253-1260, 1311-1318, 1327-1334, 1343-1350, 1359-1366, 1375-1382, 1269-1276, 1407-1414, 1423-1430, 1439-1446, 1455-1462, 1471-1478, 1277-1284, 1503-1510, 1519-1526, 1535-1542, 1551-1558, 1567-1574, 1285-1292, 1599-1606, 1615-1622, 1631-1648, 1657-1664, 1683-1690, 1303-1310, 1715-1722, 1731-1738, 1747-1754, 1763-1770, 1779-1786, 1811, 1813, 1815, 1817, 1818, 1820, 1822, 1824, 1826, or 1827.  
         [0022]     In one embodiment, a siNA molecule of the invention comprises any of SEQ ID NOs. 1-1828. The sequences shown in SEQ ID NOs: 1-1828 are not limiting. A siNA molecule of the invention can comprise any contiguous interleukin and/or interleukin receptor sequence (e.g., about 19 to about 25, or about 19, 20, 21, 22, 23, 24, or 25 contiguous interleukin and/or interleukin receptor nucleotides).  
         [0023]     In yet another embodiment, the invention features a siNA molecule comprising a sequence, for example, the antisense sequence of the siNA construct, complementary to a sequence or portion of sequence comprising sequence represented by GenBank Accession Nos. shown in Table I. Chemical modifications in Tables III and IV and described herein can be applied to any siNA construct of the invention.  
         [0024]     In one embodiment of the invention a siNA molecule comprises an antisense strand having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein the antisense strand is complementary to a RNA sequence encoding a interleukin and/or interleukin receptor protein, and wherein said siNA further comprises a sense strand having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, and wherein said sense strand and said antisense strand are distinct nucleotide sequences with at least about 19 complementary nucleotides.  
         [0025]     In another embodiment of the invention a siNA molecule of the invention comprises an antisense region having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein the antisense region is complementary to a RNA sequence encoding a interleukin and/or interleukin receptor protein, and wherein said siNA further comprises a sense region having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein said sense region and said antisense region comprise a linear molecule with at least about 19 complementary nucleotides.  
         [0026]     In one embodiment, a siNA molecule of the invention has RNAi activity that modulates expression of RNA encoded by a interleukin and/or interleukin receptor gene. Because interleukin and/or interleukin receptor genes can share some degree of sequence homology with each other, siNA molecules can be designed to target a class of interleukin and/or interleukin receptor genes or alternately specific interleukin and/or interleukin receptor genes (e.g., polymorphic variants) by selecting sequences that are either shared amongst different interleukin and/or interleukin receptor targets or alternatively that are unique for a specific interleukin and/or interleukin receptor target. Therefore, in one embodiment, the siNA molecule can be designed to target conserved regions of interleukin and/or interleukin receptor RNA sequences having homology among several interleukin and/or interleukin receptor gene variants so as to target a class of interleukin and/or interleukin receptor genes with one siNA molecule. Accordingly, in one embodiment, the siNA molecule of the invention modulates the expression of one or both interleukin and/or interleukin receptor alleles in a subject. In another embodiment, the siNA molecule can be designed to target a sequence that is unique to a specific interleukin and/or interleukin receptor RNA sequence (e.g., a single interleukin and/or interleukin receptor allele or interleukin and/or interleukin receptor single nucleotide polymorphism (SNP)) due to the high degree of specificity that the siNA molecule requires to mediate RNAi activity.  
         [0027]     In one embodiment, nucleic acid molecules of the invention that act as mediators of the RNA interference gene silencing response are double-stranded nucleic acid molecules. In another embodiment, the siNA molecules of the invention consist of duplex nucleic acid molecules containing about 19 base pairs between oligonucleotides comprising about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides. In yet another embodiment, siNA molecules of the invention comprise duplex nucleic acid molecules with overhanging ends of about about 1 to about 3 (e.g., about 1, 2, or 3) nucleotides, for example, about 21-nucleotide duplexes with about 19 base pairs and 3′-terminal mononucleotide, dinucleotide, or trinucleotide overhangs.  
         [0028]     In one embodiment, the invention features one or more chemically-modified siNA constructs having specificity for interleukin and/or interleukin receptor expressing nucleic acid molecules, such as RNA encoding a interleukin and/or interleukin receptor protein. Non-limiting examples of such chemical modifications include without limitation phosphorothioate internucleotide linkages, 2′-deoxyribonucleotides, 2′-O-methyl ribonucleotides, 2′-deoxy-2′-fluoro ribonucleotides, “universal base” nucleotides, “acyclic” nucleotides, 5-C-methyl nucleotides, and terminal glyceryl and/or inverted deoxy abasic residue incorporation. These chemical modifications, when used in various siNA constructs, are shown to preserve RNAi activity in cells while at the same time, dramatically increasing the serum stability of these compounds. Furthermore, contrary to the data published by Parrish et al., supra, applicant demonstrates that multiple (greater than one) phosphorothioate substitutions are well-tolerated and confer substantial increases in serum stability for modified siNA constructs.  
         [0029]     In one embodiment, a siNA molecule of the invention comprises modified nucleotides while maintaining the ability to mediate RNAi. The modified nucleotides can be used to improve in vitro or in vivo characteristics such as stability, activity, and/or bioavailability. For example, a siNA molecule of the invention can comprise modified nucleotides as a percentage of the total number of nucleotides present in the siNA molecule. As such, a siNA molecule of the invention can generally comprise about 5% to about 100% modified nucleotides (e.g., about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified nucleotides). The actual percentage of modified nucleotides present in a given siNA molecule will depend on the total number of nucleotides present in the siNA. If the siNA molecule is single stranded, the percent modification can be based upon the total number of nucleotides present in the single stranded siNA molecules. Likewise, if the siNA molecule is double stranded, the percent modification can be based upon the total number of nucleotides present in the sense strand, antisense strand, or both the sense and antisense strands.  
         [0030]     One aspect of the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene. In one embodiment, the double stranded siNA molecule comprises one or more chemical modifications and each strand of the double-stranded siNA is about 21 nucleotides long. In one embodiment, the double-stranded siNA molecule does not contain any ribonucleotides. In another embodiment, the double-stranded siNA molecule comprises one or more ribonucleotides. In one embodiment, each strand of the double-stranded siNA molecule comprises about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein each strand comprises about 19 nucleotides that are complementary to the nucleotides of the other strand. In one embodiment, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof of the interleukin and/or interleukin receptor gene, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence of the interleukin and/or interleukin receptor gene or a portion thereof.  
         [0031]     In another embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene comprising an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of the interleukin and/or interleukin receptor gene or a portion thereof, and a sense region, wherein the sense region comprises a nucleotide sequence substantially similar to the nucleotide sequence of the interleukin and/or interleukin receptor gene or a portion thereof. In one embodiment, the antisense region and the sense region each comprise about 19 to about 23 (e.g. about 19, 20, 21, 22, or 23) nucleotides, wherein the antisense region comprises about 19 nucleotides that are complementary to nucleotides of the sense region.  
         [0032]     In another embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene comprising a sense region and an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by the interleukin and/or interleukin receptor gene or a portion thereof and the sense region comprises a nucleotide sequence that is complementary to the antisense region.  
         [0033]     In one embodiment, a siNA molecule of the invention comprises blunt ends, i.e., ends that do not include any overhanging nucleotides. For example, a siNA molecule comprising modifications described herein (e.g., comprising nucleotides having Formulae I-VII or siNA constructs comprising “Stab 00”-“Stab 25” (Table IV) or any combination thereof (see Table IV)) and/or any length described herein can comprise blunt ends or ends with no overhanging nucleotides.  
         [0034]     In one embodiment, any siNA molecule of the invention can comprise one or more blunt ends, i.e. where a blunt end does not have any overhanging nucleotides. In one embodiment, the blunt ended siNA molecule has a number of base pairs equal to the number of nucleotides present in each strand of the siNA molecule. In another embodiment, the siNA molecule comprises one blunt end, for example wherein the 5′-end of the antisense strand and the 3′-end of the sense strand do not have any overhanging nucleotides. In another example, the siNA molecule comprises one blunt end, for example wherein the 3′-end of the antisense strand and the 5′-end of the sense strand do not have any overhanging nucleotides. In another example, a siNA molecule comprises two blunt ends, for example wherein the 3′-end of the antisense strand and the 5′-end of the sense strand as well as the 5′-end of the antisense strand and 3′-end of the sense strand do not have any overhanging nucleotides. A blunt ended siNA molecule can comprise, for example, from about 18 to about 30 nucleotides (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). Other nucleotides present in a blunt ended siNA molecule can comprise mismatches, bulges, loops, or wobble base pairs, for example, to modulate the activity of the siNA molecule to mediate RNA interference.  
         [0035]     By “blunt ends” is meant symmetric termini or termini of a double stranded siNA molecule having no overhanging nucleotides. The two strands of a double stranded siNA molecule align with each other without over-hanging nucleotides at the termini. For example, a blunt ended siNA construct comprises terminal nucleotides that are complementary between the sense and antisense regions of the siNA molecule.  
         [0036]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene, wherein the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule. The sense region can be connected to the antisense region via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker.  
         [0037]     In one embodiment, the invention features double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene, wherein the siNA molecule comprises about 19 to about 21 base pairs, and wherein each strand of the siNA molecule comprises one or more chemical modifications. In another embodiment, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence of a interleukin and/or interleukin receptor gene or a portion thereof, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or a portion thereof of the interleukin and/or interleukin receptor gene. In another embodiment, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence of a interleukin and/or interleukin receptor gene or portion thereof, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or portion thereof of the interleukin and/or interleukin receptor gene. In another embodiment, each strand of the siNA molecule comprises about 19 to about 23 nucleotides, and each strand comprises at least about 19 nucleotides that are complementary to the nucleotides of the other strand. The interleukin and/or interleukin receptor gene can comprise, for example, sequences referred to in Table I.  
         [0038]     In one embodiment, a siNA molecule of the invention comprises no ribonucleotides. In another embodiment, a siNA molecule of the invention comprises ribonucleotides.  
         [0039]     In one embodiment, a siNA molecule of the invention comprises an antisense region comprising a nucleotide sequence that is complementary to a nucleotide sequence of a interleukin and/or interleukin receptor gene or a portion thereof, and the siNA further comprises a sense region comprising a nucleotide sequence substantially similar to the nucleotide sequence of the interleukin and/or interleukin receptor gene or a portion thereof. In another embodiment, the antisense region and the sense region each comprise about 19 to about 23 nucleotides and the antisense region comprises at least about 19 nucleotides that are complementary to nucleotides of the sense region. The interleukin and/or interleukin receptor gene can comprise, for example, sequences referred to in Table I.  
         [0040]     In one embodiment, a siNA molecule of the invention comprises a sense region and an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by a interleukin and/or interleukin receptor gene, or a portion thereof, and the sense region comprises a nucleotide sequence that is complementary to the antisense region. In one embodiment, the siNA molecule is assembled from two separate oligonucleotide fragments, wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule. In another embodiment, the sense region is connected to the antisense region via a linker molecule. In another embodiment, the sense region is connected to the antisense region via a linker molecule, such as a nucleotide or non-nucleotide linker. The interleukin and/or interleukin receptor gene can comprise, for example, sequences referred in to Table I.  
         [0041]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene comprising a sense region and an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by the interleukin and/or interleukin receptor gene or a portion thereof and the sense region comprises a nucleotide sequence that is complementary to the antisense region, and wherein the siNA molecule has one or more modified pyrimidine and/or purine nucleotides. In one embodiment, the pyrimidine nucleotides in the sense region are 2′-O-methyl pyrimidine nucleotides or 2′-deoxy-2′-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2′-deoxy purine nucleotides. In another embodiment, the pyrimidine nucleotides in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2′-O-methyl purine nucleotides. In another embodiment, the pyrimidine nucleotides in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2′-deoxy purine nucleotides. In one embodiment, the pyrimidine nucleotides in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides and the purine nucleotides present in the antisense region are 2′-O-methyl or 2′-deoxy purine nucleotides. In another embodiment of any of the above-described siNA molecules, any nucleotides present in a non-complementary region of the sense strand (e.g. overhang region) are 2′-deoxy nucleotides.  
         [0042]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene, wherein the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule, and wherein the fragment comprising the sense region includes a terminal cap moiety at the 5′-end, the 3′-end, or both of the 5′ and 3′ ends of the fragment. In one embodiment, the terminal cap moiety is an inverted deoxy abasic moiety or glyceryl moiety. In one embodiment, each of the two fragments of the siNA molecule comprise about 21 nucleotides.  
         [0043]     In one embodiment, the invention features a siNA molecule comprising at least one modified nucleotide, wherein the modified nucleotide is a 2′-deoxy-2′-fluoro nucleotide. The siNA can be, for example, of length between about 12 and about 36 nucleotides. In one embodiment, all pyrimidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro pyrimidine nucleotides. In one embodiment, the modified nucleotides in the siNA include at least one 2′-deoxy-2′-fluoro cytidine or 2′-deoxy-2′-fluoro uridine nucleotide. In another embodiment, the modified nucleotides in the siNA include at least one 2′-fluoro cytidine and at least one 2′-deoxy-2′-fluoro uridine nucleotides. In one embodiment, all uridine nucleotides present in the siNA are 2′-deoxy-2′-fluoro uridine nucleotides. In one embodiment, all cytidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro cytidine nucleotides. In one embodiment, all adenosine nucleotides present in the siNA are 2′-deoxy-2′-fluoro adenosine nucleotides. In one embodiment, all guanosine nucleotides present in the siNA are 2′-deoxy-2′-fluoro guanosine nucleotides. The siNA can further comprise at least one modified internucleotidic linkage, such as phosphorothioate linkage. In one embodiment, the 2′-deoxy-2′-fluoronucleotides are present at specifically selected locations in the siNA that are sensitive to cleavage by ribonucleases, such as locations having pyrimidine nucleotides.  
         [0044]     In one embodiment, the invention features a method of increasing the stability of a siNA molecule against cleavage by ribonucleases comprising introducing at least one modified nucleotide into the siNA molecule, wherein the modified nucleotide is a 2′-deoxy-2′-fluoro nucleotide. In one embodiment, all pyrimidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro pyrimidine nucleotides. In one embodiment, the modified nucleotides in the siNA include at least one 2′-deoxy-2′-fluoro cytidine or 2′-deoxy-2′-fluoro uridine nucleotide. In another embodiment, the modified nucleotides in the siNA include at least one 2′-fluoro cytidine and at least one 2′-deoxy-2′-fluoro uridine nucleotides. In one embodiment, all uridine nucleotides present in the siNA are 2′-deoxy-2′-fluoro uridine nucleotides. In one embodiment, all cytidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro cytidine nucleotides. In one embodiment, all adenosine nucleotides present in the siNA are 2′-deoxy-2′-fluoro adenosine nucleotides. In one embodiment, all guanosine nucleotides present in the siNA are 2′-deoxy-2′-fluoro guanosine nucleotides. The siNA can further comprise at least one modified internucleotidic linkage, such as phosphorothioate linkage. In one embodiment, the 2′-deoxy-2′-fluoronucleotides are present at specifically selected locations in the siNA that are sensitive to cleavage by ribonucleases, such as locations having pyrimidine nucleotides.  
         [0045]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene comprising a sense region and an antisense region, wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by the interleukin and/or interleukin receptor gene or a portion thereof and the sense region comprises a nucleotide sequence that is complementary to the antisense region, and wherein the purine nucleotides present in the antisense region comprise 2′-deoxy-purine nucleotides. In an alternative embodiment, the purine nucleotides present in the antisense region comprise 2′-O-methyl purine nucleotides. In either of the above embodiments, the antisense region can comprise a phosphorothioate internucleotide linkage at the 3′ end of the antisense region. Alternatively, in either of the above embodiments, the antisense region can comprise a glyceryl modification at the 3′ end of the antisense region. In another embodiment of any of the above-described siNA molecules, any nucleotides present in a non-complementary region of the antisense strand (e.g. overhang region) are 2′-deoxy nucleotides.  
         [0046]     In one embodiment, the antisense region of a siNA molecule of the invention comprises sequence complementary to a portion of a interleukin and/or interleukin receptor transcript having sequence unique to a particular interleukin and/or interleukin receptor disease related allele, such as sequence comprising a single nucleotide polymorphism (SNP) associated with the disease specific allele. As such, the antisense region of a siNA molecule of the invention can comprise sequence complementary to sequences that are unique to a particular allele to provide specificity in mediating selective RNAi against the disease, condition, or trait related allele.  
         [0047]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a interleukin and/or interleukin receptor gene, wherein the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule. In another embodiment about 19 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule and wherein at least two 3′ terminal nucleotides of each fragment of the siNA molecule are not base-paired to the nucleotides of the other fragment of the siNA molecule. In one embodiment, each of the two 3′ terminal nucleotides of each fragment of the siNA molecule is a 2′-deoxy-pyrimidine nucleotide, such as a 2′-deoxy-thymidine. In another embodiment, all 21 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule. In another embodiment, about 19 nucleotides of the antisense region are base-paired to the nucleotide sequence or a portion thereof of the RNA encoded by the interleukin and/or interleukin receptor gene. In another embodiment, about 21 nucleotides of the antisense region are base-paired to the nucleotide sequence or a portion thereof of the RNA encoded by the interleukin and/or interleukin receptor gene. In any of the above embodiments, the 5′-end of the fragment comprising said antisense region can optionally include a phosphate group.  
         [0048]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of a interleukin and/or interleukin receptor RNA sequence (e.g., wherein said target RNA sequence is encoded by a interleukin and/or interleukin receptor gene involved in the interleukin and/or interleukin receptor pathway), wherein the siNA molecule does not contain any ribonucleotides and wherein each strand of the double-stranded siNA molecule is about 21 nucleotides long. Examples of non-ribonucleotide containing siNA constructs are combinations of stabilization chemistries shown in Table IV in any combination of Sense/Antisense chemistries, such as Stab 7/8, Stab 7/11, Stab 8/8, Stab 18/8, Stab 18/11, Stab 12/13, Stab 7/13, Stab 18/13, Stab 7/19, Stab 8/19, Stab 18/19, Stab 7/20, Stab 8/20, or Stab 18/20.  
         [0049]     In one embodiment, the invention features a chemically synthesized double stranded RNA molecule that directs cleavage of a interleukin and/or interleukin receptor RNA via RNA interference, wherein each strand of said RNA molecule is about 21 to about 23 nucleotides in length; one strand of the RNA molecule comprises nucleotide sequence having sufficient complementarity to the interleukin and/or interleukin receptor RNA for the RNA molecule to direct cleavage of the interleukin and/or interleukin receptor RNA via RNA interference; and wherein at least one strand of the RNA molecule comprises one or more chemically modified nucleotides described herein, such as deoxynucleotides, 2′-O-methyl nucleotides, 2′-deoxy-2′-fluoro nucloetides, 2′-O-methoxyethyl nucleotides etc.  
         [0050]     In one embodiment, the invention features a medicament comprising a siNA molecule of the invention.  
         [0051]     In one embodiment, the invention features an active ingredient comprising a siNA molecule of the invention.  
         [0052]     In one embodiment, the invention features the use of a double-stranded short interfering nucleic acid (siNA) molecule to down-regulate expression of a interleukin and/or interleukin receptor gene, wherein the siNA molecule comprises one or more chemical modifications and each strand of the double-stranded siNA is about 18 to about 28 or more (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 or more) nucleotides long.  
         [0053]     In one embodiment, the invention features the use of a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a interleukin and/or interleukin receptor gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of interleukin and/or interleukin receptor RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification.  
         [0054]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a interleukin and/or interleukin receptor gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of interleukin and/or interleukin receptor RNA or a portion thereof, wherein the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification.  
         [0055]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a interleukin and/or interleukin receptor gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of interleukin and/or interleukin receptor RNA that encodes a protein or portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification. In one embodiment, each strand of the siNA molecule comprises about 18 to about 29 or more (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 or more) nucleotides, wherein each strand comprises at least about 18 nucleotides that are complementary to the nucleotides of the other strand. In one embodiment, the siNA molecule is assembled from two oligonucleotide fragments, wherein one fragment comprises the nucleotide sequence of the antisense strand of the siNA molecule and a second fragment comprises nucleotide sequence of the sense region of the siNA molecule. In one embodiment, the sense strand is connected to the antisense strand via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker. In a further embodiment, the pyrimidine nucleotides present in the sense strand are 2′-deoxy-2′fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2′-deoxy purine nucleotides. In another embodiment, the pyrimidine nucleotides present in the sense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2′-O-methyl purine nucleotides. In still another embodiment, the pyrimidine nucleotides present in the antisense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and any purine nucleotides present in the antisense strand are 2′-deoxy purine nucleotides. In another embodiment, the antisense strand comprises one or more 2′-deoxy-2′-fluoro pyrimidine nucleotides and one or more 2′-O-methyl purine nucleotides. In another embodiment, the pyrimidine nucleotides present in the antisense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and any purine nucleotides present in the antisense strand are 2′-O-methyl purine nucleotides. In a further embodiment the sense strand comprises a 3′-end and a 5′-end, wherein a terminal cap moiety (e.g., an inverted deoxy abasic moiety or inverted deoxy nucleotide moiety such as inverted thymidine) is present at the 5′-end, the 3′-end, or both of the 5′ and 3′ ends of the sense strand. In another embodiment, the antisense strand comprises a phosphorothioate internucleotide linkage at the 3′ end of the antisense strand. In another embodiment, the antisense strand comprises a glyceryl modification at the 3′ end. In another embodiment, the 5′-end of the antisense strand optionally includes a phosphate group.  
         [0056]     In any of the above-described embodiments of a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a interleukin and/or interleukin receptor gene, wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, each of the two strands of the siNA molecule can comprise about 21 nucleotides. In one embodiment, about 21 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule. In another embodiment, about 19 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule, wherein at least two 3′ terminal nucleotides of each strand of the siNA molecule are not base-paired to the nucleotides of the other strand of the siNA molecule. In another embodiment, each of the two 3′ terminal nucleotides of each fragment of the siNA molecule is a 2′-deoxy-pyrimidine, such as 2′-deoxy-thymidine. In one embodiment, each strand of the siNA molecule is base-paired to the complementary nucleotides of the other strand of the siNA molecule. In one embodiment, about 19 nucleotides of the antisense strand are base-paired to the nucleotide sequence of the interleukin and/or interleukin receptor RNA or a portion thereof. In one embodiment, about 21 nucleotides of the antisense strand are base-paired to the nucleotide sequence of the interleukin and/or interleukin receptor RNA or a portion thereof.  
         [0057]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a interleukin and/or interleukin receptor gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of interleukin and/or interleukin receptor RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein the 5′-end of the antisense strand optionally includes a phosphate group.  
         [0058]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a interleukin and/or interleukin receptor gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of interleukin and/or interleukin receptor RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein the nucleotide sequence or a portion thereof of the antisense strand is complementary to a nucleotide sequence of the untranslated region or a portion thereof of the interleukin and/or interleukin receptor RNA.  
         [0059]     In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a interleukin and/or interleukin receptor gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of interleukin and/or interleukin receptor RNA or a portion thereof, wherein the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand, wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein the nucleotide sequence of the antisense strand is complementary to a nucleotide sequence of the interleukin and/or interleukin receptor RNA or a portion thereof that is present in the interleukin and/or interleukin receptor RNA.  
         [0060]     In one embodiment, the invention features a composition comprising a siNA molecule of the invention in a pharmaceutically acceptable carrier or diluent.  
         [0061]     In a non-limiting example, the introduction of chemically-modified nucleotides into nucleic acid molecules provides a powerful tool in overcoming potential limitations of in vivo stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically-modified nucleic acid molecules can enable a lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically-modified nucleic acid molecules tend to have a longer half-life in serum. Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving cellular uptake of the nucleic acid molecule. Therefore, even if the activity of a chemically-modified nucleic acid molecule is reduced as compared to a native nucleic acid molecule, for example, when compared to an all-RNA nucleic acid molecule, the overall activity of the modified nucleic acid molecule can be greater than that of the native molecule due to improved stability and/or delivery of the molecule. Unlike native unmodified siNA, chemically-modified siNA can also minimize the possibility of activating interferon activity in humans.  
         [0062]     In any of the embodiments of siNA molecules described herein, the antisense region of a siNA molecule of the invention can comprise a phosphorothioate internucleotide linkage at the 3′-end of said antisense region. In any of the embodiments of siNA molecules described herein, the antisense region can comprise about one to about five phosphorothioate internucleotide linkages at the 5′-end of said antisense region. In any of the embodiments of siNA molecules described herein, the 3′-terminal nucleotide overhangs of a siNA molecule of the invention can comprise ribonucleotides or deoxyribonucleotides that are chemically-modified at a nucleic acid sugar, base, or backbone. In any of the embodiments of siNA molecules described herein, the 3′-terminal nucleotide overhangs can comprise one or more universal base ribonucleotides. In any of the embodiments of siNA molecules described herein, the 3′-terminal nucleotide overhangs can comprise one or more acyclic nucleotides.  
         [0063]     One embodiment of the invention provides an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention in a manner that allows expression of the nucleic acid molecule. Another embodiment of the invention provides a mammalian cell comprising such an expression vector. The mammalian cell can be a human cell. The siNA molecule of the expression vector can comprise a sense region and an antisense region. The antisense region can comprise sequence complementary to a RNA or DNA sequence encoding interleukin and/or interleukin receptor and the sense region can comprise sequence complementary to the antisense region. The siNA molecule can comprise two distinct strands having complementary sense and antisense regions. The siNA molecule can comprise a single strand having complementary sense and antisense regions.  
         [0064]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against interleukin and/or interleukin receptor inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides comprising a backbone modified internucleotide linkage having Formula I:  
                         
        wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or polynucleotide which can be naturally-occurring or chemically-modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, or acetyl and wherein W, X, Y, and Z are optionally not all O. In another embodiment, a backbone modification of the invention comprises a phosphonoacetate and/or thiophosphonoacetate internucleotide linkage (see for example Sheehan et al., 2003 , Nucleic Acids Research,  31, 4109-4118).        
 
         [0066]     The chemically-modified internucleotide linkages having Formula I, for example, wherein any Z, W, X, and/or Y independently comprises a sulphur atom, can be present in one or both oligonucleotide strands of the siNA duplex, for example, in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) chemically-modified internucleotide linkages having Formula I at the 3′-end, the 5′-end, or both of the  3 ′ and 5′-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified internucleotide linkages having Formula I at the 5′-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In another embodiment, a siNA molecule of the invention having internucleotide linkage(s) of Formula I also comprises a chemically-modified nucleotide or non-nucleotide having any of Formulae I-VII.  
         [0067]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against interleukin and/or interleukin receptor inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula II:  
                         
 
 wherein each R3, R4, R5, R6, R7, R8, R10, R 11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I or II; R9 is O, S, CH2, S═O, CHF, or CF2, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA. 
 
         [0068]     The chemically-modified nucleotide or non-nucleotide of Formula II can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula II at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 5′-end of the sense strand, the antisense strand, or both strands. In anther non-limiting example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 3′-end of the sense strand, the antisense strand, or both strands.  
         [0069]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against interleukin and/or interleukin receptor inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula III:  
                         
 
 wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I or II; R9 is O, S, CH2, S═O, CHF, or CF2, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be employed to be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA. 
 
         [0070]     The chemically-modified nucleotide or non-nucleotide of Formula III can be present in one or both oligonucleotide strands of the siNA duplex, for example, in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula III at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotide(s) or non-nucleotide(s) of Formula III at the 5′-end of the sense strand, the antisense strand, or both strands. In anther non-limiting example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotide or non-nucleotide of Formula III at the 3′-end of the sense strand, the antisense strand, or both strands.  
         [0071]     In another embodiment, a siNA molecule of the invention comprises a nucleotide having Formula II or III, wherein the nucleotide having Formula II or III is in an inverted configuration. For example, the nucleotide having Formula II or III is connected to the siNA construct in a 3′-3′,3′-2′,2′-3′, or 5′-5′ configuration, such as at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of one or both siNA strands.  
         [0072]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against interleukin and/or interleukin receptor inside a cell or reconstituted in vitro system, wherein the chemical modification comprises a 5′-terminal phosphate group having Formula IV:  
                         
 
 wherein each X and Y is independently O, S, N, alkyl, substituted alkyl, or alkylhalo; wherein each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, alkylhalo, or acetyl; and wherein W, X, Y and Z are not all 0. 
 
         [0073]     In one embodiment, the invention features a siNA molecule having a 5′-terminal phosphate group having Formula IV on the target-complementary strand, for example, a strand complementary to a target RNA, wherein the siNA molecule comprises an all RNA siNA molecule. In another embodiment, the invention features a siNA molecule having a 5′-terminal phosphate group having Formula IV on the target-complementary strand wherein the siNA molecule also comprises about 1 to about 3 (e.g., about 1, 2, or 3) nucleotide 3′-terminal nucleotide overhangs having about 1 to about 4 (e.g., about 1, 2, 3, or 4) deoxyribonucleotides on the 3′-end of one or both strands. In another embodiment, a 5′-terminal phosphate group having Formula IV is present on the target-complementary strand of a siNA molecule of the invention, for example a siNA molecule having chemical modifications having any of Formulae I-VII.  
         [0074]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against interleukin and/or interleukin receptor inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more phosphorothioate internucleotide linkages. For example, in a non-limiting example, the invention features a chemically-modified short interfering nucleic acid (siNA) having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in one siNA strand. In yet another embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) individually having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in both siNA strands. The phosphorothioate internucleotide linkages can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more phosphorothioate internucleotide linkages at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) consecutive phosphorothioate internucleotide linkages at the 5′-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands.  
         [0075]     In one embodiment, the invention features a siNA molecule, wherein the sense strand comprises one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or about one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 10 or more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2′-deoxy, 2′-O-methyl and/or 2′-deoxy-2′-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends, being present in the same or different strand.  
         [0076]     In another embodiment, the invention features a siNA molecule, wherein the sense strand comprises about 1 to about 5, specifically about 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2′-deoxy, 2′-O-methyl and/or 2′-deoxy-2′-fluoro nucleotides, with or without about 1 to about 5 or more, for example about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends, being present in the same or different strand.  
         [0077]     In one embodiment, the invention features a siNA molecule, wherein the antisense strand comprises one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or about one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 10 or more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2′-deoxy, 2′-O-methyl and/or 2′-deoxy-2′-fluoro nucleotides, with or without one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends, being present in the same or different strand.  
         [0078]     In another embodiment, the invention features a siNA molecule, wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2′-deoxy, 2′-O-methyl and/or 2′-deoxy-2′-fluoro nucleotides, with or without about 1 to about 5, for example about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends, being present in the same or different strand.  
         [0079]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule having about 1 to about 5, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages in each strand of the siNA molecule.  
         [0080]     In another embodiment, the invention features a siNA molecule comprising 2′-5′ internucleotide linkages. The 2′-5′ internucleotide linkage(s) can be at the 3′-end, the 5′end, or both of the 3′- and 5′-ends of one or both siNA sequence strands. In addition, the 2′-5′ internucleotide linkage(s) can be present at various other positions within one or both siNA sequence strands, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a pyrimidine nucleotide in one or both strands of the siNA molecule can comprise a 2′-5′ internucleotide linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a purine nucleotide in one or both strands of the siNA molecule can comprise a 2′-5′ internucleotide linkage.  
         [0081]     In another embodiment, a chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified, wherein each strand is about 18 to about 27 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27) nucleotides in length, wherein the duplex has about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the chemical modification comprises a structure having any of Formulae I-VII. For example, an exemplary chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein each strand consists of about 21 nucleotides, each having a 2-nucleotide 3′-terminal nucleotide overhang, and wherein the duplex has about 19 base pairs. In another embodiment, a siNA molecule of the invention comprises a single stranded hairpin structure, wherein the siNA is about 36 to about 70 (e.g., about 36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having about 42 to about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms a hairpin structure having about 19 base pairs and a 2-nucleotide 3′-terminal nucleotide overhang. In another embodiment, a linear hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. For example, a linear hairpin siNA molecule of the invention is designed such that degradation of the loop portion of the siNA molecule in vivo can generate a double-stranded siNA molecule with 3′-terminal overhangs, such as 3′-terminal nucleotide overhangs comprising about 2 nucleotides.  
         [0082]     In another embodiment, a siNA molecule of the invention comprises a hairpin structure, wherein the siNA is about 25 to about 50 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides in length having about 3 to about 25 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) base pairs, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having about 25 to about 35 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) nucleotides that is chemically-modified with one or more chemical modifications having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms a hairpin structure having about 3 to about 23 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) base pairs and a 5′-terminal phosphate group that can be chemically modified as described herein (for example a 5′-terminal phosphate group having Formula IV). In another embodiment, a linear hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. In one embodiment, a linear hairpin siNA molecule of the invention comprises a loop portion comprising a non-nucleotide linker.  
         [0083]     In another embodiment, a siNA molecule of the invention comprises an asymmetric hairpin structure, wherein the siNA is about 25 to about 50 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides in length having about 3 to about 20 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) base pairs, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having about 25 to about 35 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) nucleotides that is chemically-modified with one or more chemical modifications having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms an asymmetric hairpin structure having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) base pairs and a 5′-terminal phosphate group that can be chemically modified as described herein (for example a 5′-terminal phosphate group having Formula IV). In one embodiment, an asymmetric hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. In another embodiment, an asymmetric hairpin siNA molecule of the invention comprises a loop portion comprising a non-nucleotide linker.  
         [0084]     In another embodiment, a siNA molecule of the invention comprises an asymmetric double stranded structure having separate polynucleotide strands comprising sense and antisense regions, wherein the antisense region is about 16 to about 25 (e.g., about 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length, wherein the sense region is about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides in length, wherein the sense region and the antisense region have at least 3 complementary nucleotides, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises an asymmetric double stranded structure having separate polynucleotide strands comprising sense and antisense regions, wherein the antisense region is about 18 to about 22 (e.g., about 18, 19, 20, 21, or 22) nucleotides in length and wherein the sense region is about 3 to about 15 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) nucleotides in length, wherein the sense region the antisense region have at least 3 complementary nucleotides, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. In another embodiment, the asymmetic double stranded siNA molecule can also have a 5′-terminal phosphate group that can be chemically modified as described herein (for example a 5′-terminal phosphate group having Formula IV).  
         [0085]     In another embodiment, a siNA molecule of the invention comprises a circular nucleic acid molecule, wherein the siNA is about 38 to about 70 (e.g., about 38, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification, which comprises a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a circular oligonucleotide having about 42 to about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the circular oligonucleotide forms a dumbbell shaped structure having about 19 base pairs and 2 loops.  
         [0086]     In another embodiment, a circular siNA molecule of the invention contains two loop motifs, wherein one or both loop portions of the siNA molecule is biodegradable. For example, a circular siNA molecule of the invention is designed such that degradation of the loop portions of the siNA molecule in vivo can generate a double-stranded siNA molecule with 3′-terminal overhangs, such as 3′-terminal nucleotide overhangs comprising about 2 nucleotides.  
         [0087]     In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) abasic moiety, for example a compound having Formula V:  
                         
 
 wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2,0-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I or II; and R9 is O, S, CH2, S═O, CHF, or CF2. 
 
         [0088]     In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) inverted abasic moiety, for example a compound having Formula VI:  
                         
 
 wherein each R3, R4, R5, R6, R7, R8, R0, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2,0-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I or II; R9 is O, S, CH2, S═O, CHF, or CF2, and either R2, R3, R8 or R13 serve as points of attachment to the siNA molecule of the invention. 
 
         [0089]     In another embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) substituted polyalkyl moieties, for example a compound having Formula VII:  
                         
 
 wherein each n is independently an integer from 1 to 12, each R1, R2 and R3 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or a group having Formula I, and R1, R2 or R3 serves as points of attachment to the siNA molecule of the invention. 
 
         [0090]     In another embodiment, the invention features a compound having Formula VII, wherein R1 and R2 are hydroxyl (OH) groups, n=1, and R3 comprises 0 and is the point of attachment to the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of one or both strands of a double-stranded siNA molecule of the invention or to a single-stranded siNA molecule of the invention. This modification is referred to herein as “glyceryl” (for example modification 6 in  FIG. 10 ).  
         [0091]     In another embodiment, a moiety having any of Formula V, VI or VII of the invention is at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of a siNA molecule of the invention. For example, a moiety having Formula V, VI or VII can be present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense strand, the sense strand, or both antisense and sense strands of the siNA molecule. In addition, a moiety having Formula VII can be present at the 3′-end or the 5′-end of a hairpin siNA molecule as described herein.  
         [0092]     In another embodiment, a siNA molecule of the invention comprises an abasic residue having Formula V or VI, wherein the abasic residue having Formula VI or VI is connected to the siNA construct in a 3′-3′,3′-2′,2′-3′, or 5′-5′ configuration, such as at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of one or both siNA strands.  
         [0093]     In one embodiment, a siNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) locked nucleic acid (LNA) nucleotides, for example at the 5′-end, the 3′-end, both of the 5′ and 3′-ends, or any combination thereof, of the siNA molecule.  
         [0094]     In another embodiment, a siNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) acyclic nucleotides, for example at the 5′-end, the 3′-end, both of the 5′ and 3′-ends, or any combination thereof, of the siNA molecule.  
         [0095]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention comprising a sense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the sense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides).  
         [0096]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention comprising a sense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the sense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides), wherein any nucleotides comprising a 3′-terminal nucleotide overhang that are present in said sense region are 2′-deoxy nucleotides.  
         [0097]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention comprising a sense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the sense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides).  
         [0098]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention comprising a sense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), wherein any (e.g., one or more or all) purine nucleotides present in the sense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides), and wherein any nucleotides comprising a 3′-terminal nucleotide overhang that are present in said sense region are 2′-deoxy nucleotides.  
         [0099]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention comprising an antisense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides).  
         [0100]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention comprising an antisense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides), and wherein any nucleotides comprising a 3′-terminal nucleotide overhang that are present in said antisense region are 2′-deoxy nucleotides.  
         [0101]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention comprising an antisense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides).  
         [0102]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention comprising an antisense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides).  
         [0103]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) against interleukin and/or interleukin receptor inside a cell or reconstituted in vitro system comprising a sense region, wherein one or more pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and one or more purine nucleotides present in the sense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides), and an antisense region, wherein one or more pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and one or more purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides). The sense region and/or the antisense region can have a terminal cap modification, such as any modification described herein or shown in  FIG. 10 , that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense and/or antisense sequence. The sense and/or antisense region can optionally further comprise a 3′-terminal nucleotide overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2′-deoxynucleotides. The overhang nucleotides can further comprise one or more (e.g., about 1, 2, 3, 4 or more) phosphorothioate, phosphonoacetate, and/or thiophosphonoacetate internucleotide linkages. Non-limiting examples of these chemically-modified siNAs are shown in  FIGS. 4 and 5  and Tables III and IV herein. In any of these described embodiments, the purine nucleotides present in the sense region are alternatively 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides) and one or more purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides). Also, in any of these embodiments, one or more purine nucleotides present in the sense region are alternatively purine ribonucleotides (e.g., wherein all purine nucleotides are purine ribonucleotides or alternately a plurality of purine nucleotides are purine ribonucleotides) and any purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides). Additionally, in any of these embodiments, one or more purine nucleotides present in the sense region and/or present in the antisense region are alternatively selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides (e.g., wherein all purine nucleotides are selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides or alternately a plurality of purine nucleotides are selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides).  
         [0104]     In another embodiment, any modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger,  Principles of Nucleic Acid Structure , Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, are resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi. Non-limiting examples of nucleotides having a northern configuration include locked nucleic acid (LNA) nucleotides (e.g., 2′-O, 4′-C-methylene-(D-ribofuranosyl) nucleotides); 2′-methoxyethoxy (MOE) nucleotides; 2′-methyl-thio-ethyl, 2′-deoxy-2′-fluoro nucleotides, 2′-deoxy-2′-chloro nucleotides, 2′-azido nucleotides, and 2′-O-methyl nucleotides.  
         [0105]     In one embodiment, the sense strand of a double stranded siNA molecule of the invention comprises a terminal cap moiety, (see for example  FIG. 10 ) such as an inverted deoxyabaisc moiety, at the 3′-end, 5′-end, or both 3′ and 5′-ends of the sense strand.  
         [0106]     In one embodiment, the invention features a chemically-modified short interfering nucleic acid molecule (siNA) capable of mediating RNA interference (RNAi) against interleukin and/or interleukin receptor inside a cell or reconstituted in vitro system, wherein the chemical modification comprises a conjugate covalently attached to the chemically-modified siNA molecule. Non-limiting examples of conjugates contemplated by the invention include conjugates and ligands described in Vargeese et al., U.S. Ser. No. 10/427,160, filed Apr. 30, 2003, incorporated by reference herein in its entirety, including the drawings. In another embodiment, the conjugate is covalently attached to the chemically-modified siNA molecule via a biodegradable linker. In one embodiment, the conjugate molecule is attached at the 3′-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In another embodiment, the conjugate molecule is attached at the 5′-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In yet another embodiment, the conjugate molecule is attached both the 3′-end and 5′-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule, or any combination thereof. In one embodiment, a conjugate molecule of the invention comprises a molecule that facilitates delivery of a chemically-modified siNA molecule into a biological system, such as a cell. In another embodiment, the conjugate molecule attached to the chemically-modified siNA molecule is a polyethylene glycol, human serum albumin, or a ligand for a cellular receptor that can mediate cellular uptake. Examples of specific conjugate molecules contemplated by the instant invention that can be attached to chemically-modified siNA molecules are described in Vargeese et al., U.S. Ser. No. 10/201,394, filed Jul. 22, 2002 incorporated by reference herein. The type of conjugates used and the extent of conjugation of siNA molecules of the invention can be evaluated for improved pharmacokinetic profiles, bioavailability, and/or stability of siNA constructs while at the same time maintaining the ability of the siNA to mediate RNAi activity. As such, one skilled in the art can screen siNA constructs that are modified with various conjugates to determine whether the siNA conjugate complex possesses improved properties while maintaining the ability to mediate RNAi, for example in animal models as are generally known in the art.  
         [0107]     In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule of the invention, wherein the siNA further comprises a nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker that joins the sense region of the siNA to the antisense region of the siNA. In one embodiment, a nucleotide linker of the invention can be a linker of &gt;2 nucleotides in length, for example about 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In another embodiment, the nucleotide linker can be a nucleic acid aptamer. By “aptamer” or “nucleic acid aptamer” as used herein is meant a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that comprises a sequence recognized by the target molecule in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule where the target molecule does not naturally bind to a nucleic acid. The target molecule can be any molecule of interest. For example, the aptamer can be used to bind to a ligand-binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. This is a non-limiting example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art. (See, for example, Gold et al., 1995 , Annu. Rev. Biochem.,  64, 763; Brody and Gold, 2000 , J Biotechnol.,  74, 5; Sun, 2000 , Curr. Opin. Mol. Ther.,  2, 100; Kusser, 2000 , J Biotechnol.,  74, 27; Hermann and Patel, 2000 , Science,  287, 820; and Jayasena, 1999 , Clinical Chemistry,  45, 1628.)  
         [0108]     In yet another embodiment, a non-nucleotide linker of the invention comprises abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds (e.g. polyethylene glycols such as those having between 2 and 100 ethylene glycol units). Specific examples include those described by Seela and Kaiser, Nucleic Acids Res. 1990, 18:6353 and  Nucleic Acids Res.  1987, 15:3113; Cload and Schepartz,  J. Am. Chem. Soc.  1991, 113:6324; Richardson and Schepartz,  J. Am. Chem. Soc.  1991, 113:5109; Ma et al.,  Nucleic Acids Res.  1993, 21:2585 and  Biochemistry  1993, 32:1751; Durand et al.,  Nucleic Acids Res.  1990, 18:6353; McCurdy et al.,  Nucleosides  &amp;  Nucleotides  1991, 10:287; Jschke et al.,  Tetrahedron Lett.  1993, 34:301; Ono et al.,  Biochemistry  1991, 30:9914; Arnold et al., International Publication No. WO 89/02439; Usman et al., International Publication No. WO 95/06731; Dudycz et al., International Publication No. WO 95/11910 and Ferentz and Verdine,  J. Am. Chem. Soc.  1991, 113:4000, all hereby incorporated by reference herein. A “non-nucleotide” further means any group or compound that can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine, for example at the C1 position of the sugar.  
         [0109]     In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein one or both strands of the siNA molecule that are assembled from two separate oligonucleotides do not comprise any ribonucleotides. For example, a siNA molecule can be assembled from a single oligonculeotide where the sense and antisense regions of the siNA comprise separate oligonucleotides that do not have any ribonucleotides (e.g., nucleotides having a 2′-OH group) present in the oligonucleotides. In another example, a siNA molecule can be assembled from a single oligonculeotide where the sense and antisense regions of the siNA are linked or circularized by a nucleotide or non-nucleotide linker as described herein, wherein the oligonucleotide does not have any ribonucleotides (e.g., nucleotides having a 2′-OH group) present in the oligonucleotide. Applicant has surprisingly found that the presense of ribonucleotides (e.g., nucleotides having a 2′-hydroxyl group) within the siNA molecule is not required or essential to support RNAi activity. As such, in one embodiment, all positions within the siNA can include chemically modified nucleotides and/or non-nucleotides such as nucleotides and or non-nucleotides having Formula I, II, III, IV, V, VI, or VII or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.  
         [0110]     In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system comprising a single stranded polynucleotide having complementarity to a target nucleic acid sequence. In another embodiment, the single stranded siNA molecule of the invention comprises a 5′-terminal phosphate group. In another embodiment, the single stranded siNA molecule of the invention comprises a 5′-terminal phosphate group and a 3′-terminal phosphate group (e.g., a 2′,3′-cyclic phosphate). In another embodiment, the single stranded siNA molecule of the invention comprises about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides. In yet another embodiment, the single stranded siNA molecule of the invention comprises one or more chemically modified nucleotides or non-nucleotides described herein. For example, all the positions within the siNA molecule can include chemically-modified nucleotides such as nucleotides having any of Formulae I-VII, or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.  
         [0111]     In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system comprising a single stranded polynucleotide having complementarity to a target nucleic acid sequence, wherein one or more pyrimidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein or shown in  FIG. 10 , that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence. The siNA optionally further comprises about 1 to about 4 or more (e.g., about 1, 2, 3, 4 or more) terminal 2′-deoxynucleotides at the 3′-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, 4 or more) phosphorothioate, phosphonoacetate, and/or thiophosphonoacetate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5′-terminal phosphate group. In any of these embodiments, any purine nucleotides present in the antisense region are alternatively 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides). Also, in any of these embodiments, any purine nucleotides present in the siNA (i.e., purine nucleotides present in the sense and/or antisense region) can alternatively be locked nucleic acid (LNA) nucleotides (e.g., wherein all purine nucleotides are LNA nucleotides or alternately a plurality of purine nucleotides are LNA nucleotides). Also, in any of these embodiments, any purine nucleotides present in the siNA are alternatively 2′-methoxyethyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-methoxyethyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-methoxyethyl purine nucleotides). In another embodiment, any modified nucleotides present in the single stranded siNA molecules of the invention comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger,  Principles of Nucleic Acid Structure , Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the single stranded siNA molecules of the invention are preferably resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi.  
         [0112]     In one embodiment, the invention features a method for modulating the expression of a interleukin and/or interleukin receptor gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor gene; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the cell.  
         [0113]     In one embodiment, the invention features a method for modulating the expression of a interleukin and/or interleukin receptor gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor gene and wherein the sense strand sequence of the siNA comprises a sequence identical or substantially similar to the sequence of the target RNA; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the cell.  
         [0114]     In another embodiment, the invention features a method for modulating the expression of more than one interleukin and/or interleukin receptor gene within a cell comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor genes; and (b) introducing the siNA molecules into a cell under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the cell.  
         [0115]     In another embodiment, the invention features a method for modulating the expression of two or more interleukin and/or interleukin receptor genes within a cell comprising: (a) synthesizing one or more siNA molecules of the invention, which can be chemically-modified, wherein the siNA strands comprise sequences complementary to RNA of the interleukin and/or interleukin receptor genes and wherein the sense strand sequences of the siNAs comprise sequences identical or substantially similar to the sequences of the target RNAs; and (b) introducing the siNA molecules into a cell under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the cell.  
         [0116]     In another embodiment, the invention features a method for modulating the expression of more than one interleukin and/or interleukin receptor gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor gene and wherein the sense strand sequence of the siNA comprises a sequence identical or substantially similar to the sequences of the target RNAs; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the cell.  
         [0117]     In one embodiment, siNA molecules of the invention are used as reagents in ex vivo applications. For example, siNA reagents are introduced into tissue or cells that are transplanted into a subject for therapeutic effect. The cells and/or tissue can be derived from an organism or subject that later receives the explant, or can be derived from another organism or subject prior to transplantation. The siNA molecules can be used to modulate the expression of one or more genes in the cells or tissue, such that the cells or tissue obtain a desired phenotype or are able to perform a function when transplanted in vivo. In one embodiment, certain target cells from a patient are extracted. These extracted cells are contacted with siNAs targeting a specific nucleotide sequence within the cells under conditions suitable for uptake of the siNAs by these cells (e.g. using delivery reagents such as cationic lipids, liposomes and the like or using techniques such as electroporation to facilitate the delivery of siNAs into cells). The cells are then reintroduced back into the same patient or other patients. In one embodiment, the invention features a method of modulating the expression of a interleukin and/or interleukin receptor gene in a tissue explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor gene; and (b) introducing the siNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in that organism.  
         [0118]     In one embodiment, the invention features a method of modulating the expression of a interleukin and/or interleukin receptor gene in a tissue explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor gene and wherein the sense strand sequence of the siNA comprises a sequence identical or substantially similar to the sequence of the target RNA; and (b) introducing the siNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in that organism. In another embodiment, the invention features a method of modulating the expression of more than one interleukin and/or interleukin receptor gene in a tissue explant comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor genes; and (b) introducing the siNA molecules into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in that organism.  
         [0119]     In one embodiment, the invention features a method of modulating the expression of a interleukin and/or interleukin receptor gene in an organism comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor gene; and (b) introducing the siNA molecule into the organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism. The level of interleukin and/or interleukin receptor protein or RNA can be determined as is known in the art.  
         [0120]     In another embodiment, the invention features a method of modulating the expression of more than one interleukin and/or interleukin receptor gene in an organism comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the interleukin and/or interleukin receptor genes; and (b) introducing the siNA molecules into the organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the organism. The level of interleukin and/or interleukin receptor protein or RNA can be determined as is known in the art.  
         [0121]     In one embodiment, the invention features a method for modulating the expression of a interleukin and/or interleukin receptor gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the interleukin and/or interleukin receptor gene; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the cell.  
         [0122]     In another embodiment, the invention features a method for modulating the expression of more than one interleukin and/or interleukin receptor gene within a cell comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the interleukin and/or interleukin receptor gene; and (b) contacting the cell in vitro or in vivo with the siNA molecule under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the cell.  
         [0123]     In one embodiment, the invention features a method of modulating the expression of a interleukin and/or interleukin receptor gene in a tissue explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the interleukin and/or interleukin receptor gene; and (b) contacting the cell of the tissue explant derived from a particular organism with the siNA molecule under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in that organism.  
         [0124]     In another embodiment, the invention features a method of modulating the expression of more than one interleukin and/or interleukin receptor gene in a tissue explant comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the interleukin and/or interleukin receptor gene; and (b) introducing the siNA molecules into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in that organism.  
         [0125]     In one embodiment, the invention features a method of modulating the expression of a interleukin and/or interleukin receptor gene in an organism comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the interleukin and/or interleukin receptor gene; and (b) introducing the siNA molecule into the organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0126]     In another embodiment, the invention features a method of modulating the expression of more than one interleukin and/or interleukin receptor gene in an organism comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the interleukin and/or interleukin receptor gene; and (b) introducing the siNA molecules into the organism under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the organism.  
         [0127]     In one embodiment, the invention features a method of modulating the expression of a interleukin and/or interleukin receptor gene in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0128]     In one embodiment, the invention features a method for treating or preventing a disease, condition, trait, genotype or phenotype in a subject, comprising administering to the subject a composition of the invention under conditions suitable for the treatment or prevention of the disease, condition, trait, genotype or phenotype in the subject, alone or in conjunction with one or more other therapeutic compounds. In yet another embodiment, the invention features a method for reducing or preventing tissue rejection in a subject comprising administering to the subject a composition of the invention under conditions suitable for the reduction or prevention of tissue rejection in the subject.  
         [0129]     In one embodiment, the invention features a method for treating an inflammatory disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0130]     In one embodiment, the invention features a method for treating or preventing an allergic reaction, disease, or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0131]     In one embodiment, the invention features a method for treating or preventing an autoimmune disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0132]     In one embodiment, the invention features a method for treating or preventing cancer in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0133]     In one embodiment, the invention features a method for treating or preventing a respiratory disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0134]     In one embodiment, the invention features a method for treating or preventing a pulmonary disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0135]     In one embodiment, the invention features a method for treating or preventing a neurodegenerative or nuerologic disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0136]     In one embodiment, the invention features a method for treating or preventing a proliferative disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0137]     In one embodiment, the invention features a method for treating or preventing a cardiovascular disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0138]     In one embodiment, the invention features a method for treating or preventing a renal disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0139]     In one embodiment, the invention features a method for treating or preventing a ocular disease or condition in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0140]     In one embodiment, the invention features a method for treating or preventing viral disease or infection in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor gene in the organism.  
         [0141]     The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed herein (e.g., cancers and other proliferative conditions, viral infection, inflammatory disease, autoimmunity, respiratory disease, pulmonary disease, cardiovascular disease, nuerologic disease, renal disease, ocular disease, etc.). For example, to treat a particular disease, condition, trait, genotype or phenotype, the siNA molecules can be administered to a subject or can be administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.  
         [0142]     In another embodiment, the invention features a method of modulating the expression of more than one interleukin (e.g., any IL-1 through IL-27) and/or interleukin receptor (e.g., any IL-1R through IL-27R) genes in an organism comprising contacting the organism with one or more siNA molecules of the invention under conditions suitable to modulate the expression of the interleukin and/or interleukin receptor genes in the organism.  
         [0143]     The siNA molecules of the invention can be designed to down regulate or inhibit target (e.g., interleukin and/or interleukin receptor) gene expression through RNAi targeting of a variety of RNA molecules. In one embodiment, the siNA molecules of the invention are used to target various RNAs corresponding to a target gene. Non-limiting examples of such RNAs include messenger RNA (mRNA), alternate RNA splice variants of target gene(s), post-transcriptionally modified RNA of target gene(s), pre-mRNA of target gene(s), and/or RNA templates. If alternate splicing produces a family of transcripts that are distinguished by usage of appropriate exons, the instant invention can be used to inhibit gene expression through the appropriate exons to specifically inhibit or to distinguish among the functions of gene family members. For example, a protein that contains an alternatively spliced transmembrane domain can be expressed in both membrane bound and secreted forms. Use of the invention to target the exon containing the transmembrane domain can be used to determine the functional consequences of pharmaceutical targeting of membrane bound as opposed to the secreted form of the protein. Non-limiting examples of applications of the invention relating to targeting these RNA molecules include therapeutic pharmaceutical applications, pharmaceutical discovery applications, molecular diagnostic and gene function applications, and gene mapping, for example using single nucleotide polymorphism mapping with siNA molecules of the invention. Such applications can be implemented using known gene sequences or from partial sequences available from an expressed sequence tag (EST).  
         [0144]     In another embodiment, the siNA molecules of the invention are used to target conserved sequences corresponding to a gene family or gene families such as interleukin and/or interleukin receptor family genes. As such, siNA molecules targeting multiple interleukin and/or interleukin receptor targets can provide increased therapeutic effect. In addition, siNA can be used to characterize pathways of gene function in a variety of applications. For example, the present invention can be used to inhibit the activity of target gene(s) in a pathway to determine the function of uncharacterized gene(s) in gene function analysis, mRNA function analysis, or translational analysis. The invention can be used to determine potential target gene pathways involved in various diseases and conditions toward pharmaceutical development. The invention can be used to understand pathways of gene expression involved in, for example, respiratory disease.  
         [0145]     In one embodiment, siNA molecule(s) and/or methods of the invention are used to down regulate the expression of gene(s) that encode RNA referred to by Genbank Accession, for example interleukin and/or interleukin receptor genes encoding RNA sequence(s) referred to herein by Genbank Accession number, for example, Genbank Accession Nos. shown in Table I.  
         [0146]     In one embodiment, the invention features a method comprising: (a) generating a library of siNA constructs having a predetermined complexity; and (b) assaying the siNA constructs of (a) above, under conditions suitable to determine RNAi target sites within the target RNA sequence. In one embodiment, the siNA molecules of (a) have strands of a fixed length, for example, about 23 nucleotides in length. In another embodiment, the siNA molecules of (a) are of differing length, for example having strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted in vitro siNA assay as described herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. In another embodiment, fragments of target RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNAse protection assays, to determine the most suitable target site(s) within the target RNA sequence. The target RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for in vitro systems, and by cellular expression in in vivo systems.  
         [0147]     In one embodiment, the invention features a method comprising: (a) generating a randomized library of siNA constructs having a predetermined complexity, such as of 4 N , where N represents the number of base paired nucleotides in each of the siNA construct strands (eg. for a siNA construct having 21 nucleotide sense and antisense strands with 19 base pairs, the complexity would be 4 19 ); and (b) assaying the siNA constructs of (a) above, under conditions suitable to determine RNAi target sites within the target interleukin and/or interleukin receptor RNA sequence. In another embodiment, the siNA molecules of (a) have strands of a fixed length, for example about 23 nucleotides in length. In yet another embodiment, the siNA molecules of (a) are of differing length, for example having strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted in vitro siNA assay as described in Example 6 herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. In another embodiment, fragments of interleukin and/or interleukin receptor RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNAse protection assays, to determine the most suitable target site(s) within the target interleukin and/or interleukin receptor RNA sequence. The target interleukin and/or interleukin receptor RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for in vitro systems, and by cellular expression in in vivo systems.  
         [0148]     In another embodiment, the invention features a method comprising: (a) analyzing the sequence of a RNA target encoded by a target gene; (b) synthesizing one or more sets of siNA molecules having sequence complementary to one or more regions of the RNA of (a); and (c) assaying the siNA molecules of (b) under conditions suitable to determine RNAi targets within the target RNA sequence. In one embodiment, the siNA molecules of (b) have strands of a fixed length, for example about 23 nucleotides in length. In another embodiment, the siNA molecules of (b) are of differing length, for example having strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted in vitro siNA assay as described herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. Fragments of target RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNAse protection assays, to determine the most suitable target site(s) within the target RNA sequence. The target RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for in vitro systems, and by expression in in vivo systems.  
         [0149]     By “target site” is meant a sequence within a target RNA that is “targeted” for cleavage mediated by a siNA construct which contains sequences within its antisense region that are complementary to the target sequence.  
         [0150]     By “detectable level of cleavage” is meant cleavage of target RNA (and formation of cleaved product RNAs) to an extent sufficient to discern cleavage products above the background of RNAs produced by random degradation of the target RNA. Production of cleavage products from 1-5% of the target RNA is sufficient to detect above the background for most methods of detection.  
         [0151]     In one embodiment, the invention features a composition comprising a siNA molecule of the invention, which can be chemically-modified, in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a pharmaceutical composition comprising siNA molecules of the invention, which can be chemically-modified, targeting one or more genes in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a method for diagnosing a disease or condition in a subject comprising administering to the subject a composition of the invention under conditions suitable for the diagnosis of the disease or condition in the subject. In another embodiment, the invention features a method for treating or preventing a disease or condition in a subject, comprising administering to the subject a composition of the invention under conditions suitable for the treatment or prevention of the disease or condition in the subject, alone or in conjunction with one or more other therapeutic compounds. In yet another embodiment, the invention features a method for reducing or preventing, for example, respiratory disease (e.g., asthma) in a subject, comprising administering to the subject a composition of the invention under conditions suitable for the reduction or prevention of the respiratory disease in the subject.  
         [0152]     In another embodiment, the invention features a method for validating a interleukin and/or interleukin receptor gene target, comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands includes a sequence complementary to RNA of a interleukin and/or interleukin receptor target gene; (b) introducing the siNA molecule into a cell, tissue, or organism under conditions suitable for modulating expression of the interleukin and/or interleukin receptor target gene in the cell, tissue, or organism; and (c) determining the function of the gene by assaying for any phenotypic change in the cell, tissue, or organism.  
         [0153]     In another embodiment, the invention features a method for validating a interleukin and/or interleukin receptor target comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands includes a sequence complementary to RNA of a interleukin and/or interleukin receptor target gene; (b) introducing the siNA molecule into a biological system under conditions suitable for modulating expression of the interleukin and/or interleukin receptor target gene in the biological system; and (c) determining the function of the gene by assaying for any phenotypic change in the biological system.  
         [0154]     By “biological system” is meant, material, in a purified or unpurified form, from biological sources, including but not limited to human or animal, wherein the system comprises the components required for RNAi activity. The term “biological system” includes, for example, a cell, tissue, or organism, or extract thereof. The term biological system also includes reconstituted RNAi systems that can be used in an in vitro setting.  
         [0155]     By “phenotypic change” is meant any detectable change to a cell that occurs in response to contact or treatment with a nucleic acid molecule of the invention (e.g., siNA). Such detectable changes include, but are not limited to, changes in shape, size, proliferation, motility, protein expression or RNA expression or other physical or chemical changes as can be assayed by methods known in the art. The detectable change can also include expression of reporter genes/molecules such as Green Florescent Protein (GFP) or various tags that are used to identify an expressed protein or any other cellular component that can be assayed.  
         [0156]     In one embodiment, the invention features a kit containing a siNA molecule of the invention, which can be chemically-modified, that can be used to modulate the expression of a interleukin and/or interleukin receptor target gene in a biological system, including, for example, in a cell, tissue, or organism. In another embodiment, the invention features a kit containing more than one siNA molecule of the invention, which can be chemically-modified, that can be used to modulate the expression of more than one interleukin and/or interleukin receptor target gene in a biological system, including, for example, in a cell, tissue, or organism.  
         [0157]     In one embodiment, the invention features a cell containing one or more siNA molecules of the invention, which can be chemically-modified. In another embodiment, the cell containing a siNA molecule of the invention is a mammalian cell. In yet another embodiment, the cell containing a siNA molecule of the invention is a human cell.  
         [0158]     In one embodiment, the synthesis of a siNA molecule of the invention, which can be chemically-modified, comprises: (a) synthesis of two complementary strands of the siNA molecule; (b) annealing the two complementary strands together under conditions suitable to obtain a double-stranded siNA molecule. In another embodiment, synthesis of the two complementary strands of the siNA molecule is by solid phase oligonucleotide synthesis. In yet another embodiment, synthesis of the two complementary strands of the siNA molecule is by solid phase tandem oligonucleotide synthesis.  
         [0159]     In one embodiment, the invention features a method for synthesizing a siNA duplex molecule comprising: (a) synthesizing a first oligonucleotide sequence strand of the siNA molecule, wherein the first oligonucleotide sequence strand comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of the second oligonucleotide sequence strand of the siNA; (b) synthesizing the second oligonucleotide sequence strand of siNA on the scaffold of the first oligonucleotide sequence strand, wherein the second oligonucleotide sequence strand further comprises a chemical moiety than can be used to purify the siNA duplex; (c) cleaving the linker molecule of (a) under conditions suitable for the two siNA oligonucleotide strands to hybridize and form a stable duplex; and (d) purifying the siNA duplex utilizing the chemical moiety of the second oligonucleotide sequence strand. In one embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example under hydrolysis conditions using an alkylamine base such as methylamine. In one embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place concomitantly. In another embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group, which can be employed in a trityl-on synthesis strategy as described herein. In yet another embodiment, the chemical moiety, such as a dimethoxytrityl group, is removed during purification, for example, using acidic conditions.  
         [0160]     In a further embodiment, the method for siNA synthesis is a solution phase synthesis or hybrid phase synthesis wherein both strands of the siNA duplex are synthesized in tandem using a cleavable linker attached to the first sequence which acts a scaffold for synthesis of the second sequence. Cleavage of the linker under conditions suitable for hybridization of the separate siNA sequence strands results in formation of the double-stranded siNA molecule.  
         [0161]     In another embodiment, the invention features a method for synthesizing a siNA duplex molecule comprising: (a) synthesizing one oligonucleotide sequence strand of the siNA molecule, wherein the sequence comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of another oligonucleotide sequence; (b) synthesizing a second oligonucleotide sequence having complementarity to the first sequence strand on the scaffold of (a), wherein the second sequence comprises the other strand of the double-stranded siNA molecule and wherein the second sequence further comprises a chemical moiety than can be used to isolate the attached oligonucleotide sequence; (c) purifying the product of (b) utilizing the chemical moiety of the second oligonucleotide sequence strand under conditions suitable for isolating the full-length sequence comprising both siNA oligonucleotide strands connected by the cleavable linker and under conditions suitable for the two siNA oligonucleotide strands to hybridize and form a stable duplex. In one embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example under hydrolysis conditions. In another embodiment, cleavage of the linker molecule in (c) above takes place after deprotection of the oligonucleotide. In another embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity or differing reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place either concomitantly or sequentially. In one embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group.  
         [0162]     In another embodiment, the invention features a method for making a double-stranded siNA molecule in a single synthetic process comprising: (a) synthesizing an oligonucleotide having a first and a second sequence, wherein the first sequence is complementary to the second sequence, and the first oligonucleotide sequence is linked to the second sequence via a cleavable linker, and wherein a terminal 5′-protecting group, for example, a 5′-O-dimethoxytrityl group (5′-O-DMT) remains on the oligonucleotide having the second sequence; (b) deprotecting the oligonucleotide whereby the deprotection results in the cleavage of the linker joining the two oligonucleotide sequences; and (c) purifying the product of (b) under conditions suitable for isolating the double-stranded siNA molecule, for example using a trityl-on synthesis strategy as described herein.  
         [0163]     In another embodiment, the method of synthesis of siNA molecules of the invention comprises the teachings of Scaringe et al., U.S. Pat. Nos. 5,889,136; 6,008,400; and 6,111,086, incorporated by reference herein in their entirety.  
         [0164]     In one embodiment, the invention features siNA constructs that mediate RNAi against interleukin and/or interleukin receptor, wherein the siNA construct comprises one or more chemical modifications, for example, one or more chemical modifications having any of Formulae I-VII or any combination thereof that increases the nuclease resistance of the siNA construct.  
         [0165]     In another embodiment, the invention features a method for generating siNA molecules with increased nuclease resistance comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased nuclease resistance.  
         [0166]     In one embodiment, the invention features siNA constructs that mediate RNAi against interleukin and/or interleukin receptor, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the sense and antisense strands of the siNA construct.  
         [0167]     In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the sense and antisense strands of the siNA molecule comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the sense and antisense strands of the siNA molecule.  
         [0168]     In one embodiment, the invention features siNA constructs that mediate RNAi against interleukin and/or interleukin receptor, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the antisense strand of the siNA construct and a complementary target RNA sequence within a cell.  
         [0169]     In one embodiment, the invention features siNA constructs that mediate RNAi against interleukin and/or interleukin receptor, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the antisense strand of the siNA construct and a complementary target DNA sequence within a cell.  
         [0170]     In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the antisense strand of the siNA molecule and a complementary target RNA sequence comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the antisense strand of the siNA molecule and a complementary target RNA sequence.  
         [0171]     In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the antisense strand of the siNA molecule and a complementary target DNA sequence comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the antisense strand of the siNA molecule and a complementary target DNA sequence.  
         [0172]     In one embodiment, the invention features siNA constructs that mediate RNAi against interleukin and/or interleukin receptor, wherein the siNA construct comprises one or more chemical modifications described herein that modulate the polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to the chemically-modified siNA construct.  
         [0173]     In another embodiment, the invention features a method for generating siNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to a chemically-modified siNA molecule comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to the chemically-modified siNA molecule.  
         [0174]     In one embodiment, the invention features chemically-modified siNA constructs that mediate RNAi against interleukin and/or interleukin receptor in a cell, wherein the chemical modifications do not significantly effect the interaction of siNA with a target RNA molecule, DNA molecule and/or proteins or other factors that are essential for RNAi in a manner that would decrease the efficacy of RNAi mediated by such siNA constructs.  
         [0175]     In another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against interleukin and/or interleukin receptor comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity.  
         [0176]     In yet another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against interleukin and/or interleukin receptor target RNA comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity against the target RNA.  
         [0177]     In yet another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against interleukin and/or interleukin receptor target DNA comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity against the target DNA.  
         [0178]     In one embodiment, the invention features siNA constructs that mediate RNAi against interleukin and/or interleukin receptor, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the cellular uptake of the siNA construct.  
         [0179]     In another embodiment, the invention features a method for generating siNA molecules against interleukin and/or interleukin receptor with improved cellular uptake comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved cellular uptake.  
         [0180]     In one embodiment, the invention features siNA constructs that mediate RNAi against interleukin and/or interleukin receptor, wherein the siNA construct comprises one or more chemical modifications described herein that increases the bioavailability of the siNA construct, for example, by attaching polymeric conjugates such as polyethyleneglycol or equivalent conjugates that improve the pharmacokinetics of the siNA construct, or by attaching conjugates that target specific tissue types or cell types in vivo. Non-limiting examples of such conjugates are described in Vargeese et al., U.S. Ser. No. 10/201,394 incorporated by reference herein.  
         [0181]     In one embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability, comprising (a) introducing a conjugate into the structure of a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability. Such conjugates can include ligands for cellular receptors, such as peptides derived from naturally occurring protein ligands; protein localization sequences, including cellular ZIP code sequences; antibodies; nucleic acid aptamers; vitamins and other co-factors, such as folate and N-acetylgalactosamine; polymers, such as polyethyleneglycol (PEG); phospholipids; cholesterol; polyamines, such as spermine or spermidine; and others.  
         [0182]     In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence is chemically modified in a manner that it can no longer act as a guide sequence for efficiently mediating RNA interference and/or be recognized by cellular proteins that facilitate RNAi.  
         [0183]     In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein the second sequence is designed or modified in a manner that prevents its entry into the RNAi pathway as a guide sequence or as a sequence that is complementary to a target nucleic acid (e.g., RNA) sequence. Such design or modifications are expected to enhance the activity of siNA and/or improve the specificity of siNA molecules of the invention. These modifications are also expected to minimize any off-target effects and/or associated toxicity.  
         [0184]     In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence is incapable of acting as a guide sequence for mediating RNA interference.  
         [0185]     In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence does not have a terminal 5′-hydroxyl (5′-OH) or 5′-phosphate group.  
         [0186]     In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence comprises a terminal cap moiety at the 5′-end of said second sequence. In one embodiment, the terminal cap moiety comprises an inverted abasic, inverted deoxy abasic, inverted nucleotide moiety, a group shown in  FIG. 10 , an alkyl or cycloalkyl group, a heterocycle, or any other group that prevents RNAi activity in which the second sequence serves as a guide sequence or template for RNAi.  
         [0187]     In one embodiment, the invention features a double stranded short interfering nucleic acid (siNA) molecule that comprises a first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence having complementarity to said first sequence, wherein said second sequence comprises a terminal cap moiety at the 5′-end and 3′-end of said second sequence. In one embodiment, each terminal cap moiety individually comprises an inverted abasic, inverted deoxy abasic, inverted nucleotide moiety, a group shown in  FIG. 10 , an alkyl or cycloalkyl group, a heterocycle, or any other group that prevents RNAi activity in which the second sequence serves as a guide sequence or template for RNAi.  
         [0188]     In one embodiment, the invention features a method for generating siNA molecules of the invention with improved specificity for down regulating or inhibiting the expression of a target nucleic acid (e.g., a DNA or RNA such as a gene or its corresponding RNA), comprising (a) introducing one or more chemical modifications into the structure of a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved specificity. In another embodiment, the chemical modification used to improve specificity comprises terminal cap modifications at the 5′-end, 3′-end, or both 5′ and 3′-ends of the siNA molecule. The terminal cap modifications can comprise, for example, structures shown in  FIG. 10  (e.g. inverted deoxyabasic moieties) or any other chemical modification that renders a portion of the siNA molecule (e.g. the sense strand) incapable of mediating RNA interference against an off target nucleic acid sequence. In a non-limiting example, a siNA molecule is designed such that only the antisense sequence of the siNA molecule can serve as a guide sequence for RISC mediated degradation of a corresponding target RNA sequence. This can be accomplished by rendering the sense sequence of the siNA inactive by introducing chemical modifications to the sense strand that preclude recognition of the sense strand as a guide sequence by RNAi machinery. In one embodiment, such chemical modifications comprise any chemical group at the 5′-end of the sense strand of the siNA, or any other group that serves to render the sense strand inactive as a guide sequence for mediating RNA interference. These modifications, for example, can result in a molecule where the 5′-end of the sense strand no longer has a free 5′-hydroxyl (5′-OH) or a free 5′-phosphate group (e.g., phosphate, diphosphate, triphosphate, cyclic phosphate etc.). Non-limiting examples of such siNA constructs are described herein, such as “Stab 9/10”, “Stab 7/8”, “Stab 7/19”, “Stab 17/22”, “Stab 23/24”, and “Stab 24/25” chemistries and variants thereof (see Table IV) wherein the 5′-end and 3′-end of the sense strand of the siNA do not comprise a hydroxyl group or phosphate group.  
         [0189]     In one embodiment, the invention features a method for generating siNA molecules of the invention with improved specificity for down regulating or inhibiting the expression of a target nucleic acid (e.g., a DNA or RNA such as a gene or its corresponding RNA), comprising introducing one or more chemical modifications into the structure of a siNA molecule that prevent a strand or portion of the siNA molecule from acting as a template or guide sequence for RNAi activity. In one embodiment, the inactive strand or sense region of the siNA molecule is the sense strand or sense region of the siNA molecule, i.e. the strand or region of the siNA that does not have complementarity to the target nucleic acid sequence. In one embodiment, such chemical modifications comprise any chemical group at the 5′-end of the sense strand or region of the siNA that does not comprise a 5′-hydroxyl (5′-OH) or 5′-phosphate group, or any other group that serves to render the sense strand or sense region inactive as a guide sequence for mediating RNA interference. Non-limiting examples of such siNA constructs are described herein, such as “Stab 9/10”, “Stab 7/8”, “Stab 7/19”, “Stab 17/22”, “Stab 23/24”, and “Stab 24/25” chemistries and variants thereof (see Table IV) wherein the 5′-end and 3′-end of the sense strand of the siNA do not comprise a hydroxyl group or phosphate group.  
         [0190]     In one embodiment, the invention features a method for screening siNA molecules that are active in mediating RNA interference against a target nucleic acid sequence comprising (a) generating a plurality of unmodified siNA molecules, (b) screening the siNA molecules of step (a) under conditions suitable for isolating siNA molecules that are active in mediating RNA interference against the target nucleic acid sequence, and (c) introducing chemical modifications (e.g. chemical modifications as described herein or as otherwise known in the art) into the active siNA molecules of (b). In one embodiment, the method further comprises re-screening the chemically modified siNA molecules of step (c) under conditions suitable for isolating chemically modified siNA molecules that are active in mediating RNA interference against the target nucleic acid sequence.  
         [0191]     In one embodiment, the invention features a method for screening chemically modified siNA molecules that are active in mediating RNA interference against a target nucleic acid sequence comprising (a) generating a plurality of chemically modified siNA molecules (e.g. siNA molecules as described herein or as otherwise known in the art), and (b) screening the siNA molecules of step (a) under conditions suitable for isolating chemically modified siNA molecules that are active in mediating RNA interference against the target nucleic acid sequence.  
         [0192]     The term “ligand” refers to any compound or molecule, such as a drug, peptide, hormone, or neurotransmitter, that is capable of interacting with another compound, such as a receptor, either directly or indirectly. The receptor that interacts with a ligand can be present on the surface of a cell or can alternately be an intercullular receptor. Interaction of the ligand with the receptor can result in a biochemical reaction, or can simply be a physical interaction or association.  
         [0193]     In another embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing an excipient formulation to a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability. Such excipients include polymers such as cyclodextrins, lipids, cationic lipids, polyamines, phospholipids, nanoparticles, receptors, ligands, and others.  
         [0194]     In another embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing nucleotides having any of Formulae I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability.  
         [0195]     In another embodiment, polyethylene glycol (PEG) can be covalently attached to siNA compounds of the present invention. The attached PEG can be any molecular weight, preferably from about 2,000 to about 50,000 daltons (Da).  
         [0196]     The present invention can be used alone or as a component of a kit having at least one of the reagents necessary to carry out the in vitro or in vivo introduction of RNA to test samples and/or subjects. For example, preferred components of the kit include a siNA molecule of the invention and a vehicle that promotes introduction of the siNA into cells of interest as described herein (e.g., using lipids and other methods of transfection known in the art, see for example Beigelman et al, U.S. Pat. No. 6,395,713). The kit can be used for target validation, such as in determining gene function and/or activity, or in drug optimization, and in drug discovery (see for example Usman et al., U.S. Ser. No. 60/402,996). Such a kit can also include instructions to allow a user of the kit to practice the invention.  
         [0197]     The term “short interfering nucleic acid”, “siNA”, “short interfering RNA”, “siRNA”, “short interfering nucleic acid molecule”, “short interfering oligonucleotide molecule”, or “chemically-modified short interfering nucleic acid molecule” as used herein refers to any nucleic acid molecule capable of inhibiting or down regulating gene expression or viral replication, for example by mediating RNA interference “RNAi” or gene silencing in a sequence-specific manner; see for example Zamore et al., 2000, Cell, 101, 25-33; Bass, 2001 , Nature,  411, 428-429; Elbashir et al., 2001 , Nature,  411, 494-498; and Kreutzer et al., International PCT Publication No. WO 00/44895; Zemicka-Goetz et al., International PCT Publication No. WO 01/36646; Fire, International PCT Publication No. WO 99/32619; Plaetinck et al., International PCT Publication No. WO 00/01846; Mello and Fire, International PCT Publication No. WO  01/29058; Deschamps-Depaillette, International PCT Publication No. WO  99/07409; and Li et al., International PCT Publication No. WO 00/44914; Allshire, 2002 , Science,  297, 1818-1819; Volpe et al., 2002 , Science,  297, 1833-1837; Jenuwein, 2002 , Science,  297, 2215-2218; and Hall et al., 2002 , Science,  297, 2232-2237; Hutvagner and Zamore, 2002, Science, 297, 2056-60; McManus et al., 2002 , RNA,  8, 842-850; Reinhart et al., 2002 , Gene  &amp;  Dev.,  16, 1616-1626; and Reinhart &amp; Bartel, 2002 , Science,  297, 1831). Non limiting examples of siNA molecules of the invention are shown in  FIGS. 4-6 , and Tables II and III herein. For example the siNA can be a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (i.e. each strand comprises nucleotide sequence that is complementary to nucleotide sequence in the other strand; such as where the antisense strand and sense strand form a duplex or double stranded structure, for example wherein the double stranded region is about 19 base pairs); the antisense strand comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense strand comprises nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. Alternatively, the siNA is assembled from a single oligonucleotide, where the self-complementary sense and antisense regions of the siNA are linked by means of a nucleic acid based or non-nucleic acid-based linker(s). The siNA can be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either in vivo or in vitro to generate an active siNA molecule capable of mediating RNAi. The siNA can also comprise a single stranded polynucleotide having nucleotide sequence complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof (for example, where such siNA molecule does not require the presence within the siNA molecule of nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof), wherein the single stranded polynucleotide can further comprise a terminal phosphate group, such as a 5′-phosphate (see for example Martinez et al., 2002 , Cell.,  110, 563-574 and Schwarz et al., 2002 , Molecular Cell,  10, 537-568), or 5′,3′-diphosphate. In certain embodiments, the siNA molecule of the invention comprises separate sense and antisense sequences or regions, wherein the sense and antisense regions are covalently linked by nucleotide or non-nucleotide linkers molecules as is known in the art, or are alternately non-covalently linked by ionic interactions, hydrogen bonding, van der waals interactions, hydrophobic interactions, and/or stacking interactions. In certain embodiments, the siNA molecules of the invention comprise nucleotide sequence that is complementary to nucleotide sequence of a target gene. In another embodiment, the siNA molecule of the invention interacts with nucleotide sequence of a target gene in a manner that causes inhibition of expression of the target gene. As used herein, siNA molecules need not be limited to those molecules containing only RNA, but further encompasses chemically-modified nucleotides and non-nucleotides. In certain embodiments, the short interfering nucleic acid molecules of the invention lack 2′-hydroxy (2′-OH) containing nucleotides. Applicant describes in certain embodiments short interfering nucleic acids that do not require the presence of nucleotides having a 2′-hydroxy group for mediating RNAi and as such, short interfering nucleic acid molecules of the invention optionally do not include any ribonucleotides (e.g., nucleotides having a 2′-OH group). Such siNA molecules that do not require the presence of ribonucleotides within the siNA molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2′-OH groups. Optionally, siNA molecules can comprise ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleotide positions. The modified short interfering nucleic acid molecules of the invention can also be referred to as short interfering modified oligonucleotides “siMON.” As used herein, the term siNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically-modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term RNAi is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics. For example, siNA molecules of the invention can be used to epigenetically silence genes at both the post-transcriptional level or the pre-transcriptional level. In a non-limiting example, epigenetic regulation of gene expression by siNA molecules of the invention can result from siNA mediated modification of chromatin structure or methylation pattern to alter gene expression (see, for example, Verdel et al., 2004 , Science,  303, 672-676; Pal-Bhadra et al., 2004 , Science,  303, 669-672; Allshire, 2002 , Science,  297, 1818-1819; Volpe et al., 2002 , Science,  297, 1833-1837; Jenuwein, 2002 , Science,  297, 2215-2218; and Hall et al., 2002 , Science,  297, 2232-2237).  
         [0198]     In one embodiment, a siNA molecule of the invention is a duplex forming oligonucleotide “DFO”, (see for example  FIGS. 14-15  and Vaish et al., U.S. Ser. No. 10/727,780 filed Dec. 3, 2003 and McSwiggen et al., PCT/US04/16390, filed May 24, 2004).  
         [0199]     In one embodiment, a siNA molecule of the invention is a multifunctional siNA, (see for example  FIGS. 16-22  and Jadhav et al., U.S. Ser. No. 60/543,480 filed Feb. 10, 2004 and McSwiggen et al., PCT/US04/16390, filed May 24, 2004). The multifunctional siNA of the invention can comprise sequence targeting, for example, two regions of interleukin and/or interleukin receptor RNA (see for example target sequences in Tables II and III).  
         [0200]     By “asymmetric hairpin” as used herein is meant a linear siNA molecule comprising an antisense region, a loop portion that can comprise nucleotides or non-nucleotides, and a sense region that comprises fewer nucleotides than the antisense region to the extent that the sense region has enough complementary nucleotides to base pair with the antisense region and form a duplex with loop. For example, an asymmetric hairpin siNA molecule of the invention can comprise an antisense region having length sufficient to mediate RNAi in a cell or in vitro system (e.g. about 19 to about 22, or about 19, 20, 21, or 22 nucleotides) and a loop region comprising about 4 to about 8 (e.g., about 4, 5, 6, 7, or 8) nucleotides, and a sense region having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides that are complementary to the antisense region. The asymmetric hairpin siNA molecule can also comprise a 5′-terminal phosphate group that can be chemically modified. The loop portion of the asymmetric hairpin siNA molecule can comprise nucleotides, non-nucleotides, linker molecules, or conjugate molecules as described herein.  
         [0201]     By “asymmetric duplex” as used herein is meant a siNA molecule having two separate strands comprising a sense region and an antisense region, wherein the sense region comprises fewer nucleotides than the antisense region to the extent that the sense region has enough complementary nucleotides to base pair with the antisense region and form a duplex. For example, an asymmetric duplex siNA molecule of the invention can comprise an antisense region having length sufficient to mediate RNAi in a cell or in vitro system e.g. about 19 to about 22 (e.g. about 19, 20, 21, or 22) nucleotides and a sense region having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides that are complementary to the antisense region.  
         [0202]     By “modulate” is meant that the expression of the gene, or level of RNA molecule or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits is up regulated or down regulated, such that expression, level, or activity is greater than or less than that observed in the absence of the modulator. For example, the term “modulate” can mean “inhibit,” but the use of the word “modulate” is not limited to this definition.  
         [0203]     By “inhibit”, “down-regulate”, or “reduce”, it is meant that the expression of the gene, or level of RNA molecules or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits, is reduced below that observed in the absence of the nucleic acid molecules (e.g., siNA) of the invention. In one embodiment, inhibition, down-regulation or reduction with an siNA molecule is below that level observed in the presence of an inactive or attenuated molecule. In another embodiment, inhibition, down-regulation, or reduction with siNA molecules is below that level observed in the presence of, for example, an siNA molecule with scrambled sequence or with mismatches. In another embodiment, inhibition, down-regulation, or reduction of gene expression with a nucleic acid molecule of the instant invention is greater in the presence of the nucleic acid molecule than in its absence.  
         [0204]     By “gene”, or “target gene”, is meant, a nucleic acid that encodes an RNA, for example, nucleic acid sequences including, but not limited to, structural genes encoding a polypeptide. A gene or target gene can also encode a functional RNA (fRNA) or non-coding RNA (ncRNA), such as small temporal RNA (stRNA), micro RNA (mRNA), small nuclear RNA (snRNA), short interfering RNA (siRNA), small nucleolar RNA (snRNA), ribosomal RNA (rRNA), transfer RNA (tRNA) and precursor RNAs thereof. Such non-coding RNAs can serve as target nucleic acid molecules for siNA mediated RNA interference in modulating the activity of fRNA or ncRNA involved in functional or regulatory cellular processes. Abberant fRNA or ncRNA activity leading to disease can therefore be modulated by siNA molecules of the invention. siNA molecules targeting fRNA and ncRNA can also be used to manipulate or alter the genotype or phenotype of an organism or cell, by intervening in cellular processes such as genetic imprinting, transcription, translation, or nucleic acid processing (e.g., transamination, methylation etc.). The target gene can be a gene derived from a cell, an endogenous gene, a transgene, or exogenous genes such as genes of a pathogen, for example a virus, which is present in the cell after infection thereof. The cell containing the target gene can be derived from or contained in any organism, for example a plant, animal, protozoan, virus, bacterium, or fungus. Non-limiting examples of plants include monocots, dicots, or gymnosperms. Non-limiting examples of animals include vertebrates or invertebrates. Non-limiting examples of fungi include molds or yeasts. For a review, see for example Snyder and Gerstein, 2003 , Science,  300, 258-260.  
         [0205]     By “non-canonical base pair” is meant any non-Watson Crick base pair, such as mismatches and/or wobble base pairs, inlcuding flipped mismatches, single hydrogen bond mismatches, trans-type mismatches, triple base interactions, and quadruple base interactions. Non-limiting examples of such non-canonical base pairs include, but are not limited to, AC reverse Hoogsteen, AC wobble, AU reverse Hoogsteen, GU wobble, AA N7 amino, CC 2-carbonyl-amino(H1)—N-3-amino(H2), GA sheared, UC 4-carbonyl-amino, UU imino-carbonyl, AC reverse wobble, AU Hoogsteen, AU reverse Watson Crick, CG reverse Watson Crick, GC N3-amino-amino N3, AA N1-amino symmetric, AA N7-amino symmetric, GA N7-N1 amino-carbonyl, GA+ carbonyl-amino N7-N1, GG N1-carbonyl symmetric, GG N3-amino symmetric, CC carbonyl-amino symmetric, CC N3-amino symmetric, UU 2-carbonyl-imino symmetric, UU 4-carbonyl-imino symmetric, AA amino-N3, AA N1-amino, AC amino 2-carbonyl, AC N3-amino, AC N7-amino, AU amino-4-carbonyl, AU N1-imino, AU N3-imino, AU N7-imino, CC carbonyl-amino, GA amino-N1, GA amino-N7, GA carbonyl-amino, GA N3-amino, GC amino-N3, GC carbonyl-amino, GC N3-amino, GC N7-amino, GG amino-N7, GG carbonyl-imino, GG N7-amino, GU amino-2-carbonyl, GU carbonyl-imino, GU imino-2-carbonyl, GU N7-imino, psiU imino-2-carbonyl, UC 4-carbonyl-amino, UC imino-carbonyl, UU imino-4-carbonyl, AC C2-H—N3, GA carbonyl-C2-H, UU imino-4-carbonyl 2 carbonyl-C5-H, AC amino(A) N3(C)-carbonyl, GC imino amino-carbonyl, Gpsi imino-2-carbonyl amino-2carbonyl, and GU imino amino-2-carbonyl base pairs.  
         [0206]     By “interleukin” is meant, any interleukin (e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, and IL-27) polypeptide, protein and/or a polynucleotide encoding an interleukin protein, peptide, or portion thereof (such as polynucleotides referred to by Genbank Accession numbers in Table I or any other interleukin transcript derived from an interleukin gene). The term “interleukin” is also meant to include other interleukin encoding sequence, such as mutant interleukin genes, splice variants of interleukin genes, and interleukin gene polymorphisms, such as those associated with a disease, trait, or condition.  
         [0207]     By “interleukin protein” is meant, any interleukin peptide or protein or a component thereof, wherein the peptide or protein is encoded by an interleukin gene or having interleukin activity.  
         [0208]     By “interleukin receptor” is meant, any interleukin receptor (e.g., IL-1R, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, IL-15R, IL-16R, IL-17R, IL-18R, IL-19R, IL-20R, IL-21R, IL-22R, IL-23R, IL-24R, IL-25R, IL-26R, and IL-27R) polypeptide, protein and/or a polynucleotide encoding an interleukin receptor protein, peptide, or portion thereof (such as polynucleotides referred to by Genbank Accession numbers in Table I or any other interleukin receptor transcript derived from an interleukin receptor gene). The term “interleukin receptor” is also meant to include other interleukin receptor encoding sequence, such as mutant interleukin receptor genes, splice variants of interleukin receptor genes, and interleukin receptor gene polymorphisms, such as those associated with a disease, trait, or condition.  
         [0209]     By “interleukin receptor protein” is meant, any interleukin receptor peptide or protein or a component thereof, wherein the peptide or protein is encoded by an interleukin receptor gene or having interleukin receptor activity.  
         [0210]     By “homologous sequence” is meant, a nucleotide sequence that is shared by one or more polynucleotide sequences, such as genes, gene transcripts and/or non-coding polynucleotides. For example, a homologous sequence can be a nucleotide sequence that is shared by two or more genes encoding related but different proteins, such as different members of a gene family, different protein epitopes, different protein isoforms or completely divergent genes, such as a cytokine and its corresponding receptors. A homologous sequence can be a nucleotide sequence that is shared by two or more non-coding polynucleotides, such as noncoding DNA or RNA, regulatory sequences, introns, and sites of transcriptional control or regulation. Homologous sequences can also include conserved sequence regions shared by more than one polynucleotide sequence. Homology does not need to be perfect homology (e.g., 100%), as partially homologous sequences are also contemplated by the instant invention (e.g., 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80% etc.).  
         [0211]     By “conserved sequence region” is meant, a nucleotide sequence of one or more regions in a polynucleotide does not vary significantly between generations or from one biological system or organism to another biological system or organism. The polynucleotide can include both coding and non-coding DNA and RNA.  
         [0212]     By “sense region” is meant a nucleotide sequence of a siNA molecule having complementarity to an antisense region of the siNA molecule. In addition, the sense region of a siNA molecule can comprise a nucleic acid sequence having homology with a target nucleic acid sequence.  
         [0213]     By “antisense region” is meant a nucleotide sequence of a siNA molecule having complementarity to a target nucleic acid sequence. In addition, the antisense region of a siNA molecule can optionally comprise a nucleic acid sequence having complementarity to a sense region of the siNA molecule.  
         [0214]     By “target nucleic acid” is meant any nucleic acid sequence whose expression or activity is to be modulated. The target nucleic acid can be DNA or RNA.  
         [0215]     By “complementarity” is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987, CSH  Symp. Quant. Biol . LII pp. 123-133; Frier et al., 1986 , Proc. Nat. Acad. Sci. USA  83:9373-9377; Turner et al., 1987 , J. Am. Chem. Soc.  109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out of a total of 10 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively). “Perfectly complementary” means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.  
         [0216]     In one embodiment, siNA molecules of the invention that down regulate or reduce interleukin and/or interleukin receptor gene expression are used for preventing or reducing cancers and other proliferative conditions, viral infection, inflammatory disease, autoimmunity, respiratory disease, pulmonary disease, cardiovascular disease, nuerologic disease, renal disease, ocular disease, liver disease, mitochondrial disease, endocrine disease, prion disease, reproduction related diseases and conditions or any other disease associated with interleukin and/or interleuking receptor gene expression in a subject. In one embodiment, the siNA molecules of the invention that down regulate or reduce interleukin and/or interleukin receptor gene expression are used for treating or preventing asthma, chronic obstructive pulmonary disease or “COPD”, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, or emphysema in a subject.  
         [0217]     By “cancer” is meant a group of diseases characterized by uncontrolled growth and spread of abnormal cells.  
         [0218]     By “proliferative disease” or “cancer” is meant, any disease, condition, trait, genotype or phenotype characterized by unregulated cell growth or replication as is known in the art; including AIDS related cancers such as Kaposi&#39;s sarcoma; breast cancers; bone cancers such as Osteosarcoma, Chondrosarcomas, Ewing&#39;s sarcoma, Fibrosarcomas, Giant cell tumors, Adamantinomas, and Chordomas; Brain cancers such as Meningiomas, Glioblastomas, Lower-Grade Astrocytomas, Oligodendrocytomas, Pituitary Tumors, Schwannomas, and Metastatic brain cancers; cancers of the head and neck including various lymphomas such as mantle cell lymphoma, non-Hodgkins lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma, gallbladder and bile duct cancers, cancers of the retina such as retinoblastoma, cancers of the esophagus, gastric cancers, multiple myeloma, ovarian cancer, uterine cancer, thyroid cancer, testicular cancer, endometrial cancer, melanoma, colorectal cancer, lung cancer, bladder cancer, prostate cancer, lung cancer (including non-small cell lung carcinoma), pancreatic cancer, sarcomas, Wilms&#39; tumor, cervical cancer, head and neck cancer, skin cancers, nasopharyngeal carcinoma, liposarcoma, epithelial carcinoma, renal cell carcinoma, gallbladder adeno carcinoma, parotid adenocarcinoma, endometrial sarcoma, multidrug resistant cancers; and proliferative diseases and conditions, such as neovascularization associated with tumor angiogenesis, macular degeneration (e.g., wet/dry AMD), corneal neovascularization, diabetic retinopathy, neovascular glaucoma, myopic degeneration and other proliferative diseases and conditions such as restenosis and polycystic kidney disease, and any other cancer or proliferative disease, condition, trait, genotype or phenotype that can respond to the modulation of disease related gene expression in a cell or tissue, alone or in combination with other therapies.  
         [0219]     By “inflammatory disease” or “inflammatory condition” is meant any disease, condition, trait, genotype or phenotype characterized by an inflammatory or allergic process as is known in the art, such as inflammation, acute inflammation, chronic inflammation, atherosclerosis, restenosis, asthma, allergic rhinitis, atopic dermatitis, psoriasis, septic shock, rheumatoid arthritis, inflammatory bowl disease, inflammotory pelvic disease, pain, ocular inflammatory disease, celiac disease, Leigh Syndrome, Glycerol Kinase Deficiency, Familial eosinophilia (FE), autosomal recessive spastic ataxia, laryngeal inflammatory disease; Tuberculosis, Chronic cholecystitis, Bronchiectasis, Silicosis and other pneumoconioses, and any other inflammatory disease, condition, trait, genotype or phenotype that can respond to the modulation of disease related gene expression in a cell or tissue, alone or in combination with other therapies.  
         [0220]     By “respiratory disease” is meant, any disease or condition affecting the respiratory tract, such as asthma, chronic obstructive pulmonary disease or “COPD”, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, and any other respiratory disease, condition, trait, genotype or phenotype that can respond to the modulation of disease related gene expression in a cell or tissue, alone or in combination with other therapies.  
         [0221]     By “autoimmune disease” or “autoimmune condition” is meant, any disease, condition, trait, genotype or phenotype characterized by autoimmunity as is known in the art, such as multiple sclerosis, diabetes mellitus, lupus, celiac disease, Crohn&#39;s disease, ulcerative colitis, Guillain-Barre syndrome, scleroderms, Goodpasture&#39;s syndrome, Wegener&#39;s granulomatosis, autoimmune epilepsy, Rasmussen&#39;s encephalitis, Primary biliary sclerosis, Sclerosing cholangitis, Autoimmune hepatitis, Addison&#39;s disease, Hashimoto&#39;s thyroiditis, Fibromyalgia, Menier&#39;s syndrome; transplantation rejection (e.g., prevention of allograft rejection) pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren&#39;s syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter&#39;s syndrome, Grave&#39;s disease, and any other autoimmune disease, condition, trait, genotype or phenotype that can respond to the modulation of disease related gene expression in a cell or tissue, alone or in combination with other therapies.  
         [0222]     By “nuerologic disease” or “neurological disease” is meant any disease, disorder, or condition affecting the central or peripheral nervous system, inlcuding ADHD, AIDS—Neurological Complications, Absence of the Septum Pellucidum, Acquired Epileptiform Aphasia, Acute Disseminated Encephalomyelitis, Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Agnosia, Aicardi Syndrome, Alexander Disease, Alpers&#39; Disease, Alternating Hemiplegia, Alzheimer&#39;s Disease, Amyotrophic Lateral Sclerosis, Anencephaly, Aneurysm, Angelman Syndrome, Angiomatosis, Anoxia, Aphasia, Apraxia, Arachnoid Cysts, Arachnoiditis, Amold-Chiari Malformation, Arteriovenous Malformation, Aspartame, Asperger Syndrome, Ataxia Telangiectasia, Ataxia, Attention Deficit-Hyperactivity Disorder, Autism, Autonomic Dysfunction, Back Pain, Barth Syndrome, Batten Disease, Behcet&#39;s Disease, Bell&#39;s Palsy, Benign Essential Blepharospasm, Benign Focal Amyotrophy, Benign Intracranial Hypertension, Bernhardt-Roth Syndrome, Binswanger&#39;s Disease, Blepharospasm, Bloch-Sulzberger Syndrome, Brachial Plexus Birth Injuries, Brachial Plexus Injuries, Bradbury-Eggleston Syndrome, Brain Aneurysm, Brain Injury, Brain and Spinal Tumors, Brown-Sequard Syndrome, Bulbospinal Muscular Atrophy, Canavan Disease, Carpal Tunnel Syndrome, Causalgia, Cavernomas, Cavernous Angioma, Cavernous Malformation, Central Cervical Cord Syndrome, Central Cord Syndrome, Central Pain Syndrome, Cephalic Disorders, Cerebellar Degeneration, Cerebellar Hypoplasia, Cerebral Aneurysm, Cerebral Arteriosclerosis, Cerebral Atrophy, Cerebral Beriberi, Cerebral Gigantism, Cerebral Hypoxia, Cerebral Palsy, Cerebro-Oculo-Facio-Skeletal Syndrome, Charcot-Marie-Tooth Disorder, Chiari Malformation, Chorea, Choreoacanthocytosis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Orthostatic Intolerance, Chronic Pain, Cockayne Syndrome Type II, Coffin Lowry Syndrome, Coma, including Persistent Vegetative State, Complex Regional Pain Syndrome, Congenital Facial Diplegia, Congenital Myasthenia, Congenital Myopathy, Congenital Vascular Cavernous Malformations, Corticobasal Degeneration, Cranial Arteritis, Craniosynostosis, Creutzfeldt-Jakob Disease, Cumulative Trauma Disorders, Cushing&#39;s Syndrome, Cytomegalic Inclusion Body Disease (CIBD),  cytomegalovirus  Infection, Dancing Eyes-Dancing Feet Syndrome, Dandy-Walker Syndrome, Dawson Disease, De Morsier&#39;s Syndrome, Dejerine-Klumpke Palsy, Dementia—Multi-Infarct, Dementia—Subcortical, Dementia With Lewy Bodies, Dermatomyositis, Developmental Dyspraxia, Devic&#39;s Syndrome, Diabetic Neuropathy, Diffuse Sclerosis, Dravet&#39;s Syndrome, Dysautonomia, Dysgraphia, Dyslexia, Dysphagia, Dyspraxia, Dystonias, Early Infantile Epileptic Encephalopathy, Empty Sella Syndrome, Encephalitis Lethargica, Encephalitis and Meningitis, Encephaloceles, Encephalopathy, Encephalotrigeminal Angiomatosis, Epilepsy, Erb&#39;s Palsy, Erb-Duchenne and Dejerine-Klumpke Palsies, Fabry&#39;s Disease, Fahr&#39;s Syndrome, Fainting, Familial Dysautonomia, Familial Hemangioma, Familial Idiopathic Basal Ganglia Calcification, Familial Spastic Paralysis, Febrile Seizures (e.g., GEFS and GEFS plus), Fisher Syndrome, Floppy Infant Syndrome, Friedreich&#39;s Ataxia, Gaucher&#39;s Disease, Gerstmann&#39;s Syndrome, Gerstmann-Straussler-Scheinker Disease, Giant Cell Arteritis, Giant Cell Inclusion Disease, Globoid Cell Leukodystrophy, Glossopharyngeal Neuralgia, Guillain-Barre Syndrome, HTLV-1 Associated Myelopathy, Hallervorden-Spatz Disease, Head Injury, Headache, Hemicrania Continua, Hemifacial Spasm, Hemiplegia Alterans, Hereditary Neuropathies, Hereditary Spastic Paraplegia, Heredopathia Atactica Polyneuritiformis, Herpes Zoster Oticus, Herpes Zoster, Hirayama Syndrome, Holoprosencephaly, Huntington&#39;s Disease, Hydranencephaly, Hydrocephalus—Normal Pressure, Hydrocephalus, Hydromyelia, Hypercortisolism, Hypersomnia, Hypertonia, Hypotonia, Hypoxia, Immune-Mediated Encephalomyelitis, Inclusion Body Myositis, Incontinentia Pigmenti, Infantile Hypotonia, Infantile Phytanic Acid Storage Disease, Infantile Refsum Disease, Infantile Spasms, Inflammatory Myopathy, Intestinal Lipodystrophy, Intracranial Cysts, Intracranial Hypertension, Isaac&#39;s Syndrome, Joubert Syndrome, Kearns-Sayre Syndrome, Kennedy&#39;s Disease, Kinsbourne syndrome, Kleine-Levin syndrome, Klippel Feil Syndrome, Klippel-Trenaunay Syndrome (KTS), Klüver-Bucy Syndrome, Korsakoff s Amnesic Syndrome, Krabbe Disease, Kugelberg-Welander Disease, Kuru, Lambert-Eaton Myasthenic Syndrome, Landau-Kleffner Syndrome, Lateral Femoral Cutaneous Nerve Entrapment, Lateral Medullary Syndrome, Learning Disabilities, Leigh&#39;s Disease, Lennox-Gastaut Syndrome, Lesch-Nyhan Syndrome, Leukodystrophy, Levine-Critchley Syndrome, Lewy Body Dementia, Lissencephaly, Locked-In Syndrome, Lou Gehrig&#39;s Disease, Lupus—Neurological Sequelae, Lyme Disease—Neurological Complications, Machado-Joseph Disease, Macrencephaly, Megalencephaly, Melkersson-Rosenthal Syndrome, Meningitis, Menkes Disease, Meralgia Paresthetica, Metachromatic Leukodystrophy, Microcephaly, Migraine, Miller Fisher Syndrome, Mini-Strokes, Mitochondrial Myopathies, Mobius Syndrome, Monomelic Amyotrophy, Motor Neuron Diseases, Moyamoya Disease, Mucolipidoses, Mucopolysaccharidoses, Multi-Infarct Dementia, Multifocal Motor Neuropathy, Multiple Sclerosis, Multiple System Atrophy with Orthostatic Hypotension, Multiple System Atrophy, Muscular Dystrophy, Myasthenia—Congenital, Myasthenia Gravis, Myelinoclastic Diffuse Sclerosis, Myoclonic Encephalopathy of Infants, Myoclonus, Myopathy—Congenital, Myopathy—Thyrotoxic, Myopathy, Myotonia Congenita, Myotonia, Narcolepsy, Neuroacanthocytosis, Neurodegeneration with Brain Iron Accumulation, Neurofibromatosis, Neuroleptic Malignant Syndrome, Neurological Complications of AIDS, Neurological Manifestations of Pompe Disease, Neuromyelitis Optica, Neuromyotonia, Neuronal Ceroid Lipofuscinosis, Neuronal Migration Disorders, Neuropathy—Hereditary, Neurosarcoidosis, Neurotoxicity, Nevus Cavemosus, Niemann-Pick Disease, O&#39;Sullivan-McLeod Syndrome, Occipital Neuralgia, Occult Spinal Dysraphism Sequence, Ohtahara Syndrome, Olivopontocerebellar Atrophy, Opsoclonus Myoclonus, Orthostatic Hypotension, Overuse Syndrome, Pain—Chronic, Paraneoplastic Syndromes, Paresthesia, Parkinson&#39;s Disease, Parmyotonia Congenita, Paroxysmal Choreoathetosis, Paroxysmal Hemicrania, Parry-Romberg, Pelizaeus-Merzbacher Disease, Pena Shokeir II Syndrome, Perineural Cysts, Periodic Paralyses, Peripheral Neuropathy, Periventricular Leukomalacia, Persistent Vegetative State, Pervasive Developmental Disorders, Phytanic Acid Storage Disease, Pick&#39;s Disease, Piriformis Syndrome, Pituitary Tumors, Polymyositis, Pompe Disease, Porencephaly, Post-Polio Syndrome, Postherpetic Neuralgia, Postinfectious Encephalomyelitis, Postural Hypotension, Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Primary Lateral Sclerosis, Prion Diseases, Progressive Hemifacial Atrophy, Progressive Locomotor Ataxia, Progressive Multifocal Leukoencephalopathy, Progressive Sclerosing Poliodystrophy, Progressive Supranuclear Palsy, Pseudotumor Cerebri, Pyridoxine Dependent and Pyridoxine Responsive Siezure Disorders, Ramsay Hunt Syndrome Type I, Ramsay Hunt Syndrome Type II, Rasmussen&#39;s Encephalitis and other autoimmune epilepsies, Reflex Sympathetic Dystrophy Syndrome, Refsum Disease—Infantile, Refsum Disease, Repetitive Motion Disorders, Repetitive Stress Injuries, Restless Legs Syndrome, Retrovirus-Associated Myelopathy, Rett Syndrome, Reye&#39;s Syndrome, Riley-Day Syndrome, SUNCT Headache, Sacral Nerve Root Cysts, Saint Vitus Dance, Salivary Gland Disease, Sandhoff Disease, Schilder&#39;s Disease, Schizencephaly, Seizure Disorders, Septo-Optic Dysplasia, Severe Myoclonic Epilepsy of Infancy (SMEI), Shaken Baby Syndrome, Shingles, Shy-Drager Syndrome, Sjogren&#39;s Syndrome, Sleep Apnea, Sleeping Sickness, Soto&#39;s Syndrome, Spasticity, Spina Bifida, Spinal Cord Infarction, Spinal Cord Injury, Spinal Cord Tumors, Spinal Muscular Atrophy, Spinocerebellar Atrophy, Steele-Richardson-Olszewski Syndrome, Stiff-Person Syndrome, Striatonigral Degeneration, Stroke, Sturge-Weber Syndrome, Subacute Sclerosing Panencephalitis, Subcortical Arteriosclerotic Encephalopathy, Swallowing Disorders, Sydenham Chorea, Syncope, Syphilitic Spinal Sclerosis, Syringohydromyelia, Syringomyelia, Systemic Lupus Erythematosus, Tabes Dorsalis, Tardive Dyskinesia, Tarlov Cysts, Tay-Sachs Disease, Temporal Arteritis, Tethered Spinal Cord Syndrome, Thomsen Disease, Thoracic Outlet Syndrome, Thyrotoxic Myopathy, Tic Douloureux, Todd&#39;s Paralysis, Tourette Syndrome, Transient Ischemic Attack, Transmissible Spongiform Encephalopathies, Transverse Myelitis, Traumatic Brain Injury, Tremor, Trigeminal Neuralgia, Tropical Spastic Paraparesis, Tuberous Sclerosis, Vascular Erectile Tumor, Vasculitis including Temporal Arteritis, Von Economo&#39;s Disease, Von Hippel-Lindau disease (VHL), Von Recklinghausen&#39;s Disease, Wallenberg&#39;s Syndrome, Werdnig-Hoffman Disease, Wemicke-Korsakoff Syndrome, West Syndrome, Whipple&#39;s Disease, Williams Syndrome, Wilson&#39;s Disease, X-Linked Spinal and Bulbar Muscular Atrophy, and Zellweger Syndrome.  
         [0223]     By “infectious disease” is meant any disease, condition, trait, genotype or phenotype associated with an infectious agent, such as a virus, bacteria, fungus, prion, or parasite. Non-limiting examples of various viral genes that can be targeted using siNA molecules of the invention include Hepatitis C Virus (HCV, for example Genbank Accession Nos: D11168, D50483.1, L38318 and S82227), Hepatitis B Virus (HBV, for example GenBank Accession No. AF100308.1), Human Immunodeficiency Virus type 1 (HIV-1, for example GenBank Accession No. U51188), Human Immunodeficiency Virus type 2 (HIV-2, for example GenBank Accession No. X60667), West Nile Virus (WNV for example GenBank accession No. NC — 001563),  cytomegalovirus  (CMV for example GenBank Accession No. NC — 001347), respiratory syncytial virus (RSV for example GenBank Accession No. NC — 001781), influenza virus (for example example GenBank Accession No. AF037412 , rhinovirus  (for example, GenBank accession numbers: D00239, X02316, X01087, L24917, M16248, K02121, X01087),  papillomavirus  (for example GenBank Accession No. NC — 001353), Herpes Simplex Virus (HSV for example GenBank Accession No. NC — 001345), and other viruses such as HTLV (for example GenBank Accession No. AJ430458). Due to the high sequence variability of many viral genomes, selection of siNA molecules for broad therapeutic applications would likely involve the conserved regions of the viral genome. Nonlimiting examples of conserved regions of the viral genomes include but are not limited to 5′-Non Coding Regions (NCR), 3′—Non Coding Regions (NCR) and/or internal ribosome entry sites (IRES). siNA molecules designed against conserved regions of various viral genomes will enable efficient inhibition of viral replication in diverse patient populations and may ensure the effectiveness of the siNA molecules against viral quasi species which evolve due to mutations in the non-conserved regions of the viral genome. Non-limiting examples of bacterial infections include Actinomycosis, Anthrax, Aspergillosis, Bacteremia, Bacterial Infections and Mycoses,  Bartonella  Infections, Botulism, Brucellosis,  Burkholderia  Infections,  Campylobacter  Infections, Candidiasis, Cat-Scratch Disease,  Chlamydia  Infections, Cholera,  Clostridium  Infections, Coccidioidomycosis, Cross Infection, Cryptococcosis, Dermatomycoses, Dermatomycoses, Diphtheria, Ehrlichiosis,  Escherichia coli  Infections, Fasciitis, Necrotizing,  Fusobacterium  Infections, Gas Gangrene, Gram-Negative Bacterial Infections, Gram-Positive Bacterial Infections, Histoplasmosis, Impetigo,  Klebsiella  Infections, Legionellosis, Leprosy, Leptospirosis,  Listeria  Infections, Lyme Disease,  Maduromycosis , Melioidosis,  Mycobacterium  Infections,  Mycoplasma  Infections, Mycoses,  Nocardia  Infections, Onychomycosis, Ornithosis, Plague, Pneumococcal Infections,  Pseudomonas  Infections, Q Fever, Rat-Bite Fever, Relapsing Fever, Rheumatic Fever,  Rickettsia  Infections, Rocky Mountain Spotted Fever,  Salmonella  Infections, Scarlet Fever, Scrub Typhus, Sepsis, Sexually Transmitted Diseases—Bacterial, Bacterial Skin Diseases, Staphylococcal Infections, Streptococcal Infections, Tetanus, Tick-Bome Diseases, Tuberculosis, Tularemia, Typhoid Fever, Typhus, Epidemic Louse-Bome,  Vibrio  Infections, Yaws,  Yersinia  Infections, Zoonoses, and Zygomycosis. Non-limiting examples of fungal infections include Aspergillosis, Blastomycosis, Coccidioidomycosis, Cryptococcosis, Fungal Infections of Fingernails and Toenails, Fungal Sinusitis, Histoplasmosis, Histoplasmosis, Mucormycosis, Nail Fungal Infection, Paracoccidioidomycosis, Sporotrichosis, Valley Fever (Coccidioidomycosis), and Mold Allergy.  
         [0224]     By “ocular disease” is meant, any disease, condition, trait, genotype or phenotype of the eye and related structures, such as Cystoid Macular Edema, Asteroid Hyalosis, Pathological Myopia and Posterior Staphyloma, Toxocariasis (Ocular Larva Migrans), Retinal Vein Occlusion, Posterior Vitreous Detachment, Tractional Retinal Tears, Epiretinal Membrane, Diabetic Retinopathy, Lattice Degeneration, Retinal Vein Occlusion, Retinal Artery Occlusion, Macular Degeneration (e.g., age related macular degeneration such as wet AMD or dry AMD), Toxoplasmosis, Choroidal Melanoma, Acquired Retinoschisis, Hollenhorst Plaque, Idiopathic Central Serous Chorioretinopathy, Macular Hole, Presumed Ocular Histoplasmosis Syndrome, Retinal Macroaneursym, Retinitis Pigmentosa, Retinal Detachment, Hypertensive Retinopathy, Retinal Pigment Epithelium (RPE) Detachment, Papillophlebitis, Ocular Ischemic Syndrome, Coats&#39; Disease, Leber&#39;s Miliary Aneurysm, Conjunctival Neoplasms, Allergic Conjunctivitis, Vernal Conjunctivitis, Acute Bacterial Conjunctivitis, Allergic Conjunctivitis &amp;Vernal Keratoconjunctivitis, Viral Conjunctivitis, Bacterial Conjunctivitis, Chlamydial &amp; Gonococcal Conjunctivitis, Conjunctival Laceration, Episcleritis, Scleritis, Pingueculitis, Pterygium, Superior Limbic Keratoconjunctivitis (SLK of Theodore), Toxic Conjunctivitis, Conjunctivitis with Pseudomembrane, Giant Papillary Conjunctivitis, Terrien&#39;s Marginal Degeneration, Acanthamoeba Keratitis, Fungal Keratitis, Filamentary Keratitis, Bacterial Keratitis, Keratitis Sicca/Dry Eye Syndrome, Bacterial Keratitis, Herpes Simplex Keratitis, Sterile Corneal Infiltrates, Phlyctenulosis, Comeal Abrasion &amp; Recurrent Corneal Erosion, Corneal Foreign Body, Chemical Burs, Epithelial Basement Membrane Dystrophy (EBMD), Thygeson&#39;s Superficial Punctate Keratopathy, Comeal Laceration, Salzmann&#39;s Nodular Degeneration, Fuchs&#39; Endothelial Dystrophy, Crystalline Lens Subluxation, Ciliary-Block Glaucoma, Primary Open-Angle Glaucoma, Pigment Dispersion Syndrome and Pigmentary Glaucoma, Pseudoexfoliation Syndrom and Pseudoexfoliative Glaucoma, Anterior Uveitis, Primary Open Angle Glaucoma, Uveitic Glaucoma &amp; Glaucomatocyclitic Crisis, Pigment Dispersion Syndrome &amp; Pigmentary Glaucoma, Acute Angle Closure Glaucoma, Anterior Uveitis, Hyphema, Angle Recession Glaucoma, Lens Induced Glaucoma, Pseudoexfoliation Syndrome and Pseudoexfoliative Glaucoma, Axenfeld-Rieger Syndrome, Neovascular Glaucoma, Pars Planitis, Choroidal Rupture, Duane&#39;s Retraction Syndrome, Toxic/Nutritional Optic Neuropathy, Aberrant Regeneration of Cranial Nerve III, Intracranial Mass Lesions, Carotid-Cavernous Sinus Fistula, Anterior Ischemic Optic Neuropathy, Optic Disc Edema &amp; Papilledema, Cranial Nerve III Palsy, Cranial Nerve IV Palsy, Cranial Nerve VI Palsy, Cranial Nerve VII (Facial Nerve) Palsy, Homer&#39;s Syndrome, Internuclear Ophthalmoplegia, Optic Nerve Head Hypoplasia, Optic Pit, Tonic Pupil, Optic Nerve Head Drusen, Demyelinating Optic Neuropathy (Optic Neuritis, Retrobulbar Optic Neuritis), Amaurosis Fugax and Transient Ischemic Attack, Pseudotumor Cerebri, Pituitary Adenoma, Molluscum Contagiosum, Canaliculitis, Verruca and Papilloma, Pediculosis and Pthiriasis, Blepharitis, Hordeolum, Preseptal Cellulitis, Chalazion, Basal Cell Carcinoma, Herpes Zoster Ophthalmicus, Pediculosis &amp; Phthiriasis, Blow-out Fracture, Chronic Epiphora, Dacryocystitis, Herpes Simplex Blepharitis, Orbital Cellulitis, Senile Entropion, and Squamous Cell Carcinoma.  
         [0225]     By “cardiovascular disease” is meant and disease or condition affecting the heart and vasculature, inlcuding but not limited to, coronary heart disease (CHD), cerebrovascular disease (CVD), aortic stenosis, peripheral vascular disease, atherosclerosis, arteriosclerosis, myocardial infarction (heart attack), cerebrovascular diseases (stroke), transient ischaemic attacks (TIA), angina (stable and unstable), atrial fibrillation, arrhythmia, vavular disease, and/or congestive heart failure.  
         [0226]     In one embodiment of the present invention, each sequence of a siNA molecule of the invention is independently about 18 to about 24 nucleotides in length, in specific embodiments about 18, 19, 20, 21, 22, 23, or 24 nucleotides in length. In another embodiment, the siNA duplexes of the invention independently comprise about 17 to about 23 base pairs (e.g., about 17, 18, 19, 20, 21, 22, or 23). In yet another embodiment, siNA molecules of the invention comprising hairpin or circular structures are about 35 to about 55 (e.g., about 35, 40, 45, 50 or 55) nucleotides in length, or about 38 to about 44 (e.g., about 38, 39, 40, 41, 42, 43, or 44) nucleotides in length and comprising about 16 to about 22 (e.g., about 16, 17, 18, 19, 20, 21 or 22) base pairs. Exemplary siNA molecules of the invention are shown in Table II. Exemplary synthetic siNA molecules of the invention are shown in Table III and/or  FIGS. 4-5 .  
         [0227]     As used herein “cell” is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell can be present in an organism, e.g., birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell). The cell can be of somatic or germ line origin, totipotent or pluripotent, dividing or non-dividing. The cell can also be derived from or can comprise a gamete or embryo, a stem cell, or a fully differentiated cell.  
         [0228]     The siNA molecules of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through direct dermal application, transdermal application, or injection, with or without their incorporation in biopolymers. In particular embodiments, the nucleic acid molecules of the invention comprise sequences shown in Tables II-III and/or  FIGS. 4-5 . Examples of such nucleic acid molecules consist essentially of sequences defined in these tables and figures. Furthermore, the chemically modified constructs described in Table IV can be applied to any siNA sequence of the invention.  
         [0229]     In another aspect, the invention provides mammalian cells containing one or more siNA molecules of this invention. The one or more siNA molecules can independently be targeted to the same or different sites.  
         [0230]     By “RNA” is meant a molecule comprising at least one ribonucleotide residue. By “ribonucleotide” is meant a nucleotide with a hydroxyl group at the 2′ position of a β-D-ribofuranose moiety. The terms include double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in the RNA molecules of the instant invention can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of naturally-occurring RNA.  
         [0231]     By “subject” is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. “Subject” also refers to an organism to which the nucleic acid molecules of the invention can be administered. A subject can be a mammal or mammalian cells, including a human or human cells.  
         [0232]     The term “phosphorothioate” as used herein refers to an internucleotide linkage having Formula I, wherein Z and/or W comprise a sulfur atom. Hence, the term phosphorothioate refers to both phosphorothioate and phosphorodithioate internucleotide linkages.  
         [0233]     The term “phosphonoacetate” as used herein refers to an internucleotide linkage having Formula I, wherein Z and/or W comprise an acetyl or protected acetyl group.  
         [0234]     The term “thiophosphonoacetate” as used herein refers to an internucleotide linkage having Formula I, wherein Z comprises an acetyl or protected acetyl group and W comprises a sulfur atom or alternately W comprises an acetyl or protected acetyl group and Z comprises a sulfur atom.  
         [0235]     The term “universal base” as used herein refers to nucleotide base analogs that form base pairs with each of the natural DNA/RNA bases with little discrimination between them. Non-limiting examples of universal bases include C-phenyl, C-naphthyl and other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole as known in the art (see for example Loakes, 2001 , Nucleic Acids Research,  29, 2437-2447).  
         [0236]     The term “acyclic nucleotide” as used herein refers to any nucleotide having an acyclic ribose sugar, for example where any of the ribose carbons (C1, C2, C3, C4, or C5), are independently or in combination absent from the nucleotide.  
         [0237]     The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to for preventing or treating cancers and other proliferative conditions, viral infection, inflammatory disease, autoimmunity, respiratory disease, pulmonary disease, cardiovascular disease, nuerologic disease, renal disease, ocular disease, liver disease, mitochondrial disease, endocrine disease, prion disease, or reproduction related diseases and conditions in a subject or organism. In one embodiment, siNA molecules of the invention are used in combination with anti-imflammatory agents or bronchodilators as are known in the art to treat or prevent inflammatory and respiratory diseases and/or conditions in a subject or organism.  
         [0238]     For example, the siNA molecules can be administered to a subject or can be administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs (e.g., statins, hypertensive agents etc.) under conditions suitable for the treatment.  
         [0239]     In one embodiment, the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention, in a manner which allows expression of the siNA molecule. For example, the vector can contain sequence(s) encoding both strands of a siNA molecule comprising a duplex. The vector can also contain sequence(s) encoding a single nucleic acid molecule that is self-complementary and thus forms a siNA molecule. Non-limiting examples of such expression vectors are described in Paul et al., 2002 , Nature Biotechnology,  19, 505; Miyagishi and Taira, 2002 , Nature Biotechnology,  19, 497; Lee et al., 2002 , Nature Biotechnology,  19, 500; and Novina et al., 2002 , Nature Medicine, advance online publication doi:  10.1038/nm725.  
         [0240]     In another embodiment, the invention features a mammalian cell, for example, a human cell, including an expression vector of the invention.  
         [0241]     In yet another embodiment, the expression vector of the invention comprises a sequence for a siNA molecule having complementarity to a RNA molecule referred to by a Genbank Accession numbers, for example Genbank Accession Nos. shown in Table I.  
         [0242]     In one embodiment, an expression vector of the invention comprises a nucleic acid sequence encoding two or more siNA molecules, which can be the same or different.  
         [0243]     In another aspect of the invention, siNA molecules that interact with target RNA molecules and down-regulate gene encoding target RNA molecules (for example target RNA molecules referred to by Genbank Accession numbers herein) are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the siNA molecules bind and down-regulate gene function or expression via RNA interference (RNAi). Delivery of siNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell.  
         [0244]     By “vectors” is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.  
         [0245]     Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. 
     
    
     BRIEF DESCRIPTION OF THE DRAWINGS  
       [0246]      FIG. 1  shows a non-limiting example of a scheme for the synthesis of siNA molecules. The complementary siNA sequence strands, strand 1 and strand 2, are synthesized in tandem and are connected by a cleavable linkage, such as a nucleotide succinate or abasic succinate, which can be the same or different from the cleavable linker used for solid phase synthesis on a solid support. The synthesis can be either solid phase or solution phase, in the example shown, the synthesis is a solid phase synthesis. The synthesis is performed such that a protecting group, such as a dimethoxytrityl group, remains intact on the terminal nucleotide of the tandem oligonucleotide. Upon cleavage and deprotection of the oligonucleotide, the two siNA strands spontaneously hybridize to form a siNA duplex, which allows the purification of the duplex by utilizing the properties of the terminal protecting group, for example by applying a trityl on purification method wherein only duplexes/oligonucleotides with the terminal protecting group are isolated.  
         [0247]      FIG. 2  shows a MALDI-TOF mass spectrum of a purified siNA duplex synthesized by a method of the invention. The two peaks shown correspond to the predicted mass of the separate siNA sequence strands. This result demonstrates that the siNA duplex generated from tandem synthesis can be purified as a single entity using a simple trityl-on purification methodology.  
         [0248]      FIG. 3  shows a non-limiting proposed mechanistic representation of target RNA degradation involved in RNAi. Double-stranded RNA (dsRNA), which is generated by RNA-dependent RNA polymerase (RdRP) from foreign single-stranded RNA, for example viral, transposon, or other exogenous RNA, activates the DICER enzyme that in turn generates siNA duplexes. Alternately, synthetic or expressed siNA can be introduced directly into a cell by appropriate means. An active siNA complex forms which recognizes a target RNA, resulting in degradation of the target RNA by the RISC endonuclease complex or in the synthesis of additional RNA by RNA-dependent RNA polymerase (RdRP), which can activate DICER and result in additional siNA molecules, thereby amplifying the RNAi response.  
         [0249]      FIG. 4A -F shows non-limiting examples of chemically-modified siNA constructs of the present invention. In the figure, N stands for any nucleotide (adenosine, guanosine, cytosine, uridine, or optionally thymidine, for example thymidine can be substituted in the overhanging regions designated by parenthesis (N N). Various modifications are shown for the sense and antisense strands of the siNA constructs.  
         [0250]      FIG. 4A : The sense strand comprises 21 nucleotides wherein the two terminal 3′-nucleotides are optionally base paired and wherein all nucleotides present are ribonucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3′-terminal glyceryl moiety wherein the two terminal 3′-nucleotides are optionally complementary to the target RNA sequence, and wherein all nucleotides present are ribonucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s”, optionally connects the (N N) nucleotides in the antisense strand.  
         [0251]      FIG. 4B : The sense strand comprises 21 nucleotides wherein the two terminal 3′-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides and all purine nucleotides that may be present are 2′-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3′-terminal glyceryl moiety and wherein the two terminal 3′-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides and all purine nucleotides that may be present are 2′-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s”, optionally connects the (N N) nucleotides in the sense and antisense strand.  
         [0252]      FIG. 4C : The sense strand comprises 21 nucleotides having 5′- and 3′-terminal cap moieties wherein the two terminal 3′-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2′-O-methyl or 2′-deoxy-2′-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3′-terminal glyceryl moiety and wherein the two terminal 3′-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s”, optionally connects the (N N) nucleotides in the antisense strand.  
         [0253]      FIG. 4D : The sense strand comprises 21 nucleotides having 5′- and 3′-terminal cap moieties wherein the two terminal 3′-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein and wherein and all purine nucleotides that may be present are 2′-deoxy nucleotides. The antisense strand comprises 21 nucleotides, optionally having a 3′-terminal glyceryl moiety and wherein the two terminal 3′-nucleotides are optionally complementary to the target RNA sequence, wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides and all purine nucleotides that may be present are 2′-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s”, optionally connects the (N N) nucleotides in the antisense strand.  
         [0254]      FIG. 4E : The sense strand comprises 21 nucleotides having 5′- and 3′-terminal cap moieties wherein the two terminal 3′-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3′-terminal glyceryl moiety and wherein the two terminal 3′-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides and all purine nucleotides that may be present are 2′-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s”, optionally connects the (N N) nucleotides in the antisense strand.  
         [0255]      FIG. 4F : The sense strand comprises 21 nucleotides having 5′- and 3′-terminal cap moieties wherein the two terminal 3′-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein and wherein and all purine nucleotides that may be present are 2′-deoxy nucleotides. The antisense strand comprises 21 nucleotides, optionally having a 3′-terminal glyceryl moiety and wherein the two terminal 3′-nucleotides are optionally complementary to the target RNA sequence, and having one 3′-terminal phosphorothioate internucleotide linkage and wherein all pyrimidine nucleotides that may be present are 2′-deoxy-2′-fluoro modified nucleotides and all purine nucleotides that may be present are 2′-deoxy nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s”, optionally connects the (N N) nucleotides in the antisense strand. The antisense strand of constructs A-F comprise sequence complementary to any target nucleic acid sequence of the invention. Furthermore, when a glyceryl moiety (L) is present at the 3′-end of the antisense strand for any construct shown in  FIG. 4A -F, the modified internucleotide linkage is optional.  
         [0256]      FIG. 5A -F shows non-limiting examples of specific chemically-modified siNA sequences of the invention. A-F applies the chemical modifications described in  FIG. 4A -F to an IL-4R siNA sequence. Such chemical modifications can be applied to any interleukin and/or interleukin receptor sequence and/or interleukin and/or interleukin receptor polymorphism sequence.  
         [0257]      FIG. 6  shows non-limiting examples of different siNA constructs of the invention. The examples shown (constructs 1, 2, and 3) have 19 representative base pairs; however, different embodiments of the invention include any number of base pairs described herein. Bracketed regions represent nucleotide overhangs, for example comprising about 1, 2, 3, or 4 nucleotides in length, preferably about 2 nucleotides. Constructs 1 and 2 can be used independently for RNAi activity. Construct 2 can comprise a polynucleotide or non-nucleotide linker, which can optionally be designed as a biodegradable linker. In one embodiment, the loop structure shown in construct 2 can comprise a biodegradable linker that results in the formation of construct 1 in vivo and/or in vitro. In another example, construct 3 can be used to generate construct 2 under the same principle wherein a linker is used to generate the active siNA construct 2 in vivo and/or in vitro, which can optionally utilize another biodegradable linker to generate the active siNA construct 1 in vivo and/or in vitro. As such, the stability and/or activity of the siNA constructs can be modulated based on the design of the siNA construct for use in vivo or in vitro and/or in vitro.  
         [0258]      FIG. 7A -C is a diagrammatic representation of a scheme utilized in generating an expression cassette to generate siNA hairpin constructs.  
         [0259]      FIG. 7A : A DNA oligomer is synthesized with a 5′-restriction site (R1) sequence followed by a region having sequence identical (sense region of siNA) to a predetermined interleukin and/or interleukin receptor target sequence, wherein the sense region comprises, for example, about 19, 20, 21, or 22 nucleotides (N) in length, which is followed by a loop sequence of defined sequence (X), comprising, for example, about 3 to about 10 nucleotides.  
         [0260]      FIG. 7B : The synthetic construct is then extended by DNA polymerase to generate a hairpin structure having self-complementary sequence that will result in a siNA transcript having specificity for a interleukin and/or interleukin receptor target sequence and having self-complementary sense and antisense regions.  
         [0261]      FIG. 7C : The construct is heated (for example to about 95° C.) to linearize the sequence, thus allowing extension of a complementary second DNA strand using a primer to the 3′-restriction sequence of the first strand. The double-stranded DNA is then inserted into an appropriate vector for expression in cells. The construct can be designed such that a 3′-terminal nucleotide overhang results from the transcription, for example by engineering restriction sites and/or utilizing a poly-U termination region as described in Paul et al., 2002 , Nature Biotechnology,  29, 505-508.  
         [0262]      FIG. 8A -C is a diagrammatic representation of a scheme utilized in generating an expression cassette to generate double-stranded siNA constructs.  
         [0263]      FIG. 8A : A DNA oligomer is synthesized with a 5′-restriction (R1) site sequence followed by a region having sequence identical (sense region of siNA) to a predetermined interleukin and/or interleukin receptor target sequence, wherein the sense region comprises, for example, about 19, 20, 21, or 22 nucleotides (N) in length, and which is followed by a 3′-restriction site (R2) which is adjacent to a loop sequence of defined sequence (X).  
         [0264]      FIG. 8B : The synthetic construct is then extended by DNA polymerase to generate a hairpin structure having self-complementary sequence.  
         [0265]      FIG. 8C : The construct is processed by restriction enzymes specific to R1 and R2 to generate a double-stranded DNA which is then inserted into an appropriate vector for expression in cells. The transcription cassette is designed such that a U6 promoter region flanks each side of the dsDNA which generates the separate sense and antisense strands of the siNA. Poly T termination sequences can be added to the constructs to generate U overhangs in the resulting transcript.  
         [0266]      FIG. 9A -E is a diagrammatic representation of a method used to determine target sites for siNA mediated RNAi within a particular target nucleic acid sequence, such as messenger RNA.  
         [0267]      FIG. 9A : A pool of siNA oligonucleotides are synthesized wherein the antisense region of the siNA constructs has complementarity to target sites across the target nucleic acid sequence, and wherein the sense region comprises sequence complementary to the antisense region of the siNA.  
         [0268]     FIGS.  9 B&amp;C: ( FIG. 9B ) The sequences are pooled and are inserted into vectors such that ( FIG. 9C ) transfection of a vector into cells results in the expression of the siNA.  
         [0269]      FIG. 9D : Cells are sorted based on phenotypic change that is associated with modulation of the target nucleic acid sequence.  
         [0270]      FIG. 9E : The siNA is isolated from the sorted cells and is sequenced to identify efficacious target sites within the target nucleic acid sequence.  
         [0271]      FIG. 10  shows non-limiting examples of different stabilization chemistries (1-10) that can be used, for example, to stabilize the 3′-end of siNA sequences of the invention, including (1) [3-3′]-inverted deoxyribose; (2) deoxyribonucleotide; (3) [5′-3′]-3′-deoxyribonucleotide; (4) [5′-3′]-ribonucleotide; (5) [5′-3′]-3′-O-methyl ribonucleotide; (6) 3′-glyceryl; (7) [3′-5′]-3′-deoxyribonucleotide; (8) [3′-3′]-deoxyribonucleotide; (9) [5′-2′]-deoxyribonucleotide; and (10) [5-3′]-dideoxyribonucleotide. In addition to modified and unmodified backbone chemistries indicated in the figure, these chemistries can be combined with different backbone modifications as described herein, for example, backbone modifications having Formula I. In addition, the 2′-deoxy nucleotide shown 5′ to the terminal modifications shown can be another modified or unmodified nucleotide or non-nucleotide described herein, for example modifications having any of Formulae I-VII or any combination thereof.  
         [0272]      FIG. 11  shows a non-limiting example of a strategy used to identify chemically modified siNA constructs of the invention that are nuclease resistance while preserving the ability to mediate RNAi activity. Chemical modifications are introduced into the siNA construct based on educated design parameters (e.g. introducing 2′-mofications, base modifications, backbone modifications, terminal cap modifications etc). The modified construct in tested in an appropriate system (e.g. human serum for nuclease resistance, shown, or an animal model for PK/delivery parameters). In parallel, the siNA construct is tested for RNAi activity, for example in a cell culture system such as a luciferase reporter assay). Lead siNA constructs are then identified which possess a particular characteristic while maintaining RNAi activity, and can be further modified and assayed once again. This same approach can be used to identify siNA-conjugate molecules with improved pharmacokinetic profiles, delivery, and RNAi activity.  
         [0273]      FIG. 12  shows non-limiting examples of phosphorylated siNA molecules of the invention, including linear and duplex constructs and asymmetric derivatives thereof.  
         [0274]      FIG. 13  shows non-limiting examples of chemically modified terminal phosphate groups of the invention.  
         [0275]      FIG. 14A  shows a non-limiting example of methodology used to design self complementary DFO constructs utilizing palidrome and/or repeat nucleic acid sequences that are identified in a target nucleic acid sequence. (i) A palindrome or repeat sequence is identified in a nucleic acid target sequence. (ii) A sequence is designed that is complementary to the target nucleic acid sequence and the palindrome sequence. (iii) An inverse repeat sequence of the non-palindrome/repeat portion of the complementary sequence is appended to the 3′-end of the complementary sequence to generate a self complementary DFO molecule comprising sequence complementary to the nucleic acid target. (iv) The DFO molecule can self-assemble to form a double stranded oligonucleotide.  FIG. 14B  shows a non-limiting representative example of a duplex forming oligonucleotide sequence.  FIG. 14C  shows a non-limiting example of the self assembly schematic of a representative duplex forming oligonucleotide sequence.  FIG. 14D  shows a non-limiting example of the self assembly schematic of a representative duplex forming oligonucleotide sequence followed by interaction with a target nucleic acid sequence resulting in modulation of gene expression.  
         [0276]      FIG. 15  shows a non-limiting example of the design of self complementary DFO constructs utilizing palidrome and/or repeat nucleic acid sequences that are incorporated into the DFO constructs that have sequence complementary to any target nucleic acid sequence of interest. Incorporation of these palindrome/repeat sequences allow the design of DFO constructs that form duplexes in which each strand is capable of mediating modulation of target gene expression, for example by RNAi. First, the target sequence is identified. A complementary sequence is then generated in which nucleotide or non-nucleotide modifications (shown as X or Y) are introduced into the complementary sequence that generate an artificial palindrome (shown as XYXYXY in the Figure). An inverse repeat of the non-palindrome/repeat complementary sequence is appended to the 3′-end of the complementary sequence to generate a self complementary DFO comprising sequence complementary to the nucleic acid target. The DFO can self-assemble to form a double stranded oligonucleotide.  
         [0277]      FIG. 16  shows non-limiting examples of multifunctional siNA molecules of the invention comprising two separate polynucleotide sequences that are each capable of mediating RNAi directed cleavage of differing target nucleic acid sequences.  FIG. 16A  shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first and second complementary regions are situated at the 3′-ends of each polynucleotide sequence in the multifunctional siNA. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences.  FIG. 16B  shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first and second complementary regions are situated at the 5′-ends of each polynucleotide sequence in the multifunctional siNA. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences.  
         [0278]      FIG. 17  shows non-limiting examples of multifunctional siNA molecules of the invention comprising a single polynucleotide sequence comprising distinct regions that are each capable of mediating RNAi directed cleavage of differing target nucleic acid sequences.  FIG. 17A  shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the second complementary region is situated at the 3′-end of the polynucleotide sequence in the multifunctional siNA. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences.  FIG. 17B  shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first complementary region is situated at the 5′-end of the polynucleotide sequence in the multifunctional siNA. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences. In one embodiment, these multifunctional siNA constructs are processed in vivo or in vitro to generate multifunctional siNA constructs as shown in  FIG. 16 .  
         [0279]      FIG. 18  shows non-limiting examples of multifunctional siNA molecules of the invention comprising two separate polynucleotide sequences that are each capable of mediating RNAi directed cleavage of differing target nucleic acid sequences and wherein the multifunctional siNA construct further comprises a self complementary, palindrome, or repeat region, thus enabling shorter bifuctional siNA constructs that can mediate RNA interference against differing target nucleic acid sequences.  FIG. 18A  shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first and second complementary regions are situated at the 3′-ends of each polynucleotide sequence in the multifunctional siNA, and wherein the first and second complementary regions further comprise a self complementary, palindrome, or repeat region. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences.  FIG. 18B  shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first and second complementary regions are situated at the 5′-ends of each polynucleotide sequence in the multifunctional siNA, and wherein the first and second complementary regions further comprise a self complementary, palindrome, or repeat region. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences.  
         [0280]      FIG. 19  shows non-limiting examples of multifunctional siNA molecules of the invention comprising a single polynucleotide sequence comprising distinct regions that are each capable of mediating RNAi directed cleavage of differing target nucleic acid sequences and wherein the multifunctional siNA construct further comprises a self complementary, palindrome, or repeat region, thus enabling shorter bifuctional siNA constructs that can mediate RNA interference against differing target nucleic acid sequences.  FIG. 19A  shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the second complementary region is situated at the 3′-end of the polynucleotide sequence in the multifunctional siNA, and wherein the first and second complementary regions further comprise a self complementary, palindrome, or repeat region. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences.  FIG. 19B  shows a non-limiting example of a multifunctional siNA molecule having a first region that is complementary to a first target nucleic acid sequence (complementary region 1) and a second region that is complementary to a second target nucleic acid sequence (complementary region 2), wherein the first complementary region is situated at the 5′-end of the polynucleotide sequence in the multifunctional siNA, and wherein the first and second complementary regions further comprise a self complementary, palindrome, or repeat region. The dashed portions of each polynucleotide sequence of the multifunctional siNA construct have complementarity with regard to corresponding portions of the siNA duplex, but do not have complementarity to the target nucleic acid sequences. In one embodiment, these multifunctional siNA constructs are processed in vivo or in vitro to generate multifunctional siNA constructs as shown in  FIG. 18 .  
         [0281]      FIG. 20  shows a non-limiting example of how multifunctional siNA molecules of the invention can target two separate target nucleic acid molecules, such as separate RNA molecules encoding differing proteins, for example a cytokine and its corresponding receptor, differing viral strains, a virus and a cellular protein involved in viral infection or replication, or differing proteins involved in a common or divergent biologic pathway that is implicated in the maintenance of progression of disease. Each strand of the multifunctional siNA construct comprises a region having complementarity to separate target nucleic acid molecules. The multifunctional siNA molecule is designed such that each strand of the siNA can be utilized by the RISC complex to initiate RNA interference mediated cleavage of its corresponding target. These design parameters can include destabilization of each end of the siNA construct (see for example Schwarz et al., 2003 , Cell,  115, 199-208). Such destabilization can be accomplished for example by using guanosine-cytidine base pairs, alternate base pairs (e.g., wobbles), or destabilizing chemically modified nucleotides at terminal nucleotide positions as is known in the art.  
         [0282]      FIG. 21  shows a non-limiting example of how multifunctional siNA molecules of the invention can target two separate target nucleic acid sequences within the same target nucleic acid molecule, such as alternate coding regions of a RNA, coding and non-coding regions of a RNA, or alternate splice variant regions of a RNA. Each strand of the multifunctional siNA construct comprises a region having complementarity to the separate regions of the target nucleic acid molecule. The multifunctional siNA molecule is designed such that each strand of the siNA can be utilized by the RISC complex to initiate RNA interference mediated cleavage of its corresponding target region. These design parameters can include destabilization of each end of the siNA construct (see for example Schwarz et al., 2003 , Cell,  115, 199-208). Such destabilization can be accomplished for example by using guanosine-cytidine base pairs, alternate base pairs (e.g., wobbles), or destabilizing chemically modified nucleotides at terminal nucleotide positions as is known in the art.  
         [0283]      FIG. 22  shows a non-limiting example of reduction of IL-4R mRNA in Hela cells mediated by siNAs that target IL-4R mRNA. Hela cells were transfected with 0.25 ug/well of lipid complexed with 25 nM siNA. Active siNA constructs comprising Stab 9/22 stabilization chemistry were compared to matched chemistry irrelevant siNA control constructs (IC), and cells transfected with lipid alone (transfection control). As shown in the figure, the siNA constructs significantly reduce IL-4R RNA expression. 
     
    
     DETAILED DESCRIPTION OF THE INVENTION  
       [0000]     Mechanism of Action of Nucleic Acid Molecules of the Invention  
         [0284]     The discussion that follows discusses the proposed mechanism of RNA interference mediated by short interfering RNA as is presently known, and is not meant to be limiting and is not an admission of prior art. Applicant demonstrates herein that chemically-modified short interfering nucleic acids possess similar or improved capacity to mediate RNAi as do siRNA molecules and are expected to possess improved stability and activity in vivo; therefore, this discussion is not meant to be limiting only to siRNA and can be applied to siNA as a whole. By “improved capacity to mediate RNAi” or “improved RNAi activity” is meant to include RNAi activity measured in vitro and/or in vivo where the RNAi activity is a reflection of both the ability of the siNA to mediate RNAi and the stability of the siNAs of the invention. In this invention, the product of these activities can be increased in vitro and/or in vivo compared to an all RNA siRNA or a siNA containing a plurality of ribonucleotides. In some cases, the activity or stability of the siNA molecule can be decreased (i.e., less than ten-fold), but the overall activity of the siNA molecule is enhanced in vitro and/or in vivo.  
         [0285]     RNA interference refers to the process of sequence specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire et al., 1998 , Nature,  391, 806). The corresponding process in plants is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes which is commonly shared by diverse flora and phyla (Fire et al., 1999 , Trends Genet.,  15, 358). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response though a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2′,5′-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.  
         [0286]     The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as Dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Berstein et al., 2001 , Nature,  409, 363). Short interfering RNAs derived from Dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001 , Science,  293, 834). The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence homologous to the siRNA. Cleavage of the target RNA takes place in the middle of the region complementary to the guide sequence of the siRNA duplex (Elbashir et al., 2001 , Genes Dev.,  15, 188). In addition, RNA interference can also involve small RNA (e.g., micro-RNA or mRNA) mediated gene silencing, presumably though cellular mechanisms that regulate chromatin structure and thereby prevent transcription of target gene sequences (see for example Allshire, 2002 , Science,  297, 1818-1819; Volpe et al., 2002 , Science,  297, 1833-1837; Jenuwein, 2002 , Science,  297, 2215-2218; and Hall et al., 2002 , Science,  297, 2232-2237). As such, siNA molecules of the invention can be used to mediate gene silencing via interaction with RNA transcripts or alternately by interaction with particular gene sequences, wherein such interaction results in gene silencing either at the transcriptional level or post-transcriptional level.  
         [0287]     RNAi has been studied in a variety of systems. Fire et al., 1998, Nature, 391, 806, were the first to observe RNAi in  C. elegans . Wianny and Goetz, 1999 , Nature Cell Biol.,  2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond et al., 2000 , Nature,  404, 293, describe RNAi in  Drosophila  cells transfected with dsRNA. Elbashir et al., 2001 , Nature,  411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in  Drosophila  embryonic lysates has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21 nucleotide siRNA duplexes are most active when containing two 2-nucleotide 3′-terminal nucleotide overhangs. Furthermore, substitution of one or both siRNA strands with 2′-deoxy or 2′-O-methyl nucleotides abolishes RNAi activity, whereas substitution of 3′-terminal siRNA nucleotides with deoxy nucleotides was shown to be tolerated. Mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5′-end of the siRNA guide sequence rather than the 3′-end (Elbashir et al., 2001 , EMBO J,  20, 6877). Other studies have indicated that a 5′-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5′-phosphate moiety on the siRNA (Nykanen et al., 2001 , Cell,  107, 309); however, siRNA molecules lacking a 5′-phosphate are active when introduced exogenously, suggesting that 5′-phosphorylation of siRNA constructs may occur in vivo.  
         [0000]     Synthesis of Nucleic Acid Molecules  
         [0288]     Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs (“small” refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., individual siNA oligonucleotide sequences or siNA sequences synthesized in tandem) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of protein and/or RNA structure. Exemplary molecules of the instant invention are chemically synthesized, and others can similarly be synthesized.  
         [0289]     Oligonucleotides (e.g., certain modified oligonucleotides or portions of oligonucleotides lacking ribonucleotides) are synthesized using protocols known in the art, for example as described in Caruthers et al., 1992 , Methods in Enzymology  211, 3-19, Thompson et al., International PCT Publication No. WO 99/54459, Wincott et al., 1995 , Nucleic Acids Res.  23, 2677-2684, Wincott et al., 1997 , Methods Mol. Bio.,  74, 59, Brennan et al., 1998 , Biotechnol Bioeng.,  61, 33-45, and Brennan, U.S. Pat. No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 2.5 min coupling step for 2′-O-methylated nucleotides and a 45 second coupling step for 2′-deoxy nucleotides or 2′-deoxy-2′-fluoro nucleotides. Table V outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μmol scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M=6.6 μmol) of 2′-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60 μL of 0.25 M=15 μmol) can be used in each coupling cycle of 2′-O-methyl residues relative to polymer-bound 5′-hydroxyl. A 22-fold excess (40 μL of 0.11 M=4.4 μmol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40 μL of 0.25 M=10 μmol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5′-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM 12, 49 mM pyridine, 9% water in THF (PerSeptive Biosystems, Inc.). Burdick &amp; Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.  
         [0290]     Deprotection of the DNA-based oligonucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aqueous methylamine (1 mL) at 65° C. for 10 minutes. After cooling to −20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder.  
         [0291]     The method of synthesis used for RNA including certain siNA molecules of the invention follows the procedure as described in Usman et al., 1987 , J. Am. Chem. Soc.,  109, 7845; Scaringe et al., 1990 , Nucleic Acids Res.,  18, 5433; and Wincott et al., 1995 , Nucleic Acids Res.  23, 2677-2684 Wincott et al., 1997 , Methods Mol. Bio.,  74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 mmol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2′-O-methylated nucleotides. Table V outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 mmol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M=6.6 μmol) of 2′-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 μL of 0.25 M=15 mmol) can be used in each coupling cycle of 2′-O-methyl residues relative to polymer-bound 5′-hydroxyl. A 66-fold excess (120 μL of 0.11 M=13.2 μmol) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120 μL of 0.25 M=30 μmol) can be used in each coupling cycle of ribo residues relative to polymer-bound 5′-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM 12, 49 mM pyridine, 9% water in THF (PerSeptive Biosystems, Inc.). Burdick &amp; Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide 0.05 M in acetonitrile) is used.  
         [0292]     Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65° C. for 10 min. After cooling to −20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300 μL of a solution of 1.5 mL N-methylpyrrolidinone, 750 μL TEA and 1 mL TEA·3HF to provide a 1.4 M HF concentration) and heated to 65° C. After 1.5 h, the oligomer is quenched with 1.5 M NH 4 HCO 3 .  
         [0293]     Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65° C. for 15 minutes. The vial is brought to room temperature TEA·3HF (0.1 mL) is added and the vial is heated at 65° C. for 15 minutes. The sample is cooled at −20° C. and then quenched with 1.5 M NH 4 HCO 3 .  
         [0294]     For purification of the trityl-on oligomers, the quenched NH 4 HCO 3  solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 minutes. The cartridge is then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile.  
         [0295]     The average stepwise coupling yields are typically &gt;98% (Wincott et al., 1995  Nucleic Acids Res.  23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described above including but not limited to 96-well format.  
         [0296]     Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore et al., 1992 , Science  256, 9923; Draper et al., International PCT publication No. WO 93/23569; Shabarova et al., 1991 , Nucleic Acids Research  19, 4247; Bellon et al., 1997 , Nucleosides  &amp;  Nucleotides,  16, 951; Bellon et al., 1997 , Bioconjugate Chem.  8, 204), or by hybridization following synthesis and/or deprotection.  
         [0297]     The siNA molecules of the invention can also be synthesized via a tandem synthesis methodology as described in Example 1 herein, wherein both siNA strands are synthesized as a single contiguous oligonucleotide fragment or strand separated by a cleavable linker which is subsequently cleaved to provide separate siNA fragments or strands that hybridize and permit purification of the siNA duplex. The linker can be a polynucleotide linker or a non-nucleotide linker. The tandem synthesis of siNA as described herein can be readily adapted to both multiwell/multiplate synthesis platforms such as 96 well or similarly larger multi-well platforms. The tandem synthesis of siNA as described herein can also be readily adapted to large scale synthesis platforms employing batch reactors, synthesis columns and the like.  
         [0298]     A siNA molecule can also be assembled from two distinct nucleic acid strands or fragments wherein one fragment includes the sense region and the second fragment includes the antisense region of the RNA molecule.  
         [0299]     The nucleic acid molecules of the present invention can be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-fluoro, 2′-O-methyl, 2′-H (for a review see Usman and Cedergren, 1992 , TIBS  17, 34; Usman et al., 1994 , Nucleic Acids Symp. Ser.  31, 163). siNA constructs can be purified by gel electrophoresis using general methods or can be purified by high pressure liquid chromatography (HPLC; see Wincott et al., supra, the totality of which is hereby incorporated herein by reference) and re-suspended in water.  
         [0300]     In another aspect of the invention, siNA molecules of the invention are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules.  
         [0000]     Optimizing Activity of the Nucleic Acid Molecule of the Invention.  
         [0301]     Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) can prevent their degradation by serum ribonucleases, which can increase their potency (see e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al., 1990  Nature  344, 565; Pieken et al., 1991 , Science  253, 314; Usman and Cedergren, 1992 , Trends in Biochem. Sci.  17, 334; Usman et al., International Publication No. WO 93/15187; and Rossi et al., International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; Gold et al., U.S. Pat. No. 6,300,074; and Burgin et al., supra, all of which are incorporated by reference herein). All of the above references describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules described herein. Modifications that enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired.  
         [0302]     There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-fluoro, 2′-O-methyl, 2′-O-allyl, 2′-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992 , TIBS.  17, 34; Usman et al., 1994 , Nucleic Acids Symp. Ser.  31, 163; Burgin et al., 1996 , Biochemistry,  35, 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein et al., International Publication PCT No. WO 92/07065; Perrault et al.  Nature,  1990, 344, 565-568; Pieken et al.  Science,  1991, 253, 314-317; Usman and Cedergren,  Trends in Biochem. Sci.,  1992, 17, 334-339; Usman et al. International Publication PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman et al., 1995 , J. Biol. Chem.,  270, 25702; Beigelman et al., International PCT publication No. WO 97/26270; Beigelman et al., U.S. Pat. No. 5,716,824; Usman et al., U.S. Pat. No. 5,627,053; Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., U.S. Ser. No. 60/082,404 which was filed on Apr. 20, 1998; Karpeisky et al., 1998 , Tetrahedron Lett.,  39, 1131; Earnshaw and Gait, 1998 , Biopolymers  ( Nucleic Acid Sciences ), 48, 39-55; Verma and Eckstein, 1998 , Annu. Rev. Biochem.,  67, 99-134; and Burlina et al., 1997 , Bioorg. Med. Chem.,  5, 1999-2010; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into nucleic acid molecules without modulating catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the siNA nucleic acid molecules of the instant invention so long as the ability of siNA to promote RNAi is cells is not significantly inhibited.  
         [0303]     While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorodithioate, and/or 5′-methylphosphonate linkages improves stability, excessive modifications can cause some toxicity or decreased activity. Therefore, when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity, resulting in increased efficacy and higher specificity of these molecules.  
         [0304]     Short interfering nucleic acid (siNA) molecules having chemical modifications that maintain or enhance activity are provided. Such a nucleic acid is also generally more resistant to nucleases than an unmodified nucleic acid. Accordingly, the in vitro and/or in vivo activity should not be significantly lowered. In cases in which modulation is the goal, therapeutic nucleic acid molecules delivered exogenously should optimally be stable within cells until translation of the target RNA has been modulated long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Improvements in the chemical synthesis of RNA and DNA (Wincott et al., 1995 , Nucleic Acids Res.  23, 2677; Caruthers et al., 1992 , Methods in Enzymology  211, 3-19 (incorporated by reference herein)) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability, as described above.  
         [0305]     In one embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) G-clamp nucleotides. A G-clamp nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998 , J. Am. Chem. Soc.,  120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when hybridized to complementary oligonucleotides. The inclusion of such nucleotides in nucleic acid molecules of the invention results in both enhanced affinity and specificity to nucleic acid targets, complementary sequences, or template strands. In another embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) LNA “locked nucleic acid” nucleotides such as a 2′,4′-C methylene bicyclo nucleotide (see for example Wengel et al., International PCT Publication No. WO 00/66604 and WO 99/14226).  
         [0306]     In another embodiment, the invention features conjugates and/or complexes of siNA molecules of the invention. Such conjugates and/or complexes can be used to facilitate delivery of siNA molecules into a biological system, such as a cell. The conjugates and complexes provided by the instant invention can impart therapeutic activity by transferring therapeutic compounds across cellular membranes, altering the pharmacokinetics, and/or modulating the localization of nucleic acid molecules of the invention. The present invention encompasses the design and synthesis of novel conjugates and complexes for the delivery of molecules, including, but not limited to, small molecules, lipids, cholesterol, phospholipids, nucleosides, nucleotides, nucleic acids, antibodies, toxins, negatively charged polymers and other polymers, for example proteins, peptides, hormones, carbohydrates, polyethylene glycols, or polyamines, across cellular membranes. In general, the transporters described are designed to be used either individually or as part of a multi-component system, with or without degradable linkers. These compounds are expected to improve delivery and/or localization of nucleic acid molecules of the invention into a number of cell types originating from different tissues, in the presence or absence of serum (see Sullenger and Cech, U.S. Pat. No. 5,854,038). Conjugates of the molecules described herein can be attached to biologically active molecules via linkers that are biodegradable, such as biodegradable nucleic acid linker molecules.  
         [0307]     The term “biodegradable linker” as used herein, refers to a nucleic acid or non-nucleic acid linker molecule that is designed as a biodegradable linker to connect one molecule to another molecule, for example, a biologically active molecule to a siNA molecule of the invention or the sense and antisense strands of a siNA molecule of the invention. The biodegradable linker is designed such that its stability can be modulated for a particular purpose, such as delivery to a particular tissue or cell type. The stability of a nucleic acid-based biodegradable linker molecule can be modulated by using various chemistries, for example combinations of ribonucleotides, deoxyribonucleotides, and chemically-modified nucleotides, such as 2′-O-methyl, 2′-fluoro, 2′-amino, 2′-O-amino, 2′-C-allyl, 2′-O-allyl, and other 2′-modified or base modified nucleotides. The biodegradable nucleic acid linker molecule can be a dimer, trimer, tetramer or longer nucleic acid molecule, for example, an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or can comprise a single nucleotide with a phosphorus-based linkage, for example, a phosphoramidate or phosphodiester linkage. The biodegradable nucleic acid linker molecule can also comprise nucleic acid backbone, nucleic acid sugar, or nucleic acid base modifications.  
         [0308]     The term “biodegradable” as used herein, refers to degradation in a biological system, for example enzymatic degradation or chemical degradation.  
         [0309]     The term “biologically active molecule” as used herein, refers to compounds or molecules that are capable of eliciting or modifying a biological response in a system. Non-limiting examples of biologically active siNA molecules either alone or in combination with other molecules contemplated by the instant invention include therapeutically active molecules such as antibodies, cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, siNA, dsRNA, allozymes, aptamers, decoys and analogs thereof. Biologically active molecules of the invention also include molecules capable of modulating the pharmacokinetics and/or pharmacodynamics of other biologically active molecules, for example, lipids and polymers such as polyamines, polyamides, polyethylene glycol and other polyethers.  
         [0310]     The term “phospholipid” as used herein, refers to a hydrophobic molecule comprising at least one phosphorus group. For example, a phospholipid can comprise a phosphorus-containing group and saturated or unsaturated alkyl group, optionally substituted with OH, COOH, oxo, amine, or substituted or unsubstituted aryl groups.  
         [0311]     Therapeutic nucleic acid molecules (e.g., siNA molecules) delivered exogenously optimally are stable within cells until reverse transcription of the RNA has been modulated long enough to reduce the levels of the RNA transcript. The nucleic acid molecules are resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.  
         [0312]     In yet another embodiment, siNA molecules having chemical modifications that maintain or enhance enzymatic activity of proteins involved in RNAi are provided. Such nucleic acids are also generally more resistant to nucleases than unmodified nucleic acids. Thus, in vitro and/or in vivo the activity should not be significantly lowered.  
         [0313]     Use of the nucleic acid-based molecules of the invention will lead to better treatments by affording the possibility of combination therapies (e.g., multiple siNA molecules targeted to different genes; nucleic acid molecules coupled with known small molecule modulators; or intermittent treatment with combinations of molecules, including different motifs and/or other chemical or biological molecules). The treatment of subjects with siNA molecules can also include combinations of different types of nucleic acid molecules, such as enzymatic nucleic acid molecules (ribozymes), allozymes, antisense, 2,5-A oligoadenylate, decoys, and aptamers.  
         [0314]     In another aspect a siNA molecule of the invention comprises one or more 5′ and/or a 3′-cap structure, for example on only the sense siNA strand, the antisense siNA strand, or both siNA strands.  
         [0315]     By “cap structure” is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Adamic et al., U.S. Pat. No. 5,998,203, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5′-terminus (5′-cap) or at the 3′-terminal (3′-cap) or may be present on both termini. In non-limiting examples, the 5′-cap includes, but is not limited to, glyceryl, inverted deoxy abasic residue (moiety); 4′,5′-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide; carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3′-3′-inverted nucleotide moiety; 3′-3′-inverted abasic moiety; 3′-2′-inverted nucleotide moiety; 3′-2′-inverted abasic moiety; 1,4-butanediol phosphate; 3′-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3′-phosphate; 3′-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety.  
         [0316]     Non-limiting examples of the 3′-cap include, but are not limited to, glyceryl, inverted deoxy abasic residue (moiety), 4′,5′-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide; 4′-thio nucleotide, carbocyclic nucleotide; 5′-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5′-5′-inverted nucleotide moiety; 5′-5′-inverted abasic moiety; 5′-phosphoramidate; 5′-phosphorothioate; 1,4butanediol phosphate; 5′-amino; bridging and/or non-bridging 5′-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5′-mercapto moieties (for more details see Beaucage and Iyer, 1993 , Tetrahedron  49, 1925; incorporated by reference herein).  
         [0317]     By the term “non-nucleotide” is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine and therefore lacks a base at the 1′-position.  
         [0318]     An “alkyl” group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO 2  or N(CH 3 ) 2 , amino, or SH. The term also includes alkenyl groups that are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably, it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO 2 , halogen, N(CH 3 ) 2 , amino, or SH. The term “alkyl” also includes alkynyl groups that have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably, it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO 2  or N(CH3) 2 , amino or SH.  
         [0319]     Such alkyl groups can also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An “aryl” group refers to an aromatic group that has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An “alkylaryl” group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An “amide” refers to an —C(O)—NH—R, where R is either alkyl, aryl, alkylaryl or hydrogen. An “ester” refers to an —C(O)—OR′, where R is either alkyl, aryl, alkylaryl or hydrogen.  
         [0320]     By “nucleotide” as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1′ position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see, for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; Uhlman &amp; Peyman, supra, all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994 , Nucleic Acids Res.  22, 2183. Some of the non-limiting examples of base modifications that can be introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin et al., 1996 , Biochemistry,  35, 14090; Uhlman &amp; Peyman, supra). By “modified bases” in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1′ position or their equivalents.  
         [0321]     In one embodiment, the invention features modified siNA molecules, with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, 1995 , Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods , VCH, 331-417, and Mesmaeker et al., 1994 , Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS,  24-39.  
         [0322]     By “abasic” is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1′ position, see for example Adamic et al., U.S. Pat. No. 5,998,203.  
         [0323]     By “unmodified nucleoside” is meant one of the bases adenine, cytosine, guanine, thymine, or uracil joined to the 1′ carbon of β-D-ribo-furanose.  
         [0324]     By “modified nucleoside” is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate. Non-limiting examples of modified nucleotides are shown by Formulae I-VII and/or other modifications described herein.  
         [0325]     In connection with 2′-modified nucleotides as described for the present invention, by “amino” is meant 2′-NH 2  or 2′-O—NH 2 , which can be modified or unmodified. Such modified groups are described, for example, in Eckstein et al., U.S. Pat. No. 5,672,695 and Matulic-Adamic et al., U.S. Pat. No. 6,248,878, which are both incorporated by reference in their entireties.  
         [0326]     Various modifications to nucleic acid siNA structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life in vitro, stability, and ease of introduction of such oligonucleotides to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.  
         [0000]     Administration of Nucleic Acid Molecules  
         [0327]     A siNA molecule of the invention can be adapted for use to prevent or treat cancers and other proliferative conditions, viral infection, inflammatory disease, autoimmunity, respiratory disease, pulmonary disease, cardiovascular disease, nuerologic disease, renal disease, ocular disease, liver disease, mitochondrial disease, endocrine disease, prion disease, reproduction related diseases and conditions, and/or any other trait, disease or condition that is related to or will respond to the levels of interleukin and/or interleukin receptor in a cell or tissue, alone or in combination with other therapies. For example, a siNA molecule can comprise a delivery vehicle, including liposomes, for administration to a subject, carriers and diluents and their salts, and/or can be present in pharmaceutically acceptable formulations. Methods for the delivery of nucleic acid molecules are described in Akhtar et al., 1992 , Trends Cell Bio.,  2, 139 ; Delivery Strategies for Antisense Oligonucleotide Therapeutics, ed. Akhtar,  1995, Maurer et al., 1999 , Mol. Membr. Biol.,  16, 129-140; Hofland and Huang, 1999 , Handb. Exp. Pharmacol.,  137, 165-192; and Lee et al., 2000 , ACS Symp. Ser.,  752, 184-192, all of which are incorporated herein by reference. Beigelman et al., U.S. Pat. No. 6,395,713 and Sullivan et al., PCT WO 94/02595 further describe the general methods for delivery of nucleic acid molecules. These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as biodegradable polymers, hydrogels, cyclodextrins (see for example Gonzalez et al., 1999 , Bioconjugate Chem.,  10, 1068-1074; Wang et al., International PCT publication Nos. WO 03/47518 and WO 03/46185), poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (see for example U.S. Pat. No. 6,447,796 and U.S. Patent Application Publication No. U.S. 2002130430), biodegradable nanocapsules, and bioadhesive microspheres, or by proteinaceous vectors (O&#39;Hare and Normand, International PCT Publication No. WO 00/53722). In another embodiment, the nucleic acid molecules of the invention can also be formulated or complexed with polyethyleneimine and derivatives thereof, such as polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine (PEI-PEG-GAL) or polyethyleneimine-polyethyleneglycol-tri-N-acetylgalactosamine (PEI-PEG-triGAL) derivatives.  
         [0328]     In one embodiment, a siNA molecule of the invention is complexed with membrane disruptive agents such as those described in U.S. Patent Application Publication No. 20010007666, incorporated by reference herein in its entirety including the drawings. In another embodiment, the membrane disruptive agent or agents and the siNA molecule are also complexed with a cationic lipid or helper lipid molecule, such as those lipids described in U.S. Pat. No. 6,235,310, incorporated by reference herein in its entirety including the drawings.  
         [0329]     In one embodiment, a siNA molecule of the invention is complexed with delivery systems as described in U.S. Patent Application Publication No. 2003077829 and International PCT Publication Nos. WO 00/03683 and WO 02/087541, all incorporated by reference herein in their entirety including the drawings.  
         [0330]     In addition, the invention features the use of methods to deliver the nucleic acid molecules of the instant invention to the central nervous system and/or peripheral nervous system. Experiments have demonstrated the efficient in vivo uptake of nucleic acids by neurons. As an example of local administration of nucleic acids to nerve cells, Sommer et al., 1998 , Antisense Nuc. Acid Drug Dev.,  8, 75, describe a study in which a 15mer phosphorothioate antisense nucleic acid molecule to c-fos is administered to rats via microinjection into the brain. Antisense molecules labeled with tetramethylrhodamine-isothiocyanate (TRITC) or fluorescein isothiocyanate (FITC) were taken up by exclusively by neurons thirty minutes post-injection. A diffuse cytoplasmic staining and nuclear staining was observed in these cells. As an example of systemic administration of nucleic acid to nerve cells, Epa et al., 2000 , Antisense Nuc. Acid Drug Dev.,  10, 469, describe an in vivo mouse study in which beta-cyclodextrin-adamantane-oligonucleotide conjugates were used to target the p75 neurotrophin receptor in neuronally differentiated PC12 cells. Following a two week course of IP administration, pronounced uptake of p75 neurotrophin receptor antisense was observed in dorsal root ganglion (DRG) cells. In addition, a marked and consistent down-regulation of p75 was observed in DRG neurons. Additional approaches to the targeting of nucleic acid to neurons are described in Broaddus et al., 1998 , J. Neurosurg.,  88(4), 734; Karle et al., 1997 , Eur. J. Pharmocol.,  340(2/3), 153; Bannai et al., 1998 , Brain Research,  784(1,2), 304; Rajakumar et al., 1997 , Synapse,  26(3), 199; Wu-pong et al., 1999 , BioPharm,  12(1), 32; Bannai et al., 1998 , Brain Res. Protoc.,  3(1), 83; Simantov et al., 1996 , Neuroscience,  74(1), 39. Nucleic acid molecules of the invention are therefore amenable to delivery to and uptake by cells that express repeat expansion allelic variants for modulation of RE gene expression. The delivery of nucleic acid molecules of the invention, targeting RE is provided by a variety of different strategies. Traditional approaches to CNS delivery that can be used include, but are not limited to, intrathecal and intracerebroventricular administration, implantation of catheters and pumps, direct injection or perfusion at the site of injury or lesion, injection into the brain arterial system, or by chemical or osmotic opening of the blood-brain barrier. Other approaches can include the use of various transport and carrier systems, for example though the use of conjugates and biodegradable polymers. Furthermore, gene therapy approaches, for example as described in Kaplitt et al., U.S. Pat. No. 6,180,613 and Davidson, WO 04/013280, can be used to express nucleic acid molecules in the CNS.  
         [0331]     In addition, the invention features the use of methods to deliver the nucleic acid molecules of the instant invention to hematopoietic cells, including monocytes and lymphocytes. These methods are described in detail by Hartmann et al., 1998 , J. Phamacol. Exp. Ther.,  285(2), 920-928; Kronenwett et al., 1998 , Blood,  91(3), 852-862; Filion and Phillips, 1997 , Biochim. Biophys. Acta.,  1329(2), 345-356; Ma and Wei, 1996 , Leuk. Res.,  20(11/12), 925-930; and Bongartz et al., 1994 , Nucleic Acids Research,  22(22), 4681-8. Such methods, as described above, include the use of free oligonucleitide, cationic lipid formulations, liposome formulations including pH sensitive liposomes and immunoliposomes, and bioconjugates including oligonucleotides conjugated to fusogenic peptides, for the transfection of hematopoietic cells with oligonucleotides.  
         [0332]     In one embodiment, a compound, molecule, or composition for the treatment of ocular conditions (e.g., macular degeneration, diabetic retinopathy etc.) is administered to a subject intraocularly or by intraocular means. In another embodiment, a compound, molecule, or composition for the treatment of ocular conditions (e.g., macular degeneration, diabetic retinopathy etc.) is administered to a subject periocularly or by periocular means (see for example Ahlheim et al., International PCT publication No. WO 03/24420). In one embodiment, a siNA molecule and/or formulation or composition thereof is administered to a subject intraocularly or by intraocular means. In another embodiment, a siNA molecule and/or formualtion or composition thereof is administered to a subject periocularly or by periocular means. Periocular administration generally provides a less invasive approach to administering siNA molecules and formualtion or composition thereof to a subject (see for example Ahlheim et al., International PCT publication No. WO 03/24420). The use of periocular administraction also minimizes the risk of retinal detachment, allows for more frequent dosing or administraction, provides a clinically relevant route of administraction for macular degeneration and other optic conditions, and also provides the possiblilty of using resevoirs (e.g., implants, pumps or other devices) for drug delivery.  
         [0333]     In one embodiment, the siNA molecules of the invention and formulations or compositions thereof are administered directly or topically (e.g., locally) to the dermis or follicles as is generally known in the art (see for example Brand, 2001 , Curr. Opin. Mol. Ther.,  3, 244-8; Regnier et al., 1998 , J Drug Target,  5, 275-89; Kanikkannan, 2002 , BioDrugs,  16, 339-47; Wraight et al., 2001 , Pharmacol. Ther.,  90, 89-104; and Preat and Dujardin, 2001, STP PharmaSciences, 11, 57-68.  
         [0334]     In one embodiment, dermal delivery systems of the invention include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone). In one embodiment, the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer. Examples of liposomes which can be used in this invention include the following: (1) CellFectin, 1:1.5 (M/M) liposome formulation of the cationic lipid N,NI,NII,NIII-tetramethyl-N,NI,NII,NIII-tetrapalmit-y-spermine and dioleoyl phosphatidylethanolamine (DOPE) (GIBCO BRL); (2) Cytofectin GSV, 2:1 (M/M) liposome formulation of a cationic lipid and DOPE (Glen Research); (3) DOTAP (N-[1-(2,3-dioleoyloxy)-N,N,N-tri-methyl-ammoniummethylsulfate) (Boehringer Manheim); and (4) Lipofectamine, 3:1 (M/M) liposome formulation of the polycationic lipid DOSPA and the neutral lipid DOPE (GIBCO BRL).  
         [0335]     In one embodiment, transmucosal delivery systems of the invention include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid).  
         [0336]     In one embodiment, nucleic acid molecules of the invention are administered to the central nervous system (CNS) or peripheral nervous system (PNS). Experiments have demonstrated the efficient in vivo uptake of nucleic acids by neurons. As an example of local administration of nucleic acids to nerve cells, Sommer et al., 1998 , Antisense Nuc. Acid Drug Dev.,  8, 75, describe a study in which a 15mer phosphorothioate antisense nucleic acid molecule to c-fos is administered to rats via microinjection into the brain. Antisense molecules labeled with tetramethylrhodamine-isothiocyanate (TRITC) or fluorescein isothiocyanate (FITC) were taken up by exclusively by neurons thirty minutes post-injection. A diffuse cytoplasmic staining and nuclear staining was observed in these cells. As an example of systemic administration of nucleic acid to nerve cells, Epa et al., 2000 , Antisense Nuc. Acid Drug Dev.,  10, 469, describe an in vivo mouse study in which beta-cyclodextrin-adamantane-oligonucleotide conjugates were used to target the p75 neurotrophin receptor in neuronally differentiated PC12 cells. Following a two week course of IP administration, pronounced uptake of p75 neurotrophin receptor antisense was observed in dorsal root ganglion (DRG) cells. In addition, a marked and consistent down-regulation of p75 was observed in DRG neurons. Additional approaches to the targeting of nucleic acid to neurons are described in Broaddus et al., 1998 , J. Neurosurg.,  88(4), 734; Karle et al., 1997 , Eur. J. Pharmocol.,  340(2/3), 153; Bannai et al., 1998 , Brain Research,  784(1,2), 304; Rajakumar et al., 1997 , Synapse,  26(3), 199; Wu-pong et al., 1999 , BioPharm,  12(1), 32; Bannai et al., 1998 , Brain Res. Protoc.,  3(1), 83; Simantov et al., 1996 , Neuroscience,  74(1), 39. Nucleic acid molecules of the invention are therefore amenable to delivery to and uptake by cells in the CNS and/or PNS.  
         [0337]     The delivery of nucleic acid molecules of the invention to the CNS is provided by a variety of different strategies. Traditional approaches to CNS delivery that can be used include, but are not limited to, intrathecal and intracerebroventricular administration, implantation of catheters and pumps, direct injection or perfusion at the site of injury or lesion, injection into the brain arterial system, or by chemical or osmotic opening of the blood-brain barrier. Other approaches can include the use of various transport and carrier systems, for example though the use of conjugates and biodegradable polymers. Furthermore, gene therapy approaches, for example as described in Kaplitt et al., U.S. Pat. No. 6,180,613 and Davidson, WO 04/013280, can be used to express nucleic acid molecules in the CNS.  
         [0338]     In one embodiment, the nucleic acid molecules of the invention are administered via pulmonary delivery, such as by inhalation of an aerosol or spray dried formulation administered by an inhalation device or nebulizer, providing rapid local uptake of the nucleic acid molecules into relevant pulmonary tissues. Solid particulate compositions containing respirable dry particles of micronized nucleic acid compositions can be prepared by grinding dried or lyophilized nucleic acid compositions, and then passing the micronized composition through, for example, a 400 mesh screen to break up or separate out large agglomerates. A solid particulate composition comprising the nucleic acid compositions of the invention can optionally contain a dispersant which serves to facilitate the formation of an aerosol as well as other therapeutic compounds. A suitable dispersant is lactose, which can be blended with the nucleic acid compound in any suitable ratio, such as a 1 to 1 ratio by weight.  
         [0339]     Aerosols of liquid particles comprising a nucleic acid composition of the invention can be produced by any suitable means, such as with a nebulizer (see for example U.S. Pat. No. 4,501,729). Nebulizers are commercially available devices which transform solutions or suspensions of an active ingredient into a therapeutic aerosol mist either by means of acceleration of a compressed gas, typically air or oxygen, through a narrow venturi orifice or by means of ultrasonic agitation. Suitable formulations for use in nebulizers comprise the active ingredient in a liquid carrier in an amount of up to 40% w/w preferably less than 20% w/w of the formulation. The carrier is typically water or a dilute aqueous alcoholic solution, preferably made isotonic with body fluids by the addition of, for example, sodium chloride or other suitable salts. Optional additives include preservatives if the formulation is not prepared sterile, for example, methyl hydroxybenzoate, anti-oxidants, flavorings, volatile oils, buffering agents and emulsifiers and other formulation surfactants. The aerosols of solid particles comprising the active composition and surfactant can likewise be produced with any solid particulate aerosol generator. Aerosol generators for administering solid particulate therapeutics to a subject produce particles which are respirable, as explained above, and generate a volume of aerosol containing a predetermined metered dose of a therapeutic composition at a rate suitable for human administration. One illustrative type of solid particulate aerosol generator is an insufflator. Suitable formulations for administration by insufflation include finely comminuted powders which can be delivered by means of an insufflator. In the insufflator, the powder, e.g., a metered dose thereof effective to carry out the treatments described herein, is contained in capsules or cartridges, typically made of gelatin or plastic, which are either pierced or opened in situ and the powder delivered by air drawn through the device upon inhalation or by means of a manually-operated pump. The powder employed in the insufflator consists either solely of the active ingredient or of a powder blend comprising the active ingredient, a suitable powder diluent, such as lactose, and an optional surfactant. The active ingredient typically comprises from 0.1 to 100 w/w of the formulation. A second type of illustrative aerosol generator comprises a metered dose inhaler. Metered dose inhalers are pressurized aerosol dispensers, typically containing a suspension or solution formulation of the active ingredient in a liquified propellant. During use these devices discharge the formulation through a valve adapted to deliver a metered volume to produce a fine particle spray containing the active ingredient. Suitable propellants include certain chlorofluorocarbon compounds, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof. The formulation can additionally contain one or more co-solvents, for example, ethanol, emulsifiers and other formulation surfactants, such as oleic acid or sorbitan trioleate, anti-oxidants and suitable flavoring agents. Other methods for pulmonary delivery are described in, for example U.S. Patent Application No. 20040037780, and U.S. Pat. Nos. 6,592,904; 6,582,728; 6,565,885.  
         [0340]     In one embodiment, siNA molecules of the invention are formulated or complexed with polyethylenimine (e.g., linear or branched PEI) and/or polyethylenimine derivatives, including for example grafted PEIs such as galactose PEI, cholesterol PEI, antibody derivatized PEI, and polyethylene glycol PEI (PEG-PEI) derivatives thereof (see for example Ogris et al., 2001 , AAPA PharmSci,  3, 1-11; Furgeson et al., 2003, Bioconjugate Chem., 14, 840-847; Kunath et al., 2002, Phramaceutical Research, 19, 810-817; Choi et al., 2001, Bull. Korean Chem. Soc., 22, 46-52; Bettinger et al., 1999, Bioconjugate Chem., 10, 558-561; Peterson et al., 2002, Bioconjugate Chem., 13, 845-854; Erbacher et al., 1999, Journal of Gene Medicine Preprint, 1, 1-18; Godbey et al., 1999., PNAS USA, 96, 5177-5181; Godbey et al., 1999, Journal of Controlled Release, 60, 149-160; Diebold et al., 1999, Journal of Biological Chemistry, 274, 19087-19094; Thomas and Klibanov, 2002, PNAS USA, 99, 14640-14645; and Sagara, U.S. Pat. No. 6,586,524, incorporated by reference herein.  
         [0341]     In one embodiment, a siNA molecule of the invention comprises a bioconjugate, for example a nucleic acid conjugate as described in Vargeese et al., U.S. Ser. No. 10/427,160, filed Apr. 30, 2003; U.S. Pat. No. 6,528,631; U.S. Pat. No. 6,335,434; US 6, 235,886; U.S. Pat. No. 6,153,737; U.S. Pat. No. 5,214,136; U.S. Pat. No. 5,138,045, all incorporated by reference herein.  
         [0342]     Thus, the invention features a pharmaceutical composition comprising one or more nucleic acid(s) of the invention in an acceptable carrier, such as a stabilizer, buffer, and the like. The polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a subject by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention can also be formulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions, suspensions for injectable administration, and the other compositions known in the art.  
         [0343]     The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.  
         [0344]     A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or subject, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged nucleic acid is desirable for delivery). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms that prevent the composition or formulation from exerting its effect.  
         [0345]     By “systemic administration” is meant in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes that lead to systemic absorption include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes exposes the siNA molecules of the invention to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach can provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cancer cells.  
         [0346]     By “pharmaceutically acceptable formulation” is meant a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85), which can enhance entry of drugs into the CNS (Jolliet-Riant and Tillement, 1999 , Fundam. Clin. Pharmacol.,  13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich, DF et al, 1999 , Cell Transplant,  8, 47-58) (Alkermes, Inc. Cambridge, Mass.); and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms ( Prog Neuropsychopharmacol Biol Psychiatry,  23, 941-949, 1999). Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado et al., 1998 , J. Pharm. Sci.,  87, 1308-1315; Tyler et al., 1999 , FEBS Lett.,  421, 280-284; Pardridge et al., 1995 , PNAS USA.,  92, 5592-5596; Boado, 1995 , Adv. Drug Delivery Rev.,  15, 73-107; Aldrian-Herrada et al., 1998 , Nucleic Acids Res.,  26, 4910-4916; and Tyler et al., 1999 , PNAS USA.,  96, 7053-7058.  
         [0347]     The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al.  Chem. Rev.  1995, 95, 2601-2627; Ishiwata et al.,  Chem. Pharm. Bull.  1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al.,  Science  1995, 267, 1275-1276; Oku et al., 1995 , Biochim. Biophys. Acta,  1238, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al.,  J. Biol. Chem.  1995, 42, 24864-24870; Choi et al., International PCT Publication No. WO 96/10391; Ansell et al., International PCT Publication No. WO 96/10390; Holland et al., International PCT Publication No. WO 96/10392). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.  
         [0348]     The present invention also includes compositions prepared for storage or administration that include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in  Remington&#39;s Pharmaceutical Sciences , Mack Publishing Co. (A. R. Gennaro edit. 1985), hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents can be provided. These include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. In addition, antioxidants and suspending agents can be used.  
         [0349]     A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.  
         [0350]     The nucleic acid molecules of the invention and formulations thereof can be administered orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising a nucleic acid molecule of the invention and a pharmaceutically acceptable carrier. One or more nucleic acid molecules of the invention can be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing nucleic acid molecules of the invention can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.  
         [0351]     Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate can be employed.  
         [0352]     Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.  
         [0353]     Aqueous suspensions contain the active materials in a mixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.  
         [0354]     Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid.  
         [0355]     Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.  
         [0356]     Pharmaceutical compositions of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening and flavoring agents.  
         [0357]     Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer&#39;s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.  
         [0358]     The nucleic acid molecules of the invention can also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.  
         [0359]     Nucleic acid molecules of the invention can be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.  
         [0360]     Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per subject per day). The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms generally contain between from about 1 mg to about 500 mg of an active ingredient.  
         [0361]     It is understood that the specific dose level for any particular subject depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.  
         [0362]     For administration to non-human animals, the composition can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It can also be convenient to present the composition as a premix for addition to the feed or drinking water.  
         [0363]     The nucleic acid molecules of the present invention can also be administered to a subject in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects.  
         [0364]     In one embodiment, the invention comprises compositions suitable for administering nucleic acid molecules of the invention to specific cell types. For example, the asialoglycoprotein receptor (ASGPr) (Wu and Wu, 1987 , J. Biol. Chem.  262, 4429-4432) is unique to hepatocytes and binds branched galactose-terminal glycoproteins, such as asialoorosomucoid (ASOR). In another example, the folate receptor is overexpressed in many cancer cells. Binding of such glycoproteins, synthetic glycoconjugates, or folates to the receptor takes place with an affinity that strongly depends on the degree of branching of the oligosaccharide chain, for example, triatennary structures are bound with greater affinity than biatenarry or monoatennary chains (Baenziger and Fiete, 1980 , Cell,  22, 611-620; Connolly et al., 1982 , J. Biol. Chem.,  257, 939-945). Lee and Lee, 1987 , Glycoconjugate J.,  4, 317-328, obtained this high specificity through the use of N-acetyl-D-galactosamine as the carbohydrate moiety, which has higher affinity for the receptor, compared to galactose. This “clustering effect” has also been described for the binding and uptake of mannosyl-terminating glycoproteins or glycoconjugates (Ponpipom et al., 1981 , J. Med. Chem.,  24, 1388-1395). The use of galactose, galactosamine, or folate based conjugates to transport exogenous compounds across cell membranes can provide a targeted delivery approach to, for example, the treatment of liver disease, cancers of the liver, or other cancers. The use of bioconjugates can also provide a reduction in the required dose of therapeutic compounds required for treatment. Furthermore, therapeutic bioavialability, pharmacodynamics, and pharmacokinetic parameters can be modulated through the use of nucleic acid bioconjugates of the invention. Non-limiting examples of such bioconjugates are described in Vargeese et al., U.S. Ser. No. 10/201,394, filed Aug. 13, 2001; and Matulic-Adamic et al., U.S. Ser. No. 10/151,116, filed May 17, 2002. In one embodiment, nucleic acid molecules of the invention are complexed with or covalently attached to nanoparticles, such as Hepatitis B virus S, M, or L evelope proteins (see for example Yamado et al., 2003 , Nature Biotechnology,  21, 885). In one embodiment, nucleic acid molecules of the invention are delivered with specificity for human tumor cells, specifically non-apoptotic human tumor cells including for example T-cells, hepatocytes, breast carcinoma cells, ovarian carcinoma cells, melanoma cells, intestinal epithelial cells, prostate cells, testicular cells, non-small cell lung cancers, small cell lung cancers, etc.  
         [0365]     In one embodiment, a siNA molecule of the invention is designed or formulated to specifically target endothelial cells or tumor cells. For example, various formulations and conjugates can be utilized to specifically target endothelial cells or tumor cells, including PEI-PEG-folate, PEI-PEG-RGD, PEI-PEG-biotin, PEI-PEG-cholesterol, and other conjugates known in the art that enable specific targeting to endothelial cells and/or tumor cells.  
         [0366]     Alternatively, certain siNA molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985 , Science,  229, 345; McGarry and Lindquist, 1986 , Proc. Natl. Acad. Sci., USA  83, 399; Scanlon et al., 1991 , Proc. Natl. Acad. Sci. USA,  88, 10591-5; Kashani-Sabet et al., 1992 , Antisense Res. Dev.,  2, 3-15; Dropulic et al., 1992 , J. Virol.,  66, 1432-41; Weerasinghe et al., 1991 , J. Virol.,  65, 5531-4; Ojwang et al., 1992 , Proc. Natl. Acad. Sci. USA,  89, 10802-6; Chen et al., 1992 , Nucleic Acids Res.,  20, 4581-9; Sarver et al., 1990  Science,  247, 1222-1225; Thompson et al., 1995 , Nucleic Acids Res.,  23, 2259; Good et al., 1997 , Gene Therapy,  4, 45). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., 1992 , Nucleic Acids Symp. Ser.,  27, 15-6; Taira et al., 1991 , Nucleic Acids Res.,  19, 5125-30; Ventura et al., 1993 , Nucleic Acids Res.,  21, 3249-55; Chowrira et al., 1994 , J. Biol. Chem.,  269, 25856).  
         [0367]     In another aspect of the invention, RNA molecules of the present invention can be expressed from transcription units (see for example Couture et al., 1996 , TIG.,  12, 510) inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. In another embodiment, pol III based constructs are used to express nucleic acid molecules of the invention (see for example Thompson, U.S. Pats. Nos. 5,902,880 and 6,146,886). The recombinant vectors capable of expressing the siNA molecules can be delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the siNA molecule interacts with the target mRNA and generates an RNAi response. Delivery of siNA molecule expressing vectors can be systemic, such as by intravenous or intra-muscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell (for a review see Couture et al., 1996 , TIG.,  12, 510).  
         [0368]     In one aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the instant invention. The expression vector can encode one or both strands of a siNA duplex, or a single self-complementary strand that self hybridizes into a siNA duplex. The nucleic acid sequences encoding the siNA molecules of the instant invention can be operably linked in a manner that allows expression of the siNA molecule (see for example Paul et al., 2002 , Nature Biotechnology,  19, 505; Miyagishi and Taira, 2002 , Nature Biotechnology,  19, 497; Lee et al., 2002 , Nature Biotechnology,  19, 500; and Novina et al., 2002 , Nature Medicine, advance online publication doi:  10.1038/nm725).  
         [0369]     In another aspect, the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); and c) a nucleic acid sequence encoding at least one of the siNA molecules of the instant invention, wherein said sequence is operably linked to said initiation region and said termination region in a manner that allows expression and/or delivery of the siNA molecule. The vector can optionally include an open reading frame (ORF) for a protein operably linked on the 5′ side or the 3′-side of the sequence encoding the siNA of the invention; and/or an intron (intervening sequences).  
         [0370]     Transcription of the siNA molecule sequences can be driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters are expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type depends on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990 , Proc. Natl. Acad. Sci. USA,  87, 6743-7; Gao and Huang 1993 , Nucleic Acids Res.,  21, 2867-72; Lieber et al., 1993 , Methods Enzymol.,  217, 47-66; Zhou et al., 1990 , Mol. Cell. Biol.,  10, 4529-37). Several investigators have demonstrated that nucleic acid molecules expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al., 1992 , Antisense Res. Dev.,  2, 3-15; Ojwang et al., 1992 , Proc. Natl. Acad. Sci. USA,  89, 10802-6; Chen et al., 1992 , Nucleic Acids Res.,  20, 4581-9; Yu et al., 1993 , Proc. Natl. Acad. Sci. USA,  90, 6340-4; L&#39;Huillier et al., 1992 , EMBO J,  11, 4411-8; Lisziewicz et al., 1993 , Proc. Natl. Acad. Sci. U S. A,  90, 8000-4; Thompson et al., 1995 , Nucleic Acids Res.,  23, 2259; Sullenger &amp; Cech, 1993 , Science,  262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as siNA in cells (Thompson et al., supra; Couture and Stinchcomb, 1996, supra; Noonberg et al., 1994 , Nucleic Acid Res.,  22, 2830; Noonberg et al., U.S. Pat. No. 5,624,803; Good et al., 1997 , Gene Ther.,  4, 45; Beigelman et al., International PCT Publication No. WO 96/18736. The above siNA transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, supra).  
         [0371]     In another aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the siNA molecules of the invention in a manner that allows expression of that siNA molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; and c) a nucleic acid sequence encoding at least one strand of the siNA molecule, wherein the sequence is operably linked to the initiation region and the termination region in a manner that allows expression and/or delivery of the siNA molecule.  
         [0372]     In another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; and d) a nucleic acid sequence encoding at least one strand of a siNA molecule, wherein the sequence is operably linked to the 3′-end of the open reading frame and wherein the sequence is operably linked to the initiation region, the open reading frame and the termination region in a manner that allows expression and/or delivery of the siNA molecule. In yet another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; and d) a nucleic acid sequence encoding at least one siNA molecule, wherein the sequence is operably linked to the initiation region, the intron and the termination region in a manner which allows expression and/or delivery of the nucleic acid molecule.  
         [0373]     In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; and e) a nucleic acid sequence encoding at least one strand of a siNA molecule, wherein the sequence is operably linked to the 3′-end of the open reading frame and wherein the sequence is operably linked to the initiation region, the intron, the open reading frame and the termination region in a manner which allows expression and/or delivery of the siNA molecule.  
         [0000]     Interleukin Biology and Biochemistry  
         [0374]     The following discussion is adapted from R&amp;D Systems Mini-Reveiws and Tech Notes, Cytokine Mini-Reviews, Copyright ©2002 R&amp;D Systems. Interleukin 2 (IL-2) is a lymphokine synthesized and secreted primarily by T helper lymphocytes that have been activated by stimulation with certain mitogens or by interaction of the T cell receptor complex with antigen/MHC complexes on the surfaces of antigen-presenting cells. The response of T helper cells to activation is induction of the expression of IL-2 and receptors for IL-2 and, subsequently, clonal expansion of antigen-specific T cells. At this level IL-2 is an autocrine factor, driving the expansion of the antigen-specific cells. IL-2 also acts as a paracrine factor, influencing the activity of other cells, both within the immune system and outside of it. B cells and natural killer (NK) cells respond, when properly activated, to IL-2. The so-called lymphocyte activated killer, or LAK cells, appear to be derived from NK cells under the influence of IL-2.  
         [0375]     The biological activities of IL-2 are mediated through the binding of IL-2 to a multisubunit cellular receptor. Although three distinct transmembrane glycoprotein subunits contribute to the formation of the high affinity IL-2 receptor, various combinations of receptor subunits (alpha, beta, gamma) are known to occur.  
         [0376]     Interleukin 1 (IL-1) is a general name for two distinct proteins, IL-1a and IL-1b, that are considered the first of a family of regulatory and inflammatory cytokines. Along with IL-1 receptor antagonist (IL-1Ra)2 and IL-18,3 these molecules play important roles in the up- and down-regulation of acute inflammation. In the immune system, the production of IL-1 is typically induced, generally resulting in inflammation. IL-1b and TNF-a are generally thought of as prototypical pro-inflammatory cytokines. The effects of IL-1, however, are not limited to inflammation, as IL-1 has also been associated with bone formation and remodeling, insulin secretion, appetite regulation, fever induction, neuronal phenotype development, and IGF/GH physiology. IL-1 has also been known by a number of alternative names, including lymphocyte activating factor, endogenous pyrogen, catabolin, hemopoietin-1, melanoma growth inhibition factor, and osteoclast activating factor. IL-1a and IL-1b exert their effects by binding to specific receptors. Two distinct IL-1 receptor binding proteins, plus a non-binding signaling accessory protein have been identified to date. Each have three extracellular immunoglobulin-like (Ig-like) domains, qualifying them for membership in the type IV cytokine receptor family.  
         [0377]     Interleukin-4 (IL-4) mediates important pro-inflammatory functions in asthma including induction of the IgE isotype switch, expression of vascular cell adhesion molecule-1 (VCAM-1), promotion of eosinophil transmigration across endothelium, mucus secretion, and differentiation of T helper type 2 lymphocytes leading to cytokine release. Asthma has been linked to polymorphisms in the IL-4 gene promoter and proteins involved in IL-4 signaling. Soluble recombinant IL-4 receptor lacks transmembrane and cytoplasmic activating domains and can therefore sequester IL-4 without mediating cellular activation. Genetic variants within the IL-4 signalling pathway might contribute to the risk of developing asthma in a given individual. A number of polymorphisms have been described within the IL-4 receptor α (IL-4Rα) gene, and in addition, polymorphism occurs in the promoter for the IL-4 gene itself (see for example Hall, 2000 , Respir. Res.,  1, 6-8 and Ober et al., 2000 , Am J Hum Genet.,  66, 517-526, for a review). The type 2 cytokine IL-13, which shares a receptor component and signaling pathways with IL-4, was found to be necessary and sufficient for the expression of allergic asthma (see Wills-Karp et al., 1998 , Science,  282, 2258-61). IL-13 induces the pathophysiological features of asthma in a manner that is independent of immunoglobulin E and eosinophils. Thus, IL-13 is critical to allergen-induced asthma but operates through mechanisms other than those that are classically implicated in allergic responses.  
         [0378]     Human IL-5 is a 134 amino acid polypeptide with a predicted mass of 12.5 kDa. It is secreted by a restricted number of mesenchymal cell types. In its native state, mature IL-5 is synthesized as a 115 aa, highly glycosylated 22 kDa monomer that forms a 40-50 kDa disulfide-linked homodimer. Although the content of carbohydrate is high, carbohydrate is not needed for bioactivity. Monomeric IL-5 has no activity; a homodimer is required for function. This is in contrast to the receptor-related cytokines IL-3 and GM-CSF, which exist only as monomers. Just as one IL-3 and GM-CSF monomer binds to one receptor, one IL-5 homodimer is able to engage only one IL-5 receptor. It has been suggested that IL-5 (as a dimer) undergoes a general conformational change after binding to one receptor molecule, and this change precludes binding to a second receptor. The receptor for IL-5 consists of a ligand binding a-subunit and a non-ligand binding (common) signal transducing b-subunit that is shared by the receptors for IL-3 and GM-CSF. IL-5 appears to perform a number of functions on eosinophils. These include the down modulation of Mac-1, the upregulation of receptors for IgA and IgG, the stimulation of lipid mediator (leukotriene C4 and PAF) secretion and the induction of granule release. IL-5 also promotes the growth and differentiation of eosinophils.  
         [0379]     Interleukin 6 (IL-6) is considered a prototypic pleiotrophic cytokine. This is reflected in the variety of names originally assigned to IL-6 based on function, including Interferon b2, IL-1-inducible 26 kD Protein, Hepatocyte Stimulating Factor, Cytotoxic T-cell Differentiation Factor, B cell Differentiation Factor (BCDF) and/or B cell Stimulatory Factor 2 (BSF2). A number of cytokines make up an IL-6 cytokine family. Membership in this family is typically based on a helical cytokine structure and receptor subunit makeup. The functional receptor for IL-6 is a complex of two transmembrane glycoproteins (gp130 and IL-6 receptor) that are members of the Class I cytokine receptor superfamily.  
         [0380]     Because of the central role of the interleukin family of cytokines in the mediation of immune and inflammatory responses, modulation of interleukin expression and/or activity can provide important functions in therpeutic and diagnostic applications. The use of small interfering nucleic acid molecules targeting interleukins and their corresponding receptors therefore provides a class of novel therapeutic agents that can be used in the treatment of cancers, proliferative diseases, inflammatory disease, respiratory disease, pulmonary disease, cardiovascular disease, autoimmune disease, infectious disease, prior disease, renal disease, transplant rejection, or any other disease or condition that responds to modulation of interleukin and interleukin receptor genes.  
       EXAMPLES  
       [0381]     The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention.  
       Example 1  
     Tandem Synthesis of SiNA Constructs  
       [0382]     Exemplary siNA molecules of the invention are synthesized in tandem using a cleavable linker, for example, a succinyl-based linker. Tandem synthesis as described herein is followed by a one-step purification process that provides RNAi molecules in high yield. This approach is highly amenable to siNA synthesis in support of high throughput RNAi screening, and can be readily adapted to multi-column or multi-well synthesis platforms.  
         [0383]     After completing a tandem synthesis of a siNA oligo and its complement in which the 5′-terminal dimethoxytrityl (5′-O-DMT) group remains intact (trityl on synthesis), the oligonucleotides are deprotected as described above. Following deprotection, the siNA sequence strands are allowed to spontaneously hybridize. This hybridization yields a duplex in which one strand has retained the 5′-O-DMT group while the complementary strand comprises a terminal 5′-hydroxyl. The newly formed duplex behaves as a single molecule during routine solid-phase extraction purification (Trityl-On purification) even though only one molecule has a dimethoxytrityl group. Because the strands form a stable duplex, this dimethoxytrityl group (or an equivalent group, such as other trityl groups or other hydrophobic moieties) is all that is required to purify the pair of oligos, for example, by using a C18 cartridge.  
         [0384]     Standard phosphoramidite synthesis chemistry is used up to the point of introducing a tandem linker, such as an inverted deoxy abasic succinate or glyceryl succinate linker (see  FIG. 1 ) or an equivalent cleavable linker. A non-limiting example of linker coupling conditions that can be used includes a hindered base such as diisopropylethylamine (DIPA) and/or DMAP in the presence of an activator reagent such as Bromotripyrrolidinophosphoniumhexaflurorophosphate (PyBrOP). After the linker is coupled, standard synthesis chemistry is utilized to complete synthesis of the second sequence leaving the terminal the 5′-O-DMT intact. Following synthesis, the resulting oligonucleotide is deprotected according to the procedures described herein and quenched with a suitable buffer, for example with 50 mM NaOAc or 1.5M NH 4 H 2 CO 3 .  
         [0385]     Purification of the siNA duplex can be readily accomplished using solid phase extraction, for example using a Waters C18 SepPak 1 g cartridge conditioned with 1 column volume (CV) of acetonitrile, 2 CV H2O, and 2 CV 50 mM NaOAc. The sample is loaded and then washed with 1 CV H2O or 50 mM NaOAc. Failure sequences are eluted with 1 CV 14% ACN (Aqueous with 50 mM NaOAc and 50 mM NaCl). The column is then washed, for example with 1 CV H2O followed by on-column detritylation, for example by passing 1 CV of 1% aqueous trifluoroacetic acid (TFA) over the column, then adding a second CV of 1% aqueous TFA to the column and allowing to stand for approximately 10 minutes. The remaining TFA solution is removed and the column washed with H2O followed by 1 CV 1M NaCl and additional H2O. The siNA duplex product is then eluted, for example, using 1 CV 20% aqueous CAN.  
         [0386]      FIG. 2  provides an example of MALDI-TOF mass spectrometry analysis of a purified siNA construct in which each peak corresponds to the calculated mass of an individual siNA strand of the siNA duplex. The same purified siNA provides three peaks when analyzed by capillary gel electrophoresis (CGE), one peak presumably corresponding to the duplex siNA, and two peaks presumably corresponding to the separate siNA sequence strands. Ion exchange HPLC analysis of the same siNA contract only shows a single peak. Testing of the purified siNA construct using a luciferase reporter assay described below demonstrated the same RNAi activity compared to siNA constructs generated from separately synthesized oligonucleotide sequence strands.  
       Example 2  
     Identification of Potential SiNA Target Sites in any RNA Sequence  
       [0387]     The sequence of an RNA target of interest, such as a viral or human mRNA transcript, is screened for target sites, for example by using a computer folding algorithm. In a non-limiting example, the sequence of a gene or RNA gene transcript derived from a database, such as Genbank, is used to generate siNA targets having complementarity to the target. Such sequences can be obtained from a database, or can be determined experimentally as known in the art. Target sites that are known, for example, those target sites determined to be effective target sites based on studies with other nucleic acid molecules, for example ribozymes or antisense, or those targets known to be associated with a disease or condition such as those sites containing mutations or deletions, can be used to design siNA molecules targeting those sites. Various parameters can be used to determine which sites are the most suitable target sites within the target RNA sequence. These parameters include but are not limited to secondary or tertiary RNA structure, the nucleotide base composition of the target sequence, the degree of homology between various regions of the target sequence, or the relative position of the target sequence within the RNA transcript. Based on these determinations, any number of target sites within the RNA transcript can be chosen to screen siNA molecules for efficacy, for example by using in vitro RNA cleavage assays, cell culture, or animal models. In a non-limiting example, anywhere from 1 to 1000 target sites are chosen within the transcript based on the size of the siNA construct to be used. High throughput screening assays can be developed for screening siNA molecules using methods known in the art, such as with multi-well or multi-plate assays to determine efficient reduction in target gene expression.  
       Example 3  
     Selection of SiNA Molecule Target Sites in a RNA  
       [0388]     The following non-limiting steps can be used to carry out the selection of siNAs targeting a given gene sequence or transcript. 
    1. The target sequence is parsed in silico into a list of all fragments or subsequences of a particular length, for example 23 nucleotide fragments, contained within the target sequence. This step is typically carried out using a custom Perl script, but commercial sequence analysis programs such as Oligo, MacVector, or the GCG Wisconsin Package can be employed as well.     2. In some instances the siNAs correspond to more than one target sequence; such would be the case for example in targeting different transcripts of the same gene, targeting different transcripts of more than one gene, or for targeting both the human gene and an animal homolog. In this case, a subsequence list of a particular length is generated for each of the targets, and then the lists are compared to find matching sequences in each list. The subsequences are then ranked according to the number of target sequences that contain the given subsequence; the goal is to find subsequences that are present in most or all of the target sequences. Alternately, the ranking can identify subsequences that are unique to a target sequence, such as a mutant target sequence. Such an approach would enable the use of siNA to target specifically the mutant sequence and not effect the expression of the normal sequence.     3. In some instances the siNA subsequences are absent in one or more sequences while present in the desired target sequence; such would be the case if the siNA targets a gene with a paralogous family member that is to remain untargeted. As in case 2 above, a subsequence list of a particular length is generated for each of the targets, and then the lists are compared to find sequences that are present in the target gene but are absent in the untargeted paralog.     4. The ranked siNA subsequences can be further analyzed and ranked according to GC content. A preference can be given to sites containing 30-70% GC, with a further preference to sites containing 40-60% GC.     5. The ranked siNA subsequences can be further analyzed and ranked according to self-folding and internal hairpins. Weaker internal folds are preferred; strong hairpin structures are to be avoided.     6. The ranked siNA subsequences can be further analyzed and ranked according to whether they have runs of GGG or CCC in the sequence. GGG (or even more Gs) in either strand can make oligonucleotide synthesis problematic and can potentially interfere with RNAi activity, so it is avoided whenever better sequences are available. CCC is searched in the target strand because that will place GGG in the antisense strand.     7. The ranked siNA subsequences can be further analyzed and ranked according to whether they have the dinucleotide UU (uridine dinucleotide) on the 3′-end of the sequence, and/or AA on the 5′-end of the sequence (to yield 3′ UU on the antisense sequence). These sequences allow one to design siNA molecules with terminal TT thymidine dinucleotides.     8. Four or five target sites are chosen from the ranked list of subsequences as described above. For example, in subsequences having 23 nucleotides, the right 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the upper (sense) strand of the siNA duplex, while the reverse complement of the left 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the lower (antisense) strand of the siNA duplex (see Tables II and III). If terminal TT residues are desired for the sequence (as described in paragraph 7), then the two 3′ terminal nucleotides of both the sense and antisense strands are replaced by TT prior to synthesizing the oligos.     9. The siNA molecules are screened in an in vitro, cell culture or animal model system to identify the most active siNA molecule or the most preferred target site within the target RNA sequence.     10. Other design considerations can be used when selecting target nucleic acid sequences, see for example Reynolds et al., 2004 , Nature Biotechnology Advanced Online Publication,  1 Feb. 2004, doi:10.1038/nbt936 and Ui-Tei et al., 2004, Nucleic Acids Research, 32, doi: 10.1093/nar/gkh247.    
 
         [0399]     In an alternate approach, a pool of siNA constructs specific to a interleukin and/or interleukin receptor target sequence is used to screen for target sites in cells expressing interleukin and/or interleukin receptor RNA, such as cultured Jurkat, Hela, or 293T cells. The general strategy used in this approach is shown in  FIG. 9 . A non-limiting example of such is a pool comprising sequences having any of SEQ ID NOS 1-1828. Cells expressing interleukin and/or interleukin receptor (e.g., Jurkat, Hela, or 293T cells) are transfected with the pool of siNA constructs and cells that demonstrate a phenotype associated with interleukin and/or interleukin receptor inhibition are sorted. The pool of siNA constructs can be expressed from transcription cassettes inserted into appropriate vectors (see for example  FIG. 7  and  FIG. 8 ). The siNA from cells demonstrating a positive phenotypic change (e.g., decreased interleukin and/or interleukin receptor mRNA levels or decreased interleukin and/or interleukin receptor protein expression), are sequenced to determine the most suitable target site(s) within the target interleukin and/or interleukin receptor RNA sequence.  
       Example 4  
     Interleukin and Interleukin Receptor Targeted SiNA Design  
       [0400]     siNA target sites were chosen by analyzing sequences of the interleukin and/or interleukin receptor RNA target and optionally prioritizing the target sites on the basis of folding (structure of any given sequence analyzed to determine siNA accessibility to the target), by using a library of siNA molecules as described in Example 3, or alternately by using an in vitro siNA system as described in Example 6 herein. siNA molecules were designed that could bind each target and are optionally individually analyzed by computer folding to assess whether the siNA molecule can interact with the target sequence. Varying the length of the siNA molecules can be chosen to optimize activity. Generally, a sufficient number of complementary nucleotide bases are chosen to bind to, or otherwise interact with, the target RNA, but the degree of complementarity can be modulated to accommodate siNA duplexes or varying length or base composition. By using such methodologies, siNA molecules can be designed to target sites within any known RNA sequence, for example those RNA sequences corresponding to the any gene transcript.  
         [0401]     Chemically modified siNA constructs are designed to provide nuclease stability for systemic administration in vivo and/or improved pharmacokinetic, localization, and delivery properties while preserving the ability to mediate RNAi activity. Chemical modifications as described herein are introduced synthetically using synthetic methods described herein and those generally known in the art. The synthetic siNA constructs are then assayed for nuclease stability in serum and/or cellular/tissue extracts (e.g. liver extracts). The synthetic siNA constructs are also tested in parallel for RNAi activity using an appropriate assay, such as a luciferase reporter assay as described herein or another suitable assay that can quantity RNAi activity. Synthetic siNA constructs that possess both nuclease stability and RNAi activity can be further modified and re-evaluated in stability and activity assays. The chemical modifications of the stabilized active siNA constructs can then be applied to any siNA sequence targeting any chosen RNA and used, for example, in target screening assays to pick lead siNA compounds for therapeutic development (see for example  FIG. 11 ).  
       Example 5  
     Chemical Synthesis and Purification of siNA  
       [0402]     siNA molecules can be designed to interact with various sites in the RNA message, for example, target sequences within the RNA sequences described herein. The sequence of one strand of the siNA molecule(s) is complementary to the target site sequences described above. The siNA molecules can be chemically synthesized using methods described herein. Inactive siNA molecules that are used as control sequences can be synthesized by scrambling the sequence of the siNA molecules such that it is not complementary to the target sequence. Generally, siNA constructs can by synthesized using solid phase oligonucleotide synthesis methods as described herein (see for example Usman et al., U.S. Pat. Nos. 5,804,683; 5,831,071; 5,998,203; 6,117,657; 6,353,098; 6,362,323; 6,437,117; 6,469,158; Scaringe et al., U.S. Pat. Nos. 6,111,086; 6,008,400; 6,111,086 all incorporated by reference herein in their entirety).  
         [0403]     In a non-limiting example, RNA oligonucleotides are synthesized in a stepwise fashion using the phosphoramidite chemistry as is known in the art. Standard phosphoramidite chemistry involves the use of nucleosides comprising any of 5′-O-dimethoxytrityl, 2′-O-tert-butyldimethylsilyl, 3′-O-2-Cyanoethyl N,N-diisopropylphos-phoroamidite groups, and exocyclic amine protecting groups (e.g. N6-benzoyl adenosine, N4 acetyl cytidine, and N2-isobutyryl guanosine). Alternately, 2′-O-Silyl Ethers can be used in conjunction with acid-labile 2′-O-orthoester protecting groups in the synthesis of RNA as described by Scaringe supra. Differing 2′ chemistries can require different protecting groups, for example 2′-deoxy-2′-amino nucleosides can utilize N-phthaloyl protection as described by Usman et al., U.S. Pat. No. 5,631,360, incorporated by reference herein in its entirety).  
         [0404]     During solid phase synthesis, each nucleotide is added sequentially (3′- to 5′-direction) to the solid support-bound oligonucleotide. The first nucleoside at the 3′-end of the chain is covalently attached to a solid support (e.g., controlled pore glass or polystyrene) using various linkers. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are combined resulting in the coupling of the second nucleoside phosphoramidite onto the 5′-end of the first nucleoside. The support is then washed and any unreacted 5′-hydroxyl groups are capped with a capping reagent such as acetic anhydride to yield inactive 5′-acetyl moieties. The trivalent phosphorus linkage is then oxidized to a more stable phosphate linkage. At the end of the nucleotide addition cycle, the 5′-O-protecting group is cleaved under suitable conditions (e.g., acidic conditions for trityl-based groups and Fluoride for silyl-based groups). The cycle is repeated for each subsequent nucleotide.  
         [0405]     Modification of synthesis conditions can be used to optimize coupling efficiency, for example by using differing coupling times, differing reagent/phosphoramidite concentrations, differing contact times, differing solid supports and solid support linker chemistries depending on the particular chemical composition of the siNA to be synthesized. Deprotection and purification of the siNA can be performed as is generally described in Usman et al., U.S. Pat. No. 5,831,071, U.S. Pat. No. 6,353,098, U.S. Pat. No. 6,437,117, and Bellon et al., U.S. Pat. No. 6,054,576, U.S. Pat. No. 6,162,909, U.S. Pat. No. 6,303,773, or Scaringe supra, incorporated by reference herein in their entireties. Additionally, deprotection conditions can be modified to provide the best possible yield and purity of siNA constructs. For example, applicant has observed that oligonucleotides comprising 2′-deoxy-2′-fluoro nucleotides can degrade under inappropriate deprotection conditions. Such oligonucleotides are deprotected using aqueous methylamine at about 35° C. for 30 minutes. If the 2′-deoxy-2′-fluoro containing oligonucleotide also comprises ribonucleotides, after deprotection with aqueous methylamine at about 35° C. for 30 minutes, TEA-HF is added and the reaction maintained at about 65° C. for an additional 15 minutes.  
       Example 6  
     RNAi In Vitro Assay to Assess SiNA Activity  
       [0406]     An in vitro assay that recapitulates RNAi in a cell-free system is used to evaluate siNA constructs targeting interleukin and/or interleukin receptor RNA targets. The assay comprises the system described by Tuschl et al., 1999 , Genes and Development,  13, 3191-3197 and Zamore et al., 2000 , Cell,  101, 25-33 adapted for use with interleukin and/or interleukin receptor target RNA. A  Drosophila  extract derived from syncytial blastoderm is used to reconstitute RNAi activity in vitro. Target RNA is generated via in vitro transcription from an appropriate interleukin and/or interleukin receptor expressing plasmid using T7 RNA polymerase or via chemical synthesis as described herein. Sense and antisense siNA strands (for example 20 uM each) are annealed by incubation in buffer (such as 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 minute at 90° C. followed by 1 hour at 37° C., then diluted in lysis buffer (for example 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate). Annealing can be monitored by gel electrophoresis on an agarose gel in TBE buffer and stained with ethidium bromide. The  Drosophila  lysate is prepared using zero to two-hour-old embryos from Oregon R flies collected on yeasted molasses agar that are dechorionated and lysed. The lysate is centrifuged and the supernatant isolated. The assay comprises a reaction mixture containing 50% lysate [vol/vol], RNA (10-50 pM final concentration), and 10% [vol/vol] lysis buffer containing siNA (10 nM final concentration). The reaction mixture also contains 10 mM creatine phosphate, 10 ug/ml creatine phosphokinase, 100 um GTP, 100 uM UTP, 100 uM CTP, 500 uM ATP, 5 mM DTT, 0.1 U/uL RNasin (Promega), and 100 uM of each amino acid. The final concentration of potassium acetate is adjusted to 100 mM. The reactions are pre-assembled on ice and preincubated at 25° C. for 10 minutes before adding RNA, then incubated at 25° C. for an additional 60 minutes. Reactions are quenched with 4 volumes of 1.25×Passive Lysis Buffer (Promega). Target RNA cleavage is assayed by RT-PCR analysis or other methods known in the art and are compared to control reactions in which siNA is omitted from the reaction.  
         [0407]     Alternately, internally-labeled target RNA for the assay is prepared by in vitro transcription in the presence of [alpha- 32 P] CTP, passed over a G 50 Sephadex column by spin chromatography and used as target RNA without further purification. Optionally, target RNA is 5′- 32 P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed as described above and target RNA and the specific RNA cleavage products generated by RNAi are visualized on an autoradiograph of a gel. The percentage of cleavage is determined by PHOSPHOR IMAGER® (autoradiography) quantitation of bands representing intact control RNA or RNA from control reactions without siNA and the cleavage products generated by the assay.  
         [0408]     In one embodiment, this assay is used to determine target sites the interleukin and/or interleukin receptor RNA target for siNA mediated RNAi cleavage, wherein a plurality of siNA constructs are screened for RNAi mediated cleavage of the interleukin and/or interleukin receptor RNA target, for example, by analyzing the assay reaction by electrophoresis of labeled target RNA, or by northern blotting, as well as by other methodology well known in the art.  
       Example 7  
     Nucleic Acid Inhibition of Interleukin and Interleukin Receptor Target RNA In Vitro  
       [0409]     siNA molecules targeted to the huma interleukin and/or interleukin receptor RNA are designed and synthesized as described above. These nucleic acid molecules can be tested for cleavage activity in vivo, for example, using the following procedure. The target sequences and the nucleotide location within the interleukin and/or interleukin receptor RNA are given in Table II and III.  
         [0410]     Two formats are used to test the efficacy of siNAs targeting interleukin and/or interleukin receptor. First, the reagents are tested in cell culture using, for example, Jurkat, Hela, or 293T cells, to determine the extent of RNA and protein inhibition. siNA reagents (e.g.; see Tables II and III) are selected against the interleukin and/or interleukin receptor target as described herein. RNA inhibition is measured after delivery of these reagents by a suitable transfection agent to, for example, cultured Jurkat, Hela, or 293T cells. Relative amounts of target RNA are measured versus actin using real-time PCR monitoring of amplification (eg., ABI 7700 TAQMAN®). A comparison is made to a mixture of oligonucleotide sequences made to unrelated targets or to a randomized siNA control with the same overall length and chemistry, but randomly substituted at each position. Primary and secondary lead reagents are chosen for the target and optimization performed. After an optimal transfection agent concentration is chosen, a RNA time-course of inhibition is performed with the lead siNA molecule. In addition, a cell-plating format can be used to determine RNA inhibition.  
         [0000]     Delivery of siNA to Cells  
         [0411]     Cells (e.g., Jurkat, Hela, or 293T cells) are seeded, for example, at  1 × 10   5  cells per well of a six-well dish in EGM-2 (BioWhittaker) the day before transfection. siNA (final concentration, for example 20 nM) and cationic lipid (e.g., final concentration 2 μg/ml) are complexed in EGM basal media (Bio Whittaker) at 37° C. for 30 minutes in polystyrene tubes. Following vortexing, the complexed siNA is added to each well and incubated for the times indicated. For initial optimization experiments, cells are seeded, for example, at 1×10 3  in 96 well plates and siNA complex added as described. Efficiency of delivery of siNA to cells is determined using a fluorescent siNA complexed with lipid. Cells in 6-well dishes are incubated with siNA for 24 hours, rinsed with PBS and fixed in 2% paraformaldehyde for 15 minutes at room temperature. Uptake of siNA is visualized using a fluorescent microscope.  
         [0000]     TAQMAN® (Real-Time PCR Monitoring of Amplification) and Lightcycler Quantification of mRNA  
         [0412]     Total RNA is prepared from cells following siNA delivery, for example, using Qiagen RNA purification kits for 6-well or Rneasy extraction kits for 96-well assays. For TAQMAN® analysis (real-time PCR monitoring of amplification), dual-labeled probes are synthesized with the reporter dye, FAM or JOE, covalently linked at the 5′-end and the quencher dye TAMRA conjugated to the 3′-end. One-step RT-PCR amplifications are performed on, for example, an ABI PRISM 7700 Sequence Detector using 50 μl reactions consisting of 10 μl total RNA, 100 nM forward primer, 900 nM reverse primer, 100 nM probe, 1×TaqMan PCR reaction buffer (PE-Applied Biosystems), 5.5 mM MgCl 2 , 300 μM each dATP, dCTP, dGTP, and dTTP, 10U RNase Inhibitor (Promega), 1.25U AMPLITAQ GOLD® (DNA polymerase) (PE-Applied Biosystems) and 10U M-MLV Reverse Transcriptase (Promega). The thermal cycling conditions can consist of 30 minutes at 48° C., 10 minutes at 95° C., followed by 40 cycles of 15 seconds at 95° C. and 1 minute at 60° C. Quantitation of mRNA levels is determined relative to standards generated from serially diluted total cellular RNA (300, 100, 33, 11 ng/rxn) and normalizing to β3-actin or GAPDH mRNA in parallel TAQMAN® reactions (real-time PCR monitoring of amplification). For each gene of interest an upper and lower primer and a fluorescently labeled probe are designed. Real time incorporation of SYBR Green I dye into a specific PCR product can be measured in glass capillary tubes using a lightcyler. A standard curve is generated for each primer pair using control cRNA. Values are represented as relative expression to GAPDH in each sample.  
         [0000]     Western Blotting  
         [0413]     Nuclear extracts can be prepared using a standard micro preparation technique (see for example Andrews and Faller, 1991 , Nucleic Acids Research,  19, 2499). Protein extracts from supernatants are prepared, for example using TCA precipitation. An equal volume of 20% TCA is added to the cell supernatant, incubated on ice for 1 hour and pelleted by centrifugation for 5 minutes. Pellets are washed in acetone, dried and resuspended in water. Cellular protein extracts are run on a 10% Bis-Tris NuPage (nuclear extracts) or 4-12% Tris-Glycine (supernatant extracts) polyacrylamide gel and transferred onto nitro-cellulose membranes. Non-specific binding can be blocked by incubation, for example, with 5% non-fat milk for 1 hour followed by primary antibody for 16 hour at 4° C. Following washes, the secondary antibody is applied, for example (1:10,000 dilution) for 1 hour at room temperature and the signal detected with SuperSignal reagent (Pierce).  
       Example 8  
     Animal Models Useful to Evaluate the Down-Regulation of Interleukin and/or Interleukin Receptor Gene Expression  
       [0414]     Evaluating the efficacy of anti-interleukin agents in animal models is an important prerequisite to human clinical trials. Allogeneic rejection is the most common cause of corneal graft failure. King et al., 2000, Transplantation, 70, 1225-1233, describe a study investigating the kinetics of cytokine and chemokine mRNA expression before and after the onset of corneal graft rejection. Intracorneal cytokine and chemokine mRNA levels were investigated in the Brown Norway-Lewis inbred rat model, in which rejection onset is observed at 8/9 days after grafting in all animals. Nongrafted corneas and syngeneic (Lewis-Lewis) corneal transplants were used as controls. Donor and recipient cornea were examined by quantitive competitive reverse transcription-polymerase chain reaction (RT-PCR) for hypoxyanthine phosphoribosyltransferase (HPRT), CD3, CD25, interleukin (IL)-1beta, IL-IRA, IL-2, IL-6, IL-10, interferon-gamma (IFN-gamma), tumor necrosis factor (TNF), transforming growth factor (TGF)-beta1, and macrophage inflammatory protein (MIP)-2 and by RT-PCR for IL-4, IL-5, IL-12 p40, IL-13, TGF-beta.2, monocyte chemotactic protein-1 (MCP-1), MIP-1alpha, MIP-1beta, and RANTES. A biphasic expression of cytokine and chemokine mRNA was found after transplantation. During the early phase (days 3-9), there was an elevation of the majority of the cytokines examined, including IL-1beta, IL-6, IL-10, IL-12 p40, and MIP-2. There was no difference in cytokine expression patterns between allogeneic or syngeneic recipients at this time. In syngeneic recipients, cytokine levels reduced to pretransplant levels by day 13, whereas levels of all cytokines rose after the rejection onset in the allografts, including TGF-beta.1, TGF-beta.2, and IL-1RA. The T cell-derived cytokines IL-4, IL-13, and IFN-gamma were detected only during the rejection phase in allogeneic recipients. Thus, there appears to be an early cytokine and chemokine response to the transplantation process, evident in syngeneic and allogeneic grafts, that drives angiogenesis, leukocyte recruitment, and affects other leukocyte functions. After an immune response has been generated, allogeneic rejection results in the expression of Th1 cytokines, Th2 cytokines, and anti-inflammatory/Th3 cytokines. This animal model can be used to evaluate the efficacy of nucleic acid molecules of the invention targeting interleukin expression (e.g., phenotypic change, interleuking expression etc.) toward therapeutic use in treating transplant rejection. Similarly, other animal models of transplant rejection as are known in the art can be used to evaluate nucleic acid molecules (e.g., siNA) of the invention toward therapeutic use.  
         [0415]     Other animal models are useful in evaluating the role of interleukins in asthma. For example, Kuperman et al., 2002 , Nature Medicine,  8, 885-9, describe an animal model of IL-13 mediated asthma response animal models of allergic asthma in which blockade of IL-13 markedly inhibits allergen-induced asthma. Venkayya et al., 2002 , Am J Respir Cell Mol. Biol.,  26, 202-8 and Yang et al., 2001 , Am J Respir Cell Mol. Biol.,  25, 522-30 describe animal models of airway inflammation and airway hyperresponsiveness (AHR) in which IL-4/IL-4R and IL-13 mediate asthma. These models can be used to evaluate the efficacy of siNA molecules of the invention targeting, for example, IL-4, IL-4R, IL-13, and/or IL-13R for use is treating asthma.  
       Example 9  
     RNAi Mediated Inhibition of Interleukin and/or Interleukin Receptor Expression in Cell Culture  
       [0000]     Inhibition of Interleukin and/or Interleukin Receptor RNA Expression Using SiNA Targeting Interleukin and/or Interleukin Receptor RNA  
         [0416]     siNA constructs (Table III) are tested for efficacy in reducing interleukin and/or interleukin receptor RNA expression in, for example, Jurkat, Hela, or 293T cells. Cells are plated approximately 24 hours before transfection in 96-well plates at 5,000-7,500 cells/well, 100 μl/well, such that at the time of transfection cells are 70-90% confluent. For transfection, annealed siNAs are mixed with the transfection reagent (Lipofectamine 2000, Invitrogen) in a volume of 0.5 μl/well and incubated for 20 min. at room temperature. The siNA transfection mixtures are added to cells to give a final siNA concentration of 25 nM in a volume of 150 μl. Each siNA transfection mixture is added to 3 wells for triplicate siNA treatments. Cells are incubated at 37° for 24 h in the continued presence of the siNA transfection mixture. At 24 h, RNA is prepared from each well of treated cells. The supernatants with the transfection mixtures are first removed and discarded, then the cells are lysed and RNA prepared from each well. Target gene expression following treatment is evaluated by RT-PCR for the target gene and for a control gene (36B4, an RNA polymerase subunit) for normalization. The triplicate data is averaged and the standard deviations determined for each treatment. Normalized data are graphed and the percent reduction of target mRNA by active siNAs in comparison to their respective inverted control siNAs is determined.  
         [0417]     In a non-limiting example, chemically modified siNA constructs (Table III) were tested for efficacy as described above in reducing IL-4R RNA expression in Hela cells. Active siNAs were evaluated compared to a matched chemistry inverted control (IC), and a transfection control. Results are summarized in  FIG. 22 .  FIG. 22  shows results for Stab 9/22 (Table IV) siNA constructs targeting various sites in IL-4R mRNA. As shown in  FIG. 22 , the active siNA constructs provide significant inhibition of IL-4R gene expression in cell culture experiments as determined by levels of IL-4R mRNA when compared to appropriate controls.  
       Example 10  
     Indications  
       [0418]     The siNA molecule of the invention can be used to prevent, inhibit or treat cancers and other proliferative conditions, viral infection, inflammatory disease, autoimmunity, respiratory disease, pulmonary disease, cardiovascular disease, nuerologic disease, renal disease, ocular disease, liver disease, mitochondrial disease, endocrine disease, prion disease, reproduction related diseases and conditions, and/or any other trait, disease or condition that is related to or will respond to the levels of interleukin and/or interleukin receptor in a cell or tissue, alone or in combination with other therapies. Non-limiting examples of respiratory diseases that can be treated using siNA molecules of the invention (e.g., siNA molecules targeting IL-4, IL-4R, IL-13, and/or IL-13R include asthma, chronic obstructive pulmonary disease or “COPD”, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema.  
         [0419]     The use of anticholinergic agents, anti-inflammatories, bronchodilators, adenosine inhibitors, adenosine A1 receptor inhibitors, non-selective M3 receptor antagonists such as atropine, ipratropium brominde and selective M3 receptor antagonists such as darifenacin and revatropate are all non-limiting examples of agents that can be combined with or used in conjunction with the nucleic acid molecules (e.g. siNA molecules) of the instant invention. Immunomodulators, chemotherapeutics, anti-inflammatory compounds, and anti-vrial compounds are additional non-limiting examples of pharmaceutical agents that can be combined with or used in conjunction with the nucleic acid molecules (e.g. siNA molecules) of the instant invention. Those skilled in the art will recognize that other drugs, compounds and therapies can similarly be readily combined with the nucleic acid molecules of the instant invention (e.g. siRNA molecules) are hence within the scope of the instant invention.  
       Example 11  
     Diagnostic Uses  
       [0420]     The siNA molecules of the invention can be used in a variety of diagnostic applications, such as in the identification of molecular targets (e.g., RNA) in a variety of applications, for example, in clinical, industrial, environmental, agricultural and/or research settings. Such diagnostic use of siNA molecules involves utilizing reconstituted RNAi systems, for example, using cellular lysates or partially purified cellular lysates. siNA molecules of this invention can be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of endogenous or exogenous, for example viral, RNA in a cell. The close relationship between siNA activity and the structure of the target RNA allows the detection of mutations in any region of the molecule, which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple siNA molecules described in this invention, one can map nucleotide changes, which are important to RNA structure and function in vitro, as well as in cells and tissues. Cleavage of target RNAs with siNA molecules can be used to inhibit gene expression and define the role of specified gene products in the progression of disease or infection. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple siNA molecules targeted to different genes, siNA molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations siNA molecules and/or other chemical or biological molecules). Other in vitro uses of siNA molecules of this invention are well known in the art, and include detection of the presence of mRNAs associated with a disease, infection, or related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a siNA using standard methodologies, for example, fluorescence resonance emission transfer (FRET).  
         [0421]     In a specific example, siNA molecules that cleave only wild-type or mutant forms of the target RNA are used for the assay. The first siNA molecules (i.e., those that cleave only wild-type forms of target RNA) are used to identify wild-type RNA present in the sample and the second siNA molecules (i.e., those that cleave only mutant forms of target RNA) are used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA are cleaved by both siNA molecules to demonstrate the relative siNA efficiencies in the reactions and the absence of cleavage of the “non-targeted” RNA species. The cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus, each analysis requires two siNA molecules, two substrates and one unknown sample, which is combined into six reactions. The presence of cleavage products is determined using an RNase protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (i.e., disease related or infection related) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels is adequate and decreases the cost of the initial diagnosis. Higher mutant form to wild-type ratios are correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.  
         [0422]     All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.  
         [0423]     One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.  
         [0424]     It will be readily apparent to one skilled in the art that varying substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims. The present invention teaches one skilled in the art to test various combinations and/or substitutions of chemical modifications described herein toward generating nucleic acid constructs with improved activity for mediating RNAi activity. Such improved activity can comprise improved stability, improved bioavailability, and/or improved activation of cellular responses mediating RNAi. Therefore, the specific embodiments described herein are not limiting and one skilled in the art can readily appreciate that specific combinations of the modifications described herein can be tested without undue experimentation toward identifying siNA molecules with improved RNAi activity.  
         [0425]     The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.  
         [0426]     In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.  
                                                         TABLE I                       interleukin and/or interleukin receptor Accession Numbers                   Interleukin Family            NM_000575     Homo sapiens  interleukin 1, alpha (IL1A), mRNA       NM_000576     Homo sapiens  interleukin 1, beta (IL1B), mRNA       NM_012275     Homo sapiens  interleukin 1 family, member 5 (delta) (IL1F5), mRNA       NM_014440     Homo sapiens  interleukin 1 family, member 6 (epsilon) (IL1F6), mRNA       NM_014439     Homo sapiens  interleukin 1 family, member 7 (zeta) (IL1F7), mRNA       NM_014438     Homo sapiens  interleukin 1 family, member 8 (eta) (IL1F8), mRNA       NM_019618     Homo sapiens  interleukin 1 family, member 9 (IL1F9), mRNA       NM_032556     Homo sapiens  interleukin 1 family, member 10 (theta) (IL1F10), mRNA       NM_000586     Homo sapiens  interleukin 2 (IL2), mRNA       NM_000588     Homo sapiens  interleukin 3 (colony-stimulating factor, multiple) (IL3),           mRNA       NM_000589     Homo sapiens  interleukin 4 (IL4), mRNA       NM_000879     Homo sapiens  interleukin 5 (colony-stimulating factor, eosinophil) (IL5),           mRNA       NM_000600     Homo sapiens  interleukin 6 (interferon, beta 2) (IL6), mRNA       NM_000880     Homo sapiens  interleukin 7 (IL7), mRNA       NM_000584     Homo sapiens  interleukin 8 (IL8), mRNA       NM_000590     Homo sapiens  interleukin 9 (IL9), mRNA       NM_000572     Homo sapiens  interleukin 10 (IL10), mRNA       NM_000641     Homo sapiens  interleukin 11 (IL11), mRNA       NM_000882     Homo sapiens  interleukin 12A (natural killer cell stimulatory factor 1,           cytotoxic lymphocyte maturation factor 1, p35) (IL12A), mRNA       NM_002187     Homo sapiens  interleukin 12B (natural killer cell stimulatory factor 2,           cytotoxic lymphocyte maturation factor 2, p40) (IL12B), mRNA       NM_002188     Homo sapiens  interleukin 13 (IL13), mRNA       L15344     Homo sapiens  interleukin 14 (IL14), mRNA       NM_000585     Homo sapiens  interleukin 15 (IL15), mRNA       NM_004513     Homo sapiens  interleukin 16 (lymphocyte chemoattractant factor) (IL16),           mRNA       NM_002190     Homo sapiens  interleukin 17 (cytotoxic T-lymphocyte-associated serine           esterase 8) (IL17), mRNA       NM_014443     Homo sapiens  interleukin 17B (IL17B), mRNA       NM_013278     Homo sapiens  interleukin 17C (IL17C), mRNA       NM_138284     Homo sapiens  interleukin 17D (IL17D), mRNA       NM_022789     Homo sapiens  interleukin 17E (IL17E), mRNA       NM_052872     Homo sapiens  interleukin 17F (IL17F), mRNA       NM_001562     Homo sapiens  interleukin 18 (interferon-gamma-inducing factor) (IL18),           mRNA       NM_013371     Homo sapiens  interleukin 19 (IL19), mRNA       NM_018724     Homo sapiens  interleukin 20 (IL20), mRNA       NM_021803     Homo sapiens  interleukin 21 (IL21 antisense), mRNA       NM_020525     Homo sapiens  interleukin 22 (IL22), mRNA       NM_016584     Homo sapiens  interleukin 23, alpha subunit p19 (IL23A), mRNA       NM_006850     Homo sapiens  interleukin 24 (IL24), mRNA       NM_018402     Homo sapiens  interleukin 26 (IL26), mRNA       AL365373     Homo sapiens  interleukin 27 (IL27), mRNA            Interleukin Receptor Family            NM_000877     Homo sapiens  interleukin 1 receptor, type I (IL1R1), mRNA       NM_004633     Homo sapiens  interleukin 1 receptor, type II (IL1R2), mRNA       NM_016232     Homo sapiens  interleukin 1 receptor-like 1 (IL1RL1), mRNA       NM_003856     Homo sapiens  interleukin 1 receptor-like 1 (IL1RL1), mRNA       NM_003854     Homo sapiens  interleukin 1 receptor-like 2 (IL1RL2), mRNA       NM_000417     Homo sapiens  interleukin 2 receptor, alpha (IL2RA), mRNA       NM_000878     Homo sapiens  interleukin 2 receptor, beta (IL2RB), mRNA       NM_000206     Homo sapiens  interleukin 2 receptor, gamma (severe combined           immunodeficiency) (IL2RG), mRNA       NM_002183     Homo sapiens  interleukin 3 receptor, alpha (low affinity) (IL3RA),           mRNA       NM_000418     Homo sapiens  interleukin 4 receptor (IL4R), mRNA       NM_000564     Homo sapiens  interleukin 5 receptor, alpha (IL5RA), mRNA       NM_000565     Homo sapiens  interleukin 6 receptor (IL6R), mRNA       NM_002185     Homo sapiens  interleukin 7 receptor (IL7R), mRNA       NM_000634     Homo sapiens  interleukin 8 receptor, alpha (IL8RA), mRNA       NM_001557     Homo sapiens  interleukin 8 receptor, beta (IL8RB), mRNA       NM_002186     Homo sapiens  interleukin 9 receptor (IL9R), mRNA       NM_001558     Homo sapiens  interleukin 10 receptor, alpha (IL10RA), mRNA       NM_000628     Homo sapiens  interleukin 10 receptor, beta (IL10RB), mRNA       NM_004512     Homo sapiens  interleukin 11 receptor, alpha (IL11RA), mRNA       NM_005535     Homo sapiens  interleukin 12 receptor, beta 1 (IL12RB1), mRNA       NM_001559     Homo sapiens  interleukin 12 receptor, beta 2 (IL12RB2), mRNA       NM_001560     Homo sapiens  interleukin 13 receptor, alpha 1 (IL13RA1), mRNA       NM_000640     Homo sapiens  interleukin 13 receptor, alpha 2 (IL13RA2), mRNA       NM_002189     Homo sapiens  interleukin 15 receptor, alpha (IL15RA), mRNA       NM_014339     Homo sapiens  interleukin 17 receptor (IL17R), mRNA       NM_032732     Homo sapiens  interleukin 17 receptor C (IL-17RC), mRNA       NM_144640     Homo sapiens  interleukin 17 receptor E (IL-17RE), mRNA       NM_018725     Homo sapiens  interleukin 17B receptor (IL17BR), mRNA       NM_003855     Homo sapiens  interleukin 18 receptor 1 (IL18R1), mRNA       NM_003853     Homo sapiens  interleukin 18 receptor accessory protein (IL18RAP),           mRNA       NM_014432     Homo sapiens  interleukin 20 receptor, alpha (IL20RA), mRNA       NM_021798     Homo sapiens  interleukin 21 receptor (IL21 antisenseR), mRNA       NM_021258     Homo sapiens  interleukin 22 receptor (IL22R), mRNA       NM_144701     Homo sapiens  interleukin 23 receptor (IL23R), mRNA            Interleukin Associated Proteins            NM_004514     Homo sapiens  interleukin enhancer binding factor 1 (ILF1), mRNA       NM_004515     Homo sapiens  interleukin enhancer binding factor 2, 45 kD (ILF2), mRNA       NM_012218     Homo sapiens  interleukin enhancer binding factor 3, 90 kD (ILF3), mRNA       NM_004516     Homo sapiens  interleukin enhancer binding factor 3, 90 kD (ILF3), mRNA       NM_016123     Homo sapiens  interleukin-1 receptor associated kinase 4 (IRAK4), mRNA       NM_001569     Homo sapiens  interleukin-1 receptor-associated kinase 1 (IRAK1),           mRNA       NM_001570     Homo sapiens  interleukin-1 receptor-associated kinase 2 (IRAK2),           mRNA       NM_007199     Homo sapiens  interleukin-1 receptor-associated kinase 3 (IRAK3),           mRNA       NM_134470     Homo sapiens  interleukin 1 receptor accessory protein (IL1RAP), mRNA       NM_002182     Homo sapiens  interleukin 1 receptor accessory protein (IL1RAP), mRNA       NM_014271     Homo sapiens  interleukin 1 receptor accessory protein-like 1           (IL1RAPL1), mRNA       NM_017416     Homo sapiens  interleukin 1 receptor accessory protein-like 2           (IL1RAPL2), mRNA       NM_000577     Homo sapiens  interleukin 1 receptor antagonist (IL1RN), mRNA       NM_002184     Homo sapiens  interleukin 6 signal transducer (gp130, oncostatin M           receptor) (IL6ST), mRNA       NM_005699     Homo sapiens  interleukin 18 binding protein (IL18BP), mRNA                  
 
         [0427]    
       
         
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE II 
               
               
                   
               
               
                   
               
             
             
               
                 Interleukin and Interleukin receptor siNA and Target Sequences 
                   
               
             
          
           
               
                 IL2RG NM_000206 
                   
               
             
          
           
               
                   
                 Seq 
                   
                 Seq 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Seq 
                 ID 
                 UPos 
                 Upper seq 
                 ID 
                 LPos 
                 Lower seq 
                 ID 
               
               
                   
               
             
          
           
               
                 3 
                 AGAGCAAGCGCCAUGUUGA 
                 1 
                 3 
                 AGAGCAAGCGCCAUGUUGA 
                 1 
                 25 
                 UCAACAUGGCGCUUGCUCU 
                 82 
                   
               
               
                   
               
               
                 21 
                 AAGCCAUCAUUACCAUUCA 
                 2 
                 21 
                 AAGCCAUCAUUACCAUUCA 
                 2 
                 43 
                 UGAAUGGUAAUGAUGGCUU 
                 83 
               
               
                   
               
               
                 39 
                 ACAUCCCUCUUAUUCCUGC 
                 3 
                 39 
                 ACAUCCCUCUUAUUCCUGC 
                 3 
                 61 
                 GCAGGAAUAAGAGGGAUGU 
                 84 
               
               
                   
               
               
                 57 
                 CAGCUGCCCCUGCUGGGAG 
                 4 
                 57 
                 CAGCUGCCCCUGCUGGGAG 
                 4 
                 79 
                 CUCCCAGCAGGGGCAGCUG 
                 85 
               
               
                   
               
               
                 75 
                 GUGGGGCUGAACACGACAA 
                 5 
                 75 
                 GUGGGGCUGAACACGACAA 
                 5 
                 97 
                 UUGUCGUGUUCAGCCCCAC 
                 86 
               
               
                   
               
               
                 93 
                 AUUCUGACGCCCAAUGGGA 
                 6 
                 93 
                 AUUCUGACGCCCAAUGGGA 
                 6 
                 115 
                 UCCCAUUGGGCGUCAGAAU 
                 87 
               
               
                   
               
               
                 111 
                 AAUGAAGACACCACAGCUG 
                 7 
                 111 
                 AAUGAAGACACCACAGCUG 
                 7 
                 133 
                 CAGCUGUGGUGUCUUCAUU 
                 88 
               
               
                   
               
               
                 129 
                 GAUUUCUUCCUGACCACUA 
                 8 
                 129 
                 GAUUUCUUCCUGACCACUA 
                 8 
                 151 
                 UAGUGGUCAGGAAGAAAUC 
                 89 
               
               
                   
               
               
                 147 
                 AUGCCCACUGACUCCCUCA 
                 9 
                 147 
                 AUGCCCACUGACUCCCUCA 
                 9 
                 169 
                 UGAGGGAGUCAGUGGGCAU 
                 90 
               
               
                   
               
               
                 165 
                 AGUGUUUCCACUCUGCCCC 
                 10 
                 165 
                 AGUGUUUCCACUCUGCCCC 
                 10 
                 187 
                 GGGGCAGAGUGGAAACACU 
                 91 
               
               
                   
               
               
                 183 
                 CUCCCAGAGGUUCAGUGUU 
                 11 
                 183 
                 CUCCCAGAGGUUCAGUGUU 
                 11 
                 205 
                 AACACUGAACCUCUGGGAG 
                 92 
               
               
                   
               
               
                 201 
                 UUUGUGUUCAAUGUCGAGU 
                 12 
                 201 
                 UUUGUGUUCAAUGUCGAGU 
                 12 
                 223 
                 ACUCGACAUUGAACACAAA 
                 93 
               
               
                   
               
               
                 219 
                 UACAUGAAUUGCACUUGGA 
                 13 
                 219 
                 UACAUGAAUUGCACUUGGA 
                 13 
                 241 
                 UCCAAGUGCAAUUCAUGUA 
                 94 
               
               
                   
               
               
                 237 
                 AACAGCAGCUCUGAGCCCC 
                 14 
                 237 
                 AACAGCAGCUCUGAGCCCC 
                 14 
                 259 
                 GGGGCUCAGAGCUGCUGUU 
                 95 
               
               
                   
               
               
                 255 
                 CAGCCUACCAACCUCACUC 
                 15 
                 255 
                 CAGCCUACCAACCUCACUC 
                 15 
                 277 
                 GAGUGAGGUUGGUAGGCUG 
                 96 
               
               
                   
               
               
                 273 
                 CUGCAUUAUUGGUACAAGA 
                 16 
                 273 
                 CUGCAUUAUUGGUACAAGA 
                 16 
                 295 
                 UCUUGUACCAAUAAUGCAG 
                 97 
               
               
                   
               
               
                 291 
                 AACUCGGAUAAUGAUAAAG 
                 17 
                 291 
                 AACUCGGAUAAUGAUAAAG 
                 17 
                 313 
                 CUUUAUCAUUAUCCGAGUU 
                 98 
               
               
                   
               
               
                 309 
                 GUCCAGAAGUGCAGCCACU 
                 18 
                 309 
                 GUCCAGAAGUGCAGCCACU 
                 18 
                 331 
                 AGUGGCUGCACUUCUGGAC 
                 99 
               
               
                   
               
               
                 327 
                 UAUCUAUUCUCUGAAGAAA 
                 19 
                 327 
                 UAUCUAUUCUCUGAAGAAA 
                 19 
                 349 
                 UUUCUUCAGAGAAUAGAUA 
                 100 
               
               
                   
               
               
                 345 
                 AUCACUUCUGGCUGUCAGU 
                 20 
                 345 
                 AUCACUUCUGGCUGUCAGU 
                 20 
                 367 
                 ACUGACAGCCAGAAGUGAU 
                 101 
               
               
                   
               
               
                 363 
                 UUGCAAAAAAAGGAGAUCC 
                 21 
                 363 
                 UUGCAAAAAAAGGAGAUCC 
                 21 
                 385 
                 GGAUCUCCUUUUUUUGCAA 
                 102 
               
               
                   
               
               
                 381 
                 CACCUCUACCAAACAUUUG 
                 22 
                 381 
                 CACCUCUACCAAACAUUUG 
                 22 
                 403 
                 CAAAUGUUUGGUAGAGGUG 
                 103 
               
               
                   
               
               
                 399 
                 GUUGUUCAGCUCCAGGACC 
                 23 
                 399 
                 GUUGUUCAGCUCCAGGACC 
                 23 
                 421 
                 GGUCCUGGAGCUGAACAAC 
                 104 
               
               
                   
               
               
                 417 
                 CCACGGGAACCCAGGAGAC 
                 24 
                 417 
                 CCACGGGAACCCAGGAGAC 
                 24 
                 439 
                 GUCUCCUGGGUUCCCGUGG 
                 105 
               
               
                   
               
               
                 435 
                 CAGGCCACACAGAUGCUAA 
                 25 
                 435 
                 CAGGCCACACAGAUGCUAA 
                 25 
                 457 
                 UUAGCAUCUGUGUGGCCUG 
                 106 
               
               
                   
               
               
                 453 
                 AAACUGCAGAAUCUGGUGA 
                 26 
                 453 
                 AAACUGCAGAAUCUGGUGA 
                 26 
                 475 
                 UCACCAGAUUCUGCAGUUU 
                 107 
               
               
                   
               
               
                 471 
                 AUCCCCUGGGCUCCAGAGA 
                 27 
                 471 
                 AUCCCCUGGGCUCCAGAGA 
                 27 
                 493 
                 UCUCUGGAGCCCAGGGGAU 
                 108 
               
               
                   
               
               
                 489 
                 AACCUAACACUUCACAAAC 
                 28 
                 489 
                 AACCUAACACUUCACAAAC 
                 28 
                 511 
                 GUUUGUGAAGUGUUAGGUU 
                 109 
               
               
                   
               
               
                 507 
                 CUGAGUGAAUCCCAGCUAG 
                 29 
                 507 
                 CUGAGUGAAUCCCAGCUAG 
                 29 
                 529 
                 CUAGCUGGGAUUCACUCAG 
                 110 
               
               
                   
               
               
                 525 
                 GAACUGAACUGGAACAACA 
                 30 
                 525 
                 GAACUGAACUGGAACAACA 
                 30 
                 547 
                 UGUUGUUCCAGUUCAGUUC 
                 111 
               
               
                   
               
               
                 543 
                 AGAUUCUUGAACCACUGUU 
                 31 
                 543 
                 AGAUUCUUGAACCACUGUU 
                 31 
                 565 
                 AACAGUGGUUCAAGAAUCU 
                 112 
               
               
                   
               
               
                 561 
                 UUGGAGCACUUGGUGCAGU 
                 32 
                 561 
                 UUGGAGCACUUGGUGCAGU 
                 32 
                 583 
                 ACUGCACCAAGUGCUCCAA 
                 113 
               
               
                   
               
               
                 579 
                 UACCGGACUGACUGGGACC 
                 33 
                 579 
                 UACCGGACUGACUGGGACC 
                 33 
                 601 
                 GGUCCCAGUCAGUCCGGUA 
                 114 
               
               
                   
               
               
                 597 
                 CACAGCUGGACUGAACAAU 
                 34 
                 597 
                 CACAGCUGGACUGAACAAU 
                 34 
                 619 
                 AUUGUUCAGUCCAGCUGUG 
                 115 
               
               
                   
               
               
                 615 
                 UCAGUGGAUUAUAGACAUA 
                 35 
                 615 
                 UCAGUGGAUUAUAGACAUA 
                 35 
                 637 
                 UAUGUCUAUAAUCCACUGA 
                 116 
               
               
                   
               
               
                 633 
                 AAGUUCUCCUUGCCUAGUG 
                 36 
                 633 
                 AAGUUCUCCUUGCCUAGUG 
                 36 
                 655 
                 CACUAGGCAAGGAGAACUU 
                 117 
               
               
                   
               
               
                 651 
                 GUGGAUGGGCAGAAACGCU 
                 37 
                 651 
                 GUGGAUGGGCAGAAACGCU 
                 37 
                 673 
                 AGCGUUUCUGCCCAUCCAC 
                 118 
               
               
                   
               
               
                 669 
                 UACACGUUUCGUGUUCGGA 
                 38 
                 669 
                 UACACGUUUCGUGUUCGGA 
                 38 
                 691 
                 UCCGAACACGAAACGUGUA 
                 119 
               
               
                   
               
               
                 687 
                 AGCCGCUUUAACCCACUCU 
                 39 
                 687 
                 AGCCGCUUUAACCCACUCU 
                 39 
                 709 
                 AGAGUGGGUUAAAGCGGCU 
                 120 
               
               
                   
               
               
                 705 
                 UGUGGAAGUGCUCAGCAUU 
                 40 
                 705 
                 UGUGGAAGUGCUCAGCAUU 
                 40 
                 727 
                 AAUGCUGAGCACUUCCACA 
                 121 
               
               
                   
               
               
                 723 
                 UGGAGUGAAUGGAGCCACC 
                 41 
                 723 
                 UGGAGUGAAUGGAGCCACC 
                 41 
                 745 
                 GGUGGCUCCAUUCACUCCA 
                 122 
               
               
                   
               
               
                 741 
                 CCAAUCCACUGGGGGAGCA 
                 42 
                 741 
                 CCAAUCCACUGGGGGAGCA 
                 42 
                 763 
                 UGCUCCCCCAGUGGAUUGG 
                 123 
               
               
                   
               
               
                 759 
                 AAUACUUCAAAAGAGAAUC 
                 43 
                 759 
                 AAUACUUCAAAAGAGAAUC 
                 43 
                 781 
                 GAUUCUCUUUUGAAGUAUU 
                 124 
               
               
                   
               
               
                 777 
                 CCUUUCCUGUUUGCAUUGG 
                 44 
                 777 
                 CCUUUCCUGUUUGCAUUGG 
                 44 
                 799 
                 CCAAUGCAAACAGGAAAGG 
                 125 
               
               
                   
               
               
                 795 
                 GAAGCCGUGGUUAUCUCUG 
                 45 
                 795 
                 GAAGCCGUGGUUAUCUCUG 
                 45 
                 817 
                 CAGAGAUAACCACGGCUUC 
                 126 
               
               
                   
               
               
                 813 
                 GUUGGCUCCAUGGGAUUGA 
                 46 
                 813 
                 GUUGGCUCCAUGGGAUUGA 
                 46 
                 835 
                 UCAAUCCCAUGGAGCCAAC 
                 127 
               
               
                   
               
               
                 831 
                 AUUAUCAGCCUUCUCUGUG 
                 47 
                 831 
                 AUUAUCAGCCUUCUCUGUG 
                 47 
                 853 
                 CACAGAGAAGGCUGAUAAU 
                 128 
               
               
                   
               
               
                 849 
                 GUGUAUUUCUGGCUGGAAC 
                 48 
                 849 
                 GUGUAUUUCUGGCUGGAAC 
                 48 
                 871 
                 GUUCCAGCCAGAAAUACAC 
                 129 
               
               
                   
               
               
                 867 
                 CGGACGAUGCCCCGAAUUC 
                 49 
                 867 
                 CGGACGAUGCCCCGAAUUC 
                 49 
                 889 
                 GAAUUCGGGGCAUCGUCCG 
                 130 
               
               
                   
               
               
                 885 
                 CCCACCCUGAAGAACCUAG 
                 50 
                 885 
                 CCCACCCUGAAGAACCUAG 
                 50 
                 907 
                 CUAGGUUCUUCAGGGUGGG 
                 131 
               
               
                   
               
               
                 903 
                 GAGGAUCUUGUUACUGAAU 
                 51 
                 903 
                 GAGGAUCUUGUUACUGAAU 
                 51 
                 925 
                 AUUCAGUAACAAGAUCCUC 
                 132 
               
               
                   
               
               
                 921 
                 UACCACGGGAACUUUUCGG 
                 52 
                 921 
                 UACCACGGGAACUUUUCGG 
                 52 
                 943 
                 CCGAAAAGUUCCCGUGGUA 
                 133 
               
               
                   
               
               
                 939 
                 GCCUGGAGUGGUGUGUCUA 
                 53 
                 939 
                 GCCUGGAGUGGUGUGUCUA 
                 53 
                 961 
                 UAGACACACCACUCCAGGC 
                 134 
               
               
                   
               
               
                 957 
                 AAGGGACUGGCUGAGAGUC 
                 54 
                 957 
                 AAGGGACUGGCUGAGAGUC 
                 54 
                 979 
                 GACUCUCAGCCAGUCCCUU 
                 135 
               
               
                   
               
               
                 975 
                 CUGGAGCCAGACUACAGUG 
                 55 
                 975 
                 CUGCAGCCAGACUACAGUG 
                 55 
                 997 
                 CACUGUAGUCUGGCUGCAG 
                 136 
               
               
                   
               
               
                 993 
                 GAACGACUCUGCCUCGUCA 
                 56 
                 993 
                 GAACGACUCUGCCUCGUCA 
                 56 
                 1015 
                 UGACGAGGCAGAGUCGUUC 
                 137 
               
               
                   
               
               
                 1011 
                 AGUGAGAUUCCCCCAAAAG 
                 57 
                 1011 
                 AGUGAGAUUCCCCCAAAAG 
                 57 
                 1033 
                 CUUUUGGGGGAAUCUCACU 
                 138 
               
               
                   
               
               
                 1029 
                 GGAGGGGCCCUUGGGGAGG 
                 58 
                 1029 
                 GGAGGGGCCCUUGGGGAGG 
                 58 
                 1051 
                 CCUCCCCAAGGGCCCCUCC 
                 139 
               
               
                   
               
               
                 1047 
                 GGGCCUGGGGCCUCCCCAU 
                 59 
                 1047 
                 GGGCCUGGGGCCUCCCCAU 
                 59 
                 1069 
                 AUGGGGAGGCCCCAGGCCC 
                 140 
               
               
                   
               
               
                 1065 
                 UGCAACCAGCAUAGCCCCU 
                 60 
                 1065 
                 UGCAACCAGCAUAGCCCCU 
                 60 
                 1087 
                 AGGGGCUAUGCUGGUUGCA 
                 141 
               
               
                   
               
               
                 1083 
                 UACUGGGCCCCCCCAUGUU 
                 61 
                 1083 
                 UACUGGGCCCCCCCAUGUU 
                 61 
                 1105 
                 AACAUGGGGGGGCCCAGUA 
                 142 
               
               
                   
               
               
                 1101 
                 UACACCCUAAAGCCUGAAA 
                 62 
                 1101 
                 UACACCCUAAAGCCUGAAA 
                 62 
                 1123 
                 UUUCAGGCUUUAGGGUGUA 
                 143 
               
               
                   
               
               
                 1119 
                 ACCUGAACCCCAAUCCUCU 
                 63 
                 1119 
                 ACCUGAACCCCAAUCCUCU 
                 63 
                 1141 
                 AGAGGAUUGGGGUUCAGGU 
                 144 
               
               
                   
               
               
                 1137 
                 UGACAGAAGAACCCCAGGG 
                 64 
                 1137 
                 UGACAGAAGAACCCCAGGG 
                 64 
                 1159 
                 CCCUGGGGUUCUUCUGUCA 
                 145 
               
               
                   
               
               
                 1155 
                 GUCCUGUAGCCCUAAGUGG 
                 65 
                 1155 
                 GUCCUGUAGCCCUAAGUGG 
                 65 
                 1177 
                 CCACUUAGGGCUACAGGAC 
                 146 
               
               
                   
               
               
                 1173 
                 GUACUAACUUUCCUUCAUU 
                 66 
                 1173 
                 GUACUAACUUUCCUUCAUU 
                 66 
                 1195 
                 AAUGAAGGAAAGUUAGUAC 
                 147 
               
               
                   
               
               
                 1191 
                 UCAACCCACCUGCGUCUCA 
                 67 
                 1191 
                 UCAACCCACCUGCGUCUCA 
                 67 
                 1213 
                 UGAGACGCAGGUGGGUUGA 
                 148 
               
               
                   
               
               
                 1209 
                 AUACUCACCUCACCCCACU 
                 68 
                 1209 
                 AUACUCACCUCACCCCACU 
                 68 
                 1231 
                 AGUGGGGUGAGGUGAGUAU 
                 149 
               
               
                   
               
               
                 1227 
                 UGUGGCUGAUUUGGAAUUU 
                 69 
                 1227 
                 UGUGGCUGAUUUGGAAUUU 
                 69 
                 1249 
                 AAAUUCCAAAUCAGCCACA 
                 150 
               
               
                   
               
               
                 1245 
                 UUGUGCCCCCAUGUAAGCA 
                 70 
                 1245 
                 UUGUGCCCCCAUGUAAGCA 
                 70 
                 1267 
                 UGCUUACAUGGGGGCACAA 
                 151 
               
               
                   
               
               
                 1263 
                 ACCCCUUCAUUUGGCAUUC 
                 71 
                 1263 
                 ACCCCUUCAUUUGGCAUUC 
                 71 
                 1285 
                 GAAUGCCAAAUGAAGGGGU 
                 152 
               
               
                   
               
               
                 1281 
                 CCCCACUUGAGAAUUACCC 
                 72 
                 1281 
                 CCCCACUUGAGAAUUACCC 
                 72 
                 1303 
                 GGGUAAUUCUCAAGUGGGG 
                 153 
               
               
                   
               
               
                 1299 
                 CUUUUGCCCCGAACAUGUU 
                 73 
                 1299 
                 CUUUUGCCCCGAACAUGUU 
                 73 
                 1321 
                 AACAUGUUCGGGGCAAAAG 
                 154 
               
               
                   
               
               
                 1317 
                 UUUUCUUCUCCCUCAGUCU 
                 74 
                 1317 
                 UUUUCUUCUCCCUCAGUCU 
                 74 
                 1339 
                 AGACUGAGGGAGAAGAAAA 
                 155 
               
               
                   
               
               
                 1335 
                 UGGCCCUUCCUUUUCGCAG 
                 75 
                 1335 
                 UGGCCCUUCCUUUUCGCAG 
                 75 
                 1357 
                 CUGCGAAAAGGAAGGGCCA 
                 156 
               
               
                   
               
               
                 1353 
                 GGAUUCUUCCUCCCUCCCU 
                 76 
                 1353 
                 GGAUUCUUCCUCCCUCCCU 
                 76 
                 1375 
                 AGGGAGGGAGGAAGAAUCC 
                 157 
               
               
                   
               
               
                 1371 
                 UCUUUCCCUCCCUUCCUCU 
                 77 
                 1371 
                 UCUUUCCCUCCCUUCCUCU 
                 77 
                 1393 
                 AGAGGAAGGGAGGGAAAGA 
                 158 
               
               
                   
               
               
                 1389 
                 UUUCCAUCUACCCUCCGAU 
                 78 
                 1389 
                 UUUCCAUCUACCCUCCGAU 
                 78 
                 1411 
                 AUCGGAGGGUAGAUGGAAA 
                 159 
               
               
                   
               
               
                 1407 
                 UUGUUCCUGAACCGAUGAG 
                 79 
                 1407 
                 UUGUUCCUGAACCGAUGAG 
                 79 
                 1429 
                 CUCAUCGGUUCAGGAACAA 
                 160 
               
               
                   
               
               
                 1425 
                 GAAAUAAAGUUUCUGUUGA 
                 80 
                 1425 
                 GAAAUAAAGUUUCUGUUGA 
                 80 
                 1447 
                 UCAACAGAAACUUUAUUUC 
                 161 
               
               
                   
               
               
                 1431 
                 AAGUUUCUGUUGAUAAUCA 
                 81 
                 1431 
                 AAGUUUCUGUUGAUAAUCA 
                 81 
                 1453 
                 UGAUUAUCAACAGAAACUU 
                 162 
               
               
                   
               
               
                   
               
             
          
           
               
                 IL4 NM_000589 
                   
               
             
          
           
               
                   
                 Seq 
                   
                 Seq 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Seq 
                 ID 
                 UPos 
                 Upper seq 
                 ID 
                 LPos 
                 Lower seq 
                 ID 
               
               
                   
               
             
          
           
               
                 3 
                 CUAUGCAAAGCAAAAAGCC 
                 163 
                 3 
                 CUAUGCAAAGCAAAAAGCC 
                 163 
                 25 
                 GGCUUUUUGCUUUGCAUAG 
                 214 
                   
               
               
                   
               
               
                 21 
                 CAGCAGCAGCCCCAAGCUG 
                 164 
                 21 
                 CAGCAGCAGCCCCAAGCUG 
                 164 
                 43 
                 CAGCUUGGGGCUGCUGCUG 
                 215 
               
               
                   
               
               
                 39 
                 GAUAAGAUUAAUCUAAAGA 
                 165 
                 39 
                 GAUAAGAUUAAUCUAAAGA 
                 165 
                 61 
                 UCUUUAGAUUAAUCUUAUC 
                 216 
               
               
                   
               
               
                 57 
                 AGCAAAUUAUGGUGUAAUU 
                 166 
                 57 
                 AGCAAAUUAUGGUGUAAUU 
                 166 
                 79 
                 AAUUACACCAUAAUUUGCU 
                 217 
               
               
                   
               
               
                 75 
                 UUCCUAUGCUGAAACUUUG 
                 167 
                 75 
                 UUCCUAUGCUGAAACUUUG 
                 167 
                 97 
                 CAAAGUUUCAGCAUAGGAA 
                 218 
               
               
                   
               
               
                 93 
                 GUAGUUAAUUUUUUAAAAA 
                 168 
                 93 
                 GUAGUUAAUUUUUUAAAAA 
                 168 
                 115 
                 UUUUUAAAAAAUUAACUAC 
                 219 
               
               
                   
               
               
                 111 
                 AGGUUUCAUUUUCCUAUUG 
                 169 
                 111 
                 AGGUUUCAUUUUCCUAUUG 
                 169 
                 133 
                 CAAUAGGAAAAUGAAACCU 
                 220 
               
               
                   
               
               
                 129 
                 GGUCUGAUUUCACAGGAAC 
                 170 
                 129 
                 GGUCUGAUUUCACAGGAAC 
                 170 
                 151 
                 GUUCCUGUGAAAUCAGACC 
                 221 
               
               
                   
               
               
                 147 
                 CAUUUUACCUGUUUGUGAG 
                 171 
                 147 
                 CAUUUUACCUGUUUGUGAG 
                 171 
                 169 
                 CUCACAAACAGGUAAAAUG 
                 222 
               
               
                   
               
               
                 165 
                 GGCAUUUUUUCUCCUGGAA 
                 172 
                 165 
                 GGCAUUUUUUCUCCUGGAA 
                 172 
                 187 
                 UUCCAGGAGAAAAAAUGCC 
                 223 
               
               
                   
               
               
                 183 
                 AGAGAGGUGCUGAUUGGCC 
                 173 
                 183 
                 AGAGAGGUGCUGAUUGGCC 
                 173 
                 205 
                 GGCCAAUCAGCACCUCUCU 
                 224 
               
               
                   
               
               
                 201 
                 CCCAAGUGACUGACAAUCU 
                 174 
                 201 
                 CCCAAGUGACUGACAAUCU 
                 174 
                 223 
                 AGAUUGUCAGUCACUUGGG 
                 225 
               
               
                   
               
               
                 219 
                 UGGUGUAACGAAAAUUUCC 
                 175 
                 219 
                 UGGUGUAACGAAAAUUUCC 
                 175 
                 241 
                 GGAAAUUUUCGUUACACCA 
                 226 
               
               
                   
               
               
                 237 
                 CAAUGUAAACUCAUUUUCC 
                 176 
                 237 
                 CAAUGUAAACUCAUUUUCC 
                 176 
                 259 
                 GGAAAAUGAGUUUACAUUG 
                 227 
               
               
                   
               
               
                 255 
                 CCUCGGUUUCAGCAAUUUU 
                 177 
                 255 
                 CCUCGGUUUCAGCAAUUUU 
                 177 
                 277 
                 AAAAUUGCUGAAACCGAGG 
                 228 
               
               
                   
               
               
                 273 
                 UAAAUCUAUAUAUAGAGAU 
                 178 
                 273 
                 UAAAUCUAUAUAUAGAGAU 
                 178 
                 295 
                 AUCUCUAUAUAUAGAUUUA 
                 229 
               
               
                   
               
               
                 291 
                 UAUCUUUGUCAGCAUUGCA 
                 179 
                 291 
                 UAUCUUUGUCAGCAUUGCA 
                 179 
                 313 
                 UGCAAUGCUGACAAAGAUA 
                 230 
               
               
                   
               
               
                 309 
                 AUCGUUAGCUUCUCCUGAU 
                 180 
                 309 
                 AUCGUUAGCUUCUCCUGAU 
                 180 
                 331 
                 AUCAGGAGAAGCUAACGAU 
                 231 
               
               
                   
               
               
                 327 
                 UAAACUAAUUGCCUCACAU 
                 181 
                 327 
                 UAAACUAAUUGCCUCACAU 
                 181 
                 349 
                 AUGUGAGGCAAUUAGUUUA 
                 232 
               
               
                   
               
               
                 345 
                 UUGUCACUGCAAAUCGACA 
                 182 
                 345 
                 UUGUCACUGCAAAUCGACA 
                 182 
                 367 
                 UGUCGAUUUGCAGUGACAA 
                 233 
               
               
                   
               
               
                 363 
                 ACCUAUUAAUGGGUCUCAC 
                 183 
                 363 
                 ACCUAUUAAUGGGUCUCAC 
                 183 
                 385 
                 GUGAGACCCAUUAAUAGGU 
                 234 
               
               
                   
               
               
                 381 
                 CCUCCCPACUGCUUCCCCC 
                 184 
                 381 
                 CCUCCCAACUGCUUCCCCC 
                 184 
                 403 
                 GGGGGAAGCAGUUGGGAGG 
                 235 
               
               
                   
               
               
                 399 
                 CUCUGUUCUUCCUGCUAGC 
                 185 
                 399 
                 CUCUGUUCUUCCUGCUAGC 
                 185 
                 421 
                 GCUAGCAGGAAGAACAGAG 
                 236 
               
               
                   
               
               
                 417 
                 CAUGUGCCGGCAACUUUGU 
                 186 
                 417 
                 CAUGUGCCGGCAACUUUGU 
                 186 
                 439 
                 ACAAAGUUGCCGGCACAUG 
                 237 
               
               
                   
               
               
                 435 
                 UCCACGGACACAAGUGCGA 
                 187 
                 435 
                 UCCACGGACACAAGUGCGA 
                 187 
                 457 
                 UCGCACUUGUGUCCGUGGA 
                 238 
               
               
                   
               
               
                 453 
                 AUAUCACCUUACAGGAGAU 
                 188 
                 453 
                 AUAUCACCUUACAGGAGAU 
                 188 
                 475 
                 AUCUCCUGUAAGGUGAUAU 
                 239 
               
               
                   
               
               
                 471 
                 UCAUCAAAACUUUGAACAG 
                 189 
                 471 
                 UCAUCAAAACUUUGAACAG 
                 189 
                 493 
                 CUGUUCAAAGUUUUGAUGA 
                 240 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGAC 
                 190 
                 489 
                 GCCUCACAGAGCAGAAGAC 
                 190 
                 511 
                 GUCUUCUGCUCUGUGAGGC 
                 241 
               
               
                   
               
               
                 507 
                 CUCUGUGCACCGAGUUGAC 
                 191 
                 507 
                 CUCUGUGCACCGAGUUGAC 
                 191 
                 529 
                 GUCAACUCGGUGCACAGAG 
                 242 
               
               
                   
               
               
                 525 
                 CCGUAACAGACAUCUUUGC 
                 192 
                 525 
                 CCGUAACAGACAUCUUUGC 
                 192 
                 547 
                 GCAAAGAUGUCUGUUACGG 
                 243 
               
               
                   
               
               
                 543 
                 CUGCCUCCAAGAACACAAC 
                 193 
                 543 
                 CUGCCUCCAAGAACACAAC 
                 193 
                 565 
                 GUUGUGUUCUUGGAGGCAG 
                 244 
               
               
                   
               
               
                 561 
                 CUGAGAAGGAAACCUUCUG 
                 194 
                 561 
                 CUGAGAAGGAAACCUUCUG 
                 194 
                 583 
                 CAGAAGGUUUCCUUCUCAG 
                 245 
               
               
                   
               
               
                 579 
                 GCAGGGCUGCGACUGUGCU 
                 195 
                 579 
                 GCAGGGCUGCGACUGUGCU 
                 195 
                 601 
                 AGCACAGUCGCAGCCCUGC 
                 246 
               
               
                   
               
               
                 597 
                 UCCGGCAGUUCUACAGCCA 
                 196 
                 597 
                 UCCGGCAGUUCUACAGCCA 
                 196 
                 619 
                 UGGCUGUAGAACUGCCGGA 
                 247 
               
               
                   
               
               
                 615 
                 ACCAUGAGAAGGACACUCG 
                 197 
                 615 
                 ACCAUGAGAAGGACACUCG 
                 197 
                 637 
                 CGAGUGUCCUUCUCAUGGU 
                 248 
               
               
                   
               
               
                 633 
                 GCUGCCUGGGUGCGACUGC 
                 198 
                 633 
                 GCUGCCUGGGUGCGACUGC 
                 198 
                 655 
                 GCAGUCGCACCCAGGCAGC 
                 249 
               
               
                   
               
               
                 651 
                 CACAGCAGUUCCACAGGCA 
                 199 
                 651 
                 CACAGCAGUUCCACAGGCA 
                 199 
                 673 
                 UGCCUGUGGAACUGCUGUG 
                 250 
               
               
                   
               
               
                 669 
                 ACAAGCAGCUGAUCCGAUU 
                 200 
                 669 
                 ACAAGCAGCUGAUCCGAUU 
                 200 
                 691 
                 AAUCGGAUCAGCUGCUUGU 
                 251 
               
               
                   
               
               
                 687 
                 UCCUGAAACGGCUCGACAG 
                 201 
                 687 
                 UCCUGAAACGGCUCGACAG 
                 201 
                 709 
                 CUGUCGAGCCGUUUCAGGA 
                 252 
               
               
                   
               
               
                 705 
                 GGAACCUCUGGGGCCUGGC 
                 202 
                 705 
                 GGAACCUCUGGGGCCUGGC 
                 202 
                 727 
                 GCCAGGCCCCAGAGGUUCC 
                 253 
               
               
                   
               
               
                 723 
                 CGGGCUUGAAUUCCUGUCC 
                 203 
                 723 
                 CGGGCUUGAAUUCCUGUCC 
                 203 
                 745 
                 GGACAGGAAUUCAAGCCCG 
                 254 
               
               
                   
               
               
                 741 
                 CUGUGAAGGAAGCCAACCA 
                 204 
                 741 
                 CUGUGAAGGAAGCCAACCA 
                 204 
                 763 
                 UGGUUGGCUUCCUUCACAG 
                 255 
               
               
                   
               
               
                 759 
                 AGAGUACGUUGGAAAACUU 
                 205 
                 759 
                 AGAGUACGUUGGAAAACUU 
                 205 
                 781 
                 AAGUUUUCCAACGUACUCU 
                 256 
               
               
                   
               
               
                 777 
                 UCUUGGAAAGGCUAAAGAC 
                 206 
                 777 
                 UCUUGGAAAGGCUAAAGAC 
                 206 
                 799 
                 GUCUUUAGCCUUUCCAAGA 
                 257 
               
               
                   
               
               
                 795 
                 CGAUCAUGAGAGAGAAAUA 
                 207 
                 795 
                 CGAUCAUGAGAGAGAAAUA 
                 207 
                 817 
                 UAUUUCUCUCUCAUGAUCG 
                 258 
               
               
                   
               
               
                 813 
                 AUUCAAAGUGUUCGAGCUG 
                 208 
                 813 
                 AUUCAAAGUGUUCGAGCUG 
                 208 
                 835 
                 CAGCUCGAACACUUUGAAU 
                 259 
               
               
                   
               
               
                 831 
                 GAAUAUUUUAAUUUAUGAG 
                 209 
                 831 
                 GAAUAUUUUAAUUUAUGAG 
                 209 
                 853 
                 CUCAUAAAUUAAAAUAUUC 
                 260 
               
               
                   
               
               
                 849 
                 GUUUUUGAUAGCUUUAUUU 
                 210 
                 849 
                 GUUUUUGAUAGCUUUAUUU 
                 210 
                 871 
                 AAAUAAAGCUAUCAAAAAC 
                 261 
               
               
                   
               
               
                 867 
                 UUUUAAGUAUUUAUAUAUU 
                 211 
                 867 
                 UUUUAAGUAUUUAUAUAUU 
                 211 
                 889 
                 AAUAUAUAAAUACUUAAAA 
                 262 
               
               
                   
               
               
                 885 
                 UUAUAACUCAUCAUAAAAU 
                 212 
                 885 
                 UUAUAACUCAUCAUAAAAU 
                 212 
                 907 
                 AUUUUAUGAUGAGUUAUAA 
                 263 
               
               
                   
               
               
                 901 
                 AAUAAAGUAUAUAUAGAAU 
                 213 
                 901 
                 AAUAAAGUAUAUAUAGAAU 
                 213 
                 923 
                 AUUCUAUAUAUACUUUAUU 
                 264 
               
               
                   
               
               
                   
               
             
          
           
               
                 IL4R NM_000418 
                   
               
             
          
           
               
                   
                 Seq 
                   
                 Seq 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Seq 
                 ID 
                 UPos 
                 Upper seq 
                 ID 
                 LPos 
                 Lower seq 
                 ID 
               
               
                   
               
             
          
           
               
                 3 
                 CGAAUGGAGCAGGGGCGCG 
                 265 
                 3 
                 CGAAUGGAGCAGGGGCGCG 
                 265 
                 25 
                 CGCGCCCCUGCUCCAUUCG 
                 465 
                   
               
               
                   
               
               
                 21 
                 GCAGAUAAUUAAAGAUUUA 
                 266 
                 21 
                 GCAGAUAAUUAAAGAUUUA 
                 266 
                 43 
                 UAAAUCUUUAAUUAUCUGC 
                 466 
               
               
                   
               
               
                 39 
                 ACACACAGCUGGAAGAAAU 
                 267 
                 39 
                 ACACACAGCUGGAAGAAAU 
                 267 
                 61 
                 AUUUCUUCCAGCUGUGUGU 
                 467 
               
               
                   
               
               
                 57 
                 UCAUAGAGAAGCCGGGCGU 
                 268 
                 57 
                 UCAUAGAGAAGCCGGGCGU 
                 268 
                 79 
                 ACGCCCGGCUUCUCUAUGA 
                 468 
               
               
                   
               
               
                 75 
                 UGGUGGCUCAUGCCUAUAA 
                 269 
                 75 
                 UGGUGGCUCAUGCCUAUAA 
                 269 
                 97 
                 UUAUAGGCAUGAGCCACCA 
                 469 
               
               
                   
               
               
                 93 
                 AUCCCAGCACUUUUGGAGG 
                 270 
                 93 
                 AUCCCAGCACUUUUGGAGG 
                 270 
                 115 
                 CCUCCAAAAGUGCUGGGAU 
                 470 
               
               
                   
               
               
                 111 
                 GCUGAGGCGGGCAGAUCAC 
                 271 
                 111 
                 GCUGAGGCGGGCAGAUCAC 
                 271 
                 133 
                 GUGAUCUGCCCGCCUCAGC 
                 471 
               
               
                   
               
               
                 129 
                 CUUGAGAUCAGGAGUUCGA 
                 272 
                 129 
                 CUUGAGAUCAGGAGUUCGA 
                 272 
                 151 
                 UCGAACUCCUGAUCUCAAG 
                 472 
               
               
                   
               
               
                 147 
                 AGACCAGCCUGGUGCCUUG 
                 273 
                 147 
                 AGACCAGCCUGGUGCCUUG 
                 273 
                 169 
                 CAAGGCACCAGGCUGGUCU 
                 473 
               
               
                   
               
               
                 165 
                 GGCAUCUCCCAAUGGGGUG 
                 274 
                 165 
                 GGCAUCUCCCAAUGGGGUG 
                 274 
                 187 
                 CACCCCAUUGGGAGAUGCC 
                 474 
               
               
                   
               
               
                 183 
                 GGCUUUGCUCUGGGCUCCU 
                 275 
                 183 
                 GGCUUUGCUCUGGGCUCCU 
                 275 
                 205 
                 AGGAGCCCAGAGCAAAGCC 
                 475 
               
               
                   
               
               
                 201 
                 UGUUCCCUGUGAGCUGCCU 
                 276 
                 201 
                 UGUUCCCUGUGAGCUGCCU 
                 276 
                 223 
                 AGGCAGCUCACAGGGAACA 
                 476 
               
               
                   
               
               
                 219 
                 UGGUCCUGCUGCAGGUGGC 
                 277 
                 219 
                 UGGUCCUGCUGCAGGUGGC 
                 277 
                 241 
                 GCCACCUGCAGCAGGACCA 
                 477 
               
               
                   
               
               
                 237 
                 CAAGCUCUGGGAACAUGAA 
                 278 
                 237 
                 CAAGCUCUGGGAACAUGAA 
                 278 
                 259 
                 UUCAUGUUCCCAGAGCUUG 
                 478 
               
               
                   
               
               
                 255 
                 AGGUCUUGCAGGAGCCCAC 
                 279 
                 255 
                 AGGUCUUGCAGGAGCCCAC 
                 279 
                 277 
                 GUGGGCUCCUGCAAGACCU 
                 479 
               
               
                   
               
               
                 273 
                 CCUGCGUCUCCGACUACAU 
                 280 
                 273 
                 CCUGCGUCUCCGACUACAU 
                 280 
                 295 
                 AUGUAGUCGGAGACGCAGG 
                 480 
               
               
                   
               
               
                 291 
                 UGAGCAUCUCUACUUGCGA 
                 281 
                 291 
                 UGAGCAUCUCUACUUGCGA 
                 281 
                 313 
                 UCGCAAGUAGAGAUGCUCA 
                 481 
               
               
                   
               
               
                 309 
                 AGUGGAAGAUGAAUGGUCC 
                 282 
                 309 
                 AGUGGAAGAUGAAUGGUCC 
                 282 
                 331 
                 GGACCAUUCAUCUUCCACU 
                 482 
               
               
                   
               
               
                 327 
                 CCACCAAUUGCAGCACCGA 
                 283 
                 327 
                 CCACCAAUUGCAGCACCGA 
                 283 
                 349 
                 UCGGUGCUGCAAUUGGUGG 
                 483 
               
               
                   
               
               
                 345 
                 AGCUCCGCCUGUUGUACCA 
                 284 
                 345 
                 AGCUCCGCCUGUUGUACCA 
                 284 
                 367 
                 UGGUACAACAGGCGGAGCU 
                 484 
               
               
                   
               
               
                 363 
                 AGCUGGUUUUUCUGCUCUC 
                 285 
                 363 
                 AGCUGGUUUUUCUGCUCUC 
                 285 
                 385 
                 GAGAGCAGAAAAACCAGCU 
                 485 
               
               
                   
               
               
                 381 
                 CCGAAGCCCACACGUGUAU 
                 286 
                 381 
                 CCGAAGCCCACACGUGUAU 
                 286 
                 403 
                 AUACACGUGUGGGCUUCGG 
                 486 
               
               
                   
               
               
                 399 
                 UCCCUGAGAACAACGGAGG 
                 287 
                 399 
                 UCCCUGAGAACAACGGAGG 
                 287 
                 421 
                 CCUCCGUUGUUCUCAGGGA 
                 487 
               
               
                   
               
               
                 417 
                 GCGCGGGGUGCGUGUGCCA 
                 288 
                 417 
                 GCGCGGGGUGCGUGUGCCA 
                 288 
                 439 
                 UGGCACACGCACCCCGCGC 
                 488 
               
               
                   
               
               
                 435 
                 ACCUGCUCAUGGAUGACGU 
                 289 
                 435 
                 ACCUGCUCAUGGAUGACGU 
                 289 
                 457 
                 ACGUCAUCCAUGAGCAGGU 
                 489 
               
               
                   
               
               
                 453 
                 UGGUCAGUGCGGAUAACUA 
                 290 
                 453 
                 UGGUCAGUGCGGAUAACUA 
                 290 
                 475 
                 UAGUUAUCCGCACUGACCA 
                 490 
               
               
                   
               
               
                 471 
                 AUACACUGGACCUGUGGGC 
                 291 
                 471 
                 AUACACUGGACCUGUGGGC 
                 291 
                 493 
                 GCCCACAGGUCCAGUGUAU 
                 491 
               
               
                   
               
               
                 489 
                 CUGGGCAGCAGCUGCUGUG 
                 292 
                 489 
                 CUGGGCAGCAGCUGCUGUG 
                 292 
                 511 
                 CACAGCAGCUGCUGCCCAG 
                 492 
               
               
                   
               
               
                 507 
                 GGAAGGGCUCCUUCAAGCC 
                 293 
                 507 
                 GGAAGGGCUCCUUCAAGCC 
                 293 
                 529 
                 GGCUUGAAGGAGCCCUUCC 
                 493 
               
               
                   
               
               
                 525 
                 CCAGCGAGCAUGUGAAACC 
                 294 
                 525 
                 CCAGCGAGCAUGUGAAACC 
                 294 
                 547 
                 GGUUUCACAUGCUCGCUGG 
                 494 
               
               
                   
               
               
                 543 
                 CCAGGGCCCCAGGAAACCU 
                 295 
                 543 
                 CCAGGGCCCCAGGAAACCU 
                 295 
                 565 
                 AGGUUUCCUGGGGCCCUGG 
                 495 
               
               
                   
               
               
                 561 
                 UGACAGUUCACACCAAUGU 
                 296 
                 561 
                 UGACAGUUCACACCAAUGU 
                 296 
                 583 
                 ACAUUGGUGUGAACUGUCA 
                 496 
               
               
                   
               
               
                 579 
                 UCUCCGACACUCUGCUGCU 
                 297 
                 579 
                 UCUCCGACACUCUGCUGCU 
                 297 
                 601 
                 AGCAGCAGAGUGUCGGAGA 
                 497 
               
               
                   
               
               
                 597 
                 UGACCUGGAGCAACCCGUA 
                 298 
                 597 
                 UGACCUGGAGCAACCCGUA 
                 298 
                 619 
                 UACGGGUUGCUCCAGGUCA 
                 498 
               
               
                   
               
               
                 615 
                 AUCCCCCUGACAAUUACCU 
                 299 
                 615 
                 AUCCCCCUGACAAUUACCU 
                 299 
                 637 
                 AGGUAAUUGUCAGGGGGAU 
                 499 
               
               
                   
               
               
                 633 
                 UGUAUAAUCAUCUCACCUA 
                 300 
                 633 
                 UGUAUAAUCAUCUCACCUA 
                 300 
                 655 
                 UAGGUGAGAUGAUUAUACA 
                 500 
               
               
                   
               
               
                 651 
                 AUGCAGUCAACAUUUGGAG 
                 301 
                 651 
                 AUGCAGUCAACAUUUGGAG 
                 301 
                 673 
                 CUCCAAAUGUUGACUGCAU 
                 501 
               
               
                   
               
               
                 669 
                 GUGAAAACGACCCGGCAGA 
                 302 
                 669 
                 GUGAAAACGACCCGGCAGA 
                 302 
                 691 
                 UCUGCCGGGUCGUUUUCAC 
                 502 
               
               
                   
               
               
                 687 
                 AUUUCAGAAUCUAUAACGU 
                 303 
                 687 
                 AUUUCAGAAUCUAUAACGU 
                 303 
                 709 
                 ACGUUAUAGAUUCUGAAAU 
                 503 
               
               
                   
               
               
                 705 
                 UGACCUACCUAGAACCCUC 
                 304 
                 705 
                 UGACCUACCUAGAACCCUC 
                 304 
                 727 
                 GAGGGUUCUAGGUAGGUCA 
                 504 
               
               
                   
               
               
                 723 
                 CCCUCCGCAUCGCAGCCAG 
                 305 
                 723 
                 CCCUCCGCAUCGCAGCCAG 
                 305 
                 745 
                 CUGGCUGCGAUGCGGAGGG 
                 505 
               
               
                   
               
               
                 741 
                 GCACCCUGAAGUCUGGGAU 
                 306 
                 741 
                 GCACCCUGAAGUCUGGGAU 
                 306 
                 763 
                 AUCCCAGACUUCAGGGUGC 
                 506 
               
               
                   
               
               
                 759 
                 UUUCCUACAGGGCACGGGU 
                 307 
                 759 
                 UUUCCUACAGGGCACGGGU 
                 307 
                 781 
                 ACCCGUGCCCUGUAGGAAA 
                 507 
               
               
                   
               
               
                 777 
                 UGAGGGCCUGGGCUCAGUG 
                 308 
                 777 
                 UGAGGGCCUGGGCUCAGUG 
                 308 
                 799 
                 CACUGAGCCCAGGCCCUCA 
                 508 
               
               
                   
               
               
                 795 
                 GCUAUAACACCACCUGGAG 
                 309 
                 795 
                 GCUAUAACACCACCUGGAG 
                 309 
                 817 
                 CUCCAGGUGGUGUUAUAGC 
                 509 
               
               
                   
               
               
                 813 
                 GUGAGUGGAGCCCCAGCAC 
                 310 
                 813 
                 GUGAGUGGAGCCCCAGCAC 
                 310 
                 835 
                 GUGCUGGGGCUCCACUCAC 
                 510 
               
               
                   
               
               
                 831 
                 CCAAGUGGCACAACUCCUA 
                 311 
                 831 
                 CCAAGUGGCACAACUCCUA 
                 311 
                 853 
                 UAGGAGUUGUGCCACUUGG 
                 511 
               
               
                   
               
               
                 849 
                 ACAGGGAGCCCUUCGAGCA 
                 312 
                 849 
                 ACAGGGAGCCCUUCGAGCA 
                 312 
                 871 
                 UGCUCGAAGGGCUCCCUGU 
                 512 
               
               
                   
               
               
                 867 
                 AGCACCUCCUGCUGGGCGU 
                 313 
                 867 
                 AGCACCUCCUGCUGGGCGU 
                 313 
                 889 
                 ACGCCCAGCAGGAGGUGCU 
                 513 
               
               
                   
               
               
                 885 
                 UCAGCGUUUCCUGCAUUGU 
                 314 
                 885 
                 UCAGCGUUUCCUGCAUUGU 
                 314 
                 907 
                 ACAAUGCAGGAAACGCUGA 
                 514 
               
               
                   
               
               
                 903 
                 UCAUCCUGGCCGUCUGCCU 
                 315 
                 903 
                 UCAUCCUGGCCGUCUGCCU 
                 315 
                 925 
                 AGGCAGACGGCCAGGAUGA 
                 515 
               
               
                   
               
               
                 921 
                 UGUUGUGCUAUGUCAGCAU 
                 316 
                 921 
                 UGUUGUGCUAUGUCAGCAU 
                 316 
                 943 
                 AUGCUGACAUAGCACAACA 
                 516 
               
               
                   
               
               
                 939 
                 UCACCAAGAUUAAGAAAGA 
                 317 
                 939 
                 UCACCAAGAUUAAGAAAGA 
                 317 
                 961 
                 UCUUUCUUAAUCUUGGUGA 
                 517 
               
               
                   
               
               
                 957 
                 AAUGGUGGGAUCAGAUUCC 
                 318 
                 957 
                 AAUGGUGGGAUCAGAUUCC 
                 318 
                 979 
                 GGAAUCUGAUCCCACCAUU 
                 518 
               
               
                   
               
               
                 975 
                 CCAACCCAGCCCGCAGCCG 
                 319 
                 975 
                 CCAACCCAGCCCGCAGCCG 
                 319 
                 997 
                 CGGCUGCGGGCUGGGUUGG 
                 519 
               
               
                   
               
               
                 993 
                 GCCUCGUGGCUAUAAUAAU 
                 320 
                 993 
                 GCCUCGUGGCUAUAAUAAU 
                 320 
                 1015 
                 AUUAUUAUAGCCACGAGGC 
                 520 
               
               
                   
               
               
                 1011 
                 UCCAGGAUGCUCAGGGGUC 
                 321 
                 1011 
                 UCCAGGAUGCUCAGGGGUC 
                 321 
                 1033 
                 GACCCCUGAGCAUCCUGGA 
                 521 
               
               
                   
               
               
                 1029 
                 CACAGUGGGAGAAGCGGUC 
                 322 
                 1029 
                 CACAGUGGGAGAAGCGGUC 
                 322 
                 1051 
                 GACCGCUUCUCCCACUGUG 
                 522 
               
               
                   
               
               
                 1047 
                 CCCGAGGCCAGGAACCAGC 
                 323 
                 1047 
                 CCCGAGGCCAGGAACCAGC 
                 323 
                 1069 
                 GCUGGUUCCUGGCCUCGGG 
                 523 
               
               
                   
               
               
                 1065 
                 CCAAGUGCCCACACUGGAA 
                 324 
                 1065 
                 CCAAGUGCCCACACUGGAA 
                 324 
                 1087 
                 UUCCAGUGUGGGCACUUGG 
                 524 
               
               
                   
               
               
                 1083 
                 AGAAUUGUCUUACCAAGCU 
                 325 
                 1083 
                 AGAAUUGUCUUACCAAGCU 
                 325 
                 1105 
                 AGCUUGGUAAGACAAUUCU 
                 525 
               
               
                   
               
               
                 1101 
                 UCUUGCCCUGUUUUCUGGA 
                 326 
                 1101 
                 UCUUGCCCUGUUUUCUGGA 
                 326 
                 1123 
                 UCCAGAAAACAGGGCAAGA 
                 526 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGA 
                 327 
                 1119 
                 AGCACAACAUGAAAAGGGA 
                 327 
                 1141 
                 UCCCUUUUCAUGUUGUGCU 
                 527 
               
               
                   
               
               
                 1137 
                 AUGAAGAUCCUCACAAGGC 
                 328 
                 1137 
                 AUGAAGAUCCUCACAAGGC 
                 328 
                 1159 
                 GCCUUGUGAGGAUCUUCAU 
                 528 
               
               
                   
               
               
                 1155 
                 CUGCCAAAGAGAUGCCUUU 
                 329 
                 1155 
                 CUGCCAAAGAGAUGCCUUU 
                 329 
                 1177 
                 AAAGGCAUCUCUUUGGCAG 
                 529 
               
               
                   
               
               
                 1173 
                 UCCAGGGCUCUGGAAAAUC 
                 330 
                 1173 
                 UCCAGGGCUCUGGAAAAUC 
                 330 
                 1195 
                 GAUUUUCCAGAGCCCUGGA 
                 530 
               
               
                   
               
               
                 1191 
                 CAGCAUGGUGCCCAGUGGA 
                 331 
                 1191 
                 CAGCAUGGUGCCCAGUGGA 
                 331 
                 1213 
                 UCCACUGGGCACCAUGCUG 
                 531 
               
               
                   
               
               
                 1209 
                 AGAUCAGCAAGACAGUCCU 
                 332 
                 1209 
                 AGAUCAGCAAGACAGUCCU 
                 332 
                 1231 
                 AGGACUGUCUUGCUGAUCU 
                 532 
               
               
                   
               
               
                 1227 
                 UCUGGCCAGAGAGCAUCAG 
                 333 
                 1227 
                 UCUGGCCAGAGAGCAUCAG 
                 333 
                 1249 
                 CUGAUGCUCUCUGGCCAGA 
                 533 
               
               
                   
               
               
                 1245 
                 GCGUGGUGCGAUGUGUGGA 
                 334 
                 1245 
                 GCGUGGUGCGAUGUGUGGA 
                 334 
                 1267 
                 UCCACACAUCGCACCACGC 
                 534 
               
               
                   
               
               
                 1263 
                 AGUUGUUUGAGGCCCCGGU 
                 335 
                 1263 
                 AGUUGUUUGAGGCCCCGGU 
                 335 
                 1285 
                 ACCGGGGCCUCAAACAACU 
                 535 
               
               
                   
               
               
                 1281 
                 UGGAGUGUGAGGAGGAGGA 
                 336 
                 1281 
                 UGGAGUGUGAGGAGGAGGA 
                 336 
                 1303 
                 UCCUCCUCCUCACACUCCA 
                 536 
               
               
                   
               
               
                 1299 
                 AGGAGGUAGAGGAAGAAAA 
                 337 
                 1299 
                 AGGAGGUAGAGGAAGAAAA 
                 337 
                 1321 
                 UUUUCUUCCUCUACCUCCU 
                 537 
               
               
                   
               
               
                 1317 
                 AAGGGAGCUUCUGUGCAUC 
                 338 
                 1317 
                 AAGGGAGCUUCUGUGCAUC 
                 338 
                 1339 
                 GAUGCACAGAAGCUCCCUU 
                 538 
               
               
                   
               
               
                 1335 
                 CGCCUGAGAGCAGCAGGGA 
                 339 
                 1335 
                 CGCCUGAGAGCAGCAGGGA 
                 339 
                 1357 
                 UCCCUGCUGCUCUCAGGCG 
                 539 
               
               
                   
               
               
                 1353 
                 AUGACUUCCAGGAGGGAAG 
                 340 
                 1353 
                 AUGACUUCCAGGAGGGAAG 
                 340 
                 1375 
                 CUUCCCUCCUGGAAGUCAU 
                 540 
               
               
                   
               
               
                 1371 
                 GGGAGGGCAUUGUGGCCCG 
                 341 
                 1371 
                 GGGAGGGCAUUGUGGCCCG 
                 341 
                 1393 
                 CGGGCCACAAUGCCCUCCC 
                 541 
               
               
                   
               
               
                 1389 
                 GGCUAACAGAGAGCCUGUU 
                 342 
                 1389 
                 GGCUAACAGAGAGCCUGUU 
                 342 
                 1411 
                 AACAGGCUCUCUGUUAGCC 
                 542 
               
               
                   
               
               
                 1407 
                 UCCUGGACCUGCUCGGAGA 
                 343 
                 1407 
                 UCCUGGACCUGCUCGGAGA 
                 343 
                 1429 
                 UCUCCGAGCAGGUCCAGGA 
                 543 
               
               
                   
               
               
                 1425 
                 AGGAGAAUGGGGGCUUUUG 
                 344 
                 1425 
                 AGGAGAAUGGGGGCUUUUG 
                 344 
                 1447 
                 CAAAAGCCCCCAUUCUCCU 
                 544 
               
               
                   
               
               
                 1443 
                 GCCAGCAGGACAUGGGGGA 
                 345 
                 1443 
                 GCCAGCAGGACAUGGGGGA 
                 345 
                 1465 
                 UCCCCCAUGUCCUGCUGGC 
                 545 
               
               
                   
               
               
                 1461 
                 AGUCAUGCCUUCUUCCACC 
                 346 
                 1461 
                 AGUCAUGCCUUCUUCCACC 
                 346 
                 1483 
                 GGUGGAAGAAGGCAUGACU 
                 546 
               
               
                   
               
               
                 1479 
                 CUUCGGGAAGUACGAGUGC 
                 347 
                 1479 
                 CUUCGGGAAGUACGAGUGC 
                 347 
                 1501 
                 GCACUCGUACUUCCCGAAG 
                 547 
               
               
                   
               
               
                 1497 
                 CUCACAUGCCCUGGGAUGA 
                 348 
                 1497 
                 CUCACAUGCCCUGGGAUGA 
                 348 
                 1519 
                 UCAUCCCAGGGCAUGUGAG 
                 548 
               
               
                   
               
               
                 1515 
                 AGUUCCCAAGUGCAGGGCC 
                 349 
                 1515 
                 AGUUCCCAAGUGCAGGGCC 
                 349 
                 1537 
                 GGCCCUGCACUUGGGAACU 
                 549 
               
               
                   
               
               
                 1533 
                 CCAAGGAGGCACCUCCCUG 
                 350 
                 1533 
                 CCAAGGAGGCACCUCCCUG 
                 350 
                 1555 
                 CAGGGAGGUGCCUCCUUGG 
                 550 
               
               
                   
               
               
                 1551 
                 GGGGCAAGGAGCAGCCUCU 
                 351 
                 1551 
                 GGGGCAAGGAGCAGCCUCU 
                 351 
                 1573 
                 AGAGGCUGCUCCUUGCCCC 
                 551 
               
               
                   
               
               
                 1569 
                 UCCACCUGGAGCCAAGUCC 
                 352 
                 1569 
                 UCCACCUGGAGCCAAGUCC 
                 352 
                 1591 
                 GGACUUGGCUCCAGGUGGA 
                 552 
               
               
                   
               
               
                 1587 
                 CUCCUGCCAGCCCGACCCA 
                 353 
                 1587 
                 CUCCUGCCAGCCCGACCCA 
                 353 
                 1609 
                 UGGGUCGGGCUGGCAGGAG 
                 553 
               
               
                   
               
               
                 1605 
                 AGAGUCCAGACAACCUGAC 
                 354 
                 1605 
                 AGAGUCCAGACAACCUGAC 
                 354 
                 1627 
                 GUCAGGUUGUCUGGACUCU 
                 554 
               
               
                   
               
               
                 1623 
                 CUUGCACAGAGACGCCCCU 
                 355 
                 1623 
                 CUUGCACAGAGACGCCCCU 
                 355 
                 1645 
                 AGGGGCGUCUCUGUGCAAG 
                 555 
               
               
                   
               
               
                 1641 
                 UCGUCAUCGCAGGCAACCC 
                 356 
                 1641 
                 UCGUCAUCGCAGGCAACCC 
                 356 
                 1663 
                 GGGUUGCCUGCGAUGACGA 
                 556 
               
               
                   
               
               
                 1659 
                 CUGCUUACCGCAGCUUCAG 
                 357 
                 1659 
                 CUGCUUACCGCAGCUUCAG 
                 357 
                 1681 
                 CUGAAGCUGCGGUAAGCAG 
                 557 
               
               
                   
               
               
                 1677 
                 GCAACUCCCUGAGCCAGUC 
                 358 
                 1677 
                 GCAACUCCCUGAGCCAGUC 
                 358 
                 1699 
                 GACUGGCUCAGGGAGUUGC 
                 558 
               
               
                   
               
               
                 1695 
                 CACCGUGUCCCAGAGAGCU 
                 359 
                 1695 
                 CACCGUGUCCCAGAGAGCU 
                 359 
                 1717 
                 AGCUCUCUGGGACACGGUG 
                 559 
               
               
                   
               
               
                 1713 
                 UGGGUCCAGACCCACUGCU 
                 360 
                 1713 
                 UGGGUCCAGACCCACUGCU 
                 360 
                 1735 
                 AGCAGUGGGUCUGGACCCA 
                 560 
               
               
                   
               
               
                 1731 
                 UGGCCAGACACCUGGAGGA 
                 361 
                 1731 
                 UGGCCAGACACCUGGAGGA 
                 361 
                 1753 
                 UCCUCCAGGUGUCUGGCCA 
                 561 
               
               
                   
               
               
                 1749 
                 AAGUAGAACCCGAGAUGCC 
                 362 
                 1749 
                 AAGUAGAACCCGAGAUGCC 
                 362 
                 1771 
                 GGCAUCUCGGGUUCUACUU 
                 562 
               
               
                   
               
               
                 1767 
                 CCUGUGUCCCCCAGCUCUC 
                 363 
                 1767 
                 CCUGUGUCCCCCAGCUCUC 
                 363 
                 1789 
                 GAGAGCUGGGGGACACAGG 
                 563 
               
               
                   
               
               
                 1785 
                 CUGAGCCAACCACUGUGCC 
                 364 
                 1785 
                 CUGAGCCAACCACUGUGCC 
                 364 
                 1807 
                 GGCACAGUGGUUGGCUCAG 
                 564 
               
               
                   
               
               
                 1803 
                 CCCAACCUGAGCCAGAAAC 
                 365 
                 1803 
                 CCCAACCUGAGCCAGAAAC 
                 365 
                 1825 
                 GUUUCUGGCUCAGGUUGGG 
                 565 
               
               
                   
               
               
                 1821 
                 CCUGGGAGCAGAUCCUCCG 
                 366 
                 1821 
                 CCUGGGAGCAGAUCCUCCG 
                 366 
                 1843 
                 CGGAGGAUCUGCUCCCAGG 
                 566 
               
               
                   
               
               
                 1839 
                 GCCGAAAUGUCCUCCAGCA 
                 367 
                 1839 
                 GCCGAAAUGUCCUCCAGCA 
                 367 
                 1861 
                 UGCUGGAGGACAUUUCGGC 
                 567 
               
               
                   
               
               
                 1857 
                 AUGGGGCAGCUGCAGCCCC 
                 368 
                 1857 
                 AUGGGGCAGCUGCAGCCCC 
                 368 
                 1879 
                 GGGGCUGCAGCUGCCCCAU 
                 568 
               
               
                   
               
               
                 1875 
                 CCGUCUCGGCCCCCACCAG 
                 369 
                 1875 
                 CCGUCUCGGCCCCCACCAG 
                 369 
                 1897 
                 CUGGUGGGGGCCGAGACGG 
                 569 
               
               
                   
               
               
                 1893 
                 GUGGCUAUCAGGAGUUUGU 
                 370 
                 1893 
                 GUGGCUAUCAGGAGUUUGU 
                 370 
                 1915 
                 ACAAACUCCUGAUAGCCAC 
                 570 
               
               
                   
               
               
                 1911 
                 UACAUGCGGUGGAGCAGGG 
                 371 
                 1911 
                 UACAUGCGGUGGAGCAGGG 
                 371 
                 1933 
                 CCCUGCUCCACCGCAUGUA 
                 571 
               
               
                   
               
               
                 1929 
                 GUGGCACCCAGGCCAGUGC 
                 372 
                 1929 
                 GUGGCACCCAGGCCAGUGC 
                 372 
                 1951 
                 GCACUGGCCUGGGUGCCAC 
                 572 
               
               
                   
               
               
                 1947 
                 CGGUGGUGGGCUUGGGUCC 
                 373 
                 1947 
                 CGGUGGUGGGCUUGGGUCC 
                 373 
                 1969 
                 GGACCCAAGCCCACCACCG 
                 573 
               
               
                   
               
               
                 1965 
                 CCCCAGGAGAGGCUGGUUA 
                 374 
                 1965 
                 CCCCAGGAGAGGCUGGUUA 
                 374 
                 1987 
                 UAACCAGCCUCUCCUGGGG 
                 574 
               
               
                   
               
               
                 1983 
                 ACAAGGCCUUCUCAAGCCU 
                 375 
                 1983 
                 ACAAGGCCUUCUCAAGCCU 
                 375 
                 2005 
                 AGGCUUGAGAAGGCCUUGU 
                 575 
               
               
                   
               
               
                 2001 
                 UGCUUGCCAGCAGUGCUGU 
                 376 
                 2001 
                 UGCUUGCCAGCAGUGCUGU 
                 376 
                 2023 
                 ACAGCACUGCUGGCAAGCA 
                 576 
               
               
                   
               
               
                 2019 
                 UGUCCCCAGAGAAAUGUGG 
                 377 
                 2019 
                 UGUCCCCAGAGAAAUGUGG 
                 377 
                 2041 
                 CCACAUUUCUCUGGGGACA 
                 577 
               
               
                   
               
               
                 2037 
                 GGUUUGGGGCUAGCAGUGG 
                 378 
                 2037 
                 GGUUUGGGGCUAGCAGUGG 
                 378 
                 2059 
                 CCACUGCUAGCCCCAAACC 
                 578 
               
               
                   
               
               
                 2055 
                 GGGAAGAGGGGUAUAAGCC 
                 379 
                 2055 
                 GGGAAGAGGGGUAUAAGCC 
                 379 
                 2077 
                 GGCUUAUACCCCUCUUCCC 
                 579 
               
               
                   
               
               
                 2073 
                 CUUUCCAAGACCUCAUUCC 
                 380 
                 2073 
                 CUUUCCAAGACCUCAUUCC 
                 380 
                 2095 
                 GGAAUGAGGUCUUGGAAAG 
                 580 
               
               
                   
               
               
                 2091 
                 CUGGCUGCCCUGGGGACCC 
                 381 
                 2091 
                 CUGGCUGCCCUGGGGACCC 
                 381 
                 2113 
                 GGGUCCCCAGGGCAGCCAG 
                 581 
               
               
                   
               
               
                 2109 
                 CUGCCCCAGUCCCUGUCCC 
                 382 
                 2109 
                 CUGCCCCAGUCCCUGUCCC 
                 382 
                 2131 
                 GGGACAGGGACUGGGGCAG 
                 582 
               
               
                   
               
               
                 2127 
                 CCUUGUUCACCUUUGGACU 
                 383 
                 2127 
                 CCUUGUUCACCUUUGGACU 
                 383 
                 2149 
                 AGUCCAAAGGUGAACAAGG 
                 583 
               
               
                   
               
               
                 2145 
                 UGGACAGGGAGCCACCUCG 
                 384 
                 2145 
                 UGGACAGGGAGCCACCUCG 
                 384 
                 2167 
                 CGAGGUGGCUCCCUGUCCA 
                 584 
               
               
                   
               
               
                 2163 
                 GCAGUCCGCAGAGCUCACA 
                 385 
                 2163 
                 GCAGUCCGCAGAGCUCACA 
                 385 
                 2185 
                 UGUGAGCUCUGCGGACUGC 
                 585 
               
               
                   
               
               
                 2181 
                 AUCUCCCAAGCAGCUCCCC 
                 386 
                 2181 
                 AUCUCCCAAGCAGCUCCCC 
                 386 
                 2203 
                 GGGGAGCUGCUUGGGAGAU 
                 586 
               
               
                   
               
               
                 2199 
                 CAGAGCACCUGGGUCUGGA 
                 387 
                 2199 
                 CAGAGCACCUGGGUCUGGA 
                 387 
                 2221 
                 UCCAGACCCAGGUGGUCUG 
                 587 
               
               
                   
               
               
                 2217 
                 AGCCGGGGGAAAAGGUAGA 
                 388 
                 2217 
                 AGCCGGGGGAAAAGGUAGA 
                 388 
                 2239 
                 UCUACCUUUUCCCCCGGCU 
                 588 
               
               
                   
               
               
                 2235 
                 AGGACAUGCCAAAGCCCCC 
                 389 
                 2235 
                 AGGACAUGCCAAAGCCCCC 
                 389 
                 2257 
                 GGGGGCUUUGGCAUGUCCU 
                 589 
               
               
                   
               
               
                 2253 
                 CACUUCCCCAGGAGCAGGC 
                 390 
                 2253 
                 CACUUCCCCAGGAGCAGGC 
                 390 
                 2275 
                 GCCUGCUCCUGGGGAAGUG 
                 590 
               
               
                   
               
               
                 2271 
                 CCACAGACCCCCUUGUGGA 
                 391 
                 2271 
                 CCACAGACCCCCUUGUGGA 
                 391 
                 2293 
                 UCCACAAGGGGGUCUGUGG 
                 591 
               
               
                   
               
               
                 2289 
                 ACAGCCUGGGCAGUGGCAU 
                 392 
                 2289 
                 ACAGCCUGGGCAGUGGCAU 
                 392 
                 2311 
                 AUGCCACUGCCCAGGCUGU 
                 592 
               
               
                   
               
               
                 2307 
                 UUGUCUACUCAGCCCUUAC 
                 393 
                 2307 
                 UUGUCUACUCAGCCCUUAC 
                 393 
                 2329 
                 GUAAGGGCUGAGUAGACAA 
                 593 
               
               
                   
               
               
                 2325 
                 CCUGCCACCUGUGCGGCCA 
                 394 
                 2325 
                 CCUGCCACCUGUGCGGCCA 
                 394 
                 2347 
                 UGGCCGCACAGGUGGCAGG 
                 594 
               
               
                   
               
               
                 2343 
                 ACCUGAAACAGUGUCAUGG 
                 395 
                 2343 
                 ACCUGAAACAGUGUCAUGG 
                 395 
                 2365 
                 CCAUGACACUGUUUCAGGU 
                 595 
               
               
                   
               
               
                 2361 
                 GCCAGGAGGAUGGUGGCCA 
                 396 
                 2361 
                 GCCAGGAGGAUGGUGGCCA 
                 396 
                 2383 
                 UGGCCACCAUCCUCCUGGC 
                 596 
               
               
                   
               
               
                 2379 
                 AGACCCCUGUCAUGGCCAG 
                 397 
                 2379 
                 AGACCCCUGUCAUGGCCAG 
                 397 
                 2401 
                 CUGGCCAUGACAGGGGUCU 
                 597 
               
               
                   
               
               
                 2397 
                 GUCCUUGCUGUGGCUGCUG 
                 398 
                 2397 
                 GUCCUUGCUGUGGCUGCUG 
                 398 
                 2419 
                 CAGCAGCCACAGCAAGGAC 
                 598 
               
               
                   
               
               
                 2415 
                 GCUGUGGAGACAGGUCCUC 
                 399 
                 2415 
                 GCUGUGGAGACAGGUCCUC 
                 399 
                 2437 
                 GAGGACCUGUCUCCACAGC 
                 599 
               
               
                   
               
               
                 2433 
                 CGCCCCCUACAACCCCCCU 
                 400 
                 2433 
                 CGCCCCCUACAACCCCCCU 
                 400 
                 2455 
                 AGGGGGGUUGUAGGGGGCG 
                 600 
               
               
                   
               
               
                 2451 
                 UGAGGGCCCCAGACCCCUC 
                 401 
                 2451 
                 UGAGGGCCCCAGACCCCUC 
                 401 
                 2473 
                 GAGGGGUCUGGGGCCCUCA 
                 601 
               
               
                   
               
               
                 2469 
                 CUCCAGGUGGGGUUCCACU 
                 402 
                 2469 
                 CUCCAGGUGGGGUUCCACU 
                 402 
                 2491 
                 AGUGGAACCCCACCUGGAG 
                 602 
               
               
                   
               
               
                 2487 
                 UGGAGGCCAGUCUGUGUCC 
                 403 
                 2487 
                 UGGAGGCCAGUCUGUGUCC 
                 403 
                 2509 
                 GGACACAGACUGGCCUCCA 
                 603 
               
               
                   
               
               
                 2505 
                 CGGCCUCCCUGGCACCCUC 
                 404 
                 2505 
                 CGGCCUCCCUGGCACCCUC 
                 404 
                 2527 
                 GAGGGUGCCAGGGAGGCCG 
                 604 
               
               
                   
               
               
                 2523 
                 CGGGCAUCUCAGAGAAGAG 
                 405 
                 2523 
                 CGGGCAUCUCAGAGAAGAG 
                 405 
                 2545 
                 CUCUUCUCUGAGAUGCCCG 
                 605 
               
               
                   
               
               
                 2541 
                 GUAAAUCCUCAUCAUCCUU 
                 406 
                 2541 
                 GUAAAUCCUCAUCAUCCUU 
                 406 
                 2563 
                 AAGGAUGAUGAGGAUUUAC 
                 606 
               
               
                   
               
               
                 2559 
                 UCCAUCCUGCCCCUGGCAA 
                 407 
                 2559 
                 UCCAUCCUGCCCCUGGCAA 
                 407 
                 2581 
                 UUGCCAGGGGCAGGAUGGA 
                 607 
               
               
                   
               
               
                 2577 
                 AUGCUCAGAGCUCAAGCCA 
                 408 
                 2577 
                 AUGCUCAGAGCUCAAGCCA 
                 408 
                 2599 
                 UGGCUUGAGCUCUGAGCAU 
                 608 
               
               
                   
               
               
                 2595 
                 AGACCCCCAAAAUCGUGAA 
                 409 
                 2595 
                 AGACCCCCAAAAUCGUGAA 
                 409 
                 2617 
                 UUCACGAUUUUGGGGGUCU 
                 609 
               
               
                   
               
               
                 2613 
                 ACUUUGUCUCCGUGGGACC 
                 410 
                 2613 
                 ACUUUGUCUCCGUGGGACC 
                 410 
                 2635 
                 GGUCCCACGGAGACAAAGU 
                 610 
               
               
                   
               
               
                 2631 
                 CCACAUACAUGAGGGUCUC 
                 411 
                 2631 
                 CCACAUACAUGAGGGUCUC 
                 411 
                 2653 
                 GAGACCCUCAUGUAUGUGG 
                 611 
               
               
                   
               
               
                 2649 
                 CUUAGGUGCAUGUCCUCUU 
                 412 
                 2649 
                 CUUAGGUGCAUGUCCUCUU 
                 412 
                 2671 
                 AAGAGGACAUGCACCUAAG 
                 612 
               
               
                   
               
               
                 2667 
                 UGUUGCUGAGUCUGCAGAU 
                 413 
                 2667 
                 UGUUGCUGAGUCUGCAGAU 
                 413 
                 2689 
                 AUCUGCAGACUCAGCAACA 
                 613 
               
               
                   
               
               
                 2685 
                 UGAGGACUAGGGCUUAUCC 
                 414 
                 2685 
                 UGAGGACUAGGGCUUAUCC 
                 414 
                 2707 
                 GGAUAAGCCCUAGUCCUCA 
                 614 
               
               
                   
               
               
                 2703 
                 CAUGCCUGGGAAAUGCCAC 
                 415 
                 2703 
                 CAUGCCUGGGAAAUGCCAC 
                 415 
                 2725 
                 GUGGCAUUUCCCAGGCAUG 
                 615 
               
               
                   
               
               
                 2721 
                 CCUCCUGGAAGGCAGCCAG 
                 416 
                 2721 
                 CCUCCUGGAAGGCAGCCAG 
                 416 
                 2743 
                 CUGGCUGCCUUCCAGGAGG 
                 616 
               
               
                   
               
               
                 2739 
                 GGCUGGCAGAUUUCCAAAA 
                 417 
                 2739 
                 GGCUGGCAGAUUUCCAAAA 
                 417 
                 2761 
                 UUUUGGAAAUCUGCCAGCC 
                 617 
               
               
                   
               
               
                 2757 
                 AGACUUGAAGAACCAUGGU 
                 418 
                 2757 
                 AGACUUGAAGAACCAUGGU 
                 418 
                 2779 
                 ACCAUGGUUCUUCAAGUCU 
                 618 
               
               
                   
               
               
                 2775 
                 UAUGAAGGUGAUUGGCCCC 
                 419 
                 2775 
                 UAUGAAGGUGAUUGGCCCC 
                 419 
                 2797 
                 GGGGCCAAUCACCUUCAUA 
                 619 
               
               
                   
               
               
                 2793 
                 CACUGACGUUGGCCUAACA 
                 420 
                 2793 
                 CACUGACGUUGGCCUAACA 
                 420 
                 2815 
                 UGUUAGGCCAACGUCAGUG 
                 620 
               
               
                   
               
               
                 2811 
                 ACUGGGCUGCAGAGACUGG 
                 421 
                 2811 
                 ACUGGGCUGCAGAGACUGG 
                 421 
                 2833 
                 CCAGUCUCUGCAGCCCAGU 
                 621 
               
               
                   
               
               
                 2829 
                 GACCCCGCCCAGCAUUGGG 
                 422 
                 2829 
                 GACCCCGCCCAGCAUUGGG 
                 422 
                 2851 
                 CCCAAUGCUGGGCGGGGUC 
                 622 
               
               
                   
               
               
                 2847 
                 GCUGGGCUCGCCACAUCCC 
                 423 
                 2847 
                 GCUGGGCUCGCCACAUCCC 
                 423 
                 2869 
                 GGGAUGUGGCGAGCCCAGC 
                 623 
               
               
                   
               
               
                 2865 
                 CAUGAGAGUAGAGGGCACU 
                 424 
                 2865 
                 CAUGAGAGUAGAGGGCACU 
                 424 
                 2887 
                 AGUGCCCUCUACUCUCAUG 
                 624 
               
               
                   
               
               
                 2883 
                 UGGGUCGCCGUGCCCCACG 
                 425 
                 2883 
                 UGGGUCGCCGUGCCCCACG 
                 425 
                 2905 
                 CGUGGGGCACGGCGACCCA 
                 625 
               
               
                   
               
               
                 2901 
                 GGCAGGCCCCUGCAGGAAA 
                 426 
                 2901 
                 GGCAGGCCCCUGCAGGAAA 
                 426 
                 2923 
                 UUUCCUGCAGGGGCCUGCC 
                 626 
               
               
                   
               
               
                 2919 
                 AACUGAGGCCCUUGGGCAC 
                 427 
                 2919 
                 AACUGAGGCCCUUGGGCAC 
                 427 
                 2941 
                 GUGCCCAAGGGCCUCAGUU 
                 627 
               
               
                   
               
               
                 2937 
                 CCUCGACUUGUGAACGAGU 
                 428 
                 2937 
                 CCUCGACUUGUGAACGAGU 
                 428 
                 2959 
                 ACUCGUUCACAAGUCGAGG 
                 628 
               
               
                   
               
               
                 2955 
                 UUGUUGGCUGCUCCCUCCA 
                 429 
                 2955 
                 UUGUUGGCUGCUCCCUCCA 
                 429 
                 2977 
                 UGGAGGGAGCAGCCAACAA 
                 629 
               
               
                   
               
               
                 2973 
                 ACAGCUUCUGCAGCAGACU 
                 430 
                 2973 
                 ACAGCUUCUGCAGCAGACU 
                 430 
                 2995 
                 AGUCUGCUGCAGAAGCUGU 
                 630 
               
               
                   
               
               
                 2991 
                 UGUCCCUGUUGUAACUGCC 
                 431 
                 2991 
                 UGUCCCUGUUGUAACUGCC 
                 431 
                 3013 
                 GGCAGUUACAACAGGGACA 
                 631 
               
               
                   
               
               
                 3009 
                 CCAAGGCAUGUUUUGCCCA 
                 432 
                 3009 
                 CCAAGGCAUGUUUUGCCCA 
                 432 
                 3031 
                 UGGGCAAAACAUGCCUUGG 
                 632 
               
               
                   
               
               
                 3027 
                 ACCAGAUCAUGGCCCACGU 
                 433 
                 3027 
                 ACCAGAUCAUGGCCCACGU 
                 433 
                 3049 
                 ACGUGGGCCAUGAUCUGGU 
                 633 
               
               
                   
               
               
                 3045 
                 UGGAGGCCCACCUGCCUCU 
                 434 
                 3045 
                 UGGAGGCCCACCUGCCUCU 
                 434 
                 3067 
                 AGAGGCAGGUGGGCCUCCA 
                 634 
               
               
                   
               
               
                 3063 
                 UGUCUCACUGAACUAGAAG 
                 435 
                 3063 
                 UGUCUCACUGAACUAGAAG 
                 435 
                 3085 
                 CUUCUAGUUCAGUGAGACA 
                 635 
               
               
                   
               
               
                 3081 
                 GCCGAGCCUAGAAACUAAC 
                 436 
                 3081 
                 GCCGAGCCUAGAAACUAAC 
                 436 
                 3103 
                 GUUAGUUUCUAGGCUCGGC 
                 636 
               
               
                   
               
               
                 3099 
                 CACAGCCAUCAAGGGAAUG 
                 437 
                 3099 
                 CACAGCCAUCAAGGGAAUG 
                 437 
                 3121 
                 CAUUCCCUUGAUGGCUGUG 
                 637 
               
               
                   
               
               
                 3117 
                 GACUUGGGCGGCCUUGGGA 
                 438 
                 3117 
                 GACUUGGGCGGCCUUGGGA 
                 438 
                 3139 
                 UCCCAAGGCCGCCCAAGUC 
                 638 
               
               
                   
               
               
                 3135 
                 AAAUCGAUGAGAAAUUGAA 
                 439 
                 3135 
                 AAAUCGAUGAGAAAUUGAA 
                 439 
                 3157 
                 UUCAAUUUCUCAUCGAUUU 
                 639 
               
               
                   
               
               
                 3153 
                 ACUUCAGGGAGGGUGGUCA 
                 440 
                 3153 
                 ACUUCAGGGAGGGUGGUCA 
                 440 
                 3175 
                 UGACCACCCUCCCUGAAGU 
                 640 
               
               
                   
               
               
                 3171 
                 AUUGCCUAGAGGUGCUCAU 
                 441 
                 3171 
                 AUUGCCUAGAGGUGCUCAU 
                 441 
                 3193 
                 AUGAGCACCUCUAGGCAAU 
                 641 
               
               
                   
               
               
                 3189 
                 UUCAUUUAACAGAGCUUCC 
                 442 
                 3189 
                 UUCAUUUAACAGAGCUUCC 
                 442 
                 3211 
                 GGAAGCUCUGUUAAAUGAA 
                 642 
               
               
                   
               
               
                 3207 
                 CUUAGGUUGAUGCUGGAGG 
                 443 
                 3207 
                 CUUAGGUUGAUGCUGGAGG 
                 443 
                 3229 
                 CCUCCAGCAUCAACCUAAG 
                 643 
               
               
                   
               
               
                 3225 
                 GCAGAAUCCCGGCUGUCAA 
                 444 
                 3225 
                 GCAGAAUCCCGGCUGUCAA 
                 444 
                 3247 
                 UUGACAGCCGGGAUUCUGC 
                 644 
               
               
                   
               
               
                 3243 
                 AGGGGUGUUCAGUUAAGGG 
                 445 
                 3243 
                 AGGGGUGUUCAGUUAAGGG 
                 445 
                 3265 
                 CCCUUAACUGAACACCCCU 
                 645 
               
               
                   
               
               
                 3261 
                 GGAGCAACAGAGGACAUGA 
                 446 
                 3261 
                 GGAGCAACAGAGGACAUGA 
                 446 
                 3283 
                 UCAUGUCCUCUGUUGCUCC 
                 646 
               
               
                   
               
               
                 3279 
                 AAAAAUUGCUAUGACUAAA 
                 447 
                 3279 
                 AAAAAUUGCUAUGACUAAA 
                 447 
                 3301 
                 UUUAGUCAUAGCAAUUUUU 
                 647 
               
               
                   
               
               
                 3297 
                 AGCAGGGACAAUUUGCUGC 
                 448 
                 3297 
                 AGCAGGGACAAUUUGCUGC 
                 448 
                 3319 
                 GCAGCAAAUUGUCCCUGCU 
                 648 
               
               
                   
               
               
                 3315 
                 CCAAACACCCAUGCCCAGC 
                 449 
                 3315 
                 CCAAACACCCAUGCCCAGC 
                 449 
                 3337 
                 GCUGGGCAUGGGUGUUUGG 
                 649 
               
               
                   
               
               
                 3333 
                 CUGUAUGGCUGGGGGCUCC 
                 450 
                 3333 
                 CUGUAUGGCUGGGGGCUCC 
                 450 
                 3355 
                 GGAGCCCCCAGCCAUACAG 
                 650 
               
               
                   
               
               
                 3351 
                 CUCGUAUGCAUGGAACCCC 
                 451 
                 3351 
                 CUCGUAUGCAUGGAACCCC 
                 451 
                 3373 
                 GGGGUUCCAUGCAUACGAG 
                 651 
               
               
                   
               
               
                 3369 
                 CCAGAAUAAAUAUGCUCAG 
                 452 
                 3369 
                 CCAGAAUAAAUAUGCUCAG 
                 452 
                 3391 
                 CUGAGCAUAUUUAUUCUGG 
                 652 
               
               
                   
               
               
                 3387 
                 GCCACCCUGUGGGCCGGGC 
                 453 
                 3387 
                 GCCACCCUGUGGGCCGGGC 
                 453 
                 3409 
                 GCCCGGCCCACAGGGUGGC 
                 653 
               
               
                   
               
               
                 3405 
                 CAAUCCAGACAGCAGGCAU 
                 454 
                 3405 
                 CAAUCCAGACAGCAGGCAU 
                 454 
                 3427 
                 AUGCCUGCUGUCUGGAUUG 
                 654 
               
               
                   
               
               
                 3423 
                 UAAGGCACCAGUUACCCUG 
                 455 
                 3423 
                 UAAGGCACCAGUUACCCUG 
                 455 
                 3445 
                 CAGGGUAACUGGUGCCUUA 
                 655 
               
               
                   
               
               
                 3441 
                 GCAUGUUGGCCCAGACCUC 
                 456 
                 3441 
                 GCAUGUUGGCCCAGACCUC 
                 456 
                 3463 
                 GAGGUCUGGGCCAACAUGC 
                 656 
               
               
                   
               
               
                 3459 
                 CAGGUGCUAGGGAAGGCGG 
                 457 
                 3459 
                 CAGGUGCUAGGGAAGGCGG 
                 457 
                 3481 
                 CCGCCUUCCCUAGCACCUG 
                 657 
               
               
                   
               
               
                 3477 
                 GGAACCUUGGGUUGAGUAA 
                 458 
                 3477 
                 GGAACCUUGGGUUGAGUAA 
                 458 
                 3499 
                 UUACUCAACCCAAGGUUCC 
                 658 
               
               
                   
               
               
                 3495 
                 AUGCUCGUCUGUGUGUUUU 
                 459 
                 3495 
                 AUGCUCGUCUGUGUGUUUU 
                 459 
                 3517 
                 AAAACACACAGACGAGCAU 
                 659 
               
               
                   
               
               
                 3513 
                 UAGUUUCAUCACCUGUUAU 
                 460 
                 3513 
                 UAGUUUCAUCACCUGUUAU 
                 460 
                 3535 
                 AUAACAGGUGAUGAAACUA 
                 660 
               
               
                   
               
               
                 3531 
                 UCUGUGUUUGCUGAGGAGA 
                 461 
                 3531 
                 UCUGUGUUUGCUGAGGAGA 
                 461 
                 3553 
                 UCUCCUCAGCAAACACAGA 
                 661 
               
               
                   
               
               
                 3549 
                 AGUGGAACAGAAGGGGUGG 
                 462 
                 3549 
                 AGUGGAACAGAAGGGGUGG 
                 462 
                 3571 
                 CCACCCCUUCUGUUCCACU 
                 662 
               
               
                   
               
               
                 3567 
                 GAGUUUUGUAUAAAUAAAG 
                 463 
                 3567 
                 GAGUUUUGUAUAAAUAAAG 
                 463 
                 3589 
                 CUUUAUUUAUACAAAACUC 
                 663 
               
               
                   
               
               
                 3577 
                 UAAAUAAAGUUUCUUUGUC 
                 464 
                 3577 
                 UAAAUAAAGUUUCUUUGUC 
                 464 
                 3599 
                 GACAAAGAAACUUUAUUUA 
                 664 
               
               
                   
               
               
                   
               
             
          
           
               
                 IL13 NM_002188 
                   
               
             
          
           
               
                   
                 Seq 
                   
                 Seq 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Seq 
                 ID 
                 UPos 
                 Upper seq 
                 ID 
                 LPos 
                 Lower seq 
                 ID 
               
               
                   
               
             
          
           
               
                 3 
                 GCCACCCAGCCUAUGCAUC 
                 665 
                 3 
                 GCCACCCAGCCUAUGCAUC 
                 665 
                 25 
                 GAUGCAUAGGCUGGGUGGC 
                 736 
                   
               
               
                   
               
               
                 21 
                 CCGCUCCUCAAUCCUCUCC 
                 666 
                 21 
                 CCGCUCCUCAAUCCUCUCC 
                 666 
                 43 
                 GGAGAGGAUUGAGGAGCGG 
                 737 
               
               
                   
               
               
                 39 
                 CUGUUGGCACUGGGCCUCA 
                 667 
                 39 
                 CUGUUGGCACUGGGCCUCA 
                 667 
                 61 
                 UGAGGCCCAGUGCCAACAG 
                 738 
               
               
                   
               
               
                 57 
                 AUGGCGCUUUUGUUGACCA 
                 668 
                 57 
                 AUGGCGCUUUUGUUGACCA 
                 668 
                 79 
                 UGGUCAACAAAAGCGCCAU 
                 739 
               
               
                   
               
               
                 75 
                 ACGGUCAUUGCUCUCACUU 
                 669 
                 75 
                 ACGGUCAUUGCUCUCACUU 
                 669 
                 97 
                 AAGUGAGAGCAAUGACCGU 
                 740 
               
               
                   
               
               
                 93 
                 UGCCUUGGCGGCUUUGCCU 
                 670 
                 93 
                 UGCCUUGGCGGCUUUGCCU 
                 670 
                 115 
                 AGGCAAAGCCGCCAAGGCA 
                 741 
               
               
                   
               
               
                 111 
                 UCCCCAGGCCCUGUGCCUC 
                 671 
                 111 
                 UCCCCAGGCCCUGUGCCUC 
                 671 
                 133 
                 GAGGCACAGGGCCUGGGGA 
                 742 
               
               
                   
               
               
                 129 
                 CCCUCUACAGCCCUCAGGG 
                 672 
                 129 
                 CCCUCUACAGCCCUCAGGG 
                 672 
                 151 
                 CCCUGAGGGCUGUAGAGGG 
                 743 
               
               
                   
               
               
                 147 
                 GAGCUCAUUGAGGAGCUGG 
                 673 
                 147 
                 GAGCUCAUUGAGGAGCUGG 
                 673 
                 169 
                 CCAGCUCCUCAAUGAGCUC 
                 744 
               
               
                   
               
               
                 165 
                 GUCAACAUCACCCAGAACC 
                 674 
                 165 
                 GUCAACAUCACCCAGAACC 
                 674 
                 187 
                 GGUUCUGGGUGAUGUUGAC 
                 745 
               
               
                   
               
               
                 183 
                 CAGAAGGCUCCGCUCUGCA 
                 675 
                 183 
                 CAGAAGGCUCCGCUCUGCA 
                 675 
                 205 
                 UGCAGAGCGGAGCCUUCUG 
                 746 
               
               
                   
               
               
                 201 
                 AAUGGCAGCAUGGUAUGGA 
                 676 
                 201 
                 AAUGGCAGCAUGGUAUGGA 
                 676 
                 223 
                 UCCAUACCAUGCUGCCAUU 
                 747 
               
               
                   
               
               
                 219 
                 AGCAUCAACCUGACAGCUG 
                 677 
                 219 
                 AGCAUCAACCUGACAGCUG 
                 677 
                 241 
                 CAGCUGUCAGGUUGAUGCU 
                 748 
               
               
                   
               
               
                 237 
                 GGCAUGUACUGUGCAGCCC 
                 678 
                 237 
                 GGCAUGUACUGUGCAGCCC 
                 678 
                 259 
                 GGGCUGCACAGUACAUGCC 
                 749 
               
               
                   
               
               
                 255 
                 CUGGAAUCCCUGAUCAACG 
                 679 
                 255 
                 CUGGAAUCCCUGAUCAACG 
                 679 
                 277 
                 CGUUGAUCAGGGAUUCCAG 
                 750 
               
               
                   
               
               
                 273 
                 GUGUCAGGCUGCAGUGCCA 
                 680 
                 273 
                 GUGUCAGGCUGCAGUGCCA 
                 680 
                 295 
                 UGGCACUGCAGCCUGACAC 
                 751 
               
               
                   
               
               
                 291 
                 AUCGAGAAGACCCAGAGGA 
                 681 
                 291 
                 AUCGAGAAGACCCAGAGGA 
                 681 
                 313 
                 UCCUCUGGGUCUUCUCGAU 
                 752 
               
               
                   
               
               
                 309 
                 AUGCUGAGCGGAUUCUGCC 
                 682 
                 309 
                 AUGCUGAGCGGAUUCUGCC 
                 682 
                 331 
                 GGCAGAAUCCGCUCAGCAU 
                 753 
               
               
                   
               
               
                 327 
                 CCGCACAAGGUCUCAGCUG 
                 683 
                 327 
                 CCGCACAAGGUCUCAGCUG 
                 683 
                 349 
                 CAGCUGAGACCUUGUGCGG 
                 754 
               
               
                   
               
               
                 345 
                 GGGCAGUUUUCCAGCUUGC 
                 684 
                 345 
                 GGGCAGUUUUCCAGCUUGC 
                 684 
                 367 
                 GCAAGCUGGAAAACUGCCC 
                 755 
               
               
                   
               
               
                 363 
                 CAUGUCCGAGACACCAAAA 
                 685 
                 363 
                 CAUGUCCGAGACACCAAAA 
                 685 
                 385 
                 UUUUGGUGUCUCGGACAUG 
                 756 
               
               
                   
               
               
                 381 
                 AUCGAGGUGGCCCAGUUUG 
                 686 
                 381 
                 AUCGAGGUGGCCCAGUUUG 
                 686 
                 403 
                 CAAACUGGGCCACCUCGAU 
                 757 
               
               
                   
               
               
                 399 
                 GUAAAGGACCUGCUCUUAC 
                 687 
                 399 
                 GUAAAGGACCUGCUCUUAC 
                 687 
                 421 
                 GUAAGAGCAGGUCCUUUAC 
                 758 
               
               
                   
               
               
                 417 
                 CAUUUAAAGAAACUUUUUC 
                 688 
                 417 
                 CAUUUAAAGAAACUUUUUC 
                 688 
                 439 
                 GAAAAAGUUUCUUUAAAUG 
                 759 
               
               
                   
               
               
                 435 
                 CGCGAGGGACAGUUCAACU 
                 689 
                 435 
                 CGCGAGGGACAGUUCAACU 
                 689 
                 457 
                 AGUUGAACUGUCCCUCGCG 
                 760 
               
               
                   
               
               
                 453 
                 UGAAACUUCGAAAGCAUCA 
                 690 
                 453 
                 UGAAACUUCGAAAGCAUCA 
                 690 
                 475 
                 UGAUGCUUUCGAAGUUUCA 
                 761 
               
               
                   
               
               
                 471 
                 AUUAUUUGCAGAGACAGGA 
                 691 
                 471 
                 AUUAUUUGCAGAGACAGGA 
                 691 
                 493 
                 UCCUGUCUCUGCAAAUAAU 
                 762 
               
               
                   
               
               
                 489 
                 ACCUGACUAUUGAAGUUGC 
                 692 
                 489 
                 ACCUGACUAUUGAAGUUGC 
                 692 
                 511 
                 GCAACUUCAAUAGUCAGGU 
                 763 
               
               
                   
               
               
                 507 
                 CAGAUUCAUUUUUCUUUCU 
                 693 
                 507 
                 CAGAUUCAUUUUUCUUUCU 
                 693 
                 529 
                 AGAAAGAAAAAUGAAUCUG 
                 764 
               
               
                   
               
               
                 525 
                 UGAUGUCAAAAAUGUCUUG 
                 694 
                 525 
                 UGAUGUCAAAAAUGUCUUG 
                 694 
                 547 
                 CAAGACAUUUUUGACAUCA 
                 765 
               
               
                   
               
               
                 543 
                 GGGUAGGCGGGAAGGAGGG 
                 695 
                 543 
                 GGGUAGGCGGGAAGGAGGG 
                 695 
                 565 
                 CCCUCCUUCCCGCCUACCC 
                 766 
               
               
                   
               
               
                 561 
                 GUUAGGGAGGGGUAAAAUU 
                 696 
                 561 
                 GUUAGGGAGGGGUAAAAUU 
                 696 
                 583 
                 AAUUUUACCCCUCCCUAAC 
                 767 
               
               
                   
               
               
                 579 
                 UCCUUAGCUUAGACCUCAG 
                 697 
                 579 
                 UCCUUAGCUUAGACCUCAG 
                 697 
                 601 
                 CUGAGGUCUAAGCUAAGGA 
                 768 
               
               
                   
               
               
                 597 
                 GCCUGUGCUGCCCGUCUUC 
                 698 
                 597 
                 GCCUGUGCUGCCCGUCUUC 
                 698 
                 619 
                 GAAGACGGGCAGCACAGGC 
                 769 
               
               
                   
               
               
                 615 
                 CAGCCUAGCCGACCUCAGC 
                 699 
                 615 
                 CAGCCUAGCCGACCUCAGC 
                 699 
                 637 
                 GCUGAGGUCGGCUAGGCUG 
                 770 
               
               
                   
               
               
                 633 
                 CCUUCCCCUUGCCCAGGGC 
                 700 
                 633 
                 CCUUCCCCUUGCCCAGGGC 
                 700 
                 655 
                 GCCCUGGGCAAGGGGAAGG 
                 771 
               
               
                   
               
               
                 651 
                 CUCAGCCUGGUGGGCCUCC 
                 701 
                 651 
                 CUCAGCCUGGUGGGCCUCC 
                 701 
                 673 
                 GGAGGCCCACCAGGCUGAG 
                 772 
               
               
                   
               
               
                 669 
                 CUCUGUCCAGGGCCCUGAG 
                 702 
                 669 
                 CUCUGUCCAGGGCCCUGAG 
                 702 
                 691 
                 CUCAGGGCCCUGGACAGAG 
                 773 
               
               
                   
               
               
                 687 
                 GCUCGGUGGACCCAGGGAU 
                 703 
                 687 
                 GCUCGGUGGACCCAGGGAU 
                 703 
                 709 
                 AUCCCUGGGUCCACCGAGC 
                 774 
               
               
                   
               
               
                 705 
                 UGACAUGUCCCUACACCCC 
                 704 
                 705 
                 UGACAUGUCCCUACACCCC 
                 704 
                 727 
                 GGGGUGUAGGGACAUGUCA 
                 775 
               
               
                   
               
               
                 723 
                 CUCCCCUGCCCUAGAGCAC 
                 705 
                 723 
                 CUCCCCUGCCCUAGAGCAC 
                 705 
                 745 
                 GUGCUCUAGGGCAGGGGAG 
                 776 
               
               
                   
               
               
                 741 
                 CACUGUAGCAUUACAGUGG 
                 706 
                 741 
                 CACUGUAGCAUUACAGUGG 
                 706 
                 763 
                 CCACUGUAAUGCUACAGUG 
                 777 
               
               
                   
               
               
                 759 
                 GGUGCCCCCCUUGCCAGAC 
                 707 
                 759 
                 GGUGCCCCCCUUGCCAGAC 
                 707 
                 781 
                 GUCUGGCAAGGGGGGCACC 
                 778 
               
               
                   
               
               
                 777 
                 CAUGUGGUGGGACAGGGAC 
                 708 
                 777 
                 CAUGUGGUGGGACAGGGAC 
                 708 
                 799 
                 GUCCCUGUCCCACCACAUG 
                 779 
               
               
                   
               
               
                 795 
                 CCCACUUCACACACAGGCA 
                 709 
                 795 
                 CCCACUUCACACACAGGCA 
                 709 
                 817 
                 UGCCUGUGUGUGAAGUGGG 
                 780 
               
               
                   
               
               
                 813 
                 AACUGAGGCAGACAGCAGC 
                 710 
                 813 
                 AACUGAGGCAGACAGCAGC 
                 710 
                 835 
                 GCUGCUGUCUGCCUCAGUU 
                 781 
               
               
                   
               
               
                 831 
                 CUCAGGCACACUUCUUCUU 
                 711 
                 831 
                 CUCAGGCACACUUCUUCUU 
                 711 
                 853 
                 AAGAAGAAGUGUGCCUGAG 
                 782 
               
               
                   
               
               
                 849 
                 UGGUCUUAUUUAUUAUUGU 
                 712 
                 849 
                 UGGUCUUAUUUAUUAUUGU 
                 712 
                 871 
                 ACAAUAAUAAAUAAGACCA 
                 783 
               
               
                   
               
               
                 867 
                 UGUGUUAUUUAAAUGAGUG 
                 713 
                 867 
                 UGUGUUAUUUAAAUGAGUG 
                 713 
                 889 
                 CACUCAUUUAAAUAACACA 
                 784 
               
               
                   
               
               
                 885 
                 GUGUUUGUCACCGUUGGGG 
                 714 
                 885 
                 GUGUUUGUCACCGUUGGGG 
                 714 
                 907 
                 CCCCAACGGUGACAAACAC 
                 785 
               
               
                   
               
               
                 903 
                 GAUUGGGGAAGACUGUGGC 
                 715 
                 903 
                 GAUUGGGGAAGACUGUGGC 
                 715 
                 925 
                 GCCACAGUCUUCCCCAAUC 
                 786 
               
               
                   
               
               
                 921 
                 CUGCUAGCACUUGGAGCCA 
                 716 
                 921 
                 CUGCUAGCACUUGGAGCCA 
                 716 
                 943 
                 UGGCUCCAAGUGCUAGCAG 
                 787 
               
               
                   
               
               
                 939 
                 AAGGGUUCAGAGACUCAGG 
                 717 
                 939 
                 AAGGGUUCAGAGACUCAGG 
                 717 
                 961 
                 CCUGAGUCUCUGAACCCUU 
                 788 
               
               
                   
               
               
                 957 
                 GGCCCCAGCACUAAAGCAG 
                 718 
                 957 
                 GGCCCCAGCACUAAAGCAG 
                 718 
                 97 
                 9CUGCUUUAGUGCUGGGGC 
                 C789 
               
               
                   
               
               
                 975 
                 GUGGACACCAGGAGUCCCU 
                 719 
                 975 
                 GUGGACACCAGGAGUCCCU 
                 719 
                 997 
                 AGGGACUCCUGGUGUCCAC 
                 790 
               
               
                   
               
               
                 993 
                 UGGUAAUAAGUACUGUGUA 
                 720 
                 993 
                 UGGUAAUAAGUACUGUGUA 
                 720 
                 1015 
                 UACACAGUACUUAUUACCA 
                 791 
               
               
                   
               
               
                 1011 
                 ACAGAAUUCUGCUACCUCA 
                 721 
                 1011 
                 ACAGAAUUCUGCUACCUCA 
                 721 
                 1033 
                 UGAGGUAGCAGAAUUCUGU 
                 792 
               
               
                   
               
               
                 1029 
                 ACUGGGGUCCUGGGGCCUC 
                 722 
                 1029 
                 ACUGGGGUCCUGGGGCCUC 
                 722 
                 1051 
                 GAGGCCCCAGGACCCCAGU 
                 793 
               
               
                   
               
               
                 1047 
                 CGGAGCCUCAUCCGAGGCA 
                 723 
                 1047 
                 CGGAGCCUCAUCCGAGGCA 
                 723 
                 1069 
                 UGCCUCGGAUGAGGCUCCG 
                 794 
               
               
                   
               
               
                 1065 
                 AGGGUCAGGAGAGGGGCAG 
                 724 
                 1065 
                 AGGGUCAGGAGAGGGGCAG 
                 724 
                 1087 
                 CUGCCCCUCUCCUGACCCU 
                 795 
               
               
                   
               
               
                 1083 
                 GAACAGCCGCUCCUGUCUG 
                 725 
                 1083 
                 GAACAGCCGCUCCUGUCUG 
                 725 
                 1105 
                 CAGACAGGAGCGGCUGUUC 
                 796 
               
               
                   
               
               
                 1101 
                 GCCAGCCAGCAGCCAGCUC 
                 726 
                 1101 
                 GCCAGCCAGCAGCCAGCUC 
                 726 
                 1123 
                 GAGCUGGCUGCUGGCUGGC 
                 797 
               
               
                   
               
               
                 1119 
                 CUCAGCCAACGAGUAAUUU 
                 727 
                 1119 
                 CUCAGCCAACGAGUAAUUU 
                 727 
                 1141 
                 AAAUUACUCGUUGGCUGAG 
                 798 
               
               
                   
               
               
                 1137 
                 UAUUGUUUUUCCUUGUAUU 
                 728 
                 1137 
                 UAUUGUUUUUCCUUGUAUU 
                 728 
                 1159 
                 AAUACAAGGAAAAACAAUA 
                 799 
               
               
                   
               
               
                 1155 
                 UUAAAUAUUAAAUAUGUUA 
                 729 
                 1155 
                 UUAAAUAUUAAAUAUGUUA 
                 729 
                 1177 
                 UAACAUAUUUAAUAUUUAA 
                 800 
               
               
                   
               
               
                 1173 
                 AGCAAAGAGUUAAUAUAUA 
                 730 
                 1173 
                 AGCAAAGAGUUAAUAUAUA 
                 730 
                 1195 
                 UAUAUAUUAACUCUUUGCU 
                 801 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACAC 
                 731 
                 1191 
                 AGAAGGGUACCUUGAACAC 
                 731 
                 1213 
                 GUGUUCAAGGUACCCUUCU 
                 802 
               
               
                   
               
               
                 1209 
                 CUGGGGGAGGGGACAUUGA 
                 732 
                 1209 
                 CUGGGGGAGGGGACAUUGA 
                 732 
                 1231 
                 UCAAUGUCCCCUCCCCCAG 
                 803 
               
               
                   
               
               
                 1227 
                 AACAAGUUGUUUCAUUGAC 
                 733 
                 1227 
                 AACAAGUUGUUUCAUUGAC 
                 733 
                 1249 
                 GUCAAUGAAACAACUUGUU 
                 804 
               
               
                   
               
               
                 1245 
                 CUAUCAAACUGAAGCCAGA 
                 734 
                 1245 
                 CUAUCAAACUGAAGCCAGA 
                 734 
                 1267 
                 UCUGGCUUCAGUUUGAUAG 
                 805 
               
               
                   
               
               
                 1262 
                 GAAAUAAAGUUGGUGACAG 
                 735 
                 1262 
                 GAAAUAAAGUUGGUGACAG 
                 735 
                 1284 
                 CUGUCACCAACUUUAUUUC 
                 806 
               
               
                   
               
               
                   
               
             
          
           
               
                 IL13RA1 NM_001560 
                   
               
             
          
           
               
                   
                 Seq 
                   
                 Seq 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Seq 
                 ID 
                 UPos 
                 Upper seq 
                 ID 
                 LPos 
                 Lower seq 
                 ID 
               
               
                   
               
             
          
           
               
                 3 
                 CCAAGGCUCCAGCCCGGCC 
                 807 
                 3 
                 CCAAGGCUCCAGCCCGGCC 
                 807 
                 25 
                 GGCCGGGCUGGAGCCUUGG 
                 1030 
                   
               
               
                   
               
               
                 21 
                 CGGGCUCCGAGGCGAGAGG 
                 808 
                 21 
                 CGGGCUCCGAGGCGAGAGG 
                 808 
                 43 
                 CCUCUCGCCUCGGAGCCCG 
                 1031 
               
               
                   
               
               
                 39 
                 GCUGCAUGGAGUGGCCGGC 
                 809 
                 39 
                 GCUGCAUGGAGUGGCCGGC 
                 809 
                 61 
                 GCCGGCCACUCCAUGCAGC 
                 1032 
               
               
                   
               
               
                 57 
                 CGCGGCUCUGCGGGCUGUG 
                 810 
                 57 
                 CGCGGCUCUGCGGGCUGUG 
                 810 
                 79 
                 CACAGCCCGCAGAGCCGCG 
                 1033 
               
               
                   
               
               
                 75 
                 GGGCGCUGCUGCUCUGCGC 
                 811 
                 75 
                 GGGCGCUGCUGCUCUGCGC 
                 811 
                 97 
                 GCGCAGAGCAGCAGCGCCC 
                 1034 
               
               
                   
               
               
                 93 
                 CCGGCGGCGGGGGCGGGGG 
                 812 
                 93 
                 CCGGCGGCGGGGGCGGGGG 
                 812 
                 115 
                 CCCCCGCCCCCGCCGCCGG 
                 1035 
               
               
                   
               
               
                 111 
                 GCGGGGGCGCCGCGCCUAC 
                 813 
                 111 
                 GCGGGGGCGCCGCGCCUAC 
                 813 
                 133 
                 GUAGGCGCGGCGCCCCCGC 
                 1036 
               
               
                   
               
               
                 129 
                 CGGAAACUCAGCCACCUGU 
                 814 
                 129 
                 CGGAAACUCAGCCACCUGU 
                 814 
                 151 
                 ACAGGUGGCUGAGUUUCCG 
                 1037 
               
               
                   
               
               
                 147 
                 UGACAAAUUUGAGUGUCUC 
                 815 
                 147 
                 UGACAAAUUUGAGUGUCUC 
                 815 
                 169 
                 GAGACACUCAAAUUUGUCA 
                 1038 
               
               
                   
               
               
                 165 
                 CUGUUGAAAACCUCUGCAC 
                 816 
                 165 
                 CUGUUGAAAACCUCUGCAC 
                 816 
                 187 
                 GUGCAGAGGUUUUCAACAG 
                 1039 
               
               
                   
               
               
                 183 
                 CAGUAAUAUGGACAUGGAA 
                 817 
                 183 
                 CAGUAAUAUGGACAUGGAA 
                 817 
                 205 
                 UUCCAUGUCCAUAUUACUG 
                 1040 
               
               
                   
               
               
                 201 
                 AUCCACCCGAGGGAGCCAG 
                 818 
                 201 
                 AUCCACCCGAGGGAGCCAG 
                 818 
                 223 
                 CUGGCUCCCUCGGGUGGAU 
                 1041 
               
               
                   
               
               
                 219 
                 GCUCAAAUUGUAGUCUAUG 
                 819 
                 219 
                 GCUCAAAUUGUAGUCUAUG 
                 819 
                 241 
                 CAUAGACUACAAUUUGAGC 
                 1042 
               
               
                   
               
               
                 237 
                 GGUAUUUUAGUCAUUUUGG 
                 820 
                 237 
                 GGUAUUUUAGUCAUUUUGG 
                 820 
                 259 
                 CCAAAAUGACUAAAAUACC 
                 1043 
               
               
                   
               
               
                 255 
                 GCGACAAACAAGAUAAGAA 
                 821 
                 255 
                 GCGACAAACAAGAUAAGAA 
                 821 
                 277 
                 UUCUUAUCUUGUUUGUCGC 
                 1044 
               
               
                   
               
               
                 273 
                 AAAUAGCUCCGGAAACUCG 
                 822 
                 273 
                 AAAUAGCUCCGGAAACUCG 
                 822 
                 295 
                 CGAGUUUCCGGAGCUAUUU 
                 1045 
               
               
                   
               
               
                 291 
                 GUCGUUCAAUAGAAGUACC 
                 823 
                 291 
                 GUCGUUCAAUAGAAGUACC 
                 823 
                 313 
                 GGUACUUCUAUUGAACGAC 
                 1046 
               
               
                   
               
               
                 309 
                 CCCUGAAUGAGAGGAUUUG 
                 824 
                 309 
                 CCCUGAAUGAGAGGAUUUG 
                 824 
                 331 
                 CAAAUCCUCUCAUUCAGGG 
                 1047 
               
               
                   
               
               
                 327 
                 GUCUGCAAGUGGGGUCCCA 
                 825 
                 327 
                 GUCUGCAAGUGGGGUCCCA 
                 825 
                 349 
                 UGGGACCCCACUUGCAGAC 
                 1048 
               
               
                   
               
               
                 345 
                 AGUGUAGCACCAAUGAGAG 
                 826 
                 345 
                 AGUGUAGCACCAAUGAGAG 
                 826 
                 367 
                 CUCUCAUUGGUGCUACACU 
                 1049 
               
               
                   
               
               
                 363 
                 GUGAGAAGCCUAGCAUUUU 
                 827 
                 363 
                 GUGAGAAGCCUAGCAUUUU 
                 827 
                 385 
                 AAAAUGCUAGGCUUCUCAC 
                 1050 
               
               
                   
               
               
                 381 
                 UGGUUGAAAAAUGCAUCUC 
                 828 
                 381 
                 UGGUUGAAAAAUGCAUCUC 
                 828 
                 403 
                 GAGAUGCAUUUUUCAACCA 
                 1051 
               
               
                   
               
               
                 399 
                 CACCCCCAGAAGGUGAUCC 
                 829 
                 399 
                 CACCCCCAGAAGGUGAUCC 
                 829 
                 421 
                 GGAUCACCUUCUGGGGGUG 
                 1052 
               
               
                   
               
               
                 417 
                 CUGAGUCUGCUGUGACUGA 
                 830 
                 417 
                 CUGAGUCUGCUGUGACUGA 
                 830 
                 439 
                 UCAGUCACAGCAGACUCAG 
                 1053 
               
               
                   
               
               
                 435 
                 AGCUUCAAUGCAUUUGGCA 
                 831 
                 435 
                 AGCUUCAAUGCAUUUGGCA 
                 831 
                 457 
                 UGCCAAAUGCAUUGAAGCU 
                 1054 
               
               
                   
               
               
                 453 
                 ACAACCUGAGCUACAUGAA 
                 832 
                 453 
                 ACAACCUGAGCUACAUGAA 
                 832 
                 475 
                 UUCAUGUAGCUCAGGUUGU 
                 1055 
               
               
                   
               
               
                 471 
                 AGUGUUCUUGGCUCCCUGG 
                 833 
                 471 
                 AGUGUUCUUGGCUCCCUGG 
                 833 
                 493 
                 CCAGGGAGCCAAGAACACU 
                 1056 
               
               
                   
               
               
                 489 
                 GAAGGAAUACCAGUCCCGA 
                 834 
                 489 
                 GAAGGAAUACCAGUCCCGA 
                 834 
                 511 
                 UCGGGACUGGUAUUCCUUC 
                 1057 
               
               
                   
               
               
                 507 
                 ACACUAACUAUACUCUCUA 
                 835 
                 507 
                 ACACUAACUAUACUCUCUA 
                 835 
                 529 
                 UAGAGAGUAUAGUUAGUGU 
                 1058 
               
               
                   
               
               
                 525 
                 ACUAUUGGCACAGAAGCCU 
                 836 
                 525 
                 ACUAUUGGCACAGAAGCCU 
                 836 
                 547 
                 AGGCUUCUGUGCCAAUAGU 
                 1059 
               
               
                   
               
               
                 543 
                 UGGAAAAAAUUCAUCAAUG 
                 837 
                 543 
                 UGGAAAAAAUUCAUCAAUG 
                 837 
                 565 
                 CAUUGAUGAAUUUUUUCCA 
                 1060 
               
               
                   
               
               
                 561 
                 GUGAAAACAUCUUUAGAGA 
                 838 
                 561 
                 GUGAAAACAUCUUUAGAGA 
                 838 
                 583 
                 UCUCUAAAGAUGUUUUCAC 
                 1061 
               
               
                   
               
               
                 579 
                 AAGGCCAAUACUUUGGUUG 
                 839 
                 579 
                 AAGGCCAAUACUUUGGUUG 
                 839 
                 601 
                 CAACCAAAGUAUUGGCCUU 
                 1062 
               
               
                   
               
               
                 597 
                 GUUCCUUUGAUCUGACCAA 
                 840 
                 597 
                 GUUCCUUUGAUCUGACCAA 
                 840 
                 619 
                 UUGGUCAGAUCAAAGGAAC 
                 1063 
               
               
                   
               
               
                 615 
                 AAGUGAAGGAUUCCAGUUU 
                 841 
                 615 
                 AAGUGAAGGAUUCCAGUUU 
                 841 
                 637 
                 AAACUGGAAUCCUUCACUU 
                 1064 
               
               
                   
               
               
                 633 
                 UUGAACAACACAGUGUCCA 
                 842 
                 633 
                 UUGAACAACACAGUGUCCA 
                 842 
                 655 
                 UGGACACUGUGUUGUUCAA 
                 1065 
               
               
                   
               
               
                 651 
                 AAAUAAUGGUCAAGGAUAA 
                 843 
                 651 
                 AAAUAAUGGUCAAGGAUAA 
                 843 
                 673 
                 UUAUCCUUGACCAUUAUUU 
                 1066 
               
               
                   
               
               
                 669 
                 AUGCAGGAAAAAUUAAACC 
                 844 
                 669 
                 AUGCAGGAAAAAUUAAACC 
                 844 
                 691 
                 GGUUUAAUUUUUCCUGCAU 
                 1067 
               
               
                   
               
               
                 687 
                 CAUCCUUCAAUAUAGUGCC 
                 845 
                 687 
                 CAUCCUUCAAUAUAGUGCC 
                 845 
                 709 
                 GGCACUAUAUUGAAGGAUG 
                 1068 
               
               
                   
               
               
                 705 
                 CUUUAACUUCCCGUGUGAA 
                 846 
                 705 
                 CUUUAACUUCCCGUGUGAA 
                 846 
                 727 
                 UUCACACGGGAAGUUAAAG 
                 1069 
               
               
                   
               
               
                 723 
                 AACCUGAUCCUCCACAUAU 
                 847 
                 723 
                 AACCUGAUCCUCCACAUAU 
                 847 
                 745 
                 AUAUGUGGAGGAUCAGGUU 
                 1070 
               
               
                   
               
               
                 741 
                 UUAAAAACCUCUCCUUCCA 
                 848 
                 741 
                 UUAAAAACCUCUCCUUCCA 
                 848 
                 763 
                 UGGAAGGAGAGGUUUUUAA 
                 1071 
               
               
                   
               
               
                 759 
                 ACAAUGAUGACCUAUAUGU 
                 849 
                 759 
                 ACAAUGAUGACCUAUAUGU 
                 849 
                 781 
                 ACAUAUAGGUCAUCAUUGU 
                 1072 
               
               
                   
               
               
                 777 
                 UGCAAUGGGAGAAUCCACA 
                 850 
                 777 
                 UGCAAUGGGAGAAUCCACA 
                 850 
                 799 
                 UGUGGAUUCUCCCAUUGCA 
                 1073 
               
               
                   
               
               
                 795 
                 AGAAUUUUAUUAGCAGAUG 
                 851 
                 795 
                 AGAAUUUUAUUAGCAGAUG 
                 851 
                 817 
                 CAUCUGCUAAUAAAAUUCU 
                 1074 
               
               
                   
               
               
                 813 
                 GCCUAUUUUAUGAAGUAGA 
                 852 
                 813 
                 GCCUAUUUUAUGAAGUAGA 
                 852 
                 835 
                 UCUACUUCAUAAAAUAGGC 
                 1075 
               
               
                   
               
               
                 831 
                 AAGUCAAUAACAGCCAAAC 
                 853 
                 831 
                 AAGUCAAUAACAGCCAAAC 
                 853 
                 853 
                 GUUUGGCUGUUAUUGACUU 
                 1076 
               
               
                   
               
               
                 849 
                 CUGAGACACAUAAUGUUUU 
                 854 
                 849 
                 CUGAGACACAUAAUGUUUU 
                 854 
                 871 
                 AAAACAUUAUGUGUCUCAG 
                 1077 
               
               
                   
               
               
                 867 
                 UCUACGUCCAAGAGGCUAA 
                 855 
                 867 
                 UCUACGUCCAAGAGGCUAA 
                 855 
                 889 
                 UUAGCCUCUUGGACGUAGA 
                 1078 
               
               
                   
               
               
                 885 
                 AAUGUGAGAAUCCAGAAUU 
                 856 
                 885 
                 AAUGUGAGAAUCCAGAAUU 
                 856 
                 907 
                 AAUUCUGGAUUCUCACAUU 
                 1079 
               
               
                   
               
               
                 903 
                 UUGAGAGAAAUGUGGAGAA 
                 857 
                 903 
                 UUGAGAGAAAUGUGGAGAA 
                 857 
                 925 
                 UUCUCCACAUUUCUCUCAA 
                 1080 
               
               
                   
               
               
                 921 
                 AUACAUCUUGUUUCAUGGU 
                 858 
                 921 
                 AUACAUCUUGUUUCAUGGU 
                 858 
                 943 
                 ACCAUGAAACAAGAUGUAU 
                 1081 
               
               
                   
               
               
                 939 
                 UCCCUGGUGUUCUUCCUGA 
                 859 
                 939 
                 UCCCUGGUGUUCUUCCUGA 
                 859 
                 961 
                 UCAGGAAGAACACCAGGGA 
                 1082 
               
               
                   
               
               
                 957 
                 AUACUUUGAACACAGUCAG 
                 860 
                 957 
                 AUACUUUGAACACAGUCAG 
                 860 
                 979 
                 CUGACUGUGUUCAAAGUAU 
                 1083 
               
               
                   
               
               
                 975 
                 GAAUAAGAGUCAAAACAAA 
                 861 
                 975 
                 GAAUAAGAGUCAAAACAAA 
                 861 
                 997 
                 UUUGUUUUGACUCUUAUUC 
                 1084 
               
               
                   
               
               
                 993 
                 AUAAGUUAUGCUAUGAGGA 
                 862 
                 993 
                 AUAAGUUAUGCUAUGAGGA 
                 862 
                 1015 
                 UCCUCAUAGCAUAACUUAU 
                 1085 
               
               
                   
               
               
                 1011 
                 AUGACAAACUCUGGAGUAA 
                 863 
                 1011 
                 AUGACAAACUCUGGAGUAA 
                 863 
                 1033 
                 UUACUCCAGAGUUUGUCAU 
                 1086 
               
               
                   
               
               
                 1029 
                 AUUGGAGCCAAGAAAUGAG 
                 864 
                 1029 
                 AUUGGAGCCAAGAAAUGAG 
                 864 
                 1051 
                 CUCAUUUCUUGGCUCCAAU 
                 1087 
               
               
                   
               
               
                 1047 
                 GUAUAGGUAAGAAGCGCAA 
                 865 
                 1047 
                 GUAUAGGUAAGAAGCGCAA 
                 865 
                 1069 
                 UUGCGCUUCUUACCUAUAC 
                 1088 
               
               
                   
               
               
                 1065 
                 AUUCCACACUCUACAUAAC 
                 866 
                 1065 
                 AUUCCACACUCUACAUAAC 
                 866 
                 1087 
                 GUUAUGUAGAGUGUGGAAU 
                 1089 
               
               
                   
               
               
                 1083 
                 CCAUGUUACUCAUUGUUCC 
                 867 
                 1083 
                 CCAUGUUACUCAUUGUUCC 
                 867 
                 1105 
                 GGAACAAUGAGUAACAUGG 
                 1090 
               
               
                   
               
               
                 1101 
                 CAGUCAUCGUCGCAGGUGC 
                 868 
                 1101 
                 CAGUCAUCGUCGCAGGUGC 
                 868 
                 1123 
                 GCACCUGCGACGAUGACUG 
                 1091 
               
               
                   
               
               
                 1119 
                 CAAUCAUAGUACUCCUGCU 
                 869 
                 1119 
                 CAAUCAUAGUACUCCUGCU 
                 869 
                 1141 
                 AGCAGGAGUACUAUGAUUG 
                 1092 
               
               
                   
               
               
                 1137 
                 UUUACCUAAAAAGGCUCAA 
                 870 
                 1137 
                 UUUACCUAAAAAGGCUCAA 
                 870 
                 1159 
                 UUGAGCCUUUUUAGGUAAA 
                 1093 
               
               
                   
               
               
                 1155 
                 AGAUUAUUAUAUUCCCUCC 
                 871 
                 1155 
                 AGAUUAUUAUAUUCCCUCC 
                 871 
                 1177 
                 GGAGGGAAUAUAAUAAUCU 
                 1094 
               
               
                   
               
               
                 1173 
                 CAAUUCCUGAUCCUGGCAA 
                 872 
                 1173 
                 CAAUUCCUGAUCCUGGCAA 
                 872 
                 1195 
                 UUGCCAGGAUCAGGAAUUG 
                 1095 
               
               
                   
               
               
                 1191 
                 AGAUUUUUAAAGAAAUGUU 
                 873 
                 1191 
                 AGAUUUUUAAAGAAAUGUU 
                 873 
                 1213 
                 AACAUUUCUUUAAAAAUCU 
                 1096 
               
               
                   
               
               
                 1209 
                 UUGGAGACCAGAAUGAUGA 
                 874 
                 1209 
                 UUGGAGACCAGAAUGAUGA 
                 874 
                 1231 
                 UCAUCAUUCUGGUCUCCAA 
                 1097 
               
               
                   
               
               
                 1227 
                 AUACUCUGCACUGGAAGAA 
                 875 
                 1227 
                 AUACUCUGCACUGGAAGAA 
                 875 
                 1249 
                 UUCUUCCAGUGCAGAGUAU 
                 1098 
               
               
                   
               
               
                 1245 
                 AGUACGACAUCUAUGAGAA 
                 876 
                 1245 
                 AGUACGACAUCUAUGAGAA 
                 876 
                 1267 
                 UUCUCAUAGAUGUCGUACU 
                 1099 
               
               
                   
               
               
                 1263 
                 AGCAAACCAAGGAGGAAAC 
                 877 
                 1263 
                 AGCAAACCAAGGAGGAAAC 
                 877 
                 1285 
                 GUUUCCUCCUUGGUUUGCU 
                 1100 
               
               
                   
               
               
                 1281 
                 CCGACUCUGUAGUGCUGAU 
                 878 
                 1281 
                 CCGACUCUGUAGUGCUGAU 
                 878 
                 1303 
                 AUCAGCACUACAGAGUCGG 
                 1101 
               
               
                   
               
               
                 1299 
                 UAGAAAACCUGAAGAAAGC 
                 879 
                 1299 
                 UAGAAAACCUGAAGAAAGC 
                 879 
                 1321 
                 GCUUUCUUCAGGUUUUCUA 
                 1102 
               
               
                   
               
               
                 1317 
                 CCUCUCAGUGAUGGAGAUA 
                 880 
                 1317 
                 CCUCUCAGUGAUGGAGAUA 
                 880 
                 1339 
                 UAUCUCCAUCACUGAGAGG 
                 1103 
               
               
                   
               
               
                 1335 
                 AAUUUAUUUUUACCUUCAC 
                 881 
                 1335 
                 AAUUUAUUUUUACCUUCAC 
                 881 
                 1357 
                 GUGAAGGUAAAAAUAAAUU 
                 1104 
               
               
                   
               
               
                 1353 
                 CUGUGACCUUGAGAAGAUU 
                 882 
                 1353 
                 CUGUGACCUUGAGAAGAUU 
                 882 
                 1375 
                 AAUCUUCUCAAGGUCACAG 
                 1105 
               
               
                   
               
               
                 1371 
                 UCUUCCCAUUCUCCAUUUG 
                 883 
                 1371 
                 UCUUCCCAUUCUCCAUUUG 
                 883 
                 1393 
                 CAAAUGGAGAAUGGGAAGA 
                 1106 
               
               
                   
               
               
                 1389 
                 GUUAUCUGGGAACUUAUUA 
                 884 
                 1389 
                 GUUAUCUGGGAACUUAUUA 
                 884 
                 1411 
                 UAAUAAGUUCCCAGAUAAC 
                 1107 
               
               
                   
               
               
                 1407 
                 AAAUGGAAACUGAAACUAC 
                 885 
                 1407 
                 AAAUGGAAACUGAAACUAC 
                 885 
                 1429 
                 GUAGUUUCAGUUUCCAUUU 
                 1108 
               
               
                   
               
               
                 1425 
                 CUGCACCAUUUAAAAACAG 
                 886 
                 1425 
                 CUGCACCAUUUAAAAACAG 
                 886 
                 1447 
                 CUGUUUUUAAAUGGUGCAG 
                 1109 
               
               
                   
               
               
                 1443 
                 GGCAGCUCAUAAGAGCCAC 
                 887 
                 1443 
                 GGCAGCUCAUAAGAGCCAC 
                 887 
                 1465 
                 GUGGCUCUUAUGAGCUGCC 
                 1110 
               
               
                   
               
               
                 1461 
                 CAGGUCUUUAUGUUGAGUC 
                 888 
                 1461 
                 CAGGUCUUUAUGUUGAGUC 
                 888 
                 1483 
                 GACUCAACAUAAAGACCUG 
                 1111 
               
               
                   
               
               
                 1479 
                 CGCGCACCGAAAAACUAAA 
                 889 
                 1479 
                 CGCGCACCGAAAAACUAAA 
                 889 
                 1501 
                 UUUAGUUUUUCGGUGCGCG 
                 1112 
               
               
                   
               
               
                 1497 
                 AAAUAAUGGGCGCUUUGGA 
                 890 
                 1497 
                 AAAUAAUGGGCGCUUUGGA 
                 890 
                 1519 
                 UCCAAAGCGCCCAUUAUUU 
                 1113 
               
               
                   
               
               
                 1515 
                 AGAAGAGUGUGGAGUCAUU 
                 891 
                 1515 
                 AGAAGAGUGUGGAGUCAUU 
                 891 
                 1537 
                 AAUGACUCCACACUCUUCU 
                 1114 
               
               
                   
               
               
                 1533 
                 UCUCAUUGAAUUAUAAAAG 
                 892 
                 1533 
                 UCUCAUUGAAUUAUAAAAG 
                 892 
                 1555 
                 CUUUUAUAAUUCAAUGAGA 
                 1115 
               
               
                   
               
               
                 1551 
                 GCCAGCAGGCUUCAAACUA 
                 893 
                 1551 
                 GCCAGCAGGCUUCAAACUA 
                 893 
                 1573 
                 UAGUUUGAAGCCUGCUGGC 
                 1116 
               
               
                   
               
               
                 1569 
                 AGGGGACAAAGCAAAAAGU 
                 894 
                 1569 
                 AGGGGACAAAGCAAAAAGU 
                 894 
                 1591 
                 ACUUUUUGCUUUGUCCCCU 
                 1117 
               
               
                   
               
               
                 1587 
                 UGAUGAUAGUGGUGGAGUU 
                 895 
                 1587 
                 UGAUGAUAGUGGUGGAGUU 
                 895 
                 1609 
                 AACUCCACCACUAUCAUCA 
                 1118 
               
               
                   
               
               
                 1605 
                 UAAUCUUAUCAAGAGUUGU 
                 896 
                 1605 
                 UAAUCUUAUCAAGAGUUGU 
                 896 
                 1627 
                 ACAACUCUUGAUAAGAUUA 
                 1119 
               
               
                   
               
               
                 1623 
                 UGACAACUUCCUGAGGGAU 
                 897 
                 1623 
                 UGACAACUUCCUGAGGGAU 
                 897 
                 1645 
                 AUCCCUCAGGAAGUUGUCA 
                 1120 
               
               
                   
               
               
                 1641 
                 UCUAUACUUGCUUUGUGUU 
                 898 
                 1641 
                 UCUAUACUUGCUUUGUGUU 
                 898 
                 1663 
                 AACACAAAGCAAGUAUAGA 
                 1121 
               
               
                   
               
               
                 1659 
                 UCUUUGUGUCAACAUGAAC 
                 899 
                 1659 
                 UCUUUGUGUCAACAUGAAC 
                 899 
                 1681 
                 GUUCAUGUUGACACAAAGA 
                 1122 
               
               
                   
               
               
                 1677 
                 CAAAUUUUAUUUGUAGGGG 
                 900 
                 1677 
                 CAAAUUUUAUUUGUAGGGG 
                 900 
                 1699 
                 CCCCUACAAAUAAAAUUUG 
                 1123 
               
               
                   
               
               
                 1695 
                 GAACUCAUUUGGGGUGCAA 
                 901 
                 1695 
                 GAACUCAUUUGGGGUGCAA 
                 901 
                 1717 
                 UUGCACCCCAAAUGAGUUC 
                 1124 
               
               
                   
               
               
                 1713 
                 AAUGCUAAUGUCAAACUUG 
                 902 
                 1713 
                 AAUGCUAAUGUCAAACUUG 
                 902 
                 1735 
                 CAAGUUUGACAUUAGCAUU 
                 1125 
               
               
                   
               
               
                 1731 
                 GAGUCACAAAGAACAUGUA 
                 903 
                 1731 
                 GAGUCACAAAGAACAUGUA 
                 903 
                 1753 
                 UACAUGUUCUUUGUGACUC 
                 1126 
               
               
                   
               
               
                 1749 
                 AGAAAACAAAAUGGAUAAA 
                 904 
                 1749 
                 AGAAAACAAAAUGGAUAAA 
                 904 
                 1771 
                 UUUAUCCAUUUUGUUUUCU 
                 1127 
               
               
                   
               
               
                 1767 
                 AAUCUGAUAUGUAUUGUUU 
                 905 
                 1767 
                 AAUCUGAUAUGUAUUGUUU 
                 905 
                 1789 
                 AAACAAUACAUAUCAGAUU 
                 1128 
               
               
                   
               
               
                 1785 
                 UGGGAUCCUAUUGAACCAU 
                 906 
                 1785 
                 UGGGAUCCUAUUGAACCAU 
                 906 
                 1807 
                 AUGGUUCAAUAGGAUCCCA 
                 1129 
               
               
                   
               
               
                 1803 
                 UGUUUGUGGCUAUUAAAAC 
                 907 
                 1803 
                 UGUUUGUGGCUAUUAAAAC 
                 907 
                 1825 
                 GUUUUAAUAGCCACAAACA 
                 1130 
               
               
                   
               
               
                 1821 
                 CUCUUUUAACAGUCUGGGC 
                 908 
                 1821 
                 CUCUUUUAACAGUCUGGGC 
                 908 
                 1843 
                 GCCCAGACUGUUAAAAGAG 
                 1131 
               
               
                   
               
               
                 1839 
                 CUGGGUCCGGUGGCUCACG 
                 909 
                 1839 
                 CUGGGUCCGGUGGCUCACG 
                 909 
                 1861 
                 CGUGAGCCACCGGACCCAG 
                 1132 
               
               
                   
               
               
                 1857 
                 GCCUGUAAUCCCAGCAAUU 
                 910 
                 1857 
                 GCCUGUAAUCCCAGCAAUU 
                 910 
                 1879 
                 AAUUGCUGGGAUUACAGGC 
                 1133 
               
               
                   
               
               
                 1875 
                 UUGGGAGUCCGAGGCGGGC 
                 911 
                 1875 
                 UUGGGAGUCCGAGGCGGGC 
                 911 
                 1897 
                 GCCCGCCUCGGACUCCCAA 
                 1134 
               
               
                   
               
               
                 1893 
                 CGGAUCACUCGAGGUCAGG 
                 912 
                 1893 
                 CGGAUCACUCGAGGUCAGG 
                 912 
                 1915 
                 CCUGACCUCGAGUGAUCCG 
                 1135 
               
               
                   
               
               
                 1911 
                 GAGUUCCAGACCAGCCUGA 
                 913 
                 1911 
                 GAGUUCCAGACCAGCCUGA 
                 913 
                 1933 
                 UCAGGCUGGUCUGGAACUC 
                 1136 
               
               
                   
               
               
                 1929 
                 ACCAAAAUGGUGAAACCUC 
                 914 
                 1929 
                 ACCAAAAUGGUGAAACCUC 
                 914 
                 1951 
                 GAGGUUUCACCAUUUUGGU 
                 1137 
               
               
                   
               
               
                 1947 
                 CCUCUCUACUAAAACUACA 
                 915 
                 1947 
                 CCUCUCUACUAAAACUACA 
                 915 
                 1969 
                 UGUAGUUUUAGUAGAGAGG 
                 1138 
               
               
                   
               
               
                 1965 
                 AAAAAUUAACUGGGUGUGG 
                 916 
                 1965 
                 AAAAAUUAACUGGGUGUGG 
                 916 
                 1987 
                 CCACACCCAGUUAAUUUUU 
                 1139 
               
               
                   
               
               
                 1983 
                 GUGGCGCGUGCCUGUAAUC 
                 917 
                 1983 
                 GUGGCGCGUGCCUGUAAUC 
                 917 
                 2005 
                 GAUUACAGGCACGCGCCAC 
                 1140 
               
               
                   
               
               
                 2001 
                 CCCAGCUACUCGGGAAGCU 
                 918 
                 2001 
                 CCCAGCUACUCGGGAAGCU 
                 918 
                 2023 
                 AGCUUCCCGAGUAGCUGGG 
                 1141 
               
               
                   
               
               
                 2019 
                 UGAGGCAGGUGAAUUGUUU 
                 919 
                 2019 
                 UGAGGCAGGUGAAUUGUUU 
                 919 
                 2041 
                 AAACAAUUCACCUGCCUCA 
                 1142 
               
               
                   
               
               
                 2037 
                 UGAACCUGGGAGGUGGAGG 
                 920 
                 2037 
                 UGAACCUGGGAGGUGGAGG 
                 920 
                 2059 
                 CCUCCACCUCCCAGGUUCA 
                 1143 
               
               
                   
               
               
                 2055 
                 GUUGCAGUGAGCAGAGAUC 
                 921 
                 2055 
                 GUUGCAGUGAGCAGAGAUC 
                 921 
                 2077 
                 GAUCUCUGCUCACUGCAAC 
                 1144 
               
               
                   
               
               
                 2073 
                 CACACCACUGCACUCUAGC 
                 922 
                 2073 
                 CACACCACUGCACUCUAGC 
                 922 
                 2095 
                 GCUAGAGUGCAGUGGUGUG 
                 1145 
               
               
                   
               
               
                 2091 
                 CCUGGGUGACAGAGCAAGA 
                 923 
                 2091 
                 CCUGGGUGACAGAGCAAGA 
                 923 
                 2113 
                 UCUUGCUCUGUCACCCAGG 
                 1146 
               
               
                   
               
               
                 2109 
                 ACUCUGUCUAAAAAACAAA 
                 924 
                 2109 
                 ACUCUGUCUAAAAAACAAA 
                 924 
                 2131 
                 UUUGUUUUUUAGACAGAGU 
                 1147 
               
               
                   
               
               
                 2127 
                 AACAAAACAAAACAAAACA 
                 925 
                 2127 
                 AACAAAACAAAACAAAACA 
                 925 
                 2149 
                 UGUUUUGUUUUGUUUUGUU 
                 1148 
               
               
                   
               
               
                 2145 
                 AAAAAAACCUCUUAAUAUU 
                 926 
                 2145 
                 AAAAAPACCUCUUAAUAUU 
                 926 
                 2167 
                 AAUAUUAAGAGGUUUUUUU 
                 1149 
               
               
                   
               
               
                 2163 
                 UCUGGAGUCAUCAUUCCCU 
                 927 
                 2163 
                 UCUGGAGUCAUCAUUCCCU 
                 927 
                 2185 
                 AGGGAAUGAUGACUCCAGA 
                 1150 
               
               
                   
               
               
                 2181 
                 UUCGACAGCAUUUUCCUCU 
                 928 
                 2181 
                 UUCGACAGCAUUUUCCUCU 
                 928 
                 2203 
                 AGAGGAAAAUGCUGUCGAA 
                 1151 
               
               
                   
               
               
                 2199 
                 UGCUUUGAAAGCCCCAGAA 
                 929 
                 2199 
                 UGCUUUGAAAGCCCCAGAA 
                 929 
                 2221 
                 UUCUGGGGCUUUCAAAGCA 
                 1152 
               
               
                   
               
               
                 2217 
                 AAUCAGUGUUGGCCAUGAU 
                 930 
                 2217 
                 AAUCAGUGUUGGCCAUGAU 
                 930 
                 2239 
                 AUCAUGGCCAACACUGAUU 
                 1153 
               
               
                   
               
               
                 2235 
                 UGACAACUACAGAAAAACC 
                 931 
                 2235 
                 UGACAACUACAGAAAAACC 
                 931 
                 2257 
                 GGUUUUUCUGUAGUUGUCA 
                 1154 
               
               
                   
               
               
                 2253 
                 CAGAGGCAGCUUCUUUGCC 
                 932 
                 2253 
                 CAGAGGCAGCUUCUUUGCC 
                 932 
                 2275 
                 GGCAAAGAAGCUGCCUCUG 
                 1155 
               
               
                   
               
               
                 2271 
                 CAAGACCUUUCAAAGCCAU 
                 933 
                 2271 
                 CAAGACCUUUCAAAGCCAU 
                 933 
                 2293 
                 AUGGCUUUGAAAGGUCUUG 
                 1156 
               
               
                   
               
               
                 2289 
                 UUUUAGGCUGUUAGGGGCA 
                 934 
                 2289 
                 UUUUAGGCUGUUAGGGGCA 
                 934 
                 2311 
                 UGCCCCUAACAGCCUAAAA 
                 1157 
               
               
                   
               
               
                 2307 
                 AGUGGAGGUAGAAUGACUC 
                 935 
                 2307 
                 AGUGGAGGUAGAAUGACUC 
                 935 
                 2329 
                 GAGUCAUUCUACCUCCACU 
                 1158 
               
               
                   
               
               
                 2325 
                 CCUUGGGUAUUAGAGUUUC 
                 936 
                 2325 
                 CCUUGGGUAUUAGAGUUUC 
                 936 
                 2347 
                 GAAACUCUAAUACCCAAGG 
                 1159 
               
               
                   
               
               
                 2343 
                 CAACCAUGAAGUCUCUAAC 
                 937 
                 2343 
                 CAACCAUGAAGUCUCUAAC 
                 937 
                 2365 
                 GUUAGAGACUUCAUGGUUG 
                 1160 
               
               
                   
               
               
                 2361 
                 CAAUGUAUUUUCUUCACCU 
                 938 
                 2361 
                 CAAUGUAUUUUCUUCACCU 
                 938 
                 2383 
                 AGGUGAAGAAAAUACAUUG 
                 1161 
               
               
                   
               
               
                 2379 
                 UCUGCUACUCAAGUAGCAU 
                 939 
                 2379 
                 UCUGCUACUCAAGUAGCAU 
                 939 
                 2401 
                 AUGCUACUUGAGUAGCAGA 
                 1162 
               
               
                   
               
               
                 2397 
                 UUUACUGUGUCUUUGGUUU 
                 940 
                 2397 
                 UUUACUGUGUCUUUGGUUU 
                 940 
                 2419 
                 AAACCAAAGACACAGUAAA 
                 1163 
               
               
                   
               
               
                 2415 
                 UGUGCUAGGCCCCCGGGUG 
                 941 
                 2415 
                 UGUGCUAGGCCCCCGGGUG 
                 941 
                 2437 
                 CACCCGGGGGCCUAGCACA 
                 1164 
               
               
                   
               
               
                 2433 
                 GUGAAGCACAGACCCCUUC 
                 942 
                 2433 
                 GUGAAGCACAGACCCCUUC 
                 942 
                 2455 
                 GAAGGGGUCUGUGCUUCAC 
                 1165 
               
               
                   
               
               
                 2451 
                 CCAGGGGUUUACAGUCUAU 
                 943 
                 2451 
                 CCAGGGGUUUACAGUCUAU 
                 943 
                 2473 
                 AUAGACUGUAAACCCCUGG 
                 1166 
               
               
                   
               
               
                 2469 
                 UUUGAGACUCCUCAGUUCU 
                 944 
                 2469 
                 UUUGAGACUCCUCAGUUCU 
                 944 
                 2491 
                 AGAACUGAGGAGUCUCAAA 
                 1167 
               
               
                   
               
               
                 2487 
                 UUGCCACUUUUUUUUUUAA 
                 945 
                 2487 
                 UUGCCACUUUUUUUUUUAA 
                 945 
                 2509 
                 UUAAAAAAAAAAGUGGCAA 
                 1168 
               
               
                   
               
               
                 2505 
                 AUCUCCACCAGUCAUUUUU 
                 946 
                 2505 
                 AUCUCCACCAGUCAUUUUU 
                 946 
                 2527 
                 AAAAAUGACUGGUGGAGAU 
                 1169 
               
               
                   
               
               
                 2523 
                 UCAGACCUUUUAACUCCUC 
                 947 
                 2523 
                 UCAGACCUUUUAACUCCUC 
                 947 
                 2545 
                 GAGGAGUUAAAAGGUCUGA 
                 1170 
               
               
                   
               
               
                 2541 
                 CAAUUCCAACACUGAUUUC 
                 948 
                 2541 
                 CAAUUCCAACACUGAUUUC 
                 948 
                 2563 
                 GAAAUCAGUGUUGGAAUUG 
                 1171 
               
               
                   
               
               
                 2559 
                 CCCCUUUUGCAUUCUCCCU 
                 949 
                 2559 
                 CCCCUUUUGCAUUCUCCCU 
                 949 
                 2581 
                 AGGGAGAAUGCAAAAGGGG 
                 1172 
               
               
                   
               
               
                 2577 
                 UCCUUCCCUUCCUUGUAGC 
                 950 
                 2577 
                 UCCUUCCCUUCCUUGUAGC 
                 950 
                 2599 
                 GCUACAAGGAAGGGAAGGA 
                 1173 
               
               
                   
               
               
                 2595 
                 CCUUUUGACUUUCAUUGGA 
                 951 
                 2595 
                 CCUUUUGACUUUCAUUGGA 
                 951 
                 2617 
                 UCCAAUGAAAGUCAAAAGG 
                 1174 
               
               
                   
               
               
                 2613 
                 AAAUUAGGAUGUAAAUCUG 
                 952 
                 2613 
                 AAAUUAGGAUGUAAAUCUG 
                 952 
                 2635 
                 CAGAUUUACAUCCUAAUUU 
                 1175 
               
               
                   
               
               
                 2631 
                 GCUCAGGAGACCUGGAGGA 
                 953 
                 2631 
                 GCUCAGGAGACCUGGAGGA 
                 953 
                 2653 
                 UCCUCCAGGUCUCCUGAGC 
                 1176 
               
               
                   
               
               
                 2649 
                 AGCAGAGGAUAAUUAGCAU 
                 954 
                 2649 
                 AGCAGAGGAUAAUUAGCAU 
                 954 
                 2671 
                 AUGCUAAUUAUCCUCUGCU 
                 1177 
               
               
                   
               
               
                 2667 
                 UCUCAGGUUAAGUGUGAGU 
                 955 
                 2667 
                 UCUCAGGUUAAGUGUGAGU 
                 955 
                 2689 
                 ACUCACACUUAACCUGAGA 
                 1178 
               
               
                   
               
               
                 2685 
                 UAAUCUGAGAAACAAUGAC 
                 956 
                 2685 
                 UAAUCUGAGAAACAAUGAC 
                 956 
                 2707 
                 GUCAUUGUUUCUCAGAUUA 
                 1179 
               
               
                   
               
               
                 2703 
                 CUAAUUCUUGCAUAUUUUG 
                 957 
                 2703 
                 CUAAUUCUUGCAUAUUUUG 
                 957 
                 2725 
                 CAAAAUAUGCAAGAAUUAG 
                 1180 
               
               
                   
               
               
                 2721 
                 GUAACUUCCAUGUGAGGGU 
                 958 
                 2721 
                 GUAACUUCCAUGUGAGGGU 
                 958 
                 2743 
                 ACCCUCACAUGGAAGUUAC 
                 1181 
               
               
                   
               
               
                 2739 
                 UUUUCAGCAUUGAUAUUUG 
                 959 
                 2739 
                 UUUUCAGCAUUGAUAUUUG 
                 959 
                 2761 
                 CAAAUAUCAAUGCUGAAAA 
                 1182 
               
               
                   
               
               
                 2757 
                 GUGCAUUUUCUAAACAGAG 
                 960 
                 2757 
                 GUGCAUUUUCUAAACAGAG 
                 960 
                 2779 
                 CUCUGUUUAGAAAAUGCAC 
                 1183 
               
               
                   
               
               
                 2775 
                 GAUGAGGUGGUAUCUUCAC 
                 961 
                 2775 
                 GAUGAGGUGGUAUCUUCAC 
                 961 
                 2797 
                 GUGAAGAUACCACCUCAUC 
                 1184 
               
               
                   
               
               
                 2793 
                 CGUAGAACAUUGGUAUUCG 
                 962 
                 2793 
                 CGUAGAACAUUGGUAUUCG 
                 962 
                 2815 
                 CGAAUACCAAUGUUCUACG 
                 1185 
               
               
                   
               
               
                 2811 
                 GCUUGAGAAAAAAAGAAUA 
                 963 
                 2811 
                 GCUUGAGAAAAAAAGAAUA 
                 963 
                 2833 
                 UAUUCUUUUUUUCUCAAGC 
                 1186 
               
               
                   
               
               
                 2829 
                 AGUUGAACCUAUUUCUCUU 
                 964 
                 2829 
                 AGUUGAACCUAUUUCUCUU 
                 964 
                 2851 
                 AAGAGAAAUAGGUUCAACU 
                 1187 
               
               
                   
               
               
                 2847 
                 UUCUUUACAAGAUGGGUCC 
                 965 
                 2847 
                 UUCUUUACAAGAUGGGUCC 
                 965 
                 2869 
                 GGACCCAUCUUGUAAAGAA 
                 1188 
               
               
                   
               
               
                 2865 
                 CAGGAUUCCUCUUUUCUCU 
                 966 
                 2865 
                 CAGGAUUCCUCUUUUCUCU 
                 966 
                 2887 
                 AGAGAAAAGAGGAAUCCUG 
                 1189 
               
               
                   
               
               
                 2883 
                 UGCCAUAAAUGAUUAAUUA 
                 967 
                 2883 
                 UGCCAUAAAUGAUUAAUUA 
                 967 
                 2905 
                 UAAUUAAUCAUUUAUGGCA 
                 1190 
               
               
                   
               
               
                 2901 
                 AAAUAGCUUUUGUGUCUUA 
                 968 
                 2901 
                 AAAUAGCUUUUGUGUCUUA 
                 968 
                 2923 
                 UAAGACACAAAAGCUAUUU 
                 1191 
               
               
                   
               
               
                 2919 
                 ACAUUGGUAGCCAGCCAGC 
                 969 
                 2919 
                 ACAUUGGUAGCCAGCCAGC 
                 969 
                 2941 
                 GCUGGCUGGCUACCAAUGU 
                 1192 
               
               
                   
               
               
                 2937 
                 CCAAGGCUCUGUUUAUGCU 
                 970 
                 2937 
                 CCAAGGCUCUGUUUAUGCU 
                 970 
                 2959 
                 AGCAUAAACAGAGCCUUGG 
                 1193 
               
               
                   
               
               
                 2955 
                 UUUUGGGGGGCAUAUAUUG 
                 971 
                 2955 
                 UUUUGGGGGGCAUAUAUUG 
                 971 
                 2977 
                 CAAUAUAUGCCCCCCAAAA 
                 1194 
               
               
                   
               
               
                 2973 
                 GGGUUCCAUUCUCACCUAU 
                 972 
                 2973 
                 GGGUUCCAUUCUCACCUAU 
                 972 
                 2995 
                 AUAGGUGAGAAUGGAACCC 
                 1195 
               
               
                   
               
               
                 2991 
                 UCCACACAACAUAUCCGUA 
                 973 
                 2991 
                 UCCACACAACAUAUCCGUA 
                 973 
                 3013 
                 UACGGAUAUGUUGUGUGGA 
                 1196 
               
               
                   
               
               
                 3009 
                 AUAUAUCCCCUCUACUCUU 
                 974 
                 3009 
                 AUAUAUCCCCUCUACUCUU 
                 974 
                 3031 
                 AAGAGUAGAGGGGAUAUAU 
                 1197 
               
               
                   
               
               
                 3027 
                 UACUUCCCCCAAAUUUAAA 
                 975 
                 3027 
                 UACUUCCCCCAAAUUUAAA 
                 975 
                 3049 
                 UUUAAAUUUGGGGGAAGUA 
                 1198 
               
               
                   
               
               
                 3045 
                 AGAAGUAUGGGAAAUGAGA 
                 976 
                 3045 
                 AGAAGUAUGGGAAAUGAGA 
                 976 
                 3067 
                 UCUCAUUUCCCAUACUUCU 
                 1199 
               
               
                   
               
               
                 3063 
                 AGGCAUUUCCCCCACCCCA 
                 977 
                 3063 
                 AGGCAUUUCCCCCACCCCA 
                 977 
                 3085 
                 UGGGGUGGGGGAAAUGCCU 
                 1200 
               
               
                   
               
               
                 3081 
                 AUUUCUCUCCUCACACACA 
                 978 
                 3081 
                 AUUUCUCUCCUCACACACA 
                 978 
                 3103 
                 UGUGUGUGAGGAGAGAAAU 
                 1201 
               
               
                   
               
               
                 3099 
                 AGACUCAUAUUACUGGUAG 
                 979 
                 3099 
                 AGACUCAUAUUACUGGUAG 
                 979 
                 3121 
                 CUACCAGUAAUAUGAGUCU 
                 1202 
               
               
                   
               
               
                 3117 
                 GGAACUUGAGAACUUUAUU 
                 980 
                 3117 
                 GGAACUUGAGAACUUUAUU 
                 980 
                 3139 
                 AAUAAAGUUCUCAAGUUCC 
                 1203 
               
               
                   
               
               
                 3135 
                 UUCCAAGUUGUUCAAACAU 
                 981 
                 3135 
                 UUCCAAGUUGUUCAAACAU 
                 981 
                 3157 
                 AUGUUUGAACAACUUGGAA 
                 1204 
               
               
                   
               
               
                 3153 
                 UUUACCAAUCAUAUUAAUA 
                 982 
                 3153 
                 UUUACCAAUCAUAUUAAUA 
                 982 
                 3175 
                 UAUUAAUAUGAUUGGUkAA 
                 1205 
               
               
                   
               
               
                 3171 
                 ACAAUGAUGCUAUUUGCAA 
                 983 
                 3171 
                 ACAAUGAUGCUAUUUGCAA 
                 983 
                 3193 
                 UUGCAAAUAGCAUCAUUGU 
                 1206 
               
               
                   
               
               
                 3189 
                 AUUCCUGCUCCUAGGGGAG 
                 984 
                 3189 
                 AUUCCUGCUCCUAGGGGAG 
                 984 
                 3211 
                 CUCCCCUAGGAGCAGGAAU 
                 1207 
               
               
                   
               
               
                 3207 
                 GGGGAGAUAAGAAACCCUC 
                 985 
                 3207 
                 GGGGAGAUAAGAAACCCUC 
                 985 
                 3229 
                 GAGGGUUUCUUAUCUCCCC 
                 1208 
               
               
                   
               
               
                 3225 
                 CACUCUCUACAGGUUUGGG 
                 986 
                 3225 
                 CACUCUCUACAGGUUUGGG 
                 986 
                 3247 
                 CCCAAACCUGUAGAGAGUG 
                 1209 
               
               
                   
               
               
                 3243 
                 GUACAAGUGGCAACCUGCU 
                 987 
                 3243 
                 GUACAAGUGGCAACCUGCU 
                 987 
                 3265 
                 AGCAGGUUGCCACUUGUAC 
                 1210 
               
               
                   
               
               
                 3261 
                 UUCCAUGGCCGUGUAGAAG 
                 988 
                 3261 
                 UUCCAUGGCCGUGUAGAAG 
                 988 
                 3283 
                 CUUCUACACGGCCAUGGAA 
                 1211 
               
               
                   
               
               
                 3279 
                 GCAUGGUGCCCUGGCUUCU 
                 989 
                 3279 
                 GCAUGGUGCCCUGGCUUCU 
                 989 
                 3301 
                 AGAAGCCAGGGCACCAUGC 
                 1212 
               
               
                   
               
               
                 3297 
                 UCUGAGGAAGCUGGGGUUC 
                 990 
                 3297 
                 UCUGAGGAAGCUGGGGUUC 
                 990 
                 3319 
                 GAACCCCAGCUUCCUCAGA 
                 1213 
               
               
                   
               
               
                 3315 
                 CAUGACAAUGGCAGAUGUA 
                 991 
                 3315 
                 CAUGACAAUGGCAGAUGUA 
                 991 
                 3337 
                 UACAUCUGCCAUUGUCAUG 
                 1214 
               
               
                   
               
               
                 3333 
                 AAAGUUAUUCUUGAAGUCA 
                 992 
                 3333 
                 AAAGUUAUUCUUGAAGUCA 
                 992 
                 3355 
                 UGACUUCAAGAAUAACUUU 
                 1215 
               
               
                   
               
               
                 3351 
                 AGAUUGAGGCUGGGAGACA 
                 993 
                 3351 
                 AGAUUGAGGCUGGGAGACA 
                 993 
                 3373 
                 UGUCUCCCAGCCUCAAUCU 
                 1216 
               
               
                   
               
               
                 3369 
                 AGCCGUAGUAGAUGUUCUA 
                 994 
                 3369 
                 AGCCGUAGUAGAUGUUCUA 
                 994 
                 3391 
                 UAGAACAUCUACUACGGCU 
                 1217 
               
               
                   
               
               
                 3387 
                 ACUUUGUUCUGCUGUUCUC 
                 995 
                 3387 
                 ACUUUGUUCUGCUGUUCUC 
                 995 
                 3409 
                 GAGAACAGCAGAACAAAGU 
                 1218 
               
               
                   
               
               
                 3405 
                 CUAGAAAGAAUAUUUGGUU 
                 996 
                 3405 
                 CUAGAAAGAAUAUUUGGUU 
                 996 
                 3427 
                 AACCAAAUAUUCUUUCUAG 
                 1219 
               
               
                   
               
               
                 3423 
                 UUUCCUGUAUAGGAAUGAG 
                 997 
                 3423 
                 UUUCCUGUAUAGGAAUGAG 
                 997 
                 3445 
                 CUCAUUCCUAUACAGGAAA 
                 1220 
               
               
                   
               
               
                 3441 
                 GAUUAAUUCCUUUCCAGGU 
                 998 
                 3441 
                 GAUUAAUUCCUUUCCAGGU 
                 998 
                 3463 
                 ACCUGGAAAGGAAUUAAUC 
                 1221 
               
               
                   
               
               
                 3459 
                 UAUUUUAUAAUUCUGGGAA 
                 999 
                 3459 
                 UAUUUUAUAAUUCUGGGAA 
                 999 
                 3481 
                 UUCCCAGAAUUAUAAAAUA 
                 1222 
               
               
                   
               
               
                 3477 
                 AGCAAAACCCAUGCCUCCC 
                 1000 
                 3477 
                 AGCAAAACCCAUGCCUCCC 
                 1000 
                 3499 
                 GGGAGGCAUGGGUUUUGCU 
                 1223 
               
               
                   
               
               
                 3495 
                 CCCUAGCCAUUUUUACUGU 
                 1001 
                 3495 
                 CCCUAGCCAUUUUUACUGU 
                 1001 
                 3517 
                 ACAGUAAAAAUGGCUAGGG 
                 1224 
               
               
                   
               
               
                 3513 
                 UUAUCCUAUUUAGAUGGCC 
                 1002 
                 3513 
                 UUAUCCUAUUUAGAUGGCC 
                 1002 
                 3535 
                 GGCCAUCUAAAUAGGAUAA 
                 1225 
               
               
                   
               
               
                 3531 
                 CAUGAAGAGGAUGCUGUGA 
                 1003 
                 3531 
                 CAUGAAGAGGAUGCUGUGA 
                 1003 
                 3553 
                 UCACAGCAUCCUCUUCAUG 
                 1226 
               
               
                   
               
               
                 3549 
                 AAAUUCCCAACAAACAUUG 
                 1004 
                 3549 
                 AAAUUCCCAACAAACAUUG 
                 1004 
                 3571 
                 CAAUGUUUGUUGGGAAUUU 
                 1227 
               
               
                   
               
               
                 3567 
                 GAUGCUGACAGUCAUGCAG 
                 1005 
                 3567 
                 GAUGCUGACAGUCAUGCAG 
                 1005 
                 3589 
                 CUGCAUGACUGUCAGCAUC 
                 1228 
               
               
                   
               
               
                 3585 
                 GUCUGGGAGUGGGGAAGUG 
                 1006 
                 3585 
                 GUCUGGGAGUGGGGAAGUG 
                 1006 
                 3607 
                 CACUUCCCCACUCCCAGAC 
                 1229 
               
               
                   
               
               
                 3603 
                 GAUCUUUUGUUCCCAUCCU 
                 1007 
                 3603 
                 GAUCUUUUGUUCCCAUCCU 
                 1007 
                 3625 
                 AGGAUGGGAACAAAAGAUC 
                 1230 
               
               
                   
               
               
                 3621 
                 UCUUCUUUUAGCAGUAAAA 
                 1008 
                 3621 
                 UCUUCUUUUAGCAGUAAAA 
                 1008 
                 3643 
                 UUUUACUGCUAAAAGAAGA 
                 1231 
               
               
                   
               
               
                 3639 
                 AUAGCUGAGGGAAAAGGGA 
                 1009 
                 3639 
                 AUAGCUGAGGGAAAAGGGA 
                 1009 
                 3661 
                 UCCCUUUUCCCUCAGCUAU 
                 1232 
               
               
                   
               
               
                 3657 
                 AGGGAAAAGGAAGUUAUGG 
                 1010 
                 3657 
                 AGGGAAAAGGAAGUUAUGG 
                 1010 
                 3679 
                 CCAUAACUUCCUUUUCCCU 
                 1233 
               
               
                   
               
               
                 3675 
                 GGAAUACCUGUGGUGGUUG 
                 1011 
                 3675 
                 GGAAUACCUGUGGUGGUUG 
                 1011 
                 3697 
                 CAACCACCACAGGUAUUCC 
                 1234 
               
               
                   
               
               
                 3693 
                 GUGAUCCCUAGGUCUUGGG 
                 1012 
                 3693 
                 GUGAUCCCUAGGUCUUGGG 
                 1012 
                 3715 
                 CCCAAGACCUAGGGAUCAC 
                 1235 
               
               
                   
               
               
                 3711 
                 GAGCUCUUGGAGGUGUCUG 
                 1013 
                 3711 
                 GAGCUCUUGGAGGUGUCUG 
                 1013 
                 3733 
                 CAGACACCUCCAAGAGCUC 
                 1236 
               
               
                   
               
               
                 3729 
                 GUAUCAGUGGAUUUCCCAU 
                 1014 
                 3729 
                 GUAUCAGUGGAUUUCCCAU 
                 1014 
                 3751 
                 AUGGGAAAUCCACUGAUAC 
                 1237 
               
               
                   
               
               
                 3747 
                 UCCCCUGUGGGAAAUUAGU 
                 1015 
                 3747 
                 UCCCCUGUGGGAAAUUAGU 
                 1015 
                 3769 
                 ACUAAUUUCCCACAGGGGA 
                 1238 
               
               
                   
               
               
                 3765 
                 UAGGCUCAUUUACUGUUUU 
                 1016 
                 3765 
                 UAGGCUCAUUUACUGUUUU 
                 1016 
                 3787 
                 AAAACAGUAAAUGAGCCUA 
                 1239 
               
               
                   
               
               
                 3783 
                 UAGGUCUAGCCUAUGUGGA 
                 1017 
                 3783 
                 UAGGUCUAGCCUAUGUGGA 
                 1017 
                 3805 
                 UCCACAUAGGCUAGACCUA 
                 1240 
               
               
                   
               
               
                 3801 
                 AUUUUUUCCUAACAUACCU 
                 1018 
                 3801 
                 AUUUUUUCCUAACAUACCU 
                 1018 
                 3823 
                 AGGUAUGUUAGGAAAAAAU 
                 1241 
               
               
                   
               
               
                 3819 
                 UAAGCAAACCCAGUGUCAG 
                 1019 
                 3819 
                 UAAGCAAACCCAGUGUCAG 
                 1019 
                 3841 
                 CUGACACUGGGUUUGCUUA 
                 1242 
               
               
                   
               
               
                 3837 
                 GGAUGGUAAUUCUUAUUCU 
                 1020 
                 3837 
                 GGAUGGUAAUUCUUAUUCU 
                 1020 
                 3859 
                 AGAAUAAGAAUUACCAUCC 
                 1243 
               
               
                   
               
               
                 3855 
                 UUUCGUUCAGUUAAGUUUU 
                 1021 
                 3855 
                 UUUCGUUCAGUUAAGUUUU 
                 1021 
                 3877 
                 AAAACUUAACUGAACGAAA 
                 1244 
               
               
                   
               
               
                 3873 
                 UUCCCUUCAUCUGGGCACU 
                 1022 
                 3873 
                 UUCCCUUCAUCUGGGCACU 
                 1022 
                 3895 
                 AGUGCCCAGAUGAAGGGAA 
                 1245 
               
               
                   
               
               
                 3891 
                 UGAAGGGAUAUGUGAAACA 
                 1023 
                 3891 
                 UGAAGGGAUAUGUGAAACA 
                 1023 
                 3913 
                 UGUUUCACAUAUCCCUUCA 
                 1246 
               
               
                   
               
               
                 3909 
                 AAUGUUAACAUUUUUGGUA 
                 1024 
                 3909 
                 AAUGUUAACAUUUUUGGUA 
                 1024 
                 3931 
                 UACCAAAAAUGUUAACAUU 
                 1247 
               
               
                   
               
               
                 3927 
                 AGUCUUCAACCAGGGAUUG 
                 1025 
                 3927 
                 AGUCUUCAACCAGGGAUUG 
                 1025 
                 3949 
                 CAAUCCCUGGUUGAAGACU 
                 1248 
               
               
                   
               
               
                 3945 
                 GUUUCUGUUUAACUUCUUA 
                 1026 
                 3945 
                 GUUUCUGUUUAACUUCUUA 
                 1026 
                 3967 
                 UAAGAAGUUAAACAGAAAC 
                 1249 
               
               
                   
               
               
                 3963 
                 AUAGGAAAGCUUGAGUAAA 
                 1027 
                 3963 
                 AUAGGAAAGCUUGAGUAAA 
                 1027 
                 3985 
                 UUUACUCAAGCUUUCCUAU 
                 1250 
               
               
                   
               
               
                 3981 
                 AAUAAAUAUUGUCUUUUUG 
                 1028 
                 3981 
                 AAUAAAUAUUGUCUUUUUG 
                 1028 
                 4003 
                 CAAAAAGACAAUAUUUAUU 
                 1251 
               
               
                   
               
               
                 3986 
                 AUAUUGUCUUUUUGUAUGU 
                 1029 
                 3986 
                 AUAUUGUCUUUUUGUAUGU 
                 1029 
                 4008 
                 ACAUACAAAAAGACAAUAU 
                 1252 
               
               
                   
               
               
                   The 3′-ends of the Upper sequence and the Lower sequence of the siNA construct can include an overhang sequence, for example about 1, 2, 3, or 4 nucleotides in length, preferably 2 nucleotides in length, wherein the overhanging sequence of the lower sequence is optionally complementary to a portion of the target sequence.    
               
               
                   The upper sequence is also referred to as the sense strand, whereas the lower sequence is also referred to as the antisense strand. The upper and lower sequences in the Table can further comprise a chemical modification having Formulae I-VII or any combination thereof.    
               
             
          
         
       
     
         [0428]    
       
         
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
             
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
             
           
               
                 Table III 
               
               
                   
               
               
                   
               
               
                 Interleukin and Interleukin receptor Synthetic Modified siNA constructs 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 IL2RG 
                   
               
             
          
           
               
                 Target 
                   
                 Seq 
                 Cmpd 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Target 
                 ID 
                 # 
                 Aliases 
                 Sequence 
                 ID 
               
               
                   
               
             
          
           
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:120U21 sense siNA 
                 ACCACAGCUGAUUUCUUCCTT 
                 1311 
                   
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:132U21 sense siNA 
                 UUCUUCCUGACCACUAUGCTT 
                 1312 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:140U21 sense siNA 
                 GACCACUAUGCCCACUGACTT 
                 1313 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:157U21 sense siNA 
                 ACUCCCUCAGUGUUUCCACTT 
                 1314 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:264U21 sense siNA 
                 AACCUCACUCUGCAUUAUUTT 
                 1315 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:304U21 sense siNA 
                 AUAAAGUCCAGAAGUGCAGTT 
                 1316 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:305U21 sense siNA 
                 UAAAGUCCAGAAGUGCAGCTT 
                 1317 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:346U21 sense siNA 
                 UCACUUCUGGCUGUCAGUUTT 
                 1318 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:138L21 antisense siNA 
                 GGAAGAAAUCAGCUGUGGUTT 
                 1319 
               
               
                   
                   
                   
                   
                 (120C) 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:150L21 antisense siNA 
                 GCAUAGUGGUCAGGAAGAATT 
                 1320 
               
               
                   
                   
                   
                   
                 (132C) 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:158L21 antisense siNA 
                 GUCAGUGGGCAUAGUGGUCTT 
                 1321 
               
               
                   
                   
                   
                   
                 (140C) 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:175L21 antisense siNA 
                 GUGGAAACACUGAGGGAGUTT 
                 1322 
               
               
                   
                   
                   
                   
                 (157C) 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:282L21 antisense siNA 
                 AAUAAUGCAGAGUGAGGUUTT 
                 1323 
               
               
                   
                   
                   
                   
                 (264C) 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:322L21 antisense siNA 
                 CUGCACUUCUGGACUUUAUTT 
                 1324 
               
               
                   
                   
                   
                   
                 (304C) 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:323L21 antisense siNA 
                 GCUGCACUUCUGGACUUUATT 
                 1325 
               
               
                   
                   
                   
                   
                 (305C) 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:364L21 antisense siNA 
                 AACUGACAGCCAGAAGUGATT 
                 1326 
               
               
                   
                   
                   
                   
                 (346C) 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:120U21 sense siNA 
                 B AccAcAGcuGAuuucuuccTT B 
                 1327 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:132U21 sense siNA 
                 B uucuuccuGAccAcuAuGcTT B 
                 1328 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:140U21 sense siNA 
                 B GAccAcuAuGcccAcuGAcTT B 
                 1329 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:157U21 sense siNA 
                 B AcucccucAGuGuuuccAcTT B 
                 1330 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:264U21 sense siNA 
                 B AAccucAcucuGcAuuAuuTT B 
                 1331 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:304U21 sense siNA 
                 B AuAAAGuccAGAAGuGcAGTT B 
                 1332 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:305U21 sense siNA 
                 B uAAAGuccAGAAGuGcAGcTT B 
                 1333 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:346U21 sense siNA 
                 B ucAcuucuGGcuGucAGuuTT B 
                 1334 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:138L21 antisense siNA 
                 GGAAGAAAucAGcuGuGGuTsT 
                 1335 
               
               
                   
                   
                   
                   
                 (120C) stab05 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:150L21 antisense siNA 
                 GcAuAGuGGucAGGAAGAATsT 
                 1336 
               
               
                   
                   
                   
                   
                 (132C) stab05 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:158L21 antisense siNA 
                 GucAGuGGGcAuAGuGGucTsT 
                 1337 
               
               
                   
                   
                   
                   
                 (140C) stab05 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:175L21 antisense siNA 
                 GuGGAAAcAcuGAGGGAGuTsT 
                 1338 
               
               
                   
                   
                   
                   
                 (157C) stab05 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:282L21 antisense siNA 
                 AAuAAuGcAGAGuGAGGuuTsT 
                 1339 
               
               
                   
                   
                   
                   
                 (264C) stab05 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:322L21 antisense siNA 
                 cuGcAcuucuGGAcuuuAuTsT 
                 1340 
               
               
                   
                   
                   
                   
                 (304C) stab05 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:323L21 antisense siNA 
                 GcuGcAcuucuGGAcuuuATsT 
                 1341 
               
               
                   
                   
                   
                   
                 (305C) stab05 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:364L21 antisense siNA 
                 AAcuGAcAGccAGAAGuGATsT 
                 1342 
               
               
                   
                   
                   
                   
                 (346C) stab05 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:120U21 sense siNA 
                 B  A cc A c AG cu GA uuucuuccTT B 
                 1343 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:132U21 sense siNA 
                 B uucuuccu GA cc A cu A u G cTT B 
                 1344 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCAGUGACUC 
                 1255 
                   
                 IL2RG:140U21 sense siNA 
                 B  GA cc A cu A u G ccc A cu GA cTT B 
                 1345 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:157U21 sense siNA 
                 B  A cucccuc AG u G uuucc A cTT B 
                 1346 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:264U21 sense siNA 
                 B  AA ccuc A cucu G c A uu A uuTT B 
                 1347 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:304U21 sense siNA 
                 B  A u AAAG ucc AGAAG u G c AG TT B 
                 1348 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:305U21 sense siNA 
                 B u AAAG ucc AGAAG u G c AG cTT B 
                 1349 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:346U21 sense siNA 
                 B uc A cuucu GG cu G uc AG uuTT B 
                 1350 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:138L21 antisense siNA 
                   GGAAGAAA uc AG cu G u GG uTsT 
                 1351 
               
               
                   
                   
                   
                   
                 (120C) stab11 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:150L21 antisense siNA 
                   G c A u AG u GG uc AGGAAGAA TsT 
                 1352 
               
               
                   
                   
                   
                   
                 (132C) stab11 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:158L21 antisense siNA 
                   G uc AG u GGG c A u AG u GG ucTsT 
                 1353 
               
               
                   
                   
                   
                   
                 (140C) stab11 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:175L21 antisense siNA 
                   G u GGAAA c A cu GAGGGAG uTsT 
                 1354 
               
               
                   
                   
                   
                   
                 (157C) stab11 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:282L21 antisense siNA 
                   AA u AA u G c AGAG u GAGG uuTsT 
                 1355 
               
               
                   
                   
                   
                   
                 (264C) stab11 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:322L21 antisense siNA 
                 cu G c A cuucu GGA cuuu A uTsT 
                 1356 
               
               
                   
                   
                   
                   
                 (304C) stab11 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:323L21 antisense siNA 
                   G cu G c A cuucu GGA cuuu A TsT 
                 1357 
               
               
                   
                   
                   
                   
                 (305C) stab11 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:364L21 antisense siNA 
                   AA cu GA c AG cc AGAAG u GA TsT 
                 1358 
               
               
                   
                   
                   
                   
                 (346C) stab11 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:120U21 sense siNA 
                 B  A cc A c AG cu GA uuucuuccTT B 
                 1359 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:132U21 sense siNA 
                 B uucuuccu GA cc A cu A u G cTT B 
                 1360 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:140U21 sense siNA 
                 B  GA cc A cu A u G ccc A cu GA cTT B 
                 1361 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:157U21 sense siNA 
                 B  A cucccuc AG u G uuucc A cTT B 
                 1362 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:264U21 sense siNA 
                 B  AA ccuc A cucu G c A uu A uuTT B 
                 1363 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:304U21 sense siNA 
                 B  A u AAAG ucc AGAAG u G c AG TT B 
                 1364 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:305U21 sense siNA 
                 B u AAAG ucc AGAAG u G c AG cTT B 
                 1365 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:346U21 sense siNA 
                 B uc A cuucu GG cu G uc AG uuTT B 
                 1366 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:138L21 antisense siNA 
                   GGAAGAAA uc AG cu G u GG uTsT 
                 1367 
               
               
                   
                   
                   
                   
                 (120C) stab08 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:150L21 antisense siNA 
                   G c A u AG u GG uc AGGAAGAA TsT 
                 1368 
               
               
                   
                   
                   
                   
                 (132C) stab08 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:158L21 antisense siNA 
                   G uc AG u GGG c A u AG u GG ucTsT 
                 1369 
               
               
                   
                   
                   
                   
                 (140C) stab08 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:175L21 antisense siNA 
                   G u GGAAA c A cu GAGGGAG uTsT 
                 1370 
               
               
                   
                   
                   
                   
                 (157C) stab08 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:282L21 antisense siNA 
                   AA u AA u G c AGAG u GAGG uuTsT 
                 1371 
               
               
                   
                   
                   
                   
                 (264C) stab08 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:322L21 antisense siNA 
                 cu G c A cuucu GGA cuuu A uTsT 
                 1372 
               
               
                   
                   
                   
                   
                 (304C) stab08 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:323L21 antisense siNA 
                   G cu G c A cuucu GGA cuuuA T sT 
                 1373 
               
               
                   
                   
                   
                   
                 (305C) stab08 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:364L21 antisense siNA 
                   AA cu G c AG cc AGAAG u GA TsT 
                 1374 
               
               
                   
                   
                   
                   
                 (346C) stab08 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:120U21 sense siNA 
                 B ACCACAGCUGAUUUCUUCCTT B 
                 1375 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:132U21 sense siNA 
                 B UUCUUCCUGACCACUAUGCTT B 
                 1376 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:140U21 sense siNA 
                 B GACCACUAUGCCCACUGACTT B 
                 1377 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:157U21 sense siNA 
                 B ACUCCCUCAGUGUUUCCACTT B 
                 1378 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:264U21 sense siNA 
                 B AACCUCACUCUGCAUUAUUTT B 
                 1379 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:304U21 sense siNA 
                 B AUAAAGUCCAGAAGUGCAGTT B 
                 1380 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:305U21 sense siNA 
                 B UAAAGUCCAGAAGUGCAGCTT B 
                 1381 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:346U21 sense siNA 
                 B UCACUUCUGGCUGUCAGUUTT B 
                 1382 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:138L21 antisense siNA 
                 GGAAGAAAUCAGCUGUGGUTsT 
                 1383 
               
               
                   
                   
                   
                   
                 (120C) stab10 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:150L21 antisense siNA 
                 GCAUAGUGGUCAGGAAGAATsT 
                 1384 
               
               
                   
                   
                   
                   
                 (132C) stab10 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:158L21 antisense siNA 
                 GUCAGUGGGCAUAGUGGUCTsT 
                 1385 
               
               
                   
                   
                   
                   
                 (140C) stab10 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:175L21 antisense siNA 
                 GUGGAAACACUGAGGGAGUTsT 
                 1386 
               
               
                   
                   
                   
                   
                 (157C) stab10 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:282L21 antisense siNA 
                 AAUAAUGCAGAGUGAGGUUTsT 
                 1387 
               
               
                   
                   
                   
                   
                 (264C) stab10 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:322L21 antisense siNA 
                 CUGCACUUCUGGACUUUAUTsT 
                 1388 
               
               
                   
                   
                   
                   
                 (304C) stab10 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:323L21 antisense siNA 
                 GCUGCACUUCUGGACUUUATsT 
                 1389 
               
               
                   
                   
                   
                   
                 (305C) stab10 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUG 
                 1260 
                   
                 IL2RG:364L21 antisense siNA 
                 AACUGACAGCCAGPAGUGATsT 
                 1390 
               
               
                   
                   
                   
                   
                 (346C) stab10 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:138L21 antisense siNA 
                 GGAAGAAAucAGcuGuGGuTT B 
                 1391 
               
               
                   
                   
                   
                   
                 (120C) stab19 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:150L21 antisense siNA 
                 GcAuAGuGGucAGGAAGAATT B 
                 1392 
               
               
                   
                   
                   
                   
                 (132C) stab19 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:158L21 antisense siNA 
                 GucAGuGGGcAuAGuGGucTT B 
                 1393 
               
               
                   
                   
                   
                   
                 (140C) stab19 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:175L21 antisense siNA 
                 GuGGAAAcAcuGAGGGAGuTT B 
                 1394 
               
               
                   
                   
                   
                   
                 (157C) stab19 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUGG 
                 1257 
                   
                 IL2RG:282L21 antisense siNA 
                 AAuAAuGcAGAGuGAGGuuTT B 
                 1395 
               
               
                   
                   
                   
                   
                 (264C) stab19 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGC 
                 1258 
                   
                 IL2RG:322L21 antisense siNA 
                 cuGcAcuucuGGAcuuuAuTT B 
                 1396 
               
               
                   
                   
                   
                   
                 (304C) stab19 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCCA 
                 1259 
                   
                 IL2RG:323L21 antisense siNA 
                 GcuGcAcuucuGGAcuuuATT B 
                 1397 
               
               
                   
                   
                   
                   
                 (305C) stab19 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:364L21 antisense siNA 
                 AAcuGAcAGccAGAAGuGATT B 
                 1398 
               
               
                   
                   
                   
                   
                 (346C) stab19 
               
               
                   
               
               
                 118 
                 ACACCACAGCUGAUUUCUUCCUG 
                 1253 
                   
                 IL2RG:138L21 antisense siNA 
                 GGAAGAAAUCAGCUGUGGUTT B 
                 1399 
               
               
                   
                   
                   
                   
                 (120C) stab22 
               
               
                   
               
               
                 130 
                 AUUUCUUCCUGACCACUAUGCCC 
                 1254 
                   
                 IL2RG:150L21 antisense siNA 
                 GCAUAGUGGUCAGGAAGAATT B 
                 1400 
               
               
                   
                   
                   
                   
                 (132C) stab22 
               
               
                   
               
               
                 138 
                 CUGACCACUAUGCCCACUGACUC 
                 1255 
                   
                 IL2RG:158L21 antisense siNA 
                 GUCAGUGGGCAUAGUGGUCTT B 
                 1401 
               
               
                   
                   
                   
                   
                 (140C) stab22 
               
               
                   
               
               
                 155 
                 UGACUCCCUCAGUGUUUCCACUC 
                 1256 
                   
                 IL2RG:175L21 antisense siNA 
                 GUGGAAACACUGAGGGAGUTT B 
                 1402 
               
               
                   
                   
                   
                   
                 (157C) stab22 
               
               
                   
               
               
                 262 
                 CCAACCUCACUCUGCAUUAUUG 
                 1257 
                   
                 IL2RG:282L21 antisense siNA 
                 AAUAAUGCAGAGUGAGGUUTT B 
                 1403 
               
               
                   
                   
                   
                   
                 (264C) stab22 
               
               
                   
               
               
                 302 
                 UGAUAAAGUCCAGAAGUGCAGCC 
                 1258 
                   
                 IL2RG:322L21 antisense siNA 
                 CUGCACUUCUGGACUUUAUTT B 
                 1404 
               
               
                   
                   
                   
                   
                 (304C) stab22 
               
               
                   
               
               
                 303 
                 GAUAAAGUCCAGAAGUGCAGCC 
                 1259 
                   
                 IL2RG:323L21 antisense siNA 
                 GCUGCACUUCUGGACUUUATT B 
                 1405 
               
               
                   
                   
                   
                   
                 (305C) stab22 
               
               
                   
               
               
                 344 
                 AAUCACUUCUGGCUGUCAGUUGC 
                 1260 
                   
                 IL2RG:364L21 antisense siNA 
                 AACUGACAGCCAGAAGUGAT B 
                 1406 
               
               
                   
                   
                   
                   
                 (346C) stab22 
               
               
                   
               
               
                   
               
             
          
           
               
                 IL4 
                   
               
             
          
           
               
                 Target 
                   
                 Seq 
                   
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Target 
                 ID 
                   
                 Aliases 
                 Sequence 
                 ID 
               
               
                   
               
             
          
           
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:489U1 sense siNA 
                 GCCUCACAGAGCAGAAGACTT 
                 1407 
                   
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:491U1 sense siNA 
                 CUCACAGAGCAGAAGACUCTT 
                 1408 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:518U1 sense siNA 
                 GAGUUGACCGUAACAGACATT 
                 1409 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:528U1 sense siNA 
                 UAACAGACAUCUUUGCUGCTT 
                 1410 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:547U1 sense siNA 
                 CUCCAAGAACACAACUGAGUTT 
                 1411 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:608U1 sense siNA 
                 UACAGCCACCAUGAGAAGGTT 
                 1412 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:730U1 sense siNA 
                 GAAUUCCUGUCCUGUGAAGTT 
                 1413 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:747U1 sense siNA 
                 AGGAAGCCAACCAGAGUACTT 
                 1414 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:507L21 antisense siNA 
                 GUCUUCUGCUCUGUGAGGCT 
                 1415 
               
               
                   
                   
                   
                   
                 (489C) 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:509L21 antisense siNA 
                 GAGUCUUCUGCUCUGUGAGTT 
                 1416 
               
               
                   
                   
                   
                   
                 (491C) 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:536L21 antisense siNA 
                 UGUCUGUUACGGUCAACUCTT 
                 1417 
               
               
                   
                   
                   
                   
                 (518C) 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:546L21 antisense siNA 
                 GCAGCAAAGAUGUCUGUUATT 
                 1418 
               
               
                   
                   
                   
                   
                 (528C) 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:565L21 antisense siNA 
                 CUCAGUUGUGUUCUUGGAGTT 
                 1419 
               
               
                   
                   
                   
                   
                 (547C) 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:626L21 antisense siNA 
                 CCUUCUCAUGGUGGCUGUATT 
                 1420 
               
               
                   
                   
                   
                   
                 (608C) 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:748L21 antisense siNA 
                 CUUCACAGGACAGGAAUUCTT 
                 1421 
               
               
                   
                   
                   
                   
                 (730C) 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:765L21 antisense siNA 
                 GUACUCUGGUUGGCUUCCUTT 
                 1422 
               
               
                   
                   
                   
                   
                 (747C) 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:489U1 sense siNA stab04 
                 B GccucAcAGAGcAGAAGAcTT B 
                 1423 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:491U1 sense siNA stab04 
                 B cucAcAGAGcAGAAGAcucTT B 
                 1424 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:518U1 sense siNA stab04 
                 B GAGuuGAccGuAAcAGAcATT B 
                 1425 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCu 
                 1272 
                   
                 IL4:528U1 sense siNA stab04 
                 B uAAcAGAcAucuuuGcuGcTT B 
                 1426 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:547U1 sense siNA stab04 
                 B cuccAAGAAcAcAAcuGAGTT B 
                 1427 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:608U1 sense siNA stab04 
                 B uAcAGccAccAuGAGAAGGTT B 
                 1428 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:730U1 sense siNA stab04 
                 B GAAuuccuGuccuGuGAAGTT B 
                 1429 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:747U1 sense siNA stab04 
                 B AGGAAGccAAccAGAGuAcTT B 
                 1430 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:507L21 antisense siNA 
                 GucuucuGcucuGuGAGGcTsT 
                 1431 
               
               
                   
                   
                   
                   
                 (489C) stab05 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:509L21 antisense siNA 
                 GAGucuucuGcucuGuGAGTsT 
                 1432 
               
               
                   
                   
                   
                   
                 (491C) stab05 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:536L21 antisense siNA 
                 uGucuGuuAcGGucAAcucTsT 
                 1433 
               
               
                   
                   
                   
                   
                 (581C) stab05 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:546L21 antisense siNA 
                 GcAGcAAAGAuGucuGuuATsT 
                 1434 
               
               
                   
                   
                   
                   
                 (528C) stab05 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:565L21 antisense siNA 
                 cucAGuuGuGuucuuGGAGTsT 
                 1435 
               
               
                   
                   
                   
                   
                 (547C) stab05 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:626L21 antisense siNA 
                 ccuucucAuGGuGGcuGuATsT 
                 1436 
               
               
                   
                   
                   
                   
                 (608C) stab05 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGG 
                 1275 
                   
                 IL4:748L21 antisense siNA 
                 cuucAcAGGAcAGGAAuucTsT 
                 1437 
               
               
                   
                   
                   
                   
                 (730C) stab05 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:765L21 antisense siNA 
                 GuAcucuGGuuGGcuuccuTsT 
                 1438 
               
               
                   
                   
                   
                   
                 (747C) stab05 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:489U1 sense siNA stab07 
                 B  G ccuc A c AGAG c AGAAGA cTT B 
                 1439 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:491U1 sense siNA stab07 
                 B cuc A c AGAG c AGAAGA cucTT B 
                 1440 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:518U1 sense siNA stab07 
                 B  GAG uu GA cc G u AA c AGA c A TT B 
                 1441 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:528U1 sense siNA stab07 
                 B u AA c AGA c A ucuuu G cu G cTT B 
                 1442 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:547U1 sense siNA stab07 
                 B cucc AAGAA c A c AA cu GAG TT B 
                 1443 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:608U1 sense siNA stab07 
                 B u A c AG cc A cc A u GAGAAGG TT B 
                 1444 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:730U1 sense siNA stab07 
                 B  GAA uuccu G uccu G u GAAG TT B 
                 1445 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:747U1 sense siNA stab07 
                 B  AGGAAG cc AA cc AGAG u A cTT B 
                 1446 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:507L21 antisense siNA 
                   G ucuucu G cucu G u GAGG cTsT 
                 1447 
               
               
                   
                   
                   
                   
                 (489C) stab11 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:509L21 antisense siNA 
                   GAG ucuucu G cucu G u GAG TsT 
                 1448 
               
               
                   
                   
                   
                   
                 (491C) stab11 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:536L21 antisense siNA 
                 u G ucu G uu A c GG uc AA cucTsT 
                 1449 
               
               
                   
                   
                   
                   
                 (581C) stab11 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:546L21 antisense siNA 
                   G c AG c AAAGA u G ucu G uu A TsT 
                 1450 
               
               
                   
                   
                   
                   
                 (528C) stab11 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:565L21 antisense siNA 
                 cuc AG uu G u G uucuu GGAG TsT 
                 1451 
               
               
                   
                   
                   
                   
                 (547C) stab11 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:626L21 antisense siNA 
                 ccuucuc A u GG u GG cu G u A TsT 
                 1452 
               
               
                   
                   
                   
                   
                 (608C) stab11 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:748L21 antisense siNA 
                 cuuc A c AGGA c AGGAA uucTsT 
                 1453 
               
               
                   
                   
                   
                   
                 (730C) stab11 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:765L21 antisense siNA 
                   G u A cucu GG uu GG cuuccuTsT 
                 1454 
               
               
                   
                   
                   
                   
                 (747C) stab11 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:489U21 sense siNA 
                 B  G ccuc A c AGAG c AGAAGA cTT B 
                 1455 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:491U21 sense siNA 
                 B cuc A c AGAG c AGAAGA cucTT B 
                 1456 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:518U21 sense siNA 
                 B  GAG uu GA cc G u AA c AGA c A TT B 
                 1457 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:528U21 sense siNA 
                 B u AA c AGA c A ucuuu G cu G cTT B 
                 1458 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:547U21 sense siNA 
                 B cucc AAGAA c A c AA cu GAG TT B 
                 1459 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:608U21 sense siNA 
                 B u A c AG cc A cc A u GAGAAGG TT B 
                 1460 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:730U21 sense siNA 
                 B  GAA uuccu G uccu G u GAAG TT B 
                 1461 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:747U21 sense siNA 
                 B  AGGAAG cc AA cc AGAG u A cTT B 
                 1462 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:507L21 antisense siNA 
                   G ucuucu G cucu G u GAGG cTsT 
                 1463 
               
               
                   
                   
                   
                   
                 (489C) stab08 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:509L21 antisense siNA 
                   GAG ucuucu G cucu G u GAG TsT 
                 1464 
               
               
                   
                   
                   
                   
                 (491C) stab08 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:536L21 antisense siNA 
                 u G ucu G uu A c GG uc AA cucTsT 
                 1465 
               
               
                   
                   
                   
                   
                 (518C) stab08 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:546L21 antisense siNA 
                   G c AG c AAAGA u G ucu G uu A TsT 
                 1466 
               
               
                   
                   
                   
                   
                 (528C) stab08 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:565L21 antisense siNA 
                 cuc AG uu G u G uucuu GGAG TsT 
                 1467 
               
               
                   
                   
                   
                   
                 (547C) stab08 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:626L21 antisense siNA 
                 ccuucuc A u GG u GG cu G u A TsT 
                 1468 
               
               
                   
                   
                   
                   
                 (608C) stab08 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:748L21 antisense siNA 
                 cuuc A c AGGA c AGGAA uucTsT 
                 1469 
               
               
                   
                   
                   
                   
                 (730C) stab08 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:765L21 antisense siNA 
                   G u A cucu GG uu GG cuuccuTsT 
                 1470 
               
               
                   
                   
                   
                   
                 (747C) stab08 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:489U21 sense siNA 
                 B GCCUCACAGAGCAGAAGACTT B 
                 1471 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:491U21 sense siNA 
                 B CUCACAGAGCAGAAGACUCTT B 
                 1472 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAuC 
                 1271 
                   
                 IL4:518U21 sense siNA 
                 B GAGUUGACCGUAACAGACATT B 
                 1473 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:528U21 sense siNA 
                 B UAACAGACAUCUUUGCUGCTT B 
                 1474 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:547U21 sense siNA 
                 B CUCCAAGAACACAACUGAGTT B 
                 1475 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:608U21 sense siNA 
                 B UACAGCCACCAUGAGAAGGTT B 
                 1476 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:730U21 sense siNA 
                 B GAAUUCCUGUCCUGUGAAGTT B 
                 1477 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:747U21 sense siNA 
                 B AGGAAGCCAACCAGAGUACTT B 
                 1478 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:507L21 antisense siNA 
                 GUCUUCUGCUCUGUGAGGCTsT 
                 1479 
               
               
                   
                   
                   
                   
                 (489C) stab10 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:509L21 antisense siNA 
                 GAGUCUUCUGCUCUGUGAGTsT 
                 1480 
               
               
                   
                   
                   
                   
                 (491C) stab10 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:536L21 antisense siNA 
                 UGUCUGUUACGGUCAACUCTsT 
                 1481 
               
               
                   
                   
                   
                   
                 (518C) stab10 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:546L21 antisense siNA 
                 GCAGCAAAGAUGUCUGUUATsT 
                 1482 
               
               
                   
                   
                   
                   
                 (528C) stab10 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:565L21 antisense siNA 
                 CUCAGUUGUGUUCUUGGAGTsT 
                 1483 
               
               
                   
                   
                   
                   
                 (547C) stab10 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:626L21 antisense siNA 
                 CCUUCUCAUGGUGGCUGUATsT 
                 1484 
               
               
                   
                   
                   
                   
                 (608C) stab10 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:748L21 antisense siNA 
                 CUUCACAGGACAGGAAUUCTsT 
                 1485 
               
               
                   
                   
                   
                   
                 (730C) stab10 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:765L21 antisense siNA 
                 GUACUCUGGUUGGCUUCCUTsT 
                 1486 
               
               
                   
                   
                   
                   
                 (747C) stab10 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:507L21 antisense siNA 
                 GucuucuGcucuGuGAGGcTT B 
                 1487 
               
               
                   
                   
                   
                   
                 (489C) stab19 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:509L21 antisense siNA 
                 GAGucuucuGcucuGuGAGTT B 
                 1488 
               
               
                   
                   
                   
                   
                 (491C) stab19 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:536L21 antisense siNA 
                 uGucuGuuAcGGucAAcucTT B 
                 1489 
               
               
                   
                   
                   
                   
                 (518C) stab19 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:546L21 antisense siNA 
                 GcAGcAAAGAuGucuGuuATT B 
                 1490 
               
               
                   
                   
                   
                   
                 (528C) stab19 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:565L21 antisense siNA 
                 cucAGuuGuGuucuuGGAGTT B 
                 1491 
               
               
                   
                   
                   
                   
                 (547C) stab19 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:626L21 antisense siNA 
                 ccuucucAuGGuGGcuGuATT B 
                 1492 
               
               
                   
                   
                   
                   
                 (608C) stab19 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:748L21 antisense siNA 
                 cuucAcAGGAcAGGAAuucTT B 
                 1493 
               
               
                   
                   
                   
                   
                 (730C) stab19 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:765L21 antisense siNA 
                 GuAcucuGGuuGGcuuccuTT B 
                 1494 
               
               
                   
                   
                   
                   
                 (747C) stab19 
               
               
                   
               
               
                 487 
                 CAGCCUCACAGAGCAGAAGACUC 
                 1269 
                   
                 IL4:507L21 antisense siNA 
                 GUCUUCUGCUCUGUGAGGCTT B 
                 1495 
               
               
                   
                   
                   
                   
                 (489C) stab22 
               
               
                   
               
               
                 489 
                 GCCUCACAGAGCAGAAGACUCUG 
                 1270 
                   
                 IL4:509L21 antisense siNA 
                 GAGUCUUCUGCUCUGUGAGTT B 
                 1496 
               
               
                   
                   
                   
                   
                 (491C) stab22 
               
               
                   
               
               
                 516 
                 CCGAGUUGACCGUAACAGACAUC 
                 1271 
                   
                 IL4:536L21 antisense siNA 
                 UGUCUGUUACGGUCAACUCTT B 
                 1497 
               
               
                   
                   
                   
                   
                 (518C) stab22 
               
               
                   
               
               
                 526 
                 CGUAACAGACAUCUUUGCUGCCU 
                 1272 
                   
                 IL4:546L21 antisense siNA 
                 GCAGCAAAGAUGUCUGUUATT B 
                 1498 
               
               
                   
                   
                   
                   
                 (528C) stab22 
               
               
                   
               
               
                 545 
                 GCCUCCAAGAACACAACUGAGAA 
                 1273 
                   
                 IL4:565L21 antisense siNA 
                 CUCAGUUGUGUUCUUGGAGTT B 
                 1499 
               
               
                   
                   
                   
                   
                 (547C) stab22 
               
               
                   
               
               
                 606 
                 UCUACAGCCACCAUGAGAAGGAC 
                 1274 
                   
                 IL4:626L21 antisense siNA 
                 CCUUCUCAUGGUGGCUGUATT B 
                 1500 
               
               
                   
                   
                   
                   
                 (608C) stab22 
               
               
                   
               
               
                 728 
                 UUGAAUUCCUGUCCUGUGAAGGA 
                 1275 
                   
                 IL4:748L21 antisense siNA 
                 CUUCACAGGACAGGAAUUCTT B 
                 1501 
               
               
                   
                   
                   
                   
                 (730C) stab22 
               
               
                   
               
               
                 745 
                 GAAGGAAGCCAACCAGAGUACGU 
                 1276 
                   
                 IL4:765L21 antisense siNA 
                 GUACUCUGGUUGGCUUCCUTT B 
                 1502 
               
               
                   
                   
                   
                   
                 (747C) stab22 
               
               
                   
               
               
                   
               
             
          
           
               
                 IL4R 
                   
               
             
          
           
               
                 Target 
                   
                 Seq 
                 Cmpd 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Target 
                 ID 
                 # 
                 Aliases 
                 Sequence 
                 ID 
               
               
                   
               
             
          
           
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                   
                 IL4R:471U21 sense siNA 
                 AUACACUGGACCUGUGGGCTT 
                 1503 
                   
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                   
                 IL4R:553U21 sense siNA 
                 AGGAAACCUGACAGUUCACTT 
                 1504 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1121U21 sense siNA 
                 CACAACAUGAAAAGGGAUGTT 
                 1505 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                   
                 IL4R:1122U21 sense siNA 
                 ACAACAUGAAAAGGGAUGATT 
                 1506 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                   
                 IL4R:1134U21 sense siNA 
                 GGGAUGAAGAUCCUCACAATT 
                 1507 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                   
                 IL4R:3132U21 sense siNA 
                 GGGAAAUCGAUGAGAAAUUTT 
                 1508 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                   
                 IL4R:3133U21 sense siNA 
                 GGAAAUCGAUGAGAAAUUGTT 
                 1509 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                   
                 IL4R:3171U21 sense siNA 
                 AUUGCCUAGAGGUGCUCAUTT 
                 1510 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                   
                 IL4R:489L21 antisense siNA 
                 GCCCACAGGUCCAGUGUAUTT 
                 1511 
               
               
                   
                   
                   
                   
                 (471C) 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                   
                 IL4R:571L21 antisense siNA 
                 GUGAACUGUCAGGUUUCCUTT 
                 1512 
               
               
                   
                   
                   
                   
                 (553C) 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1139L21 antisense siNA 
                 CAUCCCUUUUCAUGUUGUGTT 
                 1513 
               
               
                   
                   
                   
                   
                 (1121C) 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                   
                 IL4R:1140L21 antisense siNA 
                 UCAUCCCUUUUCAUGUUGUTT 
                 1514 
               
               
                   
                   
                   
                   
                 (1122C) 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                   
                 IL4R:1152L21 antisense siNA 
                 UUGUGAGGAUCUUCAUCCCTT 
                 1515 
               
               
                   
                   
                   
                   
                 (1134C) 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                   
                 IL4R:3150L21 antisense siNA 
                 AAUUUCUCAUCGAUUUCCCTT 
                 1516 
               
               
                   
                   
                   
                   
                 (3132C) 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                   
                 IL4R:3151L21 antisense siNA 
                 CAAUUUCUCAUCGAUUUCCTT 
                 1517 
               
               
                   
                   
                   
                   
                 (3133C) 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                   
                 IL4R:3189L21 antisense siNA 
                 AUGAGCACCUCUAGGCAAUTT 
                 1518 
               
               
                   
                   
                   
                   
                 (3171C) 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                   
                 IL4R:471U21 sense siNA 
                 B AuAcAcuGGAccuGuGGGcTT B 
                 1519 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                   
                 IL4R:553U21 sense siNA 
                 B AGGAAAccuGAcAGuucAcTT B 
                 1520 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1121U21 sense siNA 
                 B cAcAAcAuGAAAAGGGAuGTT B 
                 1521 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                   
                 IL4R:1122U21 sense siNA 
                 B AcAAcAuGAAAAGGGAuGATT B 
                 1522 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                   
                 IL4R:1134U21 sense siNA 
                 B GGGAuGAAGAuccucAcAATT B 
                 1523 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                   
                 IL4R:3132U21 sense siNA 
                 B GGGAAAucGAuGAGAAAuuTT B 
                 1524 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                   
                 IL4R:3133U21 sense siNA 
                 B GGAAAucGAuGAGAAAuuGTT B 
                 1525 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                   
                 IL4R:3171U21 sense siNA 
                 B AuuGccuAGAGGuGcucAuTT B 
                 1526 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                   
                 IL4R:489L21 antisense siNA 
                 GcccAcAGGuccAGuGuAuTsT 
                 1527 
               
               
                   
                   
                   
                   
                 (471C) stab05 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                   
                 IL4R:571L21 antisense siNA 
                 GuGAAcuGucAGGuuuccuTsT 
                 1528 
               
               
                   
                   
                   
                   
                 (553C) stab05 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1139L21 antisense siNA 
                 cAucccuuuucAuGuuGuGTsT 
                 1529 
               
               
                   
                   
                   
                   
                 (1121C) stab05 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                   
                 IL4R:1140L21 antisense siNA 
                 ucAucccuuuucAuGuuGuTsT 
                 1530 
               
               
                   
                   
                   
                   
                 (1122C) stab05 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                   
                 IL4R:1152L21 antisense siNA 
                 uuGuGAGGAucuucAucccTsT 
                 1531 
               
               
                   
                   
                   
                   
                 (1134C) stab05 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                   
                 IL4R:3150L21 antisense siNA 
                 AAuuucucAucGAuuucccTsT 
                 1532 
               
               
                   
                   
                   
                   
                 (3132C) stab05 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                   
                 IL4R:3151L21 antisense siNA 
                 cAAuuucucAucGAuuuccTsT 
                 1533 
               
               
                   
                   
                   
                   
                 (3133C) stab05 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                   
                 IL4R:3189L21 antisense siNA 
                 AuGAGcAccucuAGGcAAuTsT 
                 1534 
               
               
                   
                   
                   
                   
                 (317C) stab05 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                   
                 ILR:471U21 sense siNA 
                 B  A u A c A cu GGA ccu G u GGG cTT B 
                 1535 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                   
                 ILR:553U21 sense siNA 
                 B  AGGAAA ccu GA c AG uuc A cTT B 
                 1536 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1121U21 sense siNA 
                 B c A c AA c A u GAAAAGGGA u G TT B 
                 1537 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                   
                 IL4R:1122U21 sense siNA 
                 B  A c AA c A u GAAAAGGGA u GA TT B 
                 1538 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                   
                 IL4R:1134U21 sense siNA 
                 B  GGGA u GAAGA uccuc A c AA TT B 
                 1539 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                   
                 IL4R:3132U21 sense siNA 
                 B  GGGAAA uc GA u GAGAAA uuTT B 
                 1540 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                   
                 IL4R:3133U21 sense siNA 
                 B  GGAAA uc GA u GAGAAA uuGTT B 
                 1541 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                   
                 IL4R:3171U21 sense siNA 
                 B  A uu G ccu AGAGG u G cuc A uTT B 
                 1542 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                   
                 IL4R:489L21 antisense siNA 
                   G ccc A c AGG ucc AG u G u A uTsT 
                 1543 
               
               
                   
                   
                   
                   
                 (471C) stab11 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                   
                 IL4R:571L21 antisense siNA 
                   G u GAA cu G uc AGG uuuccuTsT 
                 1544 
               
               
                   
                   
                   
                   
                 (553C) stab11 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1139L21 antisense siNA 
                 c A ucccuuuuc A u G uu G u G TsT 
                 1545 
               
               
                   
                   
                   
                   
                 (1121C) stab11 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                   
                 IL4R:1140L21 antisense siNA 
                 uc A ucccuuuuc A u G uu G uTsT 
                 1546 
               
               
                   
                   
                   
                   
                 (1122C) stab11 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAG 
                 1281 
                   
                 IL4R:1152L21 antisense siNA 
                 uu G u GAGGA ucuuc A ucccTsT 
                 1547 
               
               
                   
                   
                   
                   
                 (1134C) stab11 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                   
                 IL4R:3150L21 antisense siNA 
                   AA uuucuc A uc GA uuucccTsT 
                 1548 
               
               
                   
                   
                   
                   
                 (3132C) stab11 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                   
                 IL4R:3151L21 antisense siNA 
                 c AA uuucuc A uc GA uuuccTsT 
                 1549 
               
               
                   
                   
                   
                   
                 (3133C) stab11 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                   
                 IL4R:3189L21 antisense siNA 
                   A u GAG c A ccucu AGG c AA uTsT 
                 1550 
               
               
                   
                   
                   
                   
                 (3171C) stab11 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                   
                 IL4R:471U21 sense siNA 
                 B  A u A c A cu GGA ccu G u GGG cTT B 
                 1551 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                   
                 IL4R:553U21 sense siNA 
                 B  AGGAAA ccu GA c AG uuc A cTT B 
                 1552 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1121U21 sense siNA 
                 B c A c AA c A u GAAAAGGGA u G TT B 
                 1553 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                   
                 IL4R:1122U21 sense siNA 
                 B  A c AA c A u GAAAAGGGA u GA TT B 
                 1554 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                   
                 IL4R:1134U21 sense siNA 
                 B  GGGA u GAAGA uccuc A c AA TT B 
                 1555 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                   
                 IL4R:3132U21 sense siNA 
                 B  GGGAAA uc GA u GAGAAA uuTT B 
                 1556 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                   
                 IL4R:3133U21 sense siNA 
                 B  GGAAA uc GA u GAGAAA uu G TT B 
                 1557 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                   
                 IL4R:3171U21 sense siNA 
                 B  A uu G ccu AGAGG u G cuc A uTT B 
                 1558 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                   
                 IL4R:489L21 antisense siNA 
                   G ccc A c AGG ucc AG u G u A uTsT 
                 1559 
               
               
                   
                   
                   
                   
                 (471C) stab08 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                   
                 IL4R:571L21 antisense siNA 
                   G u GAA cu G uc AGG uuuccuTsT 
                 1560 
               
               
                   
                   
                   
                   
                 (553C) stab08 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1139L21 antisense siNA 
                 c A ucccuuuuc A u G uu G u G TsT 
                 1561 
               
               
                   
                   
                   
                   
                 (1121C) stab08 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                   
                 IL4R:1140L21 antisense siNA 
                 uc A ucccuuuuc A u G uu G uTsT 
                 1562 
               
               
                   
                   
                   
                   
                 (1122C) stab08 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                   
                 IL4R:1152L21 antisense siNA 
                 uu G u GAGGA ucuuc A ucccTsT 
                 1563 
               
               
                   
                   
                   
                   
                 (1134C) stab08 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                   
                 ILR:3150L21 antisense siNA 
                   AA uuucuc A uc GA uuucccTsT 
                 1564 
               
               
                   
                   
                   
                   
                 (3132C) stab08 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGA 
                 1283 
                   
                 IL4R:3151L21 antisense siNA 
                 c AA uuucuc A uc GA uuuccTsT 
                 1565 
               
               
                   
                   
                   
                   
                 (3133C) stab08 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUU 
                 1284 
                   
                 IL4R:3189L21 antisense siNA 
                   A u GAG c A ccucu AGG c AA uTsT 
                 1566 
               
               
                   
                   
                   
                   
                 (3171C) stab08 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                 36729 
                 ILR:471U21 sense siNA 
                 B AUACACUGGACCUGUGGGCTT B 
                 1567 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                 36730 
                 ILR:553U21 sense siNA 
                 B AGGAAACCUGACAGUUCACTT B 
                 1568 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                 36731 
                 ILR:1121U21 sense siNA 
                 B CACAACAUGAAAAGGGAUGTT B 
                 1569 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                 36732 
                 ILR:1122U21 sense siNA 
                 B ACAACAUGAAAAGGGAUGATT B 
                 1570 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                 36733 
                 ILR:1134U21 sense siNA 
                 B GGGAUGAAGAUCCUCACAATT B 
                 1571 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                 36734 
                 ILR:3132U21 sense siNA 
                 B GGGAAAUCGAUGAGAAAUUTT B 
                 1572 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                 36735 
                 ILR:3133U21 sense siNA 
                 B GGAAAUCGAUGAGAAAUUGTT B 
                 1573 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                 36736 
                 ILR:3171U21 sense siNA 
                 B AUUGCCUAGAGGUGCUCAUTT B 
                 1574 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCU 
                 1277 
                   
                 IL4R:489L21 antisense siNA 
                 GCCCACAGGUCCAGUGUAUTsT 
                 1575 
               
               
                   
                   
                   
                   
                 (471C) stab10 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACA 
                 1278 
                   
                 IL4R:571L21 antisense siNA 
                 GUGAACUGUCAGGUUUCCUTsT 
                 1576 
               
               
                   
                   
                   
                   
                 (553C) stab10 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                   
                 IL4R:1139L21 antisense siNA 
                 CAUCCCUUUUCAUGUUGUGTsT 
                 1577 
               
               
                   
                   
                   
                   
                 (1121C) stab10 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAA 
                 1280 
                   
                 IL4R:1140L21 antisense siNA 
                 UCAUCCCUUUUCAUGUUGUTsT 
                 1578 
               
               
                   
                   
                   
                   
                 (1122C) stab10 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAGG 
                 1281 
                   
                 IL4R:1152L21 antisense siNA 
                 UUGUGAGGAUCUUCAUCCCTsT 
                 1579 
               
               
                   
                   
                   
                   
                 (1134C) stab10 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUG 
                 1282 
                   
                 IL4R:3150L21 antisense siNA 
                 AAUUUCUCAUCGAUUUCCCTsT 
                 1580 
               
               
                   
                   
                   
                   
                 (3132C) stab10 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                   
                 IL4R:3151L21 antisense siNA 
                 CAAUUUCUCAUCGAUUUCCTsT 
                 1581 
               
               
                   
                   
                   
                   
                 (3133C) stab10 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUU 
                 1284 
                   
                 IL4R:3189L21 antisense siNA 
                 AUGAGCACCUCUAGGCAAUTsT 
                 1582 
               
               
                   
                   
                   
                   
                 (3171C) stab10 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCU 
                 1277 
                 36737 
                 IL4R:489L21 antisense siNA 
                 GcccAcAGGuccAGuGuAuT 1583 
               
               
                   
                   
                   
                   
                 (471C) stab19 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACA 
                 1278 
                 36738 
                 IL4R:571L21 antisense siNA 
                 GuGAAcuGucAGGuuuccuT 1584 
               
               
                   
                   
                   
                   
                 (553C) stab19 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGA 
                 1279 
                 36739 
                 IL4R:1139L21 antisense siNA 
                 cAucccuuuucAuGuuGuGTT B 
                 1585 
               
               
                   
                   
                   
                   
                 (1121C) stab19 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAA 
                 1280 
                 36740 
                 IL4R:1140L21 antisense siNA 
                 ucAucccuuuucAuGuuGuTT B 
                 1586 
               
               
                   
                   
                   
                   
                 (1122C) stab19 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAG 
                 1281 
                 36741 
                 IL4R:1152L21 antisense siNA 
                 uuGuGAGGAucuucAucccTT B 
                 1587 
               
               
                   
                   
                   
                   
                 (1134C) stab19 
               
               
                   
               
               
                 130 
                 UUGGGAAAUCGAUGAGAAAUUG 
                 1282 
                 36742 
                 IL4R:3150L21 antisense siNA 
                 AAuuucucAucGAuuucccTT B 
                 1588 
               
               
                   
                   
                   
                   
                 (3132C) stab19 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGAA 
                 1283 
                 36743 
                 IL4R:3151L21 antisense siNA 
                 cAAuuucucAucGAuuuccTT B 
                 1589 
               
               
                   
                   
                   
                   
                 (3133C) stab19 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                 36744 
                 IL4R:3189L21 antisense siNA 
                 AuGAGcAccucuAGGcAAuTT B 
                 1590 
               
               
                   
                   
                   
                   
                 (3171C) stab19 
               
               
                   
               
               
                 469 
                 CUAUACACUGGACCUGUGGGCUG 
                 1277 
                 36745 
                 IL4R:489L21 antisense siNA 
                 GCCCACAGGUCCAGUGUAUTT B 
                 1591 
               
               
                   
                   
                   
                   
                 (471C) stab22 
               
               
                   
               
               
                 551 
                 CCAGGAAACCUGACAGUUCACAC 
                 1278 
                 36746 
                 IL4R:571L21 antisense siNA 
                 GUGAACUGUCAGGUUUCCUTT B 
                 1592 
               
               
                   
                   
                   
                   
                 (553C) stab22 
               
               
                   
               
               
                 1119 
                 AGCACAACAUGAAAAGGGAUGAA 
                 1279 
                 36747 
                 IL4R:1139L21 antisense siNA 
                 CAUCCCUUUUCAUGUUGUGTT B 
                 1593 
               
               
                   
                   
                   
                   
                 (1121C) stab22 
               
               
                   
               
               
                 1120 
                 GCACAACAUGAAAAGGGAUGAAG 
                 1280 
                 36748 
                 IL4R:1140L21 antisense siNA 
                 UCAUCCCUUUUCAUGUUGUTT B 
                 1594 
               
               
                   
                   
                   
                   
                 (1122C) stab22 
               
               
                   
               
               
                 1132 
                 AAGGGAUGAAGAUCCUCACAAG 
                 1281 
                 36749 
                 IL4R:1152L21 antisense siNA 
                 UUGUGAGGAUCUUCAUCCCTT 
                 1595 
               
               
                   
                   
                   
                   
                 (1134C) stab22 
               
               
                   
               
               
                 3130 
                 UUGGGAAAUCGAUGAGAAAUUGA 
                 1282 
                 36750 
                 IL4R:3150L21 antisense siNA 
                 AAUUUCUCAUCGAUUUCCCTT B 
                 1596 
               
               
                   
                   
                   
                   
                 (3132C) stab22 
               
               
                   
               
               
                 3131 
                 UGGGAAAUCGAUGAGAAAUUGA 
                 1283 
                 36751 
                 IL4R:3151L21 antisense siNA 
                 CAAUUUCUCAUCGAUUUCCTT B 
                 1597 
               
               
                   
                   
                   
                   
                 (3133C) stab22 
               
               
                   
               
               
                 3169 
                 UCAUUGCCUAGAGGUGCUCAUUC 
                 1284 
                 36752 
                 IL4R:3189L21 antisense siNA 
                 AUGAGCACCUCUAGGCAAUTT B 
                 1598 
               
               
                   
                   
                   
                   
                 (3171C) stab22 
               
               
                   
               
               
                   
               
             
          
           
               
                 IL13 
                   
               
             
          
           
               
                 Target 
                   
                 Seq 
                 Cmpd 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Target 
                 ID 
                 # 
                 Aliases 
                 Sequence 
                 ID 
               
               
                   
               
             
          
           
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCU 
                 1285 
                   
                 IL13:393U21 sense siNA 
                 CAGUUUGUAAAGGACCUGCTT 
                 1599 
                   
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGA 
                 1286 
                   
                 IL13:799U21 sense siNA 
                 CUUCACACACAGGCAACUGTT 
                 1600 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUC 
                 1287 
                   
                 IL13:834U21 sense siNA 
                 AGGCACACUUCUUCUUGGUTT 
                 1601 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUU 
                 1288 
                   
                 IL13:913U21 sense siNA 
                 GACUGUGGCUGCUAGCACUTT 
                 1602 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCA 
                 1289 
                   
                 IL13:965U21 sense siNA 
                 CACUAAAGCAGUGGACACCTT 
                 1603 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGG 
                 1290 
                   
                 IL13:967U21 sense siNA 
                 CUAAAGCAGUGGACACCAGTT 
                 1604 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGU 
                 1291 
                   
                 IL13:970U21 sense siNA 
                 AAGCAGUGGACACCAGGAGTT 
                 1605 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGG 
                 1292 
                   
                 IL13:1193U21 sense siNA 
                 AAGGGUACCUUGAACACUGTT 
                 1606 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCU 
                 1285 
                   
                 IL13:411L21 antisense siNA 
                 GCAGGUCCUUUACAAACUGTT 
                 1607 
               
               
                   
                   
                   
                   
                 (393C) 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGA 
                 1286 
                   
                 IL13:817L21 antisense siNA 
                 CAGUUGCCUGUGUGUGAAGTT 
                 1608 
               
               
                   
                   
                   
                   
                 (799C) 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUC 
                 1287 
                   
                 IL13:852L21 antisense siNA 
                 ACCAAGAAGAAGUGUGCCUTT 
                 1609 
               
               
                   
                   
                   
                   
                 (834C) 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUU 
                 1288 
                   
                 IL13:931L21 antisense siNA 
                 AGUGCUAGCAGCCACAGUCTT 
                 1610 
               
               
                   
                   
                   
                   
                 (913C) 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCA 
                 1289 
                   
                 IL13:983L21 antisense siNA 
                 GGUGUCCACUGCUUUAGUGTT 
                 1611 
               
               
                   
                   
                   
                   
                 (965C) 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGG 
                 1290 
                   
                 IL13:985L21 antisense siNA 
                 CUGGUGUCCACUGCUUUAGTT 
                 1612 
               
               
                   
                   
                   
                   
                 (967C) 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGU 
                 1291 
                   
                 IL13:988L21 antisense siNA 
                 CUCCUGGUGUCCACUGCUUTT 
                 1613 
               
               
                   
                   
                   
                   
                 (970C) 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:121121 antisense siNA 
                 CAGUGUUCAAGGUACCCUUTT 
                 1614 
               
               
                   
                   
                   
                   
                 (1193C) 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                   
                 IL13:393U21 sense siNA 
                 B cAGuuuGuAAAGGAccuGcTT B 
                 1615 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                   
                 IL13:799U21 sense siNA 
                 B cuucAcAcAcAGGcAAcuGTT B 
                 1616 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                   
                 IL13:834U21 sense siNA 
                 B AGGcAcAcuucuucuuGGuTT B 
                 1617 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                   
                 IL13:913U21 sense siNA 
                 B GAcuGuGGcuGcuAGcAcuTT B 
                 1618 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                   
                 IL13:965U21 sense siNA 
                 B cAcuAAAGcAGuGGAcAccTT B 
                 1619 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                   
                 IL13:967U21 sense siNA 
                 B cuAAAGcAGuGGAcAccAGTT B 
                 1620 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                   
                 IL13:970U21 sense siNA 
                 B AAGcAGuGGAcAccAGGAGTT B 
                 1621 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:1193U21 sense siNA 
                 B AAGGGuAccuuGAAcAcuGTT B 
                 1622 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                   
                 IL13:411L21 antisense siNA 
                 GcAGGuccuuuAcAAAcuGTsT 
                 1623 
               
               
                   
                   
                   
                   
                 (393C) stab05 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                   
                 IL13:817L21 antisense siNA 
                 cAGuuGccuGuGuGuGAAGTsT 
                 1624 
               
               
                   
                   
                   
                   
                 (799C) stab05 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                   
                 IL13:852L21 antisense siNA 
                 AccAAGAAGAAGuGuGccuTsT 
                 1625 
               
               
                   
                   
                   
                   
                 (834C) stab05 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                   
                 IL13:931L21 antisense siNA 
                 AGuGcuAGcAGccAcAGucTsT 
                 1626 
               
               
                   
                   
                   
                   
                 (913C) stab05 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCA 
                 1289 
                   
                 IL13:983L21 antisense siNA 
                 GGuGuccAcuGcuuuAGuGTsT 
                 1627 
               
               
                   
                   
                   
                   
                 (965C) stab05 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                   
                 IL13:985L21 antisense siNA 
                 cuGGuGuccAcuGcuuuAGTsT 
                 1628 
               
               
                   
                   
                   
                   
                 (967C) stab05 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                   
                 IL13:988L21 antisense siNA 
                 cuccuGGuGuccAcuGcuuTsT 
                 1629 
               
               
                   
                   
                   
                   
                 (970C) stab05 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:1211L21 antisense siNA 
                 cAGuGuucAAGGuAcccuuTsT 
                 1630 
               
               
                   
                   
                   
                   
                 (1193C) stab05 
               
               
                   
               
               
                 864 
                 UAUUGUGUGUUAUUUAAAUGAGU 
                 1293 
                 33355 
                 IL13:864U21 sense siNA 
                 B uu G u G u G uu A uuu AAA u GA TT B 
                 1631 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 865 
                 AUUGUGUGUUAUUUAAAUGAGUG 
                 1294 
                 33356 
                 IL13:865U21 sense siNA 
                 B u G u G u G uu A uuu AAA u GAG TT B 
                 1632 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 866 
                 UUGUGUGUUAUUUAAAUGAGUGU 
                 1295 
                 33357 
                 IL13:866U21 sense siNA 
                 B  G u G u G uu A uuu AAA u GAG uTT B 
                 1633 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 863 
                 UUAUUGUGUGUUAUUUAAAUGAG 
                 1296 
                 33358 
                 IL13:863U21 sense siNA 
                 B  A uu G u G u G uu A uuu AAA u G TT B 
                 1634 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 200 
                 UGCAAUGGCAGCAUGGUAUGGAG 
                 1297 
                 33359 
                 IL13:200U21 sense siNA 
                 B c AA u GG c AG c A u GG u A u GG TT B 
                 1635 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 201 
                 GCAAUGGCAGCAUGGUAUGGAGC 
                 1298 
                 33360 
                 IL13:201U21 sense siNA 
                 B  AA u GG c AG c A u GG u A u GGA TT B 
                 1636 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 202 
                 CAAUGGCAGCAUGGUAUGGAGCA 
                 2993 
                 33361 
                 IL13:202U21 sense siNA 
                 B  A u GG c AG c A u GG u A u GGAG TT B 
                 1637 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 860 
                 UUAUUAUUGUGUGUUAUUUAAAU 
                 1300 
                 33362 
                 IL13:860U21 sense siNA 
                 B  A uu A uu G u G u G uu A uuu AA TT B 
                 1638 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 861 
                 UAUUAUUGUGUGUUAUUUAAAUG 
                 1301 
                 33363 
                 IL13:861U21 sense siNA 
                 B uu A uu G u G u G uu A uuu AAA TT B 
                 1639 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 862 
                 AUUAUUGUGUGUUAUUUAAAUGA 
                 1302 
                 33384 
                 IL13:862U21 sense siNA 
                 B u A uu G u G u G uu A uuu AAA uTT B 
                 1640 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                   
                 IL13:393U21 sense siNA 
                 B c AG uuu G u AAAGGA ccu G cTT B 
                 1641 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                   
                 IL13:799U21 sense siNA 
                 B cuuc A c A c A c AGG c AA cu G TT B 
                 1642 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                   
                 IL13:834U21 sense siNA 
                 B  AGG c A c A cuucuucuu GG uTT B 
                 1643 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                   
                 IL13:913U21 sense siNA 
                 B  GA cu G u GG cu G cu AG c A cuTT B 
                 1644 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                   
                 IL13:965U21 sense siNA 
                 B c A cu AAAG c AG u GGA c A ccTT B 
                 1645 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                   
                 IL13:967U21 sense siNA 
                 B cu AAAG c AG u GGA c A cc AG TT B 
                 1646 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                   
                 IL13:970U21 sense siNA 
                 B  AAG c AG u GGA c A cc AGGAG TT B 
                 1647 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:1193U21 sense siNA 
                 B  AAGGG u A ccuu GAA c A cu G TT B 
                 1648 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                   
                 IL13:411L21 antisense siNA 
                   G c AGG uccuuu A c AAA cu G TsT 
                 1649 
               
               
                   
                   
                   
                   
                 (393C) stab11 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                   
                 IL13:817L21 antisense siNA 
                 c AG uu G ccu G u G u G u GAAG TsT 
                 1650 
               
               
                   
                   
                   
                   
                 (799C) stab11 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                   
                 IL13:852L21 antisense siNA 
                   A cc AAGAAGAAG u G u G ccuTsT 
                 1651 
               
               
                   
                   
                   
                   
                 (834C) stab11 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUU 
                 1288 
                   
                 IL13:931L21 antisense siNA 
                   AG u G cu AG c AG cc A c AG ucTsT 
                 1652 
               
               
                   
                   
                   
                   
                 (913C) stab11 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                   
                 IL13:983L21 antisense siNA 
                   GG u G ucc A cu G cuuu AG u G TsT 
                 1653 
               
               
                   
                   
                   
                   
                 (965C) stab11 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                   
                 IL13:985L21 antisense siNA 
                 cu GG u G ucc A cu G cuuu AG TsT 
                 1654 
               
               
                   
                   
                   
                   
                 (967C) stab11 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                   
                 IL13:988L21 antisense siNA 
                 cuccu GG u G ucc A cu G cuuTsT 
                 1655 
               
               
                   
                   
                   
                   
                 (970C) stab11 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:1211L21 antisense siNA 
                 c AG u G uuc AAGG u A cccuuTsT 
                 1656 
               
               
                   
                   
                   
                   
                 (1193C) stab11 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                   
                 IL13:393U21 sense siNA 
                 B c AG uuu G u AAAGGA ccu G cTT B 
                 1657 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                   
                 IL13:799U21 sense siNA 
                 B cuuc A c A c A c AGG c AA cu G TT B 
                 1658 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                   
                 IL13:834U21 sense siNA 
                 B  AGG c A c A cuucuucuu GG uTT B 
                 1659 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                   
                 IL13:913U21 sense siNA 
                 B  GA cu G u GG cu G cu AG c A cuTT B 
                 1660 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                   
                 IL13:965U21 sense siNA 
                 B c A cu AAAG c AG u GGA c A ccTT B 
                 1661 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                   
                 IL13:967U21 sense siNA 
                 B cu AAAG c AG u GGA c A cc AG TT B 
                 1662 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                   
                 IL13:970U21 sense siNA 
                 B  AAG c AG u GGA c A cc AGGAG TT B 
                 1663 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:1193U21 sense siNA 
                 B  AAGGG u A ccuu GAA c A cu G TT B 
                 1664 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 864 
                 UAUUGUGUGUUAUUUAAAUGAGU 
                 1293 
                 33375 
                 IL13:882L21 antisense siNA 
                 uc A uuu AAA u AA c A c A Ec AA TsT 
                 1665 
               
               
                   
                   
                   
                   
                 (864C) stab08 
               
               
                   
               
               
                 865 
                 AUUGUGUGUUAUUUAAAUGAGUG 
                 1294 
                 33376 
                 IL13:883L21 antisense siNA 
                 cuc A uuu AAA u AA c A c A c A TsT 
                 1666 
               
               
                   
                   
                   
                   
                 (865C) stab08 
               
               
                   
               
               
                 866 
                 UUGUGUGUUAUUUAAAUGAGUGU 
                 1295 
                 33377 
                 IL13:884L21 antisense siNA 
                   A cuc A uuu AAA u AA c A c A cTsT 
                 1667 
               
               
                   
                   
                   
                   
                 (866C) stab08 
               
               
                   
               
               
                 863 
                 UUAUUGUGUGUUAUUUAAAUGAG 
                 1296 
                 33378 
                 IL13:881L21 antisense siNA 
                 c A uuu AAA u AA c A c A c AA uTsT 
                 1668 
               
               
                   
                   
                   
                   
                 (863C) stab08 
               
               
                   
               
               
                 200 
                 UGCAAUGGCAGCAUGGUAUGGAG 
                 1297 
                 33379 
                 IL13:218L21 antisense siNA 
                 cc A u A cc A u G cu G cc A uu G TsT 
                 1669 
               
               
                   
                   
                   
                   
                 (200C) stab08 
               
               
                   
               
               
                 201 
                 GCAAUGGCAGCAUGGUAUGGAGC 
                 1298 
                 33380 
                 IL13:219L21 antisense siNA 
                 ucc A u A cc A u G cu G cc A uuTsT 
                 1670 
               
               
                   
                   
                   
                   
                 (201C) stab08 
               
               
                   
               
               
                 202 
                 CAAUGGCAGCAUGGUAUGGAGCA 
                 1299 
                 33381 
                 IL13:220L21 antisense siNA 
                 cucc A u A cc A u G cu G cc A uTsT 
                 1671 
               
               
                   
                   
                   
                   
                 (202C) stab08 
               
               
                   
               
               
                 860 
                 UUAUUAUUGUGUGUUAUUUAAAU 
                 1300 
                 33382 
                 IL13:878L21 antisense siNA 
                 uu AAA u AA c A c A c AA u AA uTsT 
                 1672 
               
               
                   
                   
                   
                   
                 (860C) stab08 
               
               
                   
               
               
                 861 
                 UAUUAUUGUGUGUUAUUUAAAUG 
                 1301 
                 33383 
                 IL13:879L21 antisense siNA 
                 uuu AAA u AA c A c A c AA u AA TsT 
                 1673 
               
               
                   
                   
                   
                   
                 (861C) stab08 
               
               
                   
               
               
                 862 
                 AUUAUUGUGUGUUAUUUAAAUGA 
                 1302 
                 33384 
                 IL13:880L21 antisense siNA 
                   A uuu AAA u AA c A c A c AA u A TsT 
                 1674 
               
               
                   
                   
                   
                   
                 (862C) stab08 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                   
                 IL13:411L21 antisense siNA 
                   G c AGG uccuuu A c AAA cu G TsT 
                 1675 
               
               
                   
                   
                   
                   
                 (393C) stab08 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                   
                 IL13:817L21 antisense siNA 
                 c AG uu G ccu G u G u G u GAAG TsT 
                 1676 
               
               
                   
                   
                   
                   
                 (799C) stab08 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                   
                 IL13:852L21 antisense siNA 
                   A cc AAGAAGAAG u G u G ccuTsT 
                 1677 
               
               
                   
                   
                   
                   
                 (834C) stab08 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                   
                 IL13:931L21 antisense siNA 
                   AG u G cu AG c AG cc A c AG ucTsT 
                 1678 
               
               
                   
                   
                   
                   
                 (913C) stab08 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                   
                 IL13:983L21 antisense siNA 
                   GG u G ucc A cu G cuuu AG u G TsT 
                 1679 
               
               
                   
                   
                   
                   
                 (965C) stab08 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                   
                 IL13:985L21 antisense siNA 
                 cu GG u G ucc A cu G cuuu AG TsT 
                 1680 
               
               
                   
                   
                   
                   
                 (967C) stab08 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                   
                 IL13:988L21 antisense siNA 
                 cuccu GG u G ucc A cu G cuuTsT 
                 1681 
               
               
                   
                   
                   
                   
                 (970C) stab08 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:1211L21 antisense siNA 
                 c AG u G uuc AAGG u A cccuuTsT 
                 1682 
               
               
                   
                   
                   
                   
                 (1193C) stab08 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                 36890 
                 IL13:393U21 sense siNA 
                 B CAGUUUGUAAAGGACCUGCTT B 
                 1683 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                 36891 
                 IL13:799U21 sense siNA 
                 B CUUCACACACAGGCAACUGTT B 
                 1684 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                 36892 
                 IL13:834U21 sense siNA 
                 B AGGCACACUUCUUCUUGGUTT B 
                 1685 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                 36893 
                 IL13:913U21 sense siNA 
                 B GACUGUGGCUGCUAGCACUTT B 
                 1686 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                 36894 
                 IL13:965U21 sense siNA 
                 B CACUAAAGCAGUGGACACCTT B 
                 1687 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                 36895 
                 IL13:967U21 sense siNA 
                 B CUAAAGCAGUGGACACCAGTT B 
                 1688 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                 36896 
                 IL13:970U21 sense siNA 
                 B AAGCAGUGGACACCAGGAGTT B 
                 1689 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                 36897 
                 IL13:1193U21 sense siNA 
                 B AAGGGUACCUUGAACACUGTT B 
                 1690 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                   
                 IL13:411L21 antisense siNA 
                 GCAGGUCCUUUACAAACUGTsT 
                 1691 
               
               
                   
                   
                   
                   
                 (393C) stab10 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                   
                 IL13:817L21 antisense siNA 
                 CAGUUGCCUGUGUGUGAAGTsT 
                 1692 
               
               
                   
                   
                   
                   
                 (799C) stab10 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                   
                 IL13:852L21 antisense siNA 
                 ACCAAGAAGAAGUGUGCCUTsT 
                 1693 
               
               
                   
                   
                   
                   
                 (834C) stab10 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                   
                 IL13:931L21 antisense siNA 
                 AGUGCUAGCAGCCACAGUCTsT 
                 1694 
               
               
                   
                   
                   
                   
                 (913C) stab10 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                   
                 IL13:983L21 antisense siNA 
                 GGUGUCCACUGCUUUAGUGTsT 
                 1695 
               
               
                   
                   
                   
                   
                 (965C) stab10 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                   
                 IL13:985L21 antisense siNA 
                 CUGGUGUCCACUGCUUUAGTsT 
                 1696 
               
               
                   
                   
                   
                   
                 (967C) stab10 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                   
                 IL13:988L21 antisense siNA 
                 CUCCUGGUGUCCACUGCUUTsT 
                 1697 
               
               
                   
                   
                   
                   
                 (970C) stab10 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:1211L21 antisense siNA 
                 CAGUGUUCAAGGUACCCUUTsT 
                 1698 
               
               
                   
                   
                   
                   
                 (1193C) stab10 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                   
                 IL13:411L21 antisense siNA 
                 GcAGGuccuuuAcAAAcuGTT B 
                 1699 
               
               
                   
                   
                   
                   
                 (393C) stab19 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                   
                 IL13:817L21 antisense siNA 
                 cAGuuGccuGuGuGuGAAGTT B 
                 1700 
               
               
                   
                   
                   
                   
                 (799C) stab19 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                   
                 IL13:852L21 antisense siNA 
                 AccAAGAAGAAGuGuGccuTT B 
                 1701 
               
               
                   
                   
                   
                   
                 (834C) stab19 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                   
                 IL13:931L21 antisense siNA 
                 AGuGcuAGcAGccAcAGucTT B 
                 1702 
               
               
                   
                   
                   
                   
                 (913C) stab19 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                   
                 IL13:983L21 antisense siNA 
                 GGuGuccAcuGcuuuAGuGTT B 
                 1703 
               
               
                   
                   
                   
                   
                 (965C) stab19 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                   
                 IL13:985L21 antisense siNA 
                 cuGGuGuccAcuGcuuuAGTT B 
                 1704 
               
               
                   
                   
                   
                   
                 (967C) stab19 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                   
                 IL13:988L21 antisense siNA 
                 cuccuGGuGuccAcuGcuuTT B 
                 1705 
               
               
                   
                   
                   
                   
                 (970C) stab19 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                   
                 IL13:1211L21 antisense siNA 
                 cAGuGuucAAGGuAcccuuTT B 
                 1706 
               
               
                   
                   
                   
                   
                 (1193C) stab19 
               
               
                   
               
               
                 391 
                 CCCAGUUUGUAAAGGACCUGCUC 
                 1285 
                 36898 
                 IL13:411L21 antisense siNA 
                 GCAGGUCCUUUACAAACUGTT B 
                 1707 
               
               
                   
                   
                   
                   
                 (393C) stab22 
               
               
                   
               
               
                 797 
                 CACUUCACACACAGGCAACUGAG 
                 1286 
                 36899 
                 IL13:817L21 antisense siNA 
                 CAGUUGCCUGUGUGUGAAGTT B 
                 1708 
               
               
                   
                   
                   
                   
                 (799C) stab22 
               
               
                   
               
               
                 832 
                 UCAGGCACACUUCUUCUUGGUCU 
                 1287 
                 36900 
                 IL13:852L21 antisense siNA 
                 ACCAAGAAGAAGUGUGCCUTT B 
                 1709 
               
               
                   
                   
                   
                   
                 (834C) stab22 
               
               
                   
               
               
                 911 
                 AAGACUGUGGCUGCUAGCACUUG 
                 1288 
                 36901 
                 IL13:931L21 antisense siNA 
                 AGUGCUAGCAGCCACAGUCTT B 
                 1710 
               
               
                   
                   
                   
                   
                 (913C) stab22 
               
               
                   
               
               
                 963 
                 AGCACUAAAGCAGUGGACACCAG 
                 1289 
                 36902 
                 IL13:983L21 antisense siNA 
                 GGUGUCCACUGCUUUAGUGTT B 
                 1711 
               
               
                   
                   
                   
                   
                 (965C) stab22 
               
               
                   
               
               
                 965 
                 CACUAAAGCAGUGGACACCAGGA 
                 1290 
                 36903 
                 IL13:985L21 antisense siNA 
                 CUGGUGUCCACUGCUUUAGTT B 
                 1712 
               
               
                   
                   
                   
                   
                 (967C) stab22 
               
               
                   
               
               
                 968 
                 UAAAGCAGUGGACACCAGGAGUC 
                 1291 
                 36904 
                 IL13:988L21 antisense siNA 
                 CUCCUGGUGUCCACUGCUUTT B 
                 1713 
               
               
                   
                   
                   
                   
                 (970C) stab22 
               
               
                   
               
               
                 1191 
                 AGAAGGGUACCUUGAACACUGGG 
                 1292 
                 36905 
                 IL13:1211L21 antisense siNA 
                 CAGUGUUCAAGGUACCCUUTT B 
                 1714 
               
               
                   
                   
                   
                   
                 (1193C) stab22 
               
               
                   
               
               
                   
               
             
          
           
               
                 IL13R 
                   
               
             
          
           
               
                 Target 
                   
                 Seq 
                 Cmpd 
                   
                 Seq 
                   
               
             
          
           
               
                 Pos 
                 Target 
                 ID 
                 # 
                 Aliases 
                 Sequence 
                 ID 
               
               
                   
               
             
          
           
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:410U21 sense siNA 
                 GGUGAUCCUGAGUCUGCUGTT 
                 1715 
                   
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:659U21 sense siNA 
                 GUCAAGGAUAAUGCAGGAATT 
                 1716 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:873U21 sense siNA 
                 UCCAAGAGGCUAAAUGUGATT 
                 1717 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:278U21 sense siNA 
                 AAACCGACUCUGUAGUGCUTT 
                 1718 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1310U21 sense siNA 
                 AAGAAAGCCUCUCAGUGAUTT 
                 1719 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1426U21 sense siNA 
                 UGCACCAUUUAAAAACAGGTT 
                 1720 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2188U21 sense siNA 
                 GCAUUUUCCUCUGCUUUGATT 
                 1721 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2272U21 sense siNA 
                 AAGACCUUUCAAAGCCAUUTT 
                 1722 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:428L21 antisense siNA 
                 CAGCAGACUCAGGAUCACCTT 
                 1723 
               
               
                   
                   
                   
                   
                 (410C) 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:677L21 antisense siNA 
                 UUCCUGCAUUAUCCUUGACTT 
                 1724 
               
               
                   
                   
                   
                   
                 (659C) 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:891L21 antisense siNA 
                 UCACAUUUAGCCUCUUGGATT 
                 1725 
               
               
                   
                   
                   
                   
                 (873C) 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1296L21 antisense siNA 
                 AGCACUACAGAGUCGGUUUTT 
                 1726 
               
               
                   
                   
                   
                   
                 (1278C) 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1328L21 antisense siNA 
                 AUCACUGAGAGGCUUUCUUTT 
                 1727 
               
               
                   
                   
                   
                   
                 (1310C) 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1444L21 antisense siNA 
                 CCUGUUUUUAAAUGGUGCATT 
                 1728 
               
               
                   
                   
                   
                   
                 (1426C) 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2206L21 antisense siNA 
                 UCAAAGCAGAGGAAAAUGCTT 
                 1729 
               
               
                   
                   
                   
                   
                 (2188C) 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2290L21 antisense siNA 
                 AAUGGCUUUGAAAGGUCUUTT 
                 1730 
               
               
                   
                   
                   
                   
                 (2272C) 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:410U21 sense siNA 
                 B GGuGAuccuGAGucuGcuGTT B 
                 1731 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:659U21 sense siNA 
                 B GucAAGGAuAAuGcAGGAATT B 
                 1732 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:873U21 sense siNA 
                 B uccAAGAGGcuAAAuGuGATT B 
                 1733 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1278U21 sense siNA 
                 B AAAccGAcucuGuAGuGcuTT B 
                 1734 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1310U21 sense siNA 
                 B AAGAAAGccucucAGuGAuTT B 
                 1735 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1426U21 sense siNA 
                 B uGcAccAuuuAAAAAcAGGTT B 
                 1736 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2188U21 sense siNA 
                 B GcAuuuuccucuGcuuuGATT B 
                 1737 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2272U21 sense siNA 
                 B AAGAccuuucAAAGccAuuTT B 
                 1738 
               
               
                   
                   
                   
                   
                 stab04 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:428L21 antisense siNA 
                 cAGcAGAcucAGGAucAccTsT 
                 1739 
               
               
                   
                   
                   
                   
                 (410C) stab05 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:677L21 antisense siNA 
                 uuccuGcAuuAuccuuGAcTsT 
                 1740 
               
               
                   
                   
                   
                   
                 (659C) stab05 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:891L21 antisense siNA 
                 ucAcAuuuAGccucuuGGATsT 
                 1741 
               
               
                   
                   
                   
                   
                 (873C) stab05 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1296L21 antisense siNA 
                 AGcAcuAcAGAGucGGuuuTsT 
                 1742 
               
               
                   
                   
                   
                   
                 (1278C) stab05 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1328L21 antisense siNA 
                 AucAcuGAGAGGcuuucuuTsT 
                 1743 
               
               
                   
                   
                   
                   
                 (1310C) stab05 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1444L21 antisense siNA 
                 ccuGuuuuuAAAuGGuGcATsT 
                 1744 
               
               
                   
                   
                   
                   
                 (1426C) stab05 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2206L21 antisense siNA 
                 ucAAAGcAGAGGAAAAuGcTsT 
                 1745 
               
               
                   
                   
                   
                   
                 (2188C) stab05 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2290L21 antisense siNA 
                 AAuGGcuuuGAAAGGucuuTsT 
                 1746 
               
               
                   
                   
                   
                   
                 (2272C) stab05 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:410U21 sense siNA 
                 B  GG u GA uccu GAG ucu G cu G TT B 
                 1747 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:659U21 sense siNA 
                 B  G uc AAGGA u AA u G c AGGAA TT B 
                 1748 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:873U21 sense siNA 
                 B ucc AAGAGG cu AAA u G u GA TT B 
                 1749 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1278U21 sense siNA 
                 B  AAA cc GA cucu G u AG u G cuTT B 
                 1750 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1310U21 sense siNA 
                 B  AAGAAAG ccucuc AG u GA uTT B 
                 1751 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 ILI3RA1:1426U21 sense siNA 
                 B u G c A cc A uuu AAAAA c AGG TT B 
                 1752 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2188U21 sense siNA 
                 B  G c A uuuuccucu G cuuu GA TT B 
                 1753 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2272U21 sense siNA 
                 B  AAGA ccuuuc AAAG cc A uuTT B 
                 1754 
               
               
                   
                   
                   
                   
                 stab07 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:428L21 antisense siNA 
                 c AG c AGA cuc AGGA uc A ccTsT 
                 1755 
               
               
                   
                   
                   
                   
                 (410C) stab11 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:677L21 antisense siNA 
                 uuccu G c A uu A uccuu GA cTsT 
                 1756 
               
               
                   
                   
                   
                   
                 (659C) stab11 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:891L21 antisense siNA 
                 uc A c A uuu AG ccucuu GGA TsT 
                 1757 
               
               
                   
                   
                   
                   
                 (873C) stab11 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1296L21 antisense siNA 
                   AG c A cu A c AGAG uc GG uuuTsT 
                 1758 
               
               
                   
                   
                   
                   
                 (1278C) stab11 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGGCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1328L21 antisense siNA 
                   A uc A cu GAGAGG cuuucuuTsT 
                 1759 
               
               
                   
                   
                   
                   
                 (1310C) stab11 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1444L21 antisense siNA 
                 ccu G uuuuu AAA u GG u G c A TsT 
                 1760 
               
               
                   
                   
                   
                   
                 (1426C) stab11 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2206L21 antisense siNA 
                 uc AAAG c AGAGGAAAA u G cTsT 
                 1761 
               
               
                   
                   
                   
                   
                 (2188C) stab11 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2290L21 antisense siNA 
                   AA u GG cuuu GAAAGG ucuuTsT 
                 1762 
               
               
                   
                   
                   
                   
                 (2272C) stab11 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:410U21 sense siNA 
                 B  GG u GA uccu GAG ucu G cu G TT B 
                 1763 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:659U21 sense siNA 
                 B  G uc AAGGA u AA u G c AGGAA TT B 
                 1764 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:873U21 sense siNA 
                 B ucc AAGAGG cu AAA u G u GA TT B 
                 1765 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1278U21 sense siNA 
                 B  AAA cc GA cucu G u AG u G cuTT B 
                 1766 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 ILI3RA1:1310U21 sense siNA 
                 B  AAGAAAG ccucuc AG u GA uTT B 
                 1767 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1426U21 sense siNA 
                 B u G c A cc A uuu AAAAA c AGG TT B 
                 1768 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2188U21 sense siNA 
                 B  G c A uuuuccucu G cuuu GA TT B 
                 1769 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2272U21 sense siNA 
                 B  AAGA ccuuuc AAAG cc A uuTT B 
                 1770 
               
               
                   
                   
                   
                   
                 stab18 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:428L21 antisense siNA 
                 c AG c AGA cuc AGGA uc A ccTsT 
                 1771 
               
               
                   
                   
                   
                   
                 (410C) stab08 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:677L21 antisense siNA 
                 uuccu G c A uu A uccuu GA cTsT 
                 1772 
               
               
                   
                   
                   
                   
                 (659C) stab08 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:891L21 antisense siNA 
                 uc A c A uuu AG ccucuu GGA TsT 
                 1773 
               
               
                   
                   
                   
                   
                 (873C) stab08 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1296L21 antisense siNA 
                   AG c A cu A c AGAG uc GG uuuTsT 
                 1774 
               
               
                   
                   
                   
                   
                 (1278C) stab08 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1328L21 antisense siNA 
                   A uc A cu GAGAGG cuuucuuTsT 
                 1775 
               
               
                   
                   
                   
                   
                 (1310C) stab08 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1444L21 antisense siNA 
                 ccu G uuuuu AAA u GG u G c A TsT 
                 1776 
               
               
                   
                   
                   
                   
                 (1426C) stab08 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2206L21 antisense siNA 
                 uc AAAG c AGAGGAAAA u G cTsT 
                 1777 
               
               
                   
                   
                   
                   
                 (2188C) stab08 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2290L21 antisense siNA 
                   AA u GG cuuu GAAAGG ucuuTsT 
                 1778 
               
               
                   
                   
                   
                   
                 (2272C) stab08 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                 36906 
                 IL13RA1:410U21 sense siNA 
                 B GGUGAUCCUGAGUCUGCUGTT B 
                 1779 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                 36907 
                 IL13RA1:659U21 sense siNA 
                 B GUCAAGGAUAAUGCAGGAATT B 
                 1780 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                 36908 
                 IL13RA1:873U21 sense siNA 
                 B UCCAAGAGGCUAAAUGUGATT B 
                 1781 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                 36909 
                 IL13RA1:1278U21 sense siNA 
                 B AAACCGACUCUGUAGUGCUTT B 
                 1782 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                 36910 
                 IL13RA1:1310U21 sense siNA 
                 B AAGAAAGCCUCUCAGUGAUTT B 
                 1783 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                 36911 
                 IL13RA1:1426U21 sense siNA 
                 B UGCACCAUUUAAAAACAGGTT B 
                 1784 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                 36912 
                 IL13RA1:2188U21 sense siNA 
                 B GCAUUUUCCUCUGCUUUGATT B 
                 1785 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                 36913 
                 IL13RA1:2272U21 sense siNA 
                 B AAGACCUUUCAAAGCCAUUTT B 
                 1786 
               
               
                   
                   
                   
                   
                 stab09 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:428L21 antisense siNA 
                 CAGCAGACUCAGGAUCACCTsT 
                 1787 
               
               
                   
                   
                   
                   
                 (410C) stab10 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:677L21 antisense siNA 
                 UUCCUGCAUUAUCCUUGACTsT 
                 1788 
               
               
                   
                   
                   
                   
                 (659C) stab10 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:891L21 antisense siNA 
                 UCACAUUUAGCCUCUUGGATsT 
                 1789 
               
               
                   
                   
                   
                   
                 (873C) stab10 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1296L21 antisense siNA 
                 AGCACUACAGAGUCGGUUUTsT 
                 1790 
               
               
                   
                   
                   
                   
                 (1278C) stab10 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1328L21 antisense siNA 
                 AUCACUGAGAGGCUUUCUUTsT 
                 1791 
               
               
                   
                   
                   
                   
                 (1310C) stab10 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1444L21 antisense siNA 
                 CCUGUUUUUAAAUGGUGCATsT 
                 1792 
               
               
                   
                   
                   
                   
                 (1426C) stab10 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2206L21 antisense siNA 
                 UCAAAGCAGAGGAAAAUGCTsT 
                 1793 
               
               
                   
                   
                   
                   
                 (2188C) stab10 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2290L21 antisense siNA 
                 AAUGGCUUUGAAAGGUCUUTsT 
                 1794 
               
               
                   
                   
                   
                   
                 (2272C) stab10 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                   
                 IL13RA1:428L21 antisense siNA 
                 cAGcAGAcucAGGAucAccTT B 
                 1795 
               
               
                   
                   
                   
                   
                 (410C) stab19 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                   
                 IL13RA1:677L21 antisense siNA 
                 uuccuGcAuuAuccuuGAcTT B 
                 1796 
               
               
                   
                   
                   
                   
                 (659C) stab19 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                   
                 IL13RA1:891L21 antisense siNA 
                 ucAcAuuuAGccucuuGGATT B 
                 1797 
               
               
                   
                   
                   
                   
                 (873C) stab19 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                   
                 IL13RA1:1296L21 antisense siNA 
                 AGcAcuAcAGAGucGGuuuTT B 
                 1798 
               
               
                   
                   
                   
                   
                 (1278C) stab19 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                   
                 IL13RA1:1328L21 antisense siNA 
                 AucAcuGAGAGGcuuucuuTT B 
                 1799 
               
               
                   
                   
                   
                   
                 (1310C) stab19 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                   
                 IL13RA1:1444L21 antisense siNA 
                 ccuGuuuuuAAAuGGuGcATT B 
                 1800 
               
               
                   
                   
                   
                   
                 (1426C) stab19 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                   
                 IL13RA1:2206L21 antisense siNA 
                 ucAAAGcAGAGGAAAAuGcTT B 
                 1801 
               
               
                   
                   
                   
                   
                 (2188C) stab19 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                   
                 IL13RA1:2290L21 antisense siNA 
                 AAuGGcuuuGAAAGGucuuTT B 
                 1802 
               
               
                   
                   
                   
                   
                 (2272C) stab19 
               
               
                   
               
               
                 408 
                 AAGGUGAUCCUGAGUCUGCUGUG 
                 1303 
                 36914 
                 IL13RA1:428L21 antisense siNA 
                 CAGCAGACUCAGGAUCACCTT B 
                 1803 
               
               
                   
                   
                   
                   
                 (410C) stab22 
               
               
                   
               
               
                 657 
                 UGGUCAAGGAUAAUGCAGGAAAA 
                 1304 
                 36915 
                 IL13RA1:677L21 antisense siNA 
                 UUCCUGCAUUAUCCUUGACTT B 
                 1804 
               
               
                   
                   
                   
                   
                 (659C) stab22 
               
               
                   
               
               
                 871 
                 CGUCCAAGAGGCUAAAUGUGAGA 
                 1305 
                 36916 
                 IL13RA1:891L21 antisense siNA 
                 UCACAUUUAGCCUCUUGGATT B 
                 1805 
               
               
                   
                   
                   
                   
                 (873C) stab22 
               
               
                   
               
               
                 1276 
                 GGAAACCGACUCUGUAGUGCUGA 
                 1306 
                 36917 
                 IL13RA1:1296L21 antisense siNA 
                 AGCACUACAGAGUCGGUUUTT B 
                 1806 
               
               
                   
                   
                   
                   
                 (1278C) stab22 
               
               
                   
               
               
                 1308 
                 UGAAGAAAGCCUCUCAGUGAUGG 
                 1307 
                 36918 
                 IL13RA1:1328L21 antisense siNA 
                 AUCACUGAGAGGCUUUCUUTT B 
                 1807 
               
               
                   
                   
                   
                   
                 (1310C) stab22 
               
               
                   
               
               
                 1424 
                 ACUGCACCAUUUAAAAACAGGCA 
                 1308 
                 36919 
                 IL13RA1:1444L21 antisense siNA 
                 CCUGUUUUUAAAUGGUGCATT B 
                 1808 
               
               
                   
                   
                   
                   
                 (1426C) stab22 
               
               
                   
               
               
                 2186 
                 CAGCAUUUUCCUCUGCUUUGAAA 
                 1309 
                 36920 
                 IL13RA1:2206L21 antisense siNA 
                 UCAAAGCAGAGGAAAAUGCTT B 
                 1809 
               
               
                   
                   
                   
                   
                 (2188C) stab22 
               
               
                   
               
               
                 2270 
                 CCAAGACCUUUCAAAGCCAUUUU 
                 1310 
                 36921 
                 IL13RA1:2290L21 antisense siNA 
                 AAUGGCUUUGAAAGGUCUUTT B 
                 1810 
               
               
                   
                   
                   
                   
                 (2272C) stab22 
               
               
                   
               
               
                   Uppercase = ribonucleotide    
               
               
                   u, c = 2′-deoxy-2′-fluoro U, C    
               
               
                   T = thymidine    
               
               
                   B = inverted deoxy abasic    
               
               
                   s = phosphorothioate linkage    
               
               
                     A  = deoxy Adenosine    
               
               
                     G  = deoxy Guanosine    
               
               
                     G  = 2′-O-methyl Guanosine    
               
               
                     A  = 2′-O-methyl Adenosine    
               
             
          
         
       
     
         [0429]    
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE IV 
               
             
             
               
                   
               
               
                   
               
               
                 Non-limiting examples of Stabilization Chemistries for chemically modified 
               
               
                 siNA constructs 
               
             
          
           
               
                 Chemistry 
                 pyrimidine 
                 Purine 
                 cap 
                 p = S 
                 Strand 
               
               
                   
               
               
                 “Stab 00” 
                 Ribo 
                 Ribo 
                 TT at 3′-ends 
                   
                 S/AS 
               
               
                 “Stab 1” 
                 Ribo 
                 Ribo 
                 — 
                 5 at 5′-end 
                 S/AS 
               
               
                   
                   
                   
                   
                 1 at 3′-end 
               
               
                 “Stab 2” 
                 Ribo 
                 Ribo 
                 — 
                 All linkages 
                 Usually AS 
               
               
                 “Stab 3” 
                 2′-fluoro 
                 Ribo 
                 — 
                 4 at 5′-end 
                 Usually S 
               
               
                   
                   
                   
                   
                 4 at 3′-end 
               
               
                 “Stab 4” 
                 2′-fluoro 
                 Ribo 
                 5′ and 3′-ends 
                 — 
                 Usually S 
               
               
                 “Stab 5” 
                 2′-fluoro 
                 Ribo 
                 — 
                 1 at 3′-end 
                 Usually AS 
               
               
                 “Stab 6” 
                 2′-O-Methyl 
                 Ribo 
                 5′ and 3′- 
                 — 
                 Usually S 
               
               
                   
                   
                   
                 ends 
               
               
                 “Stab 7” 
                 2′-fluoro 
                 2′-deoxy 
                 5′ and 3′- 
                 — 
                 Usually S 
               
               
                   
                   
                   
                 ends 
               
               
                 “Stab 8” 
                 2′-fluoro 
                 2′-O- 
                 — 
                 1 at 3′-end 
                 Usually AS 
               
               
                   
                   
                 Methyl 
               
               
                 “Stab 9” 
                 Ribo 
                 Ribo 
                 5′ and 3′- 
                 — 
                 Usually S 
               
               
                   
                   
                   
                 ends 
               
               
                 “Stab 10” 
                 Ribo 
                 Ribo 
                 — 
                 1 at 3′-end 
                 Usually AS 
               
               
                 “Stab 11” 
                 2′-fluoro 
                 2′-deoxy 
                 — 
                 1 at 3′-end 
                 Usually AS 
               
               
                 “Stab 12” 
                 2′-fluoro 
                 LNA 
                 5′ and 3′- 
                   
                 Usually S 
               
               
                   
                   
                   
                 ends 
               
               
                 “Stab 13” 
                 2′-fluoro 
                 LNA 
                   
                 1 at 3′-end 
                 Usually AS 
               
               
                 “Stab 14” 
                 2′-fluoro 
                 2′-deoxy 
                   
                 2 at 5′-end 
                 Usually AS 
               
               
                   
                   
                   
                   
                 1 at 3′-end 
               
               
                 “Stab 15” 
                 2′-deoxy 
                 2′-deoxy 
                   
                 2 at 5′-end 
                 Usually AS 
               
               
                   
                   
                   
                   
                 1 at 3′-end 
               
               
                 “Stab 16 
                 Ribo 
                 2′-O- 
                 5′ and 3′- 
                   
                 Usually S 
               
               
                   
                   
                 Methyl 
                 ends 
               
               
                 “Stab 17” 
                 2′-O-Methyl 
                 2′-O- 
                 5′ and 3′- 
                   
                 Usually S 
               
               
                   
                   
                 Methyl 
                 ends 
               
               
                 “Stab 18” 
                 2′-fluoro 
                 2′-O- 
                 5′ and 3′- 
                 1 at 3′-end 
                 Usually S 
               
               
                   
                   
                 Methyl 
                 ends 
               
               
                 “Stab 19” 
                 2′-fluoro 
                 2′-O- 
                 3′-end 
                   
                 Usually AS 
               
               
                   
                   
                 Methyl 
               
               
                 “Stab 20” 
                 2′-fluoro 
                 2′-deoxy 
                 3′-end 
                   
                 Usually AS 
               
               
                 “Stab 21” 
                 2′-fluoro 
                 Ribo 
                 3′-end 
                   
                 Usually AS 
               
               
                 “Stab 22” 
                 Ribo 
                 Ribo 
                 3′-end - 
                   
                 Usually AS 
               
               
                 “Stab 23” 
                 2′-fluoro* 
                 2′-deoxy* 
                 5′ and 3′- 
                   
                 Usually S 
               
               
                   
                   
                   
                 ends 
               
               
                 “Stab 24” 
                 2′-fluoro* 
                 2′-O- 
                 — 
                 1 at 3′-end 
                 Usually AS 
               
               
                   
                   
                 Methyl* 
               
               
                 “Stab 25” 
                 2′-fluoro* 
                 2′-O-Methyl* 
                 — 
                 1 at 3′-end 
                 Usually AS 
               
               
                   
               
               
                   CAP = any terminal cap, see for example  FIG. 10 .    
               
               
                   All Stab 1-25 chemistries can comprise 3′-terminal thymidine (TT) residues    
               
               
                   All Stab 1-25 chemistries typically comprise about 21 nucleotides, but can vary as described herein.    
               
               
                   S = sense strand    
               
               
                   AS = antisense strand    
               
               
                   *Stab 23 has single ribonucleotide adjacent to 3′-CAP    
               
               
                   *Stab 24 has single ribonucleotide at 5′-terminus    
               
               
                   *Stab 25 has three ribonucleotides at 5′-terminus    
               
             
          
         
       
     
         [0430]    
       
         
               
             
               
               
               
               
               
               
             
               
             
               
               
               
               
               
               
             
               
             
               
               
               
               
               
               
             
           
               
                 TABLE V 
               
               
                   
               
               
                   
               
             
             
               
                 A. 2.5 μmol Synthesis Cycle ABI 394 Instrument 
               
             
          
           
               
                   
                   
                   
                   
                 Wait Time* 
                   
               
               
                 Reagent 
                 Equivalents 
                 Amount 
                 Wait Time* DNA 
                 2′-O-methyl 
                 Wait Time*RNA 
               
               
                   
               
               
                 Phosphoramidites 
                 6.5 
                  163 μL 
                  45 sec 
                  2.5 min 
                  7.5 min 
               
               
                 S-Ethyl Tetrazole 
                 23.8 
                  238 μL 
                  45 sec 
                  2.5 min 
                  7.5 min 
               
               
                 Acetic Anhydride 
                 100 
                  233 μL 
                  5 sec 
                   5 sec 
                   5 sec 
               
               
                 N-Methyl 
                 186 
                  233 μL 
                  5 sec 
                   5 sec 
                   5 sec 
               
               
                 Imidazole 
               
               
                 TCA 
                 176 
                  2.3 mL 
                  21 sec 
                   21 sec 
                   21 sec 
               
               
                 Iodine 
                 11.2 
                  1.7 mL 
                  45 sec 
                   45 sec 
                   45 sec 
               
               
                 Beaucage 
                 12.9 
                  645 μL 
                 100 sec 
                  300 sec 
                  300 sec 
               
               
                 Acetonitrile 
                 NA 
                 6.67 mL 
                 NA 
                 NA 
                 NA 
               
               
                   
               
             
          
           
               
                 B. 0.2 μmol Synthesis Cycle ABI 394 Instrument 
               
             
          
           
               
                   
                   
                   
                   
                 Wait Time* 
                   
               
               
                 Reagent 
                 Equivalents 
                 Amount 
                 Wait Time* DNA 
                 2′-O-methyl 
                 Wait Time*RNA 
               
               
                   
               
               
                 Phosphoramidites 
                 15 
                   31 μL 
                  45 sec 
                 233 sec 
                 465 sec 
               
               
                 S-Ethyl Tetrazole 
                 38.7 
                   31 μL 
                  45 sec 
                 233 min 
                 465 sec 
               
               
                 Acetic Anhydride 
                 655 
                  124 μL 
                  5 sec 
                  5 sec 
                  5 sec 
               
               
                 N-Methyl 
                 1245 
                  124 μL 
                  5 sec 
                  5 sec 
                  5 sec 
               
               
                 Imidazole 
               
               
                 TCA 
                 700 
                  732 μL 
                  10 sec 
                  10 sec 
                  10 sec 
               
               
                 Iodine 
                 20.6 
                  244 μL 
                  15 sec 
                  15 sec 
                  15 sec 
               
               
                 Beaucage 
                 7.7 
                  232 μL 
                 100 sec 
                 300 sec 
                 300 sec 
               
               
                 Acetonitrile 
                 NA 
                 2.64 mL 
                 NA 
                 NA 
                 NA 
               
               
                   
               
             
          
           
               
                 C. 0.2 μmol Synthesis Cycle 96 well Instrument 
               
             
          
           
               
                   
                 Equivalents: DNA/ 
                 Amount: DNA/ 
                   
                 Wait Time* 
                   
               
               
                 Reagent 
                 2′-O-methyl/Ribo 
                 2′-O-methyl/Ribo 
                 Wait Time* DNA 
                 2′-O-methyl 
                 Wait Time* Ribo 
               
               
                   
               
               
                 Phosphoramidites 
                   22/33/66 
                    40/60/120 μL 
                  60 sec 
                 180 sec 
                 360 sec 
               
               
                 S-Ethyl Tetrazole 
                   70/105/210 
                    40/60/120 μL 
                  60 sec 
                 180 min 
                 360 sec 
               
               
                 Acetic Anhydride 
                  265/265/265 
                    50/50/50 μL 
                  10 sec 
                  10 sec 
                  10 sec 
               
               
                 N-Methyl 
                  502/502/502 
                    50/50/50 μL 
                  10 sec 
                  10 sec 
                  10 sec 
               
               
                 Imidazole 
               
               
                 TCA 
                  238/475/475 
                   250/500/500 μL 
                  15 sec 
                  15 sec 
                  15 sec 
               
               
                 Iodine 
                  6.8/6.8/6.8 
                    80/80/80 μL 
                  30 sec 
                  30 sec 
                  30 sec 
               
               
                 Beaucage 
                   34/51/51 
                   80/120/120 
                 100 sec 
                 200 sec 
                 200 sec 
               
               
                 Acetonitrile 
                 NA 
                 1150/1150/1150 μL 
                 NA 
                 NA 
                 NA 
               
               
                   
               
               
                   *Wait time does not include contact time during delivery.    
               
               
                   *Tandem synthesis utilizes double coupling of linker molecule